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Abstract
The primary human immunodeficiency virus type 1 (HIV-1) - specific CD8+ T 
cell response plays an important role in control of early viral replication. The 
nature of this response may thus be among the factors determining the 
prognostically-important persisting viral load. Here, the primary HIV-specific 
CD8+ T cell response was characterised in a small cohort of patients, to gain 
insight into quantitative and qualitative features of the response and their 
relationship to the efficiency of control of virus replication.
The majority of patients studied established intermediate or high persisting 
viral loads. In these individuals, no association was found between the 
persisting viral load established and the total magnitude of the early HIV- 
specific CD8+ T cell response, its epitope breadth or specificity. However the 
response was observed to be heavily biased towards the most 
immunodominant epitopes.
Kinetic analyses of epitope-specific responses revealed that in most patients, 
responses expanded asynchronously, with rapidly-expanded responses being 
immunodominant in primary infection. Mechanisms that may account for the 
rapid initial expansion of selected responses in acute viral infection, including 
high avidity and pre-existence of cross-reactive memory cells, were explored 
using murine models.
Notably, the most rapidly-expanded epitope-specific response(s) typically did 
not reach peak magnitude until several weeks after the peak in acute viral 
replication; and the fastest response was observed in the one patient studied 
who established a low persisting viral load.
Phenotypic studies suggested that HIV-specific CD8+ T cells exhibit an 
"immature” phenotype from primary infection onwards in all patients.
Although these studies need to be extended to a larger number of patients, 
the results obtained suggest that the kinetics and synchronicity of expansion 
of epitope-specific CD8+ T cell responses in primary HIV-1 infection may be 
among the factors that impact on the efficiency of control of primary viraemia.
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FLIP FLICE inhibitory protein
y6 Gamma delta
GALT Gut-associated lymphoid tissue
GM-CSF Granulocyte-macrophage colony-stimulating factor
GP Glycoprotein
HAART Highly active antiretroviral therapy
HBV Hepatitis B virus
HCMV Human cytomegalovirus
HCV Hepatitis C virus
HHV Human herpes virus
HIV Human immunodeficiency virus
HLA Human leucocyte antigen
HPV Human papilloma virus
HSV Herpes simplex virus
HTLV-1 Human T cell lymphotrophic virus type 1
i.n. Intranasal
i.p. Intraperitoneal
i.v. Intravenous
ICE IL-1£ converting enzyme
ICS Intracellular cytokine staining
IFN Interferon
IL Interleukin
IRF Interferon regulatory factor
IU International units
Jak Janus kinase
kb Kilobases
kDa Kilodaltons
KIR Killer inhibitory receptor
k/o Knock-out
KS Kaposi’s sarcoma
KSHV Kaposi’s sarcoma-related herpes virus
LCMV Lymphocytic choriomeningitis virus
LMP Latent membrane protein
LTNP Long term non-progressor
LTR Long terminal repeat
mAb Monoclonal antibody
MAC Membrane attack complex
MBL Mannan-binding lectin
MCMV Murine cytomegalovirus
MDC Myeloid dendritic cell
MFI Mean fluorescence intensity
MHC Major histocompatibility complex
MHR Major homology region
MHV Murine herpes virus
MIP Macrophage inflammatory protein
MLR Mixed lymphocyte reaction
m.o.i. Multiplicity of infection
mRNA Messenger RNA
MV Measles virus
MVA Modified vaccinia virus Ankara
MWCO Molecular weight cut-off
nAb Neutralising antibody
NFAT Nuclear factor of activated T cells
NF/cB Nuclear factor kB
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NK Natural killer
NP Nucleoprotein
NRTI Nucleoside reverse transcriptase inhibitor
NNRTI Non-nucleoside reverse transcriptase inhibitor
ORF Open reading frame
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PDC Plasmacytoid dendritic cell
pfu Plaque forming units
PHA Phytohaemagluttinin
PIC Preintegration complex
PKR dsRNA-dependent protein kinase
PRR Pattern recognition receptor
PV Pichinde virus
RANTES Regulated on activation, normal T cell expressed and secreted
RNA Ribonucleic acid
rpm Revolutions per minute
RRE Rev response element
RT Reverse transcriptase
rVV Recombinant vaccinia virus
SAM68 Src-associated in mitosis; 68 kDa
SCID Severe combined immunodeficiency
SD Standard deviation
SE Standard error
SFC Spot forming cells
SHIV Simian-human immunodeficiency virus
SIV Simian immunodeficiency virus
ss Single stranded
STAT Signal transducers and activators of transcription
STI Structured treatment interruption
TAP Transporter associated with antigen processing
TAR Transactivation response region
TCR T cell receptor
Th T helper
TLR Toll-like receptor
TNF Tumour necrosis factor
TRADD TNF receptor-associated death domain
TRAIL TNF-related apoptosis-inducing ligand
TRANCE TNF-related activation-induced cytokine
TREC T cell receptor excision circle
tRNA Transfer RNA
Tsg101 Tumour suppressor gene 101
UNAIDS The Joint United Nations Programme on HIV/AIDS
UV Ultraviolet
vFLIP Viral FLICE inhibitory protein
VSV Vesicular stomatitis virus
W Vaccinia virus
VZV , Varicella zoster virus
V/? V beta
WHO World health organisation
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Table of amino acid symbols
Amino Acid Single letter code
Alanine A
Arginine R
Asparagine N
Aspartate D
Cysteine C
Glutamate E
Glutamine Q
Glycine G
Histidine H
Isoleucine 1
Leucine L
Lysine K
Methionine M
Phenylalanine F
Proline P
Serine S
Threonine T
Tryptophan W
Tyrosine Y
Valine V
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Chapter 1 
Introduction
1.1 HIV: past and present
HIV-1 is a retrovirus in the lentivirus family that causes a persistent infection in 
humans characterised by progressive failure of host immunological function 
due predominantly to a selective depletion of helper CD4+ T lymphocytes, and 
which is ultimately associated with the development of an acquired immune 
deficiency syndrome (AIDS).
AIDS was first recognised in 1981 when clinicians in New York and California 
observed among young, previously healthy homosexual men, an unusual 
clustering of cases of rare diseases. Such cases of Kaposi’s sarcoma (KS), 
opportunistic infections such as Pneumocystis carinni pneumonia, and 
unexplained lymphadenopathy shared a common underlying cause - deficient 
cell-mediated immunity, resulting predominantly from a significant reduction of 
circulating CD4+ T cells. Also observed in other diverse risk groups, this 
syndrome was believed to be caused by an infectious microorganism 
transmitted by sexual activity or blood; epidemiological studies suggested that 
the disease might have a retroviral etiology. In 1983 the virus responsible for 
AIDS was isolated, later to become known as HIV-1 (Barre-Sinoussi et al., 
1983; Gallo eta i ,  1984).
It is now evident that cases of AIDS had occurred previously but gone 
undetected.
Molecular epidemiological studies led to discovery of the origins of the virus. It 
is believed that the emergence of HIV in the human population was the result 
of zoonotic transmission. Studies of phylogenetic relationships revealed that 
HIV-2 (a second type of HIV), first identified in West Africa in 1986 (Clavel, 
1986), is closely related to simian immunodeficiency virus isolated from sooty 
mangabey monkeys (SIVsm), and established the origins of HIV-2 (Gao et al., 
1992). HIV-1 was then shown to have probably originated from the Pan 
troglodytes troglodytes species of chimpanzee carrying SIVcpz (Gao, 1999). 
Because chimpanzees are killed for food in parts of sub-Saharan Africa, this 
may have contributed to the species jump.
Since the first reported cases in 1981, up to the end of the year 2003, HIV is 
estimated to have been responsible for approximately 20 million deaths 
worldwide. Global estimates made at the end of 2004 (UNAIDS/WHO) 
revealed that around 39 million people are thought to be living with HIV/AIDS.
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A global summary of the epidemic showed that almost 65% of this figure was 
accounted for by infected individuals living in Sub-Saharan Africa, with a 
significant proportion of the burden also concentrated in South and South-East 
Asia. Infection continues to spread at an alarming rate, with almost 5 million 
new infections in 2004 alone. Intervention is clearly needed to control the 
spread of this pandemic.
1.2 H IV  virology
1.2.1 The basic structure of HIV-1
HIV-1 is an enveloped virus, approximately 110nm in diameter. Each virus 
particle carries two molecules of single-stranded (ss) linear positive-sense 
RNA, approximately 9.7kb in length (Figure 1.1).
The envelope is composed of a lipid bilayer, into which are inserted trimers of 
a virus-encoded glycoprotein (gp). Each glycoprotein spike is composed of 
three copies of an outer envelope glycoprotein, gp120, each linked to a 
transmembrane glycoprotein, gp41. Inside the membrane is the matrix protein, 
p17, within which is found the capsid, composed of p24. Within the capsid is 
the core. This is a conical electron-dense structure visible in electron 
micrograph pictures. Inside the core are packaged two copies of the viral 
genome associated with the nucleocapsid proteins p7 and p9 along with the 
viral enzymes Protease, reverse transcriptase (RT) and integrase.
The HIV genome contains nine genes, flanked by long terminal repeat (LTR) 
sequences. Like other retroviruses, HIV has the three major genes, gag, pot 
and env, which encode structural components and enzymatic proteins. In 
addition to this, several accessory and regulatory proteins are encoded by the 
genome.
1.2.2. HIV-1 heterogeneity
HIV-1 is a highly variable virus, and the degree of HIV-1 genetic diversity 
currently present in the population is far greater than anything that has been 
described in other human viral infections studied. The genetic diversity of HIV- 
1 is reviewed in (Gaschen et al., 2002; Lai et al., 2005; McCutchan, 2000; 
Peeters & Sharp, 2000; Peeters eta i ,  2003; Robertson eta i ,  2000).
In the phylogenetic tree of HIV-1 sequences, there are three branches which 
constitute the M (major), O (outlier) and N groups (non-M, non-O). The three 
groups are though to represent three independent chimpanzee-to-human 
transmission events.
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Figure 1.1. Schematic diagram of the HIV-1 virion. The HIV-1 virion is surrounded by a lipid envelope, into which 
spikes formed of trimers of the two major viral envelope proteins gp120 and gp41, are inserted. Beneath are the 
products of the gag gene: p24 forms the chief component of the inner shelf of the nucleocapsid, whereas the p17 
protein is associated with the inner surface of the lipid bilayer. The retroviral core contains two copies of the single­
stranded HIV-1 genomic RNA, which are associated with the nucleocapsid proteins p7 and p9 plus the viral enzymes 
reverse transcriptase, integrase, ribonuclease and protease.
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The group M viruses are by far the most widespread, being the variants of 
HIV-1 that are responsible for more than 99% of infections worldwide. Intra­
group diversification within the human population has led to the formation of 
distinct genetic subtypes which represent phylogenetically-associated clades 
of HIV-1 sequences. These are labelled A1, A2, B, C, D, F1, F2, G, H, J and 
K. The M group subtypes thus represent different lineages, which have some 
geographical associations. Subtype C is the most prevalent subtype globally, 
and is common in southern Africa and India. Subtype B is the most dominant 
subtype in the US and Europe.
Intersubtype recombination creates even more HIV-1 genetic diversity. This 
may occur when a cell is infected by different viral genomes. The M group 
therefore also contains a number of recombinant viruses, carrying sections of 
two or more subtypes in a mosaic genome. When an intersubtype 
recombinant virus spreads epidemically to establish distinct lineages it is 
classed as a circulating recombinant form (CRF).
Between clades, up to 30-40% sequence variability can occur, depending on 
the particular protein under consideration. Sequence variation does not occur 
evenly throughout the genome. gp120 and Tat are highly variable in 
comparison to the more conserved gp41 and Gag p24 proteins. Viral strains 
from the same clade can differ by as much as 5 to 25% in amino acid (aa) 
sequence (Walker & Korber, 2001), for example by up to 20% in their 
envelope proteins, but to a lesser extent in the Gag region.
Within an individual, there is further variety within the circulating viral species. 
During viral replication, the error-prone polymerase generates a genetically 
diverse quasispecies, a swarm of variants that arises in vivo. Replicating 
viruses can differ as much as 10% in sequence within a single individual 
(Kuiken etal., 1996; Shankarappa etal., 1999).
From the perspective of vaccine development, the enormous degree of 
genetic and hence antigenic diversity within HIV-1 represents a formidable 
challenge.
1.2.3 The HIV-1 life-cvcle
The first interaction between HIV-1 and host cells may be a fairly non-specific 
one mediated by interaction between the virion glycoprotein and 
glycosoaminoglycans (e.g. heparan sulphate) on the host cell surface. Virion 
attachment to host cells is mediated by binding of the viral envelope 
glycoprotein to CD4 (Dalgliesh e ta l,  1984; Klatzmann et al., 1984), a protein
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found on the surface of a limited number of cell types, including T-helper cells 
and macrophages (Figure 1.2). The HIV envelope then undergoes a 
conformational change that allows binding to a second cell surface molecule, 
a co-receptor. The majority of primary HIV-1 isolates use either the chemokine 
receptor CCR5 as the co-receptor or CXCR4 (the proportion of CXCR4- 
utilising viruses frequently increases in late-stage infection) (Alkhatib et al., 
1996; Deng et al., 1996; Schuitemaker et al., 1992). The gp41 component of 
the envelope then undergoes a second conformational shift that triggers fusion 
between the viral membrane and cellular membrane, mediating the entry of 
the virion contents into the target cell.
Immediately after HIV infects a cell, it uncoats so that the central core of the 
virion is released into the cell cytoplasm and subsequently disassembled to 
free the viral genome. The viral reverse transcriptase enzyme, transported 
with the viral genome, catalyses the synthesis of a linear, double-stranded (ds) 
cDNA using the viral genomic RNA as a template. The DNA copy of the viral 
RNA is transported to the nucleus as a preintegration complex (PIC), where it 
is integrated into host cell DNA by the viral integrase to form a provirus. RNA 
transcripts produced from the integrated provirus serve as both a source of 
mRNAs to direct the synthesis of viral proteins and later as RNA genomes for 
incorporation into new viral particles. The provirus is subject to regulation by 
cellular transcription factors as well as its own regulatory proteins. T cell 
activation induces activation of cellular transcription factors such as NF/cB, 
which bind to the viral LTR and initiate low level transcription of the provirus by 
the cellular RNA polymerase. The first transcripts are processed extensively, 
producing spliced mRNAs and allowing the translation of early proteins Tat 
and Rev using the host’s ribosomes. Tat acts to amplify transcription from the 
provirus. Increased levels of Rev allow for the increased transport of singly- 
spliced or unspliced viral RNAs to the cytoplasm. The unspliced and singly- 
spliced transcripts encode the late structural proteins. The gag and pol 
mRNAs are translated to give polyproteins, long polypeptide chains that are 
then cleaved by the viral Protease into individual functional proteins. The 
product of the envgene, gp160, has to be cleaved by a host cell protease into 
gp120 and 41, which are then assembled as trimers into the viral envelope. 
New virions are created by assembly of the unspliced transcripts which are to 
be the new viral genomes with the structural viral components. These are 
released from the cell by budding through the host cell plasma membrane and 
undergo subsequent maturation due to the actions of the viral protease.
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Figure 1.2. Life-cycle of HIV-1. After interaction of gp120 with the CD4 receptor and a chemokine receptor co-receptor, gp41- 
mediated membrane fusion occurs, and the virion contents enter the cell. After internalisation and uncoating, reverse 
transcription of viral RNA occurs. This leads to production of a double stranded DNA form of the viral genome. Integrase 
promotes the insertion of this viral DNA into the cell’s genome after the DNA has entered the nucleus, giving rise to the HIV-1 
provirus. The expression of HIV-1 genes is stimulated initially by the action of specific host transcription factors with binding 
sites in the LTR. Their binding leads to the sequential production of various viral mRNAs. The first mRNAs produced 
correspond to the multiply spliced species encoding Tat, Rev and Nef proteins. Subsequently the viral structural proteins are 
produced, allowing the assembly and morphogenesis of new virions. The new HIV-1 virions mature budding from the host cell 
membrane, and can then infect other target cells.
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Mature, infectious virions can then re-initiate the life-cycle by infecting other 
target cells.
1.2.4 The function of HIV-1-encoded proteins
The HIV genome encodes structural (Gag and Env), enzymatic (Pol), plus 
regulatory (Tat and Rev) proteins and several accessory (Vif, Vpr, Vpu and 
Nef) proteins (Figure 1.3). The functions of the HIV proteins are briefly 
reviewed in the following section.
• gp160
The viral glycoprotein gp160 forms part of the viral envelope, and is composed 
of an external gp120 subunit and a membrane-spanning gp41 subunit. These 
oligermerize to form trimeric structures on the surface of the virion, composed 
of six individual subunits, three gp120s and three gp41s. The envelope 
glycoprotein complex is involved with binding to receptors on target cells and 
mediating membrane fusion prior to entry into the host cell. The viral 
glycoprotein can also promote the fusion of infected cells with uninfected 
neighbouring cells in syncytium formation.
The gp120 and gp41 components of the envelope glycoprotein complex are 
synthesised as a single co-translationally glycosylated polyprotein precursor, 
gp160. Folding and assembly into oligomeric structures then occurs (Hunter & 
Swanstrom, 1990; Willey et al., 1988), which are transported out of the 
endoplasmic reticulum (ER) to the Golgi complex. In a late Golgi 
compartment, the precursor is cleaved to gp120 and gp41 by a cellular 
proteinase. The resulting subunits remain non-covalently associated following 
cleavage of the precursor, and are transported to the cell surface.
The interactions between gp160 and host cell receptors are complex and 
involve a series of conformational changes. Both the CD4 binding site and the 
conserved co-receptor binding site are partially masked by the hypervariable 
V1/V2 loop structure. Interaction between a gp120 trimer and a cluster of CD4 
molecules displaces the V1/V2 loop and the V3 loop, creating the co-receptor 
binding site (Bandres eta l., 1998; Hill et al., 1997; Sattentau & Moore, 1991; 
Sattentau et al., 1993; Thali et al., 1993; Trkola et al., 1996; Wu et al., 1996) 
and loosening the attachment of gp120 with gp41. gp120 makes contact with 
the co-receptor, bringing the virus and cell membranes into close proximity. 
Further conformational changes then take place involving gp41. gp41 contains 
a hydrophobic, glycine-rich ‘fusion’ peptide at the amino terminus that is
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Figure 1.3. Schematic diagram of the HIV-1 genome. The HIV genome contains 9 genes, flanked by LTR 
sequences. As for other retroviruses, the HIV-1 genome has gag, pol and env coding regions. Regulatory (Tat and 
Rev) and accessory proteins (Nef, Vif, Vpr and Vpu) are also encoded. The genome can be read in 3 frames and 
several of the viral genes overlap in different reading frames. This allows the virus to encode many proteins in a small 
genome. The mRNAs for Tat, Rev and Nef proteins are produced by the splicing of viral transcripts, so their genes 
are split in the viral genome.
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essential for membrane fusion. Upon binding of gp120 to receptors, gp41 
undergoes a conformational change from a nonfusogenic, to a trimeric coiled- 
coil and then a six-helix bundle fusion-active form, exposing the fusion 
peptide. The transition of gp41 drives membrane fusion through the bringing 
together of the viral and cell membranes in close enough proximity for the 
fusion protein to insert into the target cell membrane and fusion to take place 
(Chan et al., 1997; Weissenhorn et al., 1997). The fusion step of viral entry 
into host cells is targeted by the fusion inhibitor T20, which prevents the 
conformational change required for the fusion of viral and cellular membranes 
(Kilby et al., 1998). Other inhibitors of viral entry (which inhibit gp120 binding 
to CD4 receptors) have been more recently identified (Lin et al., 2003; Wang 
et al., 2003) which not only have potential as antiviral drugs, but are also 
useful as probes to gain further understanding of the HIV-1 envelope structure 
and viral entry process (Si et al., 2004).
• Gag
The assembly of HIV-1 virions is controlled by Gag, which recruits all of the 
components needed for formation of a fully infectious virus (reviewed in 
(Bukrinskaya, 2004)). That Gag drives virus assembly is evidenced by the 
formation of virus-like particles when Gag is expressed in the absence of other 
viral proteins (Gheysen et al., 1989).
Gag is a precursor (Gag p55) which is cleaved to give the internal structural 
proteins of the mature virion (Freed, 1998; Hunter, 1994; Wills & Craven 
1991). The viral enzymes are brought into the virion as components of the 
Gag-Pol polyprotein, produced by ribosomal frame shifting between the 
overlapping gag and pol genes.
Following its synthesis, the Gag precursor becomes co-translationally modified 
through myristylation, which increases its affinity for membranes (Bryant & 
Ratner, 1990; Gottlinger et al., 1989). Myristylated Gag precursor molecules 
associate with the inner plasma membrane, where they oligomerise. 
Eventually a spherical Gag protein shell is formed which protrudes from the 
cell surface, and a membrane fusion event releases the assembled particle. 
Budding of virus particles is thought to involve the interaction of Gag 
complexes with lipid rafts within the plasma membrane (Ono & Freed, 2001). 
The immature HIV-1 particles which are generated are non-infectious 
(Gottlinger etal., 1989; Kohl etal., 1988). Subsequently the Gag polyprotein is
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processed by the HIV Protease to create four functional mature products: p17, 
p24, p7 and p6.
The liberated p17 domain remains associated with the lipid envelope, while 
the p24 and p7 domains condense around the viral genome, giving rise to the 
characteristic conical core of the mature HIV-1 virion.
During assembly, p17 has well-established roles in the targeting of Gag to the 
plasma membrane (due to a hydrophobic myristic acid moiety at its N- 
terminus (Bryant & Ratner, 1990; Gottlinger et al., 1989) and the interaction of 
a cluster of basic residues at the N-proximal region with acidic phospholipids 
on the plasma membrane (Zhou et al., 1994)) and in the incorporation of the 
viral envelope glycoprotein spikes into nascent particles during virus assembly 
(Dorfman et al., 1994; Freed & Martin, 1995; Yu et al., 1992) (due to 
interaction between the cytoplasmic domain of gp41 and p17 (Cosson, 1996)). 
p17 may also have a role in the nuclear import of the HIV-1 pre-integration 
complex (Bukrinsky etal., 1993; von Schwedler etal., 1994). 
p24 has crucial roles in particle assembly and also in uncoating following entry 
of the virus particle into a new target cell. The N-terminal domain of p24 
interacts with cyclophilin A, which leads to the incorporation of this host protein 
into virions (Franke et al., 1994; Thali et al., 1994), where it may facilitate 
virion uncoating (Gamble et al., 1996). The C-terminal domain of p24 contains 
a stretch of 20 residues termed the major homology region (MHR) because it 
is conserved among unrelated retroviruses (Wills & Craven 1991). The 
conservation of this region supports for a crucial role of the MHR in virus 
replication; mutations in this region block virus assembly (Provitera et al., 
2001).
The p7 domain contains two zinc finger motifs (Bess et al., 1992) and two 
clusters of basic residues which are essential for the specific packaging of two 
copies of the genomic viral RNA into assembling particles (encapsidation) 
(Berkowitz etal., 1996).
A major function of p6 is to promote the detachment of assembled virions from 
the cell surface and/or from each other, as evidenced by defects in virus 
separation in HIV-1 particles lacking p6 (Gottlinger et al., 1991). Viral budding 
involves the binding of p6 to the host endosomal sorting protein Tsg101 
(Carter, 2002; Freed, 2003; Garrus etal., 2001).
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• Pol
The Pol gene encodes three enzymes: Protease, RT and integrase. The Pol 
gene products are initially synthesised as a part of a polyprotein Gag-Pol 
precursor, Pr160Ga9'Po1, and are liberated by autocatalysis of the precursor. 
Retroviral proteases are related to cellular aspartic proteases (reviewed in 
(Davies, 1990)), and their primary role is to mediate the production of mature, 
infectious virions. The initial cleavage event mediated by the HIV Protease 
occurs during or immediately after virion release from the cell, and liberates 
the Protease from the Gag-Pol precursor. Following its release, the enzyme 
cleaves a number of sites in both Gag and Gag-Pol, leading to conformational 
changes and a change in virion morphology (maturation), yielding the 
characteristic condensed cone-shaped core of the virus. The HIV-1 Protease 
is an important target for antiviral drugs, and inhibition of its function can lead 
to precipitous declines in viral load (see section 1.8.2).
RT catalyses the conversion of the ss RNA genome into ds DNA during the 
early stages of the infection (Baltimore, 1970; Temin & Mizutani, 1970). Three 
steps are involved in this process, all of which are involve RT:
(i) RNA-directed DNA polymerisation, for minus-strand DNA synthesis
(ii) RNaseH activity, for the degradation of the tRNA primer and 
genomic RNA present in DNA-RNA hybrid intermediates
(iii) DNA-directed DNA polymerisation, for second/plus-strand DNA 
synthesis
Retroviruses are referred to as psuedodiploid because the genome is 
packaged into the virion as two copies of ss RNA, but only one provirus is 
formed per virion (Hu & Temin, 1990). Reverse transcription is dependent 
upon the 3’-OH group of a primer to initiate polymerisation. Specific tRNAs are 
employed for this function; HIV-1 utilises tRNALys3. The high rate of variation 
among HIV populations is largely a consequence of the error-prone nature of 
RT as it lacks proofreading activity (Temin, 1993). Along with Protease, RT is 
also a target for antiviral drugs.
Following reverse transcription, a DNA copy of the viral genome is integrated 
into the host cell chromosome. This is catalysed by integrase, a 32kDa protein 
which is composed of three structurally and functionally distinct domains: an 
N-terminal, zinc finger-containing domain, a core domain and a C-terminal 
domain. It is the core domain which plays the central role in catalysis.
In the cytoplasm, integrase is involved with the generation of a pre-integration 
substrate from both strands of the linear viral DNA, giving 3’-recessed ends. In
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the nucleus, it catalyses the cleavage of the host DNA, so that the 3’-recessed 
ends of viral DNA can join to the 5’-overhanging termini of the cleaved cellular 
DNA. In conjunction with cellular repair machinery, integrase fills in the gaps, 
thereby completing the integration process (Brown et al., 1989; Fujiwara & 
Mizuuchi, 1988; Roth etal., 1989). The integrated viral DNA is known as the 
provirus, and subsequently serves as a template for the synthesis of viral 
RNA.
• Tat
Although host cellular factors can positively regulate transcription of HIV, the 
viral Tat protein, acting as a trans-activating factor, greatly enhances the rate 
of transcription (reviewed in (Strebel, 2003)). It binds to an RNA sequence 
immediately downstream of the initiation site for transcription in the viral LTR, 
the transactivation response region (TAR) (Dingwall et al., 1989; Weekes et 
al., 1990) and markedly increases the efficiency of viral gene expression by 
augmenting the processing ability of the RNA Pol II transcription complex and 
stimulating transcription elongation (Kao et al., 1987).
Tat permits activation of the RNA polymerase which, because of its intrinsic 
instability, disengages from the DNA template prematurely unless Tat is 
present in the cell. During transactivation, the RNA polymerase carboxyl 
terminal domain (CTD) is phosphorylated. Following clearance of the 
promoter, the phosphorylated polymerase is then able to transcribe through 
the TAR region, synthesising the TAR RNA stem-loop structure which creates 
a signal for Tat recruitment to the transcription complex. Tat also binds a 
kinase complex (Herrmann & Rice, 1995), which in the presence of Tat, 
becomes constitutively activated. This leads to hyper-phosphorylation of the 
CTD of the polymerase, making the transcription complex more processive, 
allowing for high levels of HIV transcription (Isel & Karn, 1999). Tat was also 
found to suppress RT activity during the late stages of viral replication and to 
increase viral infectivity, presumably by preventing the premature synthesis of 
DNA (Kameoka et al., 2001).
Apart from its role in activating the transcription of the HIV genome, Tat is 
associated with additional activities. Because Tat is able to exit HIV-infected 
cells, some of these effects may be caused by interaction of extracellular Tat 
with specific cell surface receptors that trigger the activation of signal 
transduction pathways, or by the uptake of Tat into uninfected bystander cells. 
Tat may influence cell death, since it was found to cause neurocytotoxicity in
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the central nervous system (Kim et al., 2003; Nath et al., 1996; Sabatier et al., 
1991) and apoptosis in cultured peripheral blood mononuclear cells (PBMCs) 
and CD4+ T cell lines (Li et al., 1995; Purvis et al., 1995; Westendorp et al., 
1995a; Westendorp et al., 1995b). On the other hand, Tat was found to 
upreguiate Bcl-2 in infected primary human macrophages, suggesting that in 
some cell types, Tat expression may contribute to cell survival (Zhang et al., 
2002b).
• Rev
Rev is a viral protein which regulates the expression and utilisation of viral 
transcripts through its role in RNA transport.
Eukaryotic cells have mechanisms to prevent export from the nucleus of 
incompletely spliced mRNA transcripts. This could present a problem for a 
virus which depends on export of unspliced, singly-spliced and multiply-spliced 
mRNAs in order to translate the full complement of viral proteins. However, 
Rev is able to promote the export of unspliced and partially spliced transcripts 
from the nucleus (Fischer et al., 1995; Wen et al., 1995).
The fully-spliced mRNA transcript encoding Rev is translated early in the 
infectious cycle. The expressed Rev protein then enters nucleus through an 
interaction of its nuclear localisation signal with the nuclear import factor 
importin /? (Truant & Cullen, 1999), and binds to a specific viral RNA sequence 
present in all unspliced and partially spliced mRNAs, the Rev response 
element (RRE). A nuclear export signal is subsequently exposed which 
mediates the interaction of Rev with nuclear export factors (Meyer et al., 
1996), principally a nucleocytoplasmic transport protein, Crm1, which engages 
a host pathway for exporting mRNA species into the cytoplasm (Fornerod et 
al., 1997; Fukuda etal., 1997; Neville et al., 1997). Other host factors involved 
in Rev-mediated nuclear export include the initiation factor elF-5A (Elfgang et 
al., 1999) and SAM68, a protein postulated to play a role in cell cycle control 
(L ief al., 2002).
Rev is also thought to influence the susceptibility of HIV-infected cells to 
cytotoxic T lymphocyte (CTL) killing and thereby assist with immune evasion. 
It was found that an attenuated rev allele and variations in Rev activity could 
downmodulate late gene product expression (namely that of gag), and alter 
the sensitivity of infected cells to anti-Gag CTL killing (Bobbitt et al., 2003). 
Although the mutation in Rev was introduced artificially, viruses derived from 
asymptomatic infected individuals also had lower Rev activity, lower Gag
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expression and greater resistance to anti-Gag CTL killing. Less active rev 
alleles may therefore be specifically selected by an active immune response 
because the infected cells harbouring them have a survival advantage in the 
face of a strong CTL response against late viral genes.
• Vpr
Vpr is packaged into virions through its interaction with the Gag p6 protein 
(Paxton et al., 1993). It is the only accessory protein present in significant 
quantities in virions, suggesting that it has important functions during the early 
phase of infection.
Vpr is thought to have effects on a number of host cellular events including 
cellular proliferation, differentiation and regulation of apoptosis (possibly via 
Vpr binding to a protein in the mitochondrial membrane causing mitochondrial 
membrane permeabilisation and apoptosis (Jacotot et al., 2001)). Vpr is 
thought to increase viral production in infected cells through arrest of the cell 
cycle in the G2/M phase (Poon et al., 1998; Rogel et al., 1995). The HIV LTR 
is more active in the G2 phase of the cell cycle (Goh et al., 1998). The 
influence of Vpr on cellular proliferation and cell cycle arrest may underlie the 
suppressive effects of Vpr on host antibody and CTL production (Ayyavoo et 
al., 2002).
Vpr has also been shown to downregulate cytokine and chemokine 
production, in part through affecting NF/cB functions (thereby suppressing host 
inflammatory responses) (Ayyavoo et al., 1997; Kino et al., 1999; Muthumani 
et al., 2004; Spiegel et al., 2000). A possible role for Vpr in immune evasion 
was recently described, where it was reported that Vpr was able to inhibit 
dendritic cell (DC) maturation and T cell activation by inhibiting the expression 
of co-stimulatory molecules and cytokines essential for immune activation 
(Majumder etal., 2005; Muthumani etal., 2005).
Although HIV does not require Vpr for infection of CD4+ T cells, the presence 
of Vpr is critical for infection in macrophages. One important specific role of 
Vpr is to facilitate the infection of non-dividing cells by transporting the pre­
integration complex into the nucleus (Connor et al., 1995; Hattori et al., 1990; 
Heinzinger et al., 1994).
Mutations in vpr and functionally defective Vpr have been associated with slow 
disease progression, but further evidence is required to support this 
correlation (Lunn etal., 2003; Somasundaran et al., 2002; Zhao et al., 2002).
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•  Vpu
The Vpu gene encodes a small integral membrane phosphoprotein with 
functions in the induction of proteolytic degradation of newly-synthesised CD4 
in the ER (Willey et al., 1992a), and enhancement of viral release from the 
plasma membrane of infected cells (Schubert et al., 1996). In the ER, Vpu 
binds to CD4 and targets it for proteolysis in the cytosolic ubiquitin-dependent 
proteasome pathway (Bour & Strebel, 2000). One consequence of Vpu- 
mediated CD4 proteolysis is to facilitate the transport and processing of the 
envelope glycoprotein gp160 (Willey et al., 1992b) which would otherwise be 
trapped in the ER because of its propensity to form stable complexes with 
CD4 (Buonocore & Rose, 1990).
Vpu has also been shown to decrease the surface expression of major 
histocompatibility complex (MHC) class I molecules by interfering with their 
synthesis, thereby hindering the presentation of HIV antigenic epitopes to HIV- 
specific CTL (Kerkau etal., 1997).
•  Vif
Vif is a gene which is common to all lentiviruses with the exception of equine 
infectious anaemia virus (Kawakami et al., 1987). It encodes a -2 2 0  amino 
acid cytoplasmic protein that is essential for virus infectivity (Sodroski et al., 
1986b; Strebel etal., 1987).
Vif may play an important role in viral disassembly after infection, the transport 
of the incoming viral PIC to the nucleus, and provirus formation (Borman etal., 
1995; Gabuzda etal., 1994; Gabuzda etal., 1992; von Schwedler etal., 1993; 
Zhang et al., 2000). Vif is also important for the stability of viral cores (Ohagen 
& Gabuzda, 2000) and for virus infectivity.
One described indirect role of Vif in enhancing viral infectivity is through its 
ability to degrade APOBEC3G (apolipoprotein B mRNA-editing enzyme 
catalytic polypeptide-like 3G), a cellular restriction factor. Cellular restriction 
factors render retroviruses non-infectious in some species. Vif is able to 
negate this activity of APOBEC3G (and APOBEC3F). APOBEC3G and 
APOBEC3F belong to family of cytodine deaminases with RNA-editing activity, 
involved with post-transcriptional alteration of cellular RNA in which specific 
nucleotides are catalytically changed. Such alterations may involve the 
deamination of target bases. APOBEC3G/F induces deamination of the viral 
cDNA as it is being synthesised, rendering it inactive. In studies using Avif HIV 
virions, APOBEC3G/F generates G-> A mutations in reverse transcripts
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(Bishop et al., 2004; Harris et al., 2003; Lecossier et al., 2003; Liddament et 
al., 2004; Mangeat et al., 2003; Mariani et al., 2003; Wiegand et al., 2004; 
Zhang et al., 2003b; Zheng et al., 2004). These result from the APOBEC- 
catalysed deamination of cytosines in the template minus strand, resulting in a 
C-^U change. A is subsequently synthesised on the plus strand opposite the 
U, resulting in G->A switches. The consequences of cytosine deamination for 
HIV replication are the degradation of most reverse transcripts prior to 
integration (Mariani et al., 2003) and introduction of stop codons into the open 
reading frames (ORFs) of the virus through G-> A mutations (Yu et al., 2004). 
APOBEC3G and APOBEC3F are encapsidated in Avif HIV virions, but are 
almost absent in wild-type virions (Kao et al., 2003; Mariani et al., 2003; Marin 
et al., 2003; Mehle et al., 2004; Sheehy et al., 2003; Stopak et al., 2003; 
Wiegand et al., 2004; Zheng et al., 2004), suggesting that Vif functions to 
prevent APOBEC3G and APOBEC3F encapsidation. APOBEC3G is excluded 
from virions by the actions of Vif, which induces ubiquitination and targets 
APOBEC3G for destruction in the proteasome (Yu et al., 2003).
• Nef
Nef is a myristoylated protein of 206 amino acids which is expressed early in 
the viral life cycle. Nef is an important virulence factor (reviewed in (Das & 
Jameel, 2005)). It has been found to stimulate viral growth in cell culture and 
in vivo, and to be important for achieving high levels of viraemia and for 
disease induction in rhesus monkeys (Kestler et al., 1991). That it plays a role 
in enhancing pathogenicity is shown by the presence in non-progressors of 
attenuated forms of HIV with deletions in regions of nef (Deacon et al., 1995; 
Kirchhoff etal., 1995).
Nef increases viral budding from lipid rafts, which augments viral infectivity, 
possibly by optimising the maturation process of the virion (Zheng et al.,
2001). Nef also has roles in the downregulation of CD4 (Garcia & Miller, 1991) 
and MHC class I molecules (Schwartz et al., 1996) on infected cells. Nef 
mediates the downregulation of CD4 by acting as a connector between the 
receptor and components of the cell protein trafficking machinery, triggering 
accelerated internalisation of molecules that have reached the cell surface, 
redirecting some CD4 from the trans-Golgi network to the endosomal 
compartment, and from the endosome to the lysosome (Aiken et al., 1994; 
Kim et al., 1999; Lu et al., 1998; Managasarian et al., 1997; Piguet et al., 
1998; Piguet et al., 1999; Rhee & Marsh, 1994). Downregulation of CD4 can
36
enhance HIV replication, for high levels of CD4 on the surface of HIV- 
producing cells inhibit the infectivity of released virions by trapping the viral 
envelope (Lama et al., 1999) and can block virion release from infected cells 
(Ross et al., 1999). The downmodulation of CD4 could also prevent potentially 
lethal superinfection events (Lama, 2003). Likewise, Nef can also mediate 
removal of MHC class I molecules from the surface of infected cells, helping to 
prevent CD8+ T cell recognition (Cohen et al., 1999; Collins et al., 1998; 
Greenberg et al., 1998; Le Gall et al., 1998; Piguet et al., 1998; Schwartz et 
al., 1996). Nef also mediates internalisation of CD28, a co-stimulatory 
molecule necessary for maximal T cell activation (Bell et al., 2001; Swigut et 
al., 2001). Lower surface levels of CD28 on infected T cells may result in such 
cells being unable to receive effective co-stimulation following T cell receptor 
(TCR) engagement, which may be a way for the virus to block T cell 
activation. Nef is also though to disrupt MHC class ll-restricted antigen 
presentation to CD4+ T cells by downregulating surface expression of MHC 
class II, thereby inhibiting virus-specific T cell help (Schindler et al., 2003; 
Stumptner-Cuvelette etal., 2001; Stumptner-Cuvelette et al., 2003).
Nef can also recruit several protein kinases involved in cell signalling and is 
therefore able to trigger intracellular activation pathways. By intersecting the 
CD40 signalling pathway in a Nef-dependent manner, HIV induces 
macrophages to produce and release chemokines which attract resting T cells 
and stimulate them so that they can support productive viral replication 
(Swingler etal., 2003). By interacting with signalling proteins acting in the TCR  
environment and with the TCR-^ chain, Nef is able to modulate T cell 
signalling and sensitise T cells to activation via their TCR (Schrager & Marsh, 
1999), rendering them more susceptible to efficient viral replication.
Nef is also able to induce upregulation of Fas ligand (FasL) on infected T cells 
(Xu etal., 1999). The upregulation of FasL expression results in Fas-mediated 
apoptosis of virus-specific CTL and bystander cells that come into contact with 
infected cells. In addition, HIV-infected cells themselves are protected from 
being killed through Fas ligation, as Nef mediates anti-apoptotic effects. Nef 
blocks the induction of apoptosis via both Fas and TNF (tumour necrosis 
factor) receptor-mediated death signals. These require activation of apoptosis 
signalling regulating kinase 1 (ASK-1), the activity of which is blocked by Nef 
(Geleziunas et al., 2001). Nef is also able to phosphorylate Bad, a pro- 
apoptotic molecule, resulting in a block in apoptosis (Wolf et al., 2001). HIV-1
37
infected cells are also protected from p53-mediated apoptosis due to the 
destabilisation of p53 upon interaction with Nef (Greenway et al., 2002).
In summary, Nef-mediated signalling is able to support viral replication and 
enable viral survival through a variety of different mechanisms.
1.3 The course o f HIV-1 infection
The course of HIV infection can be divided into three stages (Figure 1.4):
a) Primary infection, characterised by an acute burst of viral replication, 
accompanied by a transient drop in the drop in the number of circulating CD4 
T cells. The acute viral burst typically occurs after a 2-4 week incubation 
period, and in -70%  of individuals is symptomatic (symptoms typically 
including fever, rash, oral ulcers and lymphadenopathy) (Cooper et al., 1985; 
Kinloch-de Loes et al., 1993). Seroconversion usually takes place as the acute 
viral burst is contained.
b) An asymptomatic period, during which viral replication continues, 
accompanied by a gradual and progressive decline in the number of 
circulating CD4+ T cells and impairment in helper T cell (Th) function. The 
duration of this period varies and may be prolonged in some individuals.
c) The late phase, which is preceded by an increase in viral replication and a 
sharper drop in CD4+ T cell numbers. This stage is characterised by very low 
CD4 counts and an increased incidence of opportunistic infections and 
tumours associated with end-stage AIDS disease, culminating in death.
(a) Events during primary infection
HIV-1 infection generally occurs across a mucosal surface and/or following 
virus transmission into the blood. The main route of spread is by sexual 
contact; other important routes include exposure to contaminated blood and 
blood products and vertical spread from mother to child. Transmission is dose- 
related, with a direct relationship between the viral load in peripheral blood 
and frequency of transmission (Gray et al., 2001b; Quinn, 2000).
After the virus enters a host, a sequence of events leads to its dissemination 
around the body. The virus is infectious either as a free particle or in 
association with virus-infected cells. Once HIV crosses the mucosal barrier (in 
the case of sexual transmission), the virus makes initial interactions with host 
cells and local amplification of infection occurs. Dissemination to draining 
lymph nodes follows, and then the systemic dissemination of virus and 
infected cells, leading to an acute burst of viral replication, much of which is
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Figure 1.4. Diagram to illustrate the typical course of HIV-1 infection. HIV-1 infection can be divided into three phases. 
During the acute phase an acute burst of viral replication occurs, accompanied by a transient decline in the CD4+ T cell count, 
after which viral replication is contained to a setpoint level of persisting virus. The asymptomatic phase is a period of continued 
viral replication and gradual depletion of CD4+ T cells. In the late phase of infection there is an increase in the level of viral 
replication accompanied by a more dramatic drop in the CD4+ T cell count. This is associated with AIDS-defining illnesses which 
eventually result in death.
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thought to occur in memory CD4+ T cells in gut-associated and other lymphoid 
tissues (Li etal., 2005; Mattapallil etal., 2005).
After the virus is transported across the mucosal barrier, local propagation of 
the virus can occur through the infection of CD4+ T cells, macrophages, and 
possibly also DCs. Although DCs may constitute a cellular site of productive 
viral replication, DCs are thought to be more important in the initial capture of 
HIV in mucosal tissues, and the transport of virions into lymphoid tissues. A 
surface glycoprotein, DC-specific ICAM-3 grabbing non-integrin (DC-SIGN), 
expressed by DCs enables these cells to bind to HIV gp120, capturing HIV 
without infection occurring (Geijtenbeek et al., 2000). Virions bound to DC- 
SIGN can then be passed from DCs to CD4+ T cells with which they interact. 
Macrophages are also thought to be important in enhancing viral spread, 
owing to the actions of HIV Nef. Through mechanisms involving the CD40 
signalling pathway, macrophages release a paracrine factor that renders T 
cells permissive to infection (Swingler et al., 2003), thereby facilitating the 
infection of resting T cells and promoting viral spread.
The majority of viral amplification during acute infection has been found to 
occur in memory CD4+ T cells (both resting and activated). The extent of 
infection is significant, with 30-60% of memory CD4+ cells throughout body 
estimated to be infected by virus at the peak of SIV infection (Mattapallil et al., 
2005). It has recently become appreciated that, in accordance with the degree 
of infection, there is a tremendous loss of CD4+ T cells from lymphoid tissues 
(especially the gut-associated lymphoid tissue (GALT)) during primary 
infection (Li et al., 2005; Mattapallil et al., 2005). The loss of CD4+ cells could 
either be due to the direct killing of infected cells and/or may occur as an 
indirect consequence of viral replication (i.e. the bystander death of cells not 
infected with virus):
• virus-induced destruction
HIV replicates preferentially in memory CD4+ cells (at least 99% of circulating 
virus is produced by infected memory CD4+ T cells) which consequently die. 
The half life for infected, virus-producing CD4+ cells is thought to be less than 
one day (Markowitz et al., 2003). The death of HIV-infected cells can result 
from the tendency of infected lymphocytes to form short-lived syncytia or from 
increased susceptibility of cells to death. Specific HIV proteins may mediate 
these effects. For example, Env, by binding nascent CD4/coreceptor proteins
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in the ER, may disrupt membrane integrity through the exposure of envelope 
fusogenic domains (LaBonte etal., 2000; Lifson, 1986; Sodroski etal., 1986a). 
Vpr is able to activate caspases and induce host cell apoptosis 
(Somasundaran et al., 2002; Stewart et al., 1997). In addition, virus-infected 
cells may be destroyed by host immune effector mechanisms, for example as 
a result of the lytic activity of natural killer (NK) cells or virus-specific CD8+ 
CTL.
• Bystander death/immune activation
In addition to infected CD4+ T cells being destroyed as a consequence of 
infection, both infected and uninfected cells may potentially be destroyed in a 
bystander fashion as a consequence of the immune activation occurring 
during HIV infection. HIV induces a state of chronic immune activation due to 
the massive antigen stimulation by HIV plus antigen-independent stimulation 
by cytokines produced by activated antigen presenting cells (APCs) and T 
cells. Such immune activation can drive further virus replication through the 
generation of activated CD4 cells, which are good targets for virus replication. 
However, such chronic activation is associated with deleterious effects on the 
host, for example it may induce bystander apoptosis of enormous magnitude. 
This may occur non-specifically owing to the activated APC and cytokine-rich 
environment associated with immune activation and subsequent activation- 
induced cell death. In addition, viral proteins may contribute to bystander 
apoptosis. Nef upregulates FasL on infected cells (Geleziunas et al., 2001). 
Activated Fas-expressing CD4 cells and CTLs may undergo bystander 
apoptosis after interacting with FasL on infected CD4 T cells. Env has also 
been implicated in the initiation of Fas-mediated apoptosis in SIV infection (Li 
et al., 2005).
Evidence suggests that both mechanisms of CD4 cell depletion may be 
important in primary HIV infection. Direct viral infection was reported to 
account for the bulk of the CD4 cell depletion in one study (Mattapallil et al., 
2005), but another suggested that only a proportion of memory CD4 cell 
depletion could be accounted for by direct infection, and that extensive levels 
of indirect depletion could occur through Fas-mediated apoptosis (Li et al., 
2005).
In support of the latter study, it has been shown by in situ labelling of lymph 
nodes of HIV and SIV-infected subjects that apoptosis occurs predominantly in
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bystander cells and not in the productively infected cells themselves (Finkel et 
al., 1995).
The massive viraemia that occurs during primary infection is transient (Daar et 
al., 1991). The virus is then contained (in as little as 10 days). Part of the 
decrease in viraemia is probably due to the loss of susceptible target cells 
(Phillips, 1996). However, because the containment of the acute viral burst is 
concomitant with the induction of antiviral immune responses, the rapid and 
spontaneous decline in the large viral burden during the primary phase of 
infection suggests an effective immune response in the host (Clark et al., 
1991). However, immunological control is only partial; the virus is not 
completely cleared and, instead, a steady state of ongoing viral replication, 
associated with a ‘stable’ viral RNA load (termed the setpoint viral load) is 
reached and a chronic infection is established.
The clinical course of disease widely varies among different individuals 
(Haynes et al., 1996). The median time between the acquisition of HIV and 
development of AIDS is around 10 years. However, -10%  of HIV-infected 
individuals progress to AIDS within 2-3 years of seroconversion and are 
classified as rapid progressors. At the other end of the spectrum, 5-10% of 
HIV-infected individuals remain asymptomatic with stable CD4 counts for at 
least 10 years after seroconversion, and are classified as non-progressors.
The setpoint viral load established during primary infection is thought to be a 
prognostic indicator of subsequent disease progression (Lyles et al., 2000; 
Mellors et al., 1996): the higher the setpoint plasma RNA load, the faster the 
loss of CD4+ T cells and the shorter the duration of infection before death 
(Figure 1.5). This highlights the importance of events that take place during 
the early stages of infection. These early events are affected by multiple 
factors, including the virulence of the virus isolate, host genetic factors and 
host antiviral immune responses.
Less pathogenic viruses (such as those with attenuating nef mutations) are 
more readily controlled and are associated with non-progression (Deacon et 
al., 1995; Kestler et al., 1991; Kirchhoff et al., 1995), highlighting how the 
intrinsic pathogenicity of the virus can influence the disease course.
The genetics of the host can determine whether infection even occurs, and 
then if so, can influence the rate of disease progression. For example,
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Figure 1.5. The setpoint viral load established at ~six months post-infection is predictive of the subsequent 
disease course. The level of persisting virus established at -six moths post-infection (the setpoint viral load) has been 
shown to be a prognostic indicator, predicting the time to development of AIDS. Patients can be divided up into four 
different quartiles on the basis of their setpoint viral load; these are schematically represented in the diagram above. The 
viral load range of each quartile is given, along with the estimated survival time of patients falling into each of the four 
quartiles (data from Mellors etal., 1996).
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individuals homozygous for a deletion of 32 base pairs in the CCR5 gene 
(-1%  of white populations) are extremely resistant to HIV infection (Dean et 
al., 1996; Liu et al., 1996; Samson et al., 1996), and an association has been 
found between CCR5 genotype and disease progression rate (Balfe et al., 
1998). Many of the genes that influence the course of infection probably do so 
via affecting immune control of virus replication. For example, the human 
leucocyte antigen (HLA) type of the individual can influence the course of 
infection, as discussed later (Carrington & Bontrop, 2002; Carrington & 
O'Brien, 2003; O'Brien et al., 2001; Roger, 1998); HLA-B alleles are thought to 
have a particularly dominant influence (Kiepiela et al., 2004). The role of host 
antiviral immune responses in control of HIV replication is discussed in section 
1.6 .
(b) The asymptomatic stage of HIV infection
After the acute viral burst, HIV replication continues at a lower level, 
predominantly within activated CD4+ T cells. HIV preferentially infects and 
eliminates HIV-specific CD4 cells (Douek et al., 2002) (further compromising 
the virus-specific immune response), but there is also a general loss of 
activated CD4 cells which, as in the primary phase of infection, likely reflects a 
combination of death of infected cells and bystander cell destruction.
The continuing replication of HIV during the asymptomatic period is associated 
with the rapid turnover of CD4 cells. It is estimated that at least 1010 virions are 
produced each day, and that infected CD4 cells have a half-life of less than a 
day (Ho etal., 1995; Markowitz etal., 2003; Wei etal., 1995).
Much of the data on viral dynamics were calculated from studies of the effects 
of highly active antiretroviral therapy (HAART) on the viral load and CD4 count 
in treated patients. After initiation of HAART there is an initial rapid decline in 
viral load (due to antiviral effects on virus produced predominantly from 
activated CD4 cells), and then slower phases of decline reflecting different 
viral reservoirs which decay with differing kinetics. Follicular dendritic cells 
(FDCs) represent one such stable reservoir. FDCs harbour trapped stores of 
virus which remain infectious for long periods (Smith et al., 2001), facilitating 
the transmission of infection to cells migrating through lymphoid follicles 
(Embretson et al., 1993). HIV also maintains stable reservoirs by establishing 
latent infection in quiescent (G0) T cells. The activity of integrated viral 
genomes is influenced by the metabolic and activation state of the host cell, 
and so in such quiescent cells the HIV provirus is not transcribed and can
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persist in a latent form until their activation (Chun et al., 1997; Finzi et al., 
1997; Wong et al., 1997). It is the long-lived sources of virus represented by 
FDCs and latently infected cells which are particularly resistant to eradication 
by HAART and make it difficult to eliminate the virus. The big increase in CD4 
cell numbers in the periphery after HAART is thought to be due in part to 
redistribution of cells from lymphoid tissues to the blood (Bucy et al., 1999; 
Pakker et al., 1998). When APCs initiate the induction of immune responses 
within lymphoid organs, CD4+ T cells are stimulated and retained within them 
(whilst activated CD8+ T cells move into the circulation) (Bishop et al., 1990; 
Bujdoso et al., 1989). This leads to an apparent decrease in the proportion of 
CD4+ T cells in the peripheral circulation (Grossman etal., 1993; Rosenberg et 
al., 1993), which is redressed when viral loads and immune activation are 
reduced by HAART.
The peripheral CD4+ T cell pool can normally be replenished by production of 
new T cells from the thymus and by extrathymic proliferation of mature T cell 
subpopulations. Interleukin (IL)-7 has been shown to be able to stimulate 
proliferation of progenitor cells and mature T cell subpopulations and inhibit 
apoptosis to mediate T cell homeostasis (Schluns et al., 2000). IL-7 therefore 
stimulates increased T cell production both in the general setting of 
lymphopenia (Schluns et al., 2000) as well as in the context of HIV infection 
(Fry et al., 2001; Napolitano et al., 2001) (although IL-7 can actually 
exacerbate infection by driving the division of cells in which the virus can 
efficiently replicate and also by acting as a cofactor in transactivation of the 
viral LTR (Chene etal., 1999)).
However the attempts of such compensatory feedback mechanisms to 
replenish the peripheral CD4+ T cell pool by production of new T cells from the 
thymus (and by proliferation of mature T cell subpopulations) are frustrated by 
impairment of thymic function in HIV infection. Using the number of TCR  
excision circles (TRECs) as a measurement for T cell output by the thymus, a 
decrease in the thymic production of naive T cells was observed (Douek et al., 
1998). This may reflect two direct effects of the virus: the destruction of 
progenitor cells from which naive CD4 cells can be produced and disruption of 
the thymic microenvironment (the integrity of which is important for T cell 
maturation).
Therefore, although initially, homeostatic mechanisms act to stop CD4+ cell 
numbers falling, the production of naive CD4+ T cells does not keep pace with
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CD4+ T cell destruction over time, and CD4+ T cell numbers gradually 
decrease.
In summary, during the period of asymptomatic infection, a high level of 
ongoing viral replication continues. This causes a gradual depletion of CD4+ 
cells not only by direct infection and killing of cells, but also through indirect 
effects of viral replication on uninfected cells. Over time, the rate of CD4+ T 
cell destruction exceeds that of the ability to replace them due to impaired 
production of new T cells, and peripheral CD4+ numbers fall, eventually 
declining below the level required for normal immune function, leading to the 
end stage of AIDS disease (Douek, 2003; McCune, 2001).
(c) Late stage infection
When CD4+ T cell numbers decline below a critical level, immune responses 
that require effective T cell-mediated immunity for host defence are 
compromised. The profound immunosupression in AIDS patients therefore 
leads to increased susceptibility to a variety of opportunistic infections 
including those by Pneumocystis carinii and mycobacteria. AIDS patients are 
also susceptible to malignancies, such as Kaposi’s sarcoma, a cancer 
associated with infection with human herpes virus (HHV) -8. With the 
occurrence of tumours, opportunistic infections and/or wasting/central nervous 
system (CNS) disease in late stage infection, untreated HIV-1 infection is 
almost invariably fatal.
1.4 Overview o f antiviral immune responses
Infection of a host by a pathogen induces both an innate and an adaptive 
immune response. The innate response is the first line of defence 
encountered by a pathogen. It is mounted rapidly to deal with an infection, 
being activated in response to conserved microbial patterns which are 
characteristic of pathogens but not mammalian cells, rather than specific 
antigens. For example, dendritic cells and macrophages express pattern 
recognition receptors (PRRs) such as the toll-like receptors (TLRs) (Akira & 
Hemmi, 2003), and lectin-type receptors. Upon the detection of the presence 
of a foreign pathogen, intracellular signalling pathways are activated by the 
PRRs and a cascade of processes are initiated, resulting in the activation of 
transcription factors, and the induction of cytokines which mediate effector and 
immunomodulatory roles in the early stages of infection. Other cell types
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involved in the innate immune response include NK cells, NK-T cells & gamma 
delta (y6) T cells. The adaptive immune response, comprising a humoral, 
antibody-mediated response, and a T cell mediated response, is more slow to 
evolve, but targets infections in an antigen-specific manner. Further, the 
adaptive response possesses immune memory, which may confer long lasting 
protection and/or enable a more rapid secondary response to be mounted on 
re-encounter with the pathogen. The different arms of the immune system 
operate in a co-ordinate manner, with cells and soluble mediators of the innate 
and adaptive responses interacting to orchestrate an antiviral response that 
will deal with the pathogen efficiently, and either contain or eliminate it.
1.4.1 Innate immunity
1.4.1 (a) Type I interferons (IFNs)
The IFN-ar subtypes, IFN-/? and several other IFN species make up the family 
of type I interferons, cytokines that are rapidly produced in response to 
infection and which have important antiviral effector roles, in addition to key 
immunoregulatory functions (Muller et al., 1994). Type I IFNs can be 
synthesised by many cell types when they are infected. However, the major 
producer of type I IFNs in most infections is the plasmacytoid dendritic cell 
(PDC), a precursor to the type 2 DC (reviewed in (Santini et al., 2002; Tough, 
2004)). Such cells produce 200-1000 times more IFN than other blood cells 
after microbial challenge (Siegal et al., 1999). PDCs can be triggered to 
produce type I IFNs following recognition of viral components via TLRs (Akira 
& Hemmi, 2003). PDCs express particularly high levels of TLR-7, which 
recognises single stranded RNA (e.g. influenza virus and vesicular stomatitis 
virus (VSV) RNAs (Diebold et al., 2004; Lund et al., 2004)) and TLR-9, which 
recognises double stranded viral DNA (e.g. herpes simplex virus (HSV) -2 
DNA (Lund et al., 2003)). Glycoproteins on viral envelopes can be also be 
recognised (by lectin receptors) to induce IFN production (Ito, 1994). The 
requirement for type I IFNs for control of virus infections has been 
demonstrated using type I IFN-R deficient mice; these animals are unable to 
control infection even with a low dose of viruses such as lymphocytic 
choriomeningitis virus (LCMV) (Muller et al., 1994; van den Broek et al., 1995). 
The type I IFNs mediate their effects through binding to receptors that are 
broadly expressed on many cell types, and signalling the induction of many 
different genes. These may contribute to antiviral defence indirectly, for 
example IFNs increase MHC class I expression, and mediate activation of NK
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cells, or directly, by conferring resistance to viral replication on the responding 
cell. IFNs are also important in linking innate and adaptive immunity, since 
IFNs can promote the activation and differentiation of DCs to stimulate Th1 
responses and cross-prime CD8+ T cell responses (reviewed in (Santini et al.,
2002)).
1.4.1 (b) Dendritic cells
DCs are resident in most tissues throughout the body, and play a prominent 
role in pathogen surveillance and the orchestration of both innate and adaptive 
immune responses.
DCs were initially identified as potent APCs, specialised in capture of antigens 
at sites of infection, migration to secondary lymphoid organs and T cell 
priming, having the unique ability to mediate the activation of naive antigen- 
specific T cells (reviewed in (Bancherau & Steinmann, 1998; Banchereau et 
al., 2000)). However it is now recognised that they have a central 
immunoregulatory role in the adaptive response, being involved in the 
maintenance of peripheral tolerance in addition to the triggering of antigen- 
specific T cell responses (Steinman et al., 2003), and functioning not only to 
initiate adaptive responses, but also to direct the nature of the response (e.g. 
type 1 or type 2-biased) that is induced (Kapsenberg, 2003). Further, they 
have been shown to serve both an effector role (via production of cytokines 
such as type I IFNs) and a regulatory role (e.g. modulating NK cell activity 
(Andrews et al., 2003; Ferlazzo et al., 2002; Gerosa et al., 2002)) in the innate 
response.
These diverse functions are performed by heterogeneous DC subpopulations; 
for example in human peripheral blood, CD123+ PDCs (which as discussed 
above, act as a potent source of type I IFN production) and CD11c+ CD123 dim 
myeloid DCs (MDCs) are two of the principal DC subsets. The functional 
properties of DC subsets are determined in part by their developmental 
lineage and in part by the maturation and activation signals they receive -  
hence DCs act as a medium via which signals from the local environment can 
be translated into initiation of an appropriate type of immune response 
(Shortman & Liu, 2002). DCs are highly responsive to stimuli such as 
microbial infection, inflammation and tissue damage (Reis e Sousa, 2001); 
and their maturation is further driven by interaction with T cells. As discussed 
below, one of the ways in which CD4+ T cells provide help for the induction of
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CD8+ T cell responses is via DC activation (Bennet et al., 1998; Ridge et al., 
1998; Schoenberger etal., 1998).
1.4.1 (c) NK cells
NK cells are non T cell lymphocytes (CD3 ) which make up -15%  of the 
lymphocyte pool and typically express the marker CD56 in humans (Cooper et 
al., 2001). Two functionally and developmental^ distinct NK cell subsets can 
be distinguished on the basis of their cell surface density of CD56 expression. 
-90%  of NK cells fall into the CD56dim subset. These cells are more cytotoxic 
and express higher levels of FCyRIII/CD16 than the CD56bright subset (Cooper 
et al., 2001). Consequently they can ligate antibody-coated targets more 
efficiently and mediate greater levels of antibody-dependent cell-mediated 
cytotoxicity (ADCC). CD56bnght NK cells are hypothesised to have a more 
immunoregulatory role.
NK cells play an important role in innate defence as they can lyse infected 
cells (via perforin-mediated effects) and provide an early source of effector 
and immunoregulatory cytokines. Cytokines and chemokines produced by NK 
cells include IFN-y, TNF-ar, IL-10, IL-13, macrophage inflammatory protein 
(MIP) 1 a, MIP1/? and granulocyte-macrophage colony-stimulating factor (GM- 
CSF) (Fehniger et al., 1999) (Aste-Amezaga et al., 1994) (Colucci et al., 
2003). NK cell activity is enhanced by innate cytokines such as IL-12, IL-18 
and type I IFNs (Biron & Brossay, 2001). Their effector functions are controlled 
by the balance of signals received via surface receptors which fall into two 
types: activatory receptors and inhibitory receptors (Leibson, 1997) (Lanier, 
2001). Activatory receptors (such as NKG2D) associate with adaptor 
molecules which bear activating motifs associated with signalling pathways 
which function in NK cell activation. By contrast, inhibitory receptors (which 
include the killer cell immunoglobulin-like receptor (KIR) family and the CD94- 
NKG2A heterodimers) have inhibitory motifs in their cytoplasmic domain which 
prevent NK cell functions. The importance of NK cell function in some viral 
infections is unclear (e.g. LCMV, (Welsh, 1996)); but is known to be 
particularly important in control of primary herpersvirus infections (Biron et al., 
1989; Biron etal., 1999; Bukowski etal., 1985).
1.4.1 (d) NK-T cells and y6 T cells
NK-T cells and yS T cells are minor lymphocyte subsets which express only a 
limited diversity of receptors. Both behave as intermediates between innate
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and adaptive immunity. Like NK cells, NK-T cells and yS T  cells perform anti­
viral functions by direct lysis of infected cells, or through the production of 
cytokines and chemokines that interfere with viral transmission and/or 
replication or that activate other effector cells (Lang et al., 1995).
NK-T cells have phenotypic properties of both NK cells and T cells, expressing 
both NK cell markers and T cell receptor molecules. Unlike T cells, NK-T cells 
have a restricted T cell receptor repertoire, and are stimulated as a result of 
presentation of a non-peptide antigen (or-GalCer) by the non classical-MHC 
class l-like molecule CD1d. In humans, NK-T cells have an invariant or chain 
(Vor24) and most express V/?11. They play an important regulatory role in a 
number of immune responses. Like NK cells, NK-T cells can also recognise 
targets deficient in expression of MHC class I molecules (Poccia etal., 2001). 
y6 T cells are a subset of T cells that express CD3 and y6 rather than a/3 
TCRs. They also recognise non-peptidic antigens without MHC restriction. The 
repertoire of yS T cell receptors is relatively limited; at least some yS T cells 
can be activated in vitro with nonpeptidic phosphorylated molecules of 
mycobacterial origin, to induce cytotoxicity and TNF production (Lang et al., 
1995). Although y6 T cells constitute a minor population of T cells in lymphoid 
tissues, a high proportion of T cells in epithelial tissues express yd receptors.
1.4.1 (e) The complement system
The complement system comprises a series of interacting complement 
proteins which are sequentially activated from an inactive to an active form in 
an enzyme-driven amplification cascade. The activation of complement can 
occur by way of three pathways:
i) The classical activation pathway which involves the binding of the 
complement protein C1q to antigen-antibody complexes or directly to virions.
ii) The mannan-binding lectin (MBL) pathway, where MBL binds to 
oligosaccharides on pathogen surfaces.
(iii) The alternative pathway, which involves deposition of the complement 
factor C3b on the surface of host cells or pathogens.
Activation of any of these pathways results in cleavage and activation of C3, 
followed by cleavage of C5 and further downstream events which culminate in 
the formation of membrane attack complexes (MAC). Assembly of the 
membrane attack complex on the surface of an infected cell or lipid-enveloped 
virus generates a pore in the lipid bilayer membrane which disturbs the
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osmotic potential, and results in the eventual destruction of the cell or 
pathogen.
The potentially destructive effects of uncontrolled complement activation are 
avoided by the activity of complement-regulators (e.g. CD46, CD55 and 
CD59) which act to modulate the complement activation cascade by 
dissociating complexes or catalyzing the enzymatic degradation of covalently 
bound complement proteins.
Complement activation does not contribute to control of viral infections only by 
way of MAC-mediated destruction of infected cells or enveloped viruses. 
Opsonisation of virions and infected cells by the deposition of C3b and 
subsequent uptake by complement receptor (CR) bearing cells may lead to 
phagocytic removal of the pathogen. The production of various activated 
complement proteins can also result in recruitment of antibody, complement 
and leucocytes to the site of infection. Furthermore, interaction of complement 
components with virion surfaces in itself has been reported to inhibit the 
infectivity of certain viruses (e.g. C1q and human T cell lymphotrophic virus 
type 1 (HTLV-I) or MBL and influenza A).
1.4.2 The adaptive immune response
Each arm of the adaptive immune response has an important role in 
controlling viral infections, but the relative contributions of each may vary 
according to the infection. This can be revealed by depletion and adoptive 
transfer studies in mice, or inferred in human infections by study of patients
with selective immunodeficiencies. For example, patients with
hypogammaglobulinaemia (a defect in antibody production), have an 
increased risk of infection with enteroviruses, highlighting the importance of 
antibody-mediated immunity during infection with these viruses (Sanna & 
Burton, 2000). By contrast, people with T cell deficiencies are prone to 
infection with cytomegalovirus (CMV), HSV, varicella zoster virus (VZV) and 
measles virus (MV) indicating that T cell-mediated immunity is critical to 
containing infection with these viruses (Borrow & Oldstone, 1994). Although 
particular arms of the adaptive immune response may play a more dominant 
role in control of different virus infections, the synergistic interaction between 
different components of the adaptive immune response is often key to an
effective immune response (Doherty et al., 2001; Marten et al., 2001;
Thomsen et al., 2000).
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1.4.2 (a) Humoral immunity
When triggered by cognate antigen, B cells (in the presence of T cell helper 
activity) are activated and differentiate into plasma cells which secrete 
antibodies that can act in various ways to combat extracellular pathogens and 
may also target infected cells. Although cell-mediated immunity is typically 
more important in elimination of established virus infections, humoral immunity 
can play an important role by limiting the spread of infection and thereby 
contributing to containment of viral replication (reviewed in (Casadevall & 
Pirofski, 2003)). In addition, pre-existing antibodies play an important role in 
preventing re-infection on secondary exposure to a particular pathogen. 
Neutralising antibodies can bind directly to viruses and may limit their 
infectivity by interfering with their interaction with host cell receptors or 
blocking infection at post-entry steps, and thus prevent viruses from 
establishing primary infection. Antibodies can also interact with components of 
the innate immune response to aid destruction of pathogens. Antibodies can 
bind to pathogens and opsonise them for recognition by cells which express 
Fc receptors that are able to bind to the constant region of the antibody, for 
example phagocytic cells or NK cells (the latter promoting killing by ADCC). 
Alternatively, antibodies binding to the surface of a pathogen can activate 
complement via the classical pathway. Complement-coated pathogens can 
then be bound by CR-bearing phagocytic cells or destroyed by the terminal 
MAC complex assembled upon activation of complement.
1.4.2 (b) Cell-mediated immunity
The activities of virus-specific CD4+ and CD8+ T cells make up the antiviral 
cell-mediated immune response. CD4+ T cells predominantly provide helper 
functions, not only for virus-specific CD8+ T cell responses, but also for 
antibody responses. CD8+ T cells on the other hand are the cell type which is 
mainly responsible for the direct cytotoxic and other antiviral activities of the 
cell-mediated immune response.
• The CD4+ T cell response
CD4 T cells are activated upon recognition of peptides presented by MHC 
class II molecules on antigen presenting cells. Peptide antigens 10-12 amino 
acids in length are generated from extracellular antigens taken up by 
endocytosis. The acidification of endocytic vesicles activates proteases which 
degrade the antigens into peptide fragments. MHC class II molecules are
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synthesised in the ER, and their peptide binding groove occupied by the 
invariant chain to prevent peptide binding. The invariant chain directs newly 
synthesised MHC class II molecules to vesicles which fuse with endocytic 
vesicles containing peptide fragments. The invariant chain is released to allow 
peptides to bind, a process assisted by HLA-DM, and MHC class II: peptide 
complexes are assembled and transported to the cell surface for recognition 
by CD4+ T cells.
Via the provision of cytokines and via cell-cell contact mediated mechanisms, 
CD4+ T cells play an important role in orchestrating both the antibody 
response and the CD8+ T cell response to an invading pathogen. CD4+ T cells 
provide important activation and co-stimulatory signals to B cells for the 
production of antibodies, and also for isotype class switching. CD4+ T cell- 
deficient mice are unable to generate strong neutralising antibody (nAb) 
responses. CD4+ cells also have important roles in the priming of CD8 
responses (Ridge et al., 1998), maintenance of CD8+ T cell memory (Battegay 
et al., 1994) and maturation of CD8+ T cell function (Zajac et al., 1998).
The requirement for CD4 help during the induction of a CD8 response is 
controversial and seems dependent on the nature of the antigen. While earlier 
studies focused on the secretion of cytokines such as IL-2 as being the key 
role played by CD4+ cells in activation of CD8+ T cells (Keene & Forman, 
1982), later studies focused on the role of CD4+ T cells in APC activation 
(which in turn facilitates the induction of antigen-specific CD8 responses). 
CD4+ cells provide co-stimulatory signals for the activation of APCs via 
CD40L-CD40 signalling (Bennett et al., 1998; Ridge et al., 1998; 
Schoenberger et al., 1998) (and possibly other membrane-membrane receptor 
ligand interactions such as TNF-related activation induced cytokine (TRANCE) 
and TRANCE receptor (Bachmann et al., 1999)), resulting in effective priming 
of a CD8 response. During some virus infections, sufficient levels of APC 
activation are induced by the virus and/or associated innate immune response 
to obviate the requirement for CD4 help (for example during LCMV infection of 
mice (Christensen et al., 1994; Leist et al., 1987; Moskophidis et al., 1987a)). 
A number of studies have however provided evidence for a more critical 
requirement for CD4 help in memory cell generation. In murine infection 
models, depletion of CD4 cells during the priming phase was found not to 
have a major effect on the primary response mounted, but resulted in impaired 
responses by memory cells to reinfection (Janssen et al., 2003; Shedlock & 
Shen, 2003; Sun & Bevan, 2003).
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The importance of CD4-CD8 cell collaboration in controlling persistent viral 
infections is highlighted by experiments carried out in CD4 deficient mice 
infected with LCMV. In the absence of CD4 help, infection with a high dose of 
virus or rapidly replicating or disseminating strains of LCMV led to loss of 
virus-specific CTLs and establishment of viral persistence (Battegay et al., 
1994; Matloubian et al., 1994). Furthermore, in a model of chronic LCMV 
infection it was revealed the CD8 response may be impaired in the absence of 
helper function by either the deletion of CTL, or the functional silencing of CTL 
(Zajac etal., 1998).
•  The CD8+ T cell response
CD8+ T cells recognise peptide antigens on the surface of APCs bound to 
MHC class I molecules. Peptide fragments 8-10 amino acids in length with 
appropriate termini for binding to MHC class I molecules are generated by 
degradation of cytosolic proteins by the proteasome, a large mutlicatalytic 
protease complex. The peptides are transported into the endoplasmic 
reticulum by the transporter associated with antigen processing (TAP) and are 
assembled together with newly-synthesised a  chain:/?2microglobulin (/?2m) 
complexes to form MHC-peptide complexes which are transported to the cell 
surface via the Golgi apparatus for presentation to CD8+ T cells. In addition to 
endogenously processed peptides, dendritic cells are able to present 
exogenously acquired peptides (cross-presentation).
In response to signalling through the T cell receptor, CD8 cells are triggered to 
undergo clonal expansion and differentiation into functional effector cells, CTL 
which can lyse infected cells. CTL can induce apoptosis of target cells using 
two distinct mechanisms: a calcium-dependent granule exocytosis pathway 
involving the release of perforin and granzymes from preformed cytolytic 
granules; and a calcium-independent pathway involving the ligation of death 
receptors on susceptible cell types by death-inducing ligands such as Fas L 
and TNF (reviewed in (Barry & Bleackley, 2002; Catalfamo & Henkart, 2003; 
Thorburn, 2004)). Virus-specific CD8+ T cells can also produce soluble factors 
which mediate anti-viral effects, such as IFN-yand TNF-a.
By virtue of their functions, CD8+ T cells play a key role in the immune 
response to many pathogens (reviewed in (Harty et al., 2000; Wong & Pamer,
2003)). For example, CD8+ T cells are essential for virus clearance in acute 
LCMV infection (Fung-Leung et al., 1991; Gegin & Lehmann-Grube, 1992), 
and chronic infections such as Epstein Barr virus (EBV), CMV and HTLV-1 are
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perpetually held in check by CD8 T cells (Bieganowska et al., 1999; Moss & 
Khan, 2004; Rickinson & Moss, 1997). The relative importance of ‘curative’ 
and lytic mechanisms of CD8+ T cell control of viral infection may be 
dependent on the virus, the stage of infection and host cell type (Guidotti & 
Chisari, 2001). For example, it has been shown using perforin-deficient mice 
that in acute LCMV infection perforin-mediated destruction of infected cells is 
critical for viral clearance (Kagi et al., 1994; Walsh et al., 1994). However, in 
an infection such as hepatitis B, viral clearance may involve non-cytopathic 
cytokine-dependent ‘curative’ processes. Using a transgenic mouse model of 
hepatitis B virus (HBV) infection, it was shown that CTLs producing IFN-y and 
TNF-or were able to inhibit viral gene expression and replication without killing 
the hepatocyte (Guidotti et al., 1996; Guidotti et al., 1994).
1.4.3 Utility of murine virus infection models for elucidation of mechanisms 
involved in antiviral immunity
Murine virus infection models can provide several advantages in the 
elucidation of general concepts in immunity and antiviral defence. The 
possibility of studying infection with well-defined viruses within inbred hosts, 
sampling multiple timepoints and/or tissues, their amenity to experimental 
manipulation and the availability of reagents such as transgenic and knockout 
mice can prove to be invaluable for such purposes. Two of the murine virus 
infection models that have been most extensively utilised in the field of viral 
immunology are the LCMV and influenza virus infection models.
LCMV is an arenavirus which is a natural pathogen of mice. The outcome of 
infection with LCMV is dependent on both viral (e.g. virus isolate, dose and 
route of administration) and host factors (age, genetic background and 
immunocompetence) (reviewed in (Borrow and Oldstone, 1997)). Infection of 
adult immunocompetent mice by the intraperitoneal or intravenous route with 
moderate doses of most LCMV isolates results in an acute infection which is 
cleared within 7-10 days. CD8+ T cells play a key role in mediating virus 
clearance (Fung-Leung et al., 1991; Moskophidis et al., 1987; Murali-Krishna 
et al., 1998) although optimal control of virus replication also requires input 
from other arms of the immune response (Klenerman, 2004). This infection 
system therefore provides a good model for studying mechanisms involved in 
acute control of systemic virus infection.
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By contrast, infection of mice in utero or neonatally, or infection as adults with 
high doses of certain LCMV isolates results in the establishment of persistent 
infection. This provides a good model for studying mechanisms underlying the 
failure of immune control of virus infection and defining therapeutic 
approaches for combating viral infections.
Influenza viruses belong to the Orthomyxoviridae family of viruses. A number 
of genera exist. Influenza viruses can naturally occur in many species, but 
mice can be experimentally infected with influenza A or B viruses to study 
aspects of pathogenesis and immune responses to the virus. Productive 
infection and high titre viral replication is limited to the respiratory tract (Rott et 
al., 1995; Walker et al., 1992). Respiratory infection of H2b mice causes an 
acute pneumonia, with the virus being cleared by day 10 after infection (Allan 
et al., 1990). This model thus allows for the study of a localized, transient 
infection (Turner et al., 2004; Woodland and Randall, 2004).
Mice that have been infected with a particular strain of influenza are 
substantially protected for life, providing a good system for studying memory 
immune responses (Woodland et al., 2001) and cross-protection against 
infection by different viral subtypes (Tamura et al., 2005). Although 
neutralising antibody responses are critical for protection from influenza virus 
infection (Gerhard, 2001), various components of the immune response act 
together to provide optimal protection (Doherty et al., 1997; Woodland et al., 
2001).
The value of using the LCMV and influenza virus infection models is 
evidenced by the many important concepts which have been defined using 
these models. These include the demonstration of MHC restriction of CD8+ T 
cell responses (using the LCMV model (Zinkernagel and Doherty, 1974a; 
Zinkernagel and Doherty, 1974b)); the roles of different arms of the immune 
response in protection and prevention of re-infection (both LCMV (Khanolkar 
et al., 2002; Klenerman, 2004) and influenza (Tamura and Kurata, 2004)); the 
concept that antiviral immunity can contribute to disease pathogenesis (as in 
the case of meningitis associated with LCMV infection (McGavern et al., 2002) 
and pneumonia caused by influenza virus infection (Tsurita et al., 2001)); 
definition of mechanisms involved in the induction of immune responses to 
infections acquired by a mucosal route (influenza (Brandtzaeg, 2003; Tamura 
and Kurata, 2004)); and characterisation of the mechanisms contributing to
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viral persistence (LCMV) such as neonatal tolerance (Pircher et al., 1989), 
CTL exhaustion (Moskophidis et al., 1993) and CTL escape (Pircher et al., 
1990).
In this thesis I also made use of the well characterised LCMV and influenza 
virus murine infection models to address the effects of limited CD4+ T cell help 
at the time of immune priming on the antiviral CD8+ T cell responses induced 
under such conditions. More specifically, I explored whether a lack of CD4 
help results in biasing of the response to epitopes (with their resultant 
immunodominance) that are targeted by CD8+ T cells with less stringent 
activation requirements, e.g. high affinity epitopes or epitopes that are able to 
be cross-recognised by memory T cells.
1.5 Viral immune evasion strategies
Viruses have evolved the means to co-exist in their human hosts by employing 
various strategies to evade elimination by host immune responses. Various 
viral-encoded factors mediating immune evasion may play a role in virulence, 
as evidenced by the attenuation of viruses carrying targeted mutations of such 
factors (Fleming et al., 1999; Saederup et al., 1999; Tortorella et al., 2000). 
The large genome of certain DNA viruses, such as pox viruses and herpes 
viruses, allows them to devote a large number of genes to immune defence; 
many are viral homologues of host genes (Alcami & Koszinowski, 2000). RNA 
viruses, which typically have a more limited genome size are not as able 
devote individual genes to host control, and therefore proteins encoded by 
RNA viruses are multifunctional, and they frequently employ rapid replication 
and mutation as means to evade immune control (Lucas et al., 2001).
The mechanisms used by viruses to subvert the host immune response can 
be broadly divided up into three categories: those that allow viruses to avoid 
recognition by the antiviral immune response, those that impair the response, 
and those that confer resistance to immune effector mechanisms. Each of 
these are reviewed in the following section, with those specific immune 
evasion strategies used by HIV-1 discussed in section 1.7.
1.5.1 Strategies to avoid recognition by the antiviral immune response
(a) Latency
Some viruses avoid the host immune response by downregulating the 
expression of viral gene products during certain phases of the replication cycle
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in a state which is known as latency. With minimal expression of viral proteins 
and therefore few virus-derived peptides available for presentation on the cell 
surface, virus-infected cells are essentially invisible to immune surveillance. 
Such latent infections can be reactivated periodically, leading to recurrent 
illness. This is a period in which the virus undergoes productive replication and 
infection to allow transmission to new hosts. Examples of viruses which can 
enter latency are HSV (latent in sensory neurons), VZV (latent in dorsal root 
ganglia) and EBV (latent in B cells). Primary infection with EBV is controlled by 
virus-specific CD8+ T cells (reviewed in (Rickinson & Moss, 1997)). However 
EBV remains quiescent in a fraction of B cells. These latently infected cells 
express few viral proteins. One protein which is needed to maintain the viral 
genome, Epstein Barr virus nuclear antigen (EBNA) -1, is expressed but for 
reasons explained later EBNA-1 is unable to elicit a T cell response.
(b) Infection of immune privileged sites
By infecting areas with little immune surveillance, viruses are able to hide from 
the immune system. Such areas include the CNS, the kidney, salivary glands 
and the anterior chamber of the eye. Viruses which can infect the CNS (such 
as the JC polyoma virus, varicella zoster virus and measles virus) are 
protected by the blood brain barrier, which limits trafficking of immune cells, 
low levels of MHC expression on cells of the CNS, and a generally 
immunosuppressive environment.
(c) Interference with MHC class I antigen presentation
Virus-derived peptides must be presented on the cell surface in the context of 
MHC class I in order to be recognised by antigen specific CD8+ T cells. 
Antigen presentation can be prevented at several different stages to enable 
the virus to escape recognition by the CD8 response. The generation of 
peptide, transport of the antigenic peptide into the ER via TAP and surface 
expression of MHC class l-bound peptide are all subject to interference by 
viruses.
That inefficient antigen processing results in failure of CD8 recognition is 
evidenced by the EBNA-1 protein of EBV. The failure of EBNA-1-specific CTL 
to be activated is attributed to the resistance of EBNA-1 to proteolysis due to a 
long stretch of gly-ala repeats in its sequence (Levitskaya et al., 1995). This 
sequence is not included in EBNA -2, -3 and -4, which are degraded,
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presented and do stimulate CTL responses (Khanna et al., 1992; Murray et 
al., 1990).
Certain viral gene products (for example HSV ICP47 (Fruh et al., 1995; Hill et 
al., 1995; York et al., 1994) and human cytomegalovirus (HCMV) US6 (Ahn et 
al., 1997; Hengel et al., 1996; Hengel et al., 1997; Lehner et al., 1997)) are 
able to inhibit peptide transport from the cytosol into the ER where MHC class 
l-peptide complexes are assembled by interfering with TAP function, e.g. 
HCMV US6 prevents peptide transport possibly by occluding the exit pore of 
the TAP complex. Consequently, peptide loading of class I molecules is 
unable to occur.
Various mechanisms are used by different viruses to target the maturation, 
assembly and export of MHC class I molecules. HCMV gpUS2 and gpUS11 
mediate the downregulation of MHC class I molecules on the cell surface by 
selectively targeting class I heavy chains for degradation by the proteasome 
(Wiertz et al., 1996a; Wiertz et al., 1996b), whereas the product of gpUS3 
retains class I molecules in the ER (Ahn et al., 1996; Jones et al., 1996), as 
does the E3/19K product of adenovirus (Cox et al., 1991). Murine 
cytomegalovirus (MCMV) m152, through a retention signal, retains class I 
molecules within the ER-Golgi intermediate compartment, preventing surface 
expression (Ziegler et al., 1997).
Kaposi’s sarcoma-related herpes virus/HHV type-8 (KSHV/HHV-8) K3 and K5 
proteins enhance the endocytosis of MHC class I from the cell surface, 
although with varying degrees of specificity for different HLA alleles (Coscoy & 
Ganem, 2000; Ishido et al., 2000). K3 mediates enhanced internalisation of 
HLA-A, -B, -C and -E whereas K5 is implicated in rapid endocytosis of HLA-A 
and -B, and a lesser amount of endocytosis of HLA-C. The MCMV m06 gene 
product binds MHC class I molecules and targets them to the lysososme for 
degradation (Reusch etal., 1999).
(d) Avoiding recognition by NK cells
The downregulation of MHC class I on the cell surface, used as a mechanism 
to avoid CD8+ T cell recognition, is associated with the increased susceptibility 
of such cells to attack by NK cells since certain MHC molecules act as ligands 
for inhibitory receptors on NK cells.
This may be avoided by allele-specific MHC class I downregulation. HLA-A, -B 
and -C locus products function primarily in presentation of peptide to CTL, 
whereas HLA -E and -G locus products may function primarily in inhibition of
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NK cell-mediated lysis. HCMV infection of cells results in the partial 
downregulation of MHC class I, sparing some HLA-C alleles, thereby providing 
a ligand for the inhibitory receptor KIR2D (Huard & Fruh, 2000; Schust et al., 
1998; Valiante et al., 1997). In addition, HCMV is able to upregulate the 
expression of HLA-E (Tomasec et al., 2000; Ulbrecht et al., 2000), a 
nonclassical MHC class I molecule that interacts with the NK cell inhibitory 
receptor CD94/NKG2A, B and C to prevent lysis by NK cells (Borrego et al., 
1998; Braud etal., 1998).
Another mechanism to avoid the NK response is via the production of class I 
homologues that may be able to substitute for the inhibitory MHC class I 
ligands and prevent NK cell activation, for example the class I homologue, 
UL18, carried by HCMV (Beck & Barrell, 1988).
(e) Interference with MHC class II antigen presentation
Preventing Class II antigen presentation is a way of interfering with activation
of helper T cells (which may impact on other responses dependent on T cell
help). As for the inhibition of MHC class I antigen presentation, the processing
of antigenic peptides or MHC class II expression can be interfered with by
viruses to prevent presentation of viral antigens by MHC class II to CD4+ T
cells.
Virus encoded proteins may affect processing of proteins in the endocytic 
pathway. Human- and bovine- papillomavirus (HPV and BPV) encode E5 and 
E6, proteins which interact with components of the endocytic pathway. E5 
(encoded by both) interferes with a proton pump required for endosomal 
acidification (Andresson et al., 1995) and may disrupt processing of antigenic 
proteins by altering events that take place in the endocytic pathway. E6 
produced by BPV binds to AP1 (Tong et al., 1998), an adaptor protein 
associated with clathrin-coated vesicles in the trans-Golgi network, and also 
may affect processing of proteins.
The inhibition of surface expression of class II molecules can be mediated by 
both transcriptional and post-translational effects. Adenovirus, MCMV and 
HCMV are all able to affect class II transcription. HMCV US2 translocates the 
MHC class II DRor and DMa chain into the cytosol for degradation by the 
proteasome (Tomazin etal., 1999).
Viruses can also indirectly inhibit the expression of MHC class II by interfering 
with IFN-induced expression of MHC class II, for example MCMV (Heise & 
Virgin, 1995) can interfere with IFN-signalling pathways.
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(f) Antigenic variation
Pathogens can also evade immune surveillance by altering their antigenic 
composition. Antigenic variation can be achieved by several different 
mechanisms including reassortment (for viruses with a segmented genome), 
recombination and mutation. Mutation is common for RNA viruses which have 
an RNA polymerase that lacks proof reading ability. Their high mutation rate 
and short replication times enable them to rapidly adapt in response to 
environmental changes such as immune selection pressure. Thus the 
generation and selection of variants which can evade recognition by 
neutralising antibodies is common in RNA viruses, for example equine 
infectious anaemia virus (Montelaro et al., 1984; Salinovich et al., 1986) and 
visna virus (Scott et al., 1979). In influenza virus infection, the emergence of 
point mutations that alter the binding sites for protective antibodies on the 
virion surface allows the virus to evade neutralisation by antibodies. Here the 
mutation allows for reinfection of a host rather than promoting persistence. 
Mutation in viral CTL epitopes can also abrogate epitope-specific CD8+ T cell 
responses by modifying peptide processing or transport, altering peptide 
binding to MHC class I molecules or peptide interaction with the TCR. This is 
discussed in more detail in the context of HIV-1 infection in section 1.7.
1.5.2 Strategies which impair the host antiviral immune response 
Viruses can impair the immune response in order to establish persistent 
infections within a host. In the case of some viruses, infection can be 
associated with a generalised immunosuppression; in many virus infections, 
more restricted defects in the virus-specific immune response are associated 
with virus persistence.
(a) Generalised immunosuppression
Measles is a leading cause of childhood disease and is associated with a 
transient profound immunosuppression. Infection can be fatal, the cause of 
death usually being a secondary bacterial infection, such as pneumonia, 
caused by measles-induced immunosuppression.
Measles virus can infect T cells, B cells, monocytes and DCs in vitro and 
induce syncytium formation or apoptosis and thereby cause the destruction of 
key immune cells (Joseph et al., 1975). Besides causing the loss of cells, 
other immune responses are impaired due to reduced T and B cell function 
(reviewed in (Borrow & Oldstone, 1995; Klagge & Schneider-Schaulies,
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1999)), such as reduced delayed type hypersensitivity (DTH) responses 
(children have increased susceptibility to mycobacterial infections) and 
impaired antibody (Casali et al., 1984; McChesney et al., 1986; Tishon et al.,
1996) and IL-12 (required for activation of Th1 CD4+ T cells) production 
(Fugier-Vivier et al., 1997; Karp et al., 1996). Two structural components of 
the measles virus may contribute to measles-induced immunosuppression. 
The virus nucleocapsid protein binds to FcyRII and delivers negative signals to 
attenuate B cell antibody production in vitro (Ravanel et al., 1997); and 
measles haemagglutinin binding to CD46 suppresses IL-12 production by 
macrophages (Karp, 1999; Karp etal., 1996).
(b) Impairment of cytokine production
IFNs are an important class of cytokines which both mediate 
immunoregulatory activities and have a key role in protecting cells from viral 
infection. Viruses are able to impair IFN induction by blocking the synthesis or 
activity of factors required for their production. For example IL-18 and IL-12 
are required for the production of IFN-y. CrmA from Cow pox virus inhibits 
caspase-1 (also known as IL-1/? converting enzyme, or ICE), which in turn 
may inhibit the maturation of IL-18 (Smith et al., 1998; Smith et al., 1997); 
various poxviruses encode soluble IL-18 binding proteins (Smith et al., 2000; 
Xiang & Moss, 1999); measles virus binds CD46 in macrophages and inhibits 
IL-12 production (Karp, 1999); and herpes and poxviruses express IL-10 
homologs that diminish the Th1 response by downregulating production of IL- 
12 (Kotenko etal., 2000; Spriggs, 1996). Impaired IFN induction could impede 
local control of virus replication and potentially have consequences for 
activation of the innate and/or adaptive immune response.
As with the IFNs, the activity of other cytokines can be also modulated or 
inhibited through interference with their production. HCMV inhibits the 
transcription of the chemokine monocyte chemoattractant protein-1 and, as 
already mentioned, measles virus inhibits production of IL-12 by monocytes, 
macrophages and DCs (Karp, 1999; Karp et al., 1996). Viruses which encode 
homologues of IkB are able to block cytokine expression mediated by NF/cB 
and the nuclear factor of activated T cells (NFAT) transcription factors (e.g. 
African swine fever virus (Miskin et al., 1998)).
The process of cytokine maturation may also be interrupted, e.g. pox viruses 
synthesise inhibitors of ICE (Kettle et al., 1997; Ray et al., 1992), preventing
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secretion of mature IL-1/?, and reducing the inflammatory response triggered 
by this cytokine.
(c) Neonatal tolerance
Some viruses are able to establish persistent infections if they infect the host 
early enough during life at the time when tolerance is being established. 
During T cell maturation in the thymus in early life, clones that bind with high 
affinity to antigens presented in the thymus are eliminated by negative 
selection as a mechanism to delete cells that have the potential to react with 
self antigens. Hence, for example, if mice are infected with LCMV in utero or 
as neonates, viral antigens will be present in the thymus to cause deletion of 
LCMV-specific T cells as they begin to mature. The peripheral CD8+ T cell 
repertoire that develops will be unable to clear the infection and the virus will 
be able to persist (Pircher et al., 1989). The clonal deletion of HBV-specific T 
cells also occurs following transplacental HBV infection. A reduction in the 
frequency of HBV-specific T cells may also account for the increased 
likelihood of developing chronic hepatitis if an individual is infected neonatally 
compared to during adulthood (Chisari & Ferrari, 1997).
(d) Immune Exhaustion
Immune exhaustion is another way of enabling a persistent infection to be 
established. T cell exhaustion, defined here as the rapid disappearance of 
antigen-specific T cells, is likely to occur in the face of a high antigen load, as 
may be generated with a virus which replicates to high titres and spreads 
rapidly in lymphoid tissues. This has been shown for more aggressive strains 
of LCMV such as LCMV DOCILE (Moskophidis et al., 1993). If stimulated 
under conditions of antigen excess, T cells may undergo apoptosis rather than 
the usual response of expansion and differentiation. The mechanisms behind 
this are not fully understood, but may involve the incorrect priming of T cells by 
non-professional APCs presenting viral peptides or by professional APCs 
whose functions have been impaired, resulting in T cell apoptosis; or CD8 
cells becoming a target for LCMV-specific CTL as a result of their direct 
infection (Borrow et al., 1991) or the acquisition of peptide-MHC complexes 
from APC (Huang et al., 1999).
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(e) Induction of T cells with impaired effector functions 
Another way in which viruses can evade clearance by T cell-mediated 
immunity is by inducing a T cell response which is functionally impaired. 
Primary hepatitis C virus (HCV) infection has been associated with transient 
dysfunction of antigen-specific T cells, where temporarily ‘stunned’ cells are 
unable to produce IFN-y and do not proliferate in vitro (Lechner et al., 2000a; 
Thimme et ai., 2001). In addition, the perforin content and lytic activity of virus- 
specific T cells have been observed to be significantly impaired during primary 
HCV infection (Urbani et al., 2002). This impairment is fully reversible when 
viraemia falls and HCV-specific CD4 responses become detectable but 
persists when chronic infection develops, and so the defective function of 
HCV-specific CD8 cells may contribute to viral persistence in chronic infection. 
That function is restored when the viral load falls suggests that the 
dysfunctional phenotype may have been induced by the high antigen levels 
during acute infection. Overstimulation of cells may induce anergy or be 
associated with presentation of viral antigens by non-professional APCs which 
may aberrantly activate T cells.
However, the impaired effector function of HCV-specific CD8+ T cells observed 
during chronic infection is associated with weak HCV-specific CD4 responses 
(Wedemeyer et al., 2002), giving rise to the possibility that the virus-specific 
CD8+ T cells may be arrested in an immature state due continuous antigenic 
stimulation in the absence of sufficient CD4 help. Furthermore, impaired 
effector function is associated with incomplete effector cell differentiation 
(Wedemeyer et al., 2002), and so HCV may block or divert the differentiation 
of HCV-specific cells.
That conditions of helper cell deficiency may contribute to the functional 
impairment of cells is supported by observations made in a chronic LCMV 
model (Zajac et al., 1998). LCMV-specific CD8+ T cells specific for a dominant 
epitope persisted but were noncytotoxic and did not produce IFN-y, 
contributing to the inability to clear infection. This functional unresponsiveness 
was more marked under conditions of CD4 deficiency. What may happen 
during HIV infection, which is associated with a deficit in CD4+ T cell frequency 
and function, is the subject of discussion later on.
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1.5.3 Strategies which aid viral resistance to immune effector mechanisms
(a) Resistance to the effects of cytokines and chemokines 
Another strategy used by viruses to evade the host immune response involves 
interference with the effector functions of cytokines induced by viral infection. 
Cytokines and chemokines coordinate a variety of events in the immune 
response, including inflammation, cellular activation, proliferation, 
differentiation and chemotaxis. By acting as immune mediators, they 
orchestrate the induction and maintenance of innate and adaptive antiviral 
responses. A number of cytokines and some chemokines also have direct 
antiviral effects. By interfering with their actions, viruses are able to avoid such 
cytokine-mediated activities.
• IFNs
As already mentioned, IFNs are a family of cytokines which have important 
antiviral activity and have a role in the activation of cells within the innate and 
adaptive immune systems. Upon binding of IFNs to their receptors, a signal 
transduction cascade is initiated that leads to activation of IFN-inducible genes 
(reviewed in (Schindler, 1999)). Following receptor binding, tyrosine 
phosphorylation of the receptor-associated tyrosine kinases (Janus kinase 
(Jak) 1 /Tyk2 for type I IFNs; Jak1/Jak2 -  for type II IFNs), as well as tyrosine 
phosphorylation of the individual receptors, takes place. Once activated, the 
Janus kinases phosphorylate a family of proteins, the STAT (signal 
transducers and activators of transcription) proteins. This leads to dimerisation 
of different STATs and their translocation into the nucleus. There, they 
assemble with other factors to become large transcriptional activation 
complexes. These include genes which switch the responding cell into an 
‘anti-viral state’ which culminates in the arrest of protein translation and 
cellular proliferation, the upregulation of enzymes that degrade viral RNA and 
apoptosis. One protein induced is an enzyme (2’ 5’ oligoadenylate synthetase 
(2’ 5’ OAS)) which activates an endoribonuclease (RNase L) that degrades 
viral RNA. IFN also induces the synthesis of ds RNA-dependent protein kinase 
(PKR). This phosphorylates elF-2, an initiation factor for protein synthesis, 
thereby inhibiting translation. Many viruses are able to interfere with the 
activities of IFNs by targeting various points along the signalling pathway 
(reviewed in (Cebulla etal., 1999)).
Poxviruses encode soluble versions of receptors for IFNs (which may be 
localised at the cell surface) that block the functions of IFNs (Smith et al.,
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1998). For example vaccinia virus (W )  secretes a type I IFN receptor 
homolog B18-R (Symons et al., 1995) and a type II receptor homolog B8-R 
(Alcami & Smith, 1995) which can bind to and inhibit IFN-or and -y respectively. 
Viruses can use various methods to inhibit the JAK/STAT pathway to abrogate 
IFN signalling. Many viruses (Simian virus 5, Sendai virus (Didcock et al., 
1999b), human parainfluenza viruses (Young et al., 2000), adenovirus 
(Leonard & Sen, 1996)) have effects on STATs to block either or both type I or 
II responses. For example, the V protein of Simian virus 5 causes 
proteasome-mediated degradation of STAT 1, needed for both type I and II 
IFN signalling (Didcock et al., 1999a). HMCV diminishes levels of Janus 
kinase-1, which interferes with IFN-a-stimulated gene expression (Miller et al.,
1998).
Interferon regulatory factors (IRFs) are proteins that regulate IFN-induced 
transcription, and can be manipulated by viruses to inhibit transcriptional 
responses induced by viruses. HHV-8, for example, encodes proteins with 
homology to IRFs which may modulate the expression of IFN-inducible genes 
(Burysek etal., 1999; Li etal., 1998a).
Viruses use various strategies to inhibit the activity of PKR, an RNA- 
dependent enzyme that is part of an IFN-induced mechanism to inhibit protein 
synthesis. Adenovirus and EBV encode RNAs that inhibit PKR activation 
(Clemens, 1993; Ma & Matthews, 1996; Sharp et al., 1999); HCV E2 binds to 
and inhibits PKR activation (Taylor et al., 1999); and HSV-1 counteracts PKR 
activity by activating a phosphatase to dephosphorylate e lF2-ar (He et al.,
1997).
The RNase L system, which degrades viral RNAs, is also targeted by viruses, 
for example HSV, which produces antagonists of 2’ 5’ OAS, the enzyme 
responsible for activating RNase L (Cayley et al., 1984).
•  Other cytokines/chemokines 
Viruses are able to produce homologues of a range of cytokines and cytokine 
receptors. Mimicry of cytokines might redirect the immune response for the 
benefit of virus, for example they might use the homologue to induce signalling 
in the infected cell in ways which might promote virus replication. Members of 
the herpes family viruses produce vlL-6 and -17, which might have 
immunomodulatory activity but might also increase proliferation of cells that 
are targets for viral replication (Spriggs, 1996). As already mentioned for the
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IFN receptor homologues, cytokine receptors (or cytokine binding proteins) 
may be able to neutralise cytokine activity.
Virus-encoded chemokines are either antagonists that block leukocyte 
recruitment to sites of infection, or agonists that enhance recruitment of cells 
for their advantage, for example to support viral replication or prevent Th1 
anti-viral responses. KSHV synthesises vMIP-ll, a broad-chemokine receptor 
antagonist, which blocks monocyte chemotactic responses to RANTES 
(Regulated on activation, normal T cell expressed and secreted), MIP-1a and 
MIP-1/? (Kledal et al., 1997). The HHV-6 chemokine U83 binds to chemokine 
receptors and may recruit mononuclear cells to sites of viral replication, 
facilitating virus dissemination (Zou et al., 1999). HHV-8 produces the 
chemokine vMIP-1 which interacts with CCR8, a chemokine receptor 
preferentially expressed by Th2 cells. Thus HHV-8 may use vMIP-1 to 
selectively recruit and activate Th2 cells to areas of viral infection, biasing the 
Th1/2 balance of the antiviral immune response (Dairaghi et al., 1999; Endres 
etal., 1999).
Another way in which the activities of cytokines/chemokines can be influenced 
is by alteration of their interaction with host receptors. Viruses may encode 
secreted receptors which compete with cellular receptors for 
cytokine/chemokine binding. Alternatively, they can use membrane-bound 
receptors to interfere with target cell recognition of cytokines.
Many poxviruses are able to produce TNF receptor homologues to interfere 
with the interaction of TNF with cellular receptors (Alcami et al., 1999; Loparev 
et al., 1998), thereby inhibiting the antiviral effects of TNF, including induction 
of apoptosis (discussed later).
Binding proteins for chemokines may also provide a way of neutralising their 
activity, for example MCMV encodes several secreted glycoproteins with 
homology to the IL-18 binding protein (Smith et al., 2000; Xiang & Moss,
1999). These are able to sequester IL-18, which is involved in NK cell 
activation and induction of Th1 responses.
Membrane-bound cytokine receptors can often retain their signalling function 
(such as the HCMV chemokine receptor homolog US28 (Billstrom et al.,
1998)), and alter the cell physiology in response to cytokine signals. Such 
signals may force the cells to create an environment that is of direct benefit to 
the virus, for example by allowing more efficient replication or by blocking 
apoptosis.
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Viruses are also able to inactivate host cytokine receptors directly. For 
example, HHV-6 and -7 downregulate the expression of CXCR4 upon 
infection of CD4+ T cells (Yasukawa et al., 1999), resulting in diminished 
calcium flux and chemotaxis in response to CXCR4 ligand.
(b) Resistance to antibody and complement-mediated immunity
Viruses can also evade the effector activities of responses involving antibodies 
and complement.
Some viruses encode viral Fc receptors (FcRs). The binding of non-immune 
IgG to these receptors may sterically restrict the access of virus-specific 
immune IgG. The FcRs can also bind to exposed Fc domains of antiviral 
antibodies after the Fab region binds to the virus antigen and prevent 
subsequent Fc-dependent immune activation of complement and phagocytes. 
The HSV-1 gE and gl glycoproteins form a complex that binds IgG on HSV-1 
virions and on infected cells, and so gE/gl function may account for the 
relative ineffectiveness of anti-HSV Ig against HSV infection (Baucke & Spear, 
1979; Johnson etal., 1988).
In order to limit complement activation and neutralisation of virus particles, 
some viruses possess homologues of complement control proteins or can 
utilise host control proteins that act at various stages along the pathway of 
complement activation.
Poxviruses, herpesviruses and retroviruses are able to encode proteins with 
functional similarities to complement control proteins which inhibit the 
complement cascade (reviewed in (Favoreel etal., 2003)), for example herpes 
virus saimiri encodes a CD59 homolog that inhibits C9 polymerisation and 
formation of the terminal membrane attack complex pore (Rother et al., 1994). 
Some viruses alter the cellular expression of host complement control 
proteins, for example, HCMV upregulates CD46 and CD55 expression on 
infected cells in vitro (Spiller et al., 1996).
Also, viruses that bud through the plasma membrane can acquire host 
membrane proteins, including regulators of complement activation such as 
CD46, CD55 and CD59, and incorporate them into the viral envelope (e.g. 
vaccinia virus (Vanderplasschen etal., 1998)).
(c) Resistance to apoptosis
Viruses depend on living cells for replication, but viral infection often triggers 
apoptosis of infected cells. This can occur as a direct effect of the virus
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infection, or the cell simply self-destructing after sensing some unanticipated 
occurrence that affects normal cellular homeostasis, such as unscheduled 
DNA synthesis; or alternatively may be triggered by immune effector 
pathways. Prolonging the survival of infected cells is clearly in the interests of 
the virus, to allow it to complete its full replicative cycle, mature and 
disseminate. It is therefore not surprising that many viruses encode proteins 
that inhibit apoptosis.
Pathways for the induction of apoptotic death contain molecules that can 
serve as targets for viral-encoded proteins. These pathways involve:
• Death receptors (DRs) on the cell surface (e.g. TNF-R1, Fas, DR4 and 
DR5), which interact with specific ligands (TNF-or, FasL and TNF- 
related apoptosis-inducing ligand (TRAIL)). Binding to their ligands 
causes the oligomerisation of receptors which can transduce death 
signals through death domains.
• The participation of mitochondria and the release of cytochrome c into 
the cell cytosol. This is regulated by members of the Bcl-2 family which 
form heterodimers, including antiapoptotic molecules bcl-2 and bcl-XL, 
and death-promoting molecules, bad, bax, or bak.
• The release of perforin and granzymes from the cytoplasmic granules 
of cytolytic cells.
Most apoptotic stimuli, regardless of which pathway they trigger, converge on 
and activate, a common set of caspases. Caspases comprise a family of 
aspartate-specific cysteine proteases that orchestrate the apoptotic program 
by proteolytically activating other caspases and other cellular targets, leading 
to DNA fragmentation and cell death.
The apoptotic pathway can be targeted at several points by viral anti-apoptotic 
mechanisms. The modulation of death-inducing ligands or their receptors can 
be one level at which viruses can prevent apoptosis. The adenovirus E3- 
10.4/14.5K proteins cause the internalisation of Fas from the cell surface and 
its degradation inside lysosomes (Tollefson et al., 1998). Also, various viruses 
encode TNF receptor homologues which can bind and block the action of the 
death-inducing cytokine (e.g. rabbit myxoma virus, M-T2 (Schreiber et al.,
1997)).
Following the ligation of death receptors, death signals are relayed through 
adaptor molecules, Fas-associated and TNF receptor-associated death 
domains (FADDs and TRADDs), to upstream, initiator caspases (e.g. caspase
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-8 (FLICE) and -10). A caspase cascade ensues, with downstream caspases 
(caspase -3, -6 and -7) being active during the more terminal stages of death. 
The FADD-caspase contacts rely on interactions between death effector 
domains in each. To interfere with this interaction, several viruses encode 
death-effector-domain-containing proteins called viral FLICE inhibitory proteins 
(vFLIPs). These bind FADD and/or caspases and prevent recruitment and 
activation of initiator caspases upon ligation of death-inducing ligands. vFLIPs 
are encoded by several herpes viruses. For example, KSHV/HHV-8 ORF71 
disrupts the recruitment of caspase 8 to FADD (Thorne et al., 1997).
Inhibition of caspase activity is another way in which viruses can prevent 
apoptosis in response to apoptotic stimuli, crm A encoded by cowpox virus 
can block the activity of caspase 8 and caspase-1 (Dbaibo & Hannun, 1998). 
Other viruses which encode caspase inhibitors include adenovirus (14.7K) 
(Chen etal., 1998) and vaccinia virus (SPI-2) (Dobbelstein & Shenk, 1996). 
The bcl-2 family members are also targeted to prevent apoptosis. Several 
viruses encode homologues of the antiapoptotic molecule bcl-2, for example 
KSHV (ORF16) (Sarid et al., 1997) and EBV (BHRF 1 and BALF-1) 
(Henderson et al., 1993; Marshall et al., 1999). The expression of cellular bcl-2 
members can also be modulated by viruses, for example EBV latent 
membrane protein (LMP) -1 upregulates the expression of cellular Bcl-2 
(Henderson etal., 1991).
Many viruses also encode molecules that target co-ordinators of the cell cycle 
such as p53, a molecule which promotes apoptosis; for example the product 
of the E6 gene of HPV binds p53 and targets it for ubiquitin-dependent 
proteolysis (Scheffner et al., 1993).
Related to the subject of apoptotic death is another immune evasion 
mechanism by which virus-infected cells avoid CTL-mediated attack. This is 
by counterattack and triggering the death of virus-specific T cells. For 
example, HTLV-1 and measles virus are thought to counterattack virus- 
specific cells using pathways of death initiated by FasL and TRAIL (Xu et al.,
2001).
To summarise, viruses utilise a whole variety of strategies, targeting all arms 
of the antiviral response, to avoid detection and clearance by the host immune 
response. This allows such viruses to coexist with the host and often establish 
persisting infection. Viruses which are best able to persist in their hosts often 
use more than one type of immune evasion strategy. As described in sections
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1.6 and 1.7, HIV uses multiple strategies to evade both the humoral and cell- 
mediated antiviral immune responses and to establish a persistent infection.
1.6 The HIV-specific immune response
HIV stimulates all the arms of the host immune response discussed in section 
1.4. Here, each component of the anti-viral immune response is discussed in 
more detail, highlighting some of the experimental evidence which contributed 
to our understanding of the mechanisms used by the host to contain HIV 
replication. Despite the induction of the several arms of attack against the 
virus, the virus is able to persist in the host. The different ways in which the 
immune response is perturbed in HIV infection and immune evasion strategies 
used by HIV that contribute to virus persistence are also discussed here.
1.6.1 The innate response
(a) Type I IFNs in the host immune response to HIV
Elevated levels of type I IFN can be transiently detected in the serum during 
acute HIV-1 infection (von Sydow et al., 1991). Peak serum type I IFN levels 
are observed prior to the peak in acute viral replication -  IFNs may therefore 
have a role in containing viral replication during the initial stages of viral 
infection. By analogy with other virus infections, it is likely that PDCs play an 
important role in type I IFN production during primary HIV-1 infection. IFN 
production may be triggered by viral nucleic acids; and gp120 has also been 
implicated in the induction of IFN (Francis & Meltzer, 1993; Capobianchi et al.,
1992).
In mid-stage infection, levels of type I IFN in the serum are below detectable 
levels, so the contribution of type I IFNs to immune control of HIV during this 
stage is unclear. However this does not rule out the possibility that local type I 
IFN is produced in tissues and might play a role.
As disease progresses, IFN-a is again detected in the serum of infected 
individuals. Significant titres of IFN-a were found in the serum of patients who 
had progressed to AIDS (Grunfeld et al., 1991; Kunzi et al., 1995), including 
homosexuals with Kaposi’s sarcoma (DeStefano et al., 1982; Krown et al.,
1991). However, this was an unusual acid-labile form of IFN-o, raising 
questions about its efficacy. It has been suggested that production of this form 
of IFN may in fact contribute to HIV replication and disease progression (Hess 
etal., 1991).
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Cell culture models support a role for type I IFNs in limiting HIV infection. Type 
I IFNs have been shown to exhibit antiviral activity against HIV replication in 
vitro (Hartshorn et al., 1987; Pitha, 1994). IFN-a administered at the time of 
viral challenge is able to block infection of monocytes (Francis et al., 1992), 
and it is also able to suppress HIV expression in chronically infected cell lines 
(Poli et al., 1989). Type I IFNs may indirectly contribute to suppression of HIV 
replication by inducing lysis of infected cells by NK cells (Biron, 2001). Other 
actions of IFNs may also contribute to an overall enhanced antiviral immune 
response, such as enhancing survival of PDCs (Celia et al., 2000; Kadowaki 
et al., 2000); promoting monocyte differentiation into potent antigen-presenting 
DCs (Lapenta et al., 2003); and enhancing cross-presentation of viral antigens 
(Le Bon etal., 2003).
The beneficial effects of type I IFNs are further highlighted by the therapeutic 
use of IFN-a in HIV-infected individuals. IFN-a was found to have efficacious 
antiretroviral and anti-tumour effects against KS (de Wit et al., 1988; Lane et 
al., 1988; Krown, 1998). Also, in a trial to test the clinical efficacy of IFN-a in 
patients with asymptomatic HIV infection, it was found that treatment of 
patients during primary HIV infection with IFN-a can result in a decrease in the 
frequency of virus isolation, suggesting a potential role in slowing down the 
progression of disease (Lane etal., 1990).
The fact that administration of exogenous type I IFNs has a beneficial effect in 
HIV infection suggests that the production of type I IFNs may be compromised 
in infected individuals. Notably, the number of PDCs in the blood is generally 
reduced in HIV infection, both in primary infection (Kamga et al., 2005; 
Pacanowski et al., 2001; Soumelis etal., 2002) and chronic infection (Feldman 
et al., 2001; Soumelis et al., 2001). It is unclear whether this is due to PDC 
loss, or a redistribution of these cells to LNs or other sites. However in addition 
to the numerical reduction in circulating PDCs there are also functional 
deficiencies too, for among those cells that remain, there is a lower frequency 
of responding cells (Feldman et al., 2001). A strong positive correlation 
between IFN production and PDC count has been observed in control subjects 
but not in HIV-infected patients, who have lower IFN production on a per cell 
basis (Kamga et al., 2005). The ability of PDCs from HIV-infected patients to 
stimulate allogeneic T cell proliferation in a mixed lymphocyte reaction (MLR) 
was also shown to be impaired (Donaghy et al., 2003). Both the decrease in
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number and the dysfunction of PDCs likely contribute to a reduction in IFN-a 
production by PDCs (Feldman et al., 2001).
The plasma viral load in subjects has shown to be negatively correlated with 
IFN production or the number of functional PDCs (Donaghy et al., 2001; 
Feldman etal., 2001; Pacanowski etal., 2001; Siegal etal., 2001; Soumelis et 
al., 2001). Also, IFN-a generation and PDC counts are recovered during HIV- 
suppressive therapy (Kamga et al., 2005; Siegal et al., 2001), suggesting that 
viral burden is inversely related to IFN-a generation. There is thus a direct 
correlation between the number of PDCs in the blood, IFN-a production and 
the clinical status of subjects (Soumelis et al., 2001). PDCs are greater in 
number and also have increased function in long term non-progressors 
(LTNPs) relative to that found in progressors, AIDS-patients, and healthy 
controls (Soumelis et al., 2001; Almeida et al., 2005; Levy et al., 2003). 
Numbers of PDCs and IFN production are markedly reduced in AIDS patients 
developing opportunistic infections and cancers (Feldman et al., 2001; Lopez 
etal., 1983; Siegal etal., 2001; Siegel etal., 1986; Soumelis etal., 2001).
Infection of PDCs by HIV may represent a potential mechanism to account for 
the loss of PDCs in infected individuals. PDCs express CD4 and the 
chemokine co-receptors used by HIV for entry, and as such, are susceptible to 
infection. It has been demonstrated that they can be infected with HIV in vitro 
(Fong et al., 2002; Patterson et al., 1999; Patterson et al., 2001; Smed- 
Sorensen et al., 2005), and the presence of provirus was detected in purified 
PDC samples from HIV-infected patients (Donaghy et al., 2003).
Primary HIV isolates, unlike laboratory-adapted strains, display variable 
sensitivity to the effects of IFN-a in vitro (Kunzi et al., 1995), hence it is 
possible that in addition to the production of IFNs being compromised in HIV- 
infected individuals, resistance to IFN control may also contribute to the ability 
of the virus to persist in vivo.
(b) NK cells in the host immune response to HIV
NK cells may have a role in limiting HIV replication through their cytotoxic 
activity against infected cells, and via the production of C-C chemokines and 
IFN-y which can suppress HIV infection (Fehniger et al., 1998; Oliva et al., 
1998; Biron & Brossay, 2001). That NK cells may protect against HIV is
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supported by observations made in intravenous drug users who remained 
uninfected despite high-risk exposure. When compared with drug users who 
did become infected, their NK cells were found to have significantly greater 
lytic activity in vitro (Scott-Algara et al., 2003). In addition, there is evidence 
that NK cells make an important contribution to control of viral replication in 
infected individuals. Co-expression of a particular NK cell receptor, KIR3DS1, 
and its cognate ligand, Bw4, with a particular amino acid at residue 80, has 
been shown to be associated with slow disease progression (Martin et al.,
2002).
There are a number of mechanisms by which NK cell control of viral 
replication may be impaired in HIV-infected individuals, including reduction of 
NK cell numbers and functional capacity, and viral evasion of NK cell 
recognition.
It has been shown that despite a reported elevation in NK cell numbers in 
primary infection (Alter et al., 2005), NK cells are lost from the periphery 
thereafter and are functionally suppressed (Alter et al., 2005; Sinicco et al.,
1993). This becomes more pronounced in individuals with progressive 
disease, with NK cell-mediated lysis and cell numbers being most severely 
depressed in patients with AIDS (Cai etal., 1990; Ratcliffe et al., 1994). 
Impaired cytotoxic ability and reduced IFN-y production by NK cells in HIV 
infected individuals is associated with alterations in the expression of 
activating and inhibiting NK cell receptors, with enhanced expression of 
inhibitory receptors and decreased expression of activating receptors (Mavilio 
et al., 2003; Eger & Unutmaz, 2004; Ahmad et al., 2001; De Maria et al., 2003; 
Parato et al., 2002; Fogli et al., 2004). This is particularly evident in viraemic 
patients when compared to aviraemic patients (those in which viraemia had 
been suppressed to undetectable levels by antiretroviral therapy (ART)), 
suggesting that ongoing active viral replication has an important influence on 
NK cells. In agreement with this, receptor expression and cell number are 
returned to normal when viraemia is controlled with ART (Goodier et al., 2003; 
Kottilil et al., 2004).
There are also alterations in subpopulations of NK cells in HIV infection, with a 
selective reduction in the more cytotoxic CD56dim subset of NK cells, and an 
expansion of a functionally defective CD56VCD16+ population of NK cells 
reported (Alter et al., 2005; Oliva et al., 1998; Scott-Algara & Paul, 2002; 
Tarazona et al., 2002). These subset alterations are more pronounced in
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viraemic patients compared to aviraemic or healthy donors (Mavilio et al., 
2003).
The causes of the perturbed NK cell numbers and function in HIV infection are 
unknown. The loss of NK cells may be in part a consequence of their 
participation in ADCC of gp120-coated CD4 cells, where concomitant loss of 
the CD4 targets and the NK cells by activation-induced cell death (AICD) or 
apoptosis occurs. The NK cells that do recover from the ADCC reaction show 
a loss of cytotoxic function, and acquire a CD16dim/' or CD56dim/' phenotype 
(Jewett et al., 1997). Reduced numbers could also conceivably be due to 
direct infection of NK cells (a rare subset expressing CD4 and chemokine 
coreceptors for entry can be productively infected in vitro (Valentin et al.,
2002)), but this is unlikely to account for the significant reduction in numbers 
seen. What is perhaps most likely is that NK cell abnormalities may be 
secondary to other immune system defects in HIV-infected individuals; for 
example levels of IL-15, a cytokine involved in NK cell homeostasis, are 
reduced in HIV infection (Ahmad etal., 2003).
Several HIV-encoded proteins have been shown to downregulate MHC class I 
expression in infected cells as a mechanism to avoid antigen presentation to 
HIV-specific CD8+ T cells and thereby avoid CTL recognition. This could leave 
the cells susceptible to NK cell attack, since MHC molecules are recognised 
by inhibitory NK cell receptors, and act to deliver a negative signal to block NK 
cell function. However, expression of HLA-C molecules is retained on HIV- 
infected cells. The selective downregulation of MHC class I molecules by HIV, 
with downregulation of HLA-A and -B but not HLA-C, achieves a balance 
between minimising antigen presentation by MHC whilst still avoiding attack 
by NK cells (Cohen et al., 1999).
(c) NK-T cells and y6T  cells in HIV infection
NK-T cells and yS T cells may contribute to early containment of HIV 
replication since they can perform anti-viral functions such as lysis of infected 
cells, or producing cytokines and chemokines that interfere with viral 
transmission and/or replication or that activate other effector cells.
Peripheral blood NK-T cells are markedly depleted in HIV infected individuals, 
particularly in those with uncontrolled viraemia and marked CD4+ T cell 
depletion. It is the CD4+ subset of Va24 NK-T cells that is selectively lost 
(Sandberg et al., 2002). These NK-T cells express CD4 and chemokine
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coreceptors, making them a target for infection by HIV (Motsinger et al., 2002; 
Unutmaz, 2003), and this may explain their loss. Since they express Fas, their 
depletion may be potentially involve Fas-mediated apoptosis. NK-T cell 
depletion may be one factor which contributes to the increased susceptibility 
to tumours and opportunistic infections associated with development of AIDS 
(Unutmaz, 2003).
That yS T cells respond to HIV infection is evidenced by the lytic and 
proliferative responses observed against HIV-infected cells by Vy9V62 TCR T 
cell clones (Wallace et al., 1996), where an expansion of cells is accompanied 
by a decline in p24 levels. Phosphoantigen-activated \fy9V62 T cells have 
also been shown to release chemokines with suppressive activity on HIV 
replication (Poccia et al., 1999). The increase in the numbers of y6 T cells at 
mucosal sites in a model of protective immunity in rhesus macaques 
challenged with SIV by a rectal mucosal route suggests that these cells may 
be important in protection in the initial stages of transmission of virus (Lehner 
et al., 2000a). The mechanism by which protection is thought to be mediated 
is by chemokines generated by yS T cells preventing SIV infection by binding 
to CCR5 coreceptors (Lehner et al., 2000a; Lehner et al., 2000b).
A deletion of V62 cells has been observed in HIV infection and those cells 
which remain are functionally anergic and frequently do not proliferate upon 
stimulation, perhaps as a consequence of chronic antigenic stimulation. IL-2 is 
not able to restore the responsiveness of these cells, which is mirrored by a 
defect in CD25 expression (Poccia et al., 1996). The failure of these cells to 
produce IFN-y and TNF-a cannot be restored by provision of IL-12 and IL-15 
(Boullier et al., 1999). However anergy can be reversed and functionality 
restored by HAART (Martini et al., 2000); this may reflect the recovery of CD4+ 
T cell helper function.
(d) The role of complement in HIV infection
Complement can be activated by HIV virions and may contribute to clearance 
of plasma virus. Activation of complement by HIV can result from direct 
interaction between C1q and specific sites in gp41, leading to activation of the 
classical pathway (Ebenbichler et al., 1991; Stoiber et al., 1994; Thielens et 
al., 1993). Other routes to complement activation can be via the binding of 
antibody to plasma virus and activation of the alternative pathway (Sullivan et 
al., 1996), and via the interaction of MBL with carbohydrate structures on the
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viral glycoprotein leading to activation of the lectin pathway (Saifuddin et al.,
2000).
However, despite activation of complement and the resulting deposition of 
complement fragments on the viral surface, HIV is resistant to MAC-mediated 
lysis and can thus evade complement-mediated lysis (Stoiber et al., 2001). 
HIV is intrinsically resistant to complement due to recruitment of negative 
regulators of complement activation to the virus surface, such as CD59, CD46, 
decay-accelerating factor (DAF), and factor H (Favoreel et al., 2003; Stoiber et 
al., 1996), which have a protective action.
HIV instead uses opsonisation with complement to its own advantage to 
enhance its spread. Opsonised virions can interact with CR-expressing cells, 
and these can be infected with high efficiency or retain viral particles on their 
surface, promoting transmission of virus to other permissive cells (Kacani et 
al., 2001; Stoiber et al., 2001). It has been shown that B cells in lymph nodes 
and peripheral blood expressing CRs can bind infectious immune complexes 
containing HIV, and this can facilitate infection of autologous T cells (Doepper 
et al., 2000; Jakubik et al., 1999). That a subset of CD4 T cells which 
expresses CRs is also more efficiently infected in vitro in the presence of 
complement represents another example of how HIV can use complement to 
facilitate transmission to CR-expressing cells (Delibrias etal., 1993).
1.6.2 The adaptive immune response to HIV infection
HIV-1 also stimulates an HIV-specific immune response involving the 
development of antibodies, CD8+ CTL and CD4+ T helper cells (Figure 1.6).
(a) The HIV-specific antibody response
During primary HIV infection, envelope-specific IgG is detected before/at the 
time of the initial decline in plasma viraemia (Aasa-Chapman et al., 2004; 
Ariyoshi et al., 1992; Lindback et al., 2000a; Lindback et al., 2000b), 3-6 
weeks following infection. However antibodies with neutralising activity are not 
generally detected until several months after infection (Aasa-Chapman et al., 
2004; Pilgrim etal., 1997; Wei etal., 2003; Legrand etal., 1997), and so it was 
originally thought that it was unlikely that antibodies contribute to the control of 
viraemia during primary infection. A similar delay is seen in development of 
nAb is seen in SIV infection of rhesus macaques (Montefiori et al., 1996; 
Reimann et al., 1994). Although the antibodies produced during primary 
infection may not possess neutralising activity, it is possible that other effector
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Figure 1.6. Diagrammatic representation of the HIV-specific immune response and the course of HIV-1 infection. The acute 
phase of infection is characterised by a burst of viral replication which is contained to a steady state level of persisting virus. Virus- 
specific CD8+ T cell responses can be detected concomitant with containment of the acute viral burst; high levels of HIV-specific 
CD8+ CTL are frequently detected during the chronic phase of infection and are thought to play an important role in control of viral 
replication. CD4+ T cell responses are weak or undetectable throughout HIV infection in most individuals. Seroconversion occurs as 
or just after the acute burst of viral replication is contained, but the production of neutralising antibody may be delayed further. In 
end-stage infection there is a universal failure of host immunological function.
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functions of antibody may play a role in controlling viraemia during primary 
infection (Aasa-Chapman et al., 2004). In support of this, plasma or IgG from 
acutely infected patients was found to be able to inhibit the replication of 
primary HIV strains in the presence of NK cells. Antibody that was able to 
mediate ADCC was present in the majority of patients within days or weeks 
after the onset of symptomatic illness of primary infection (Forthal et al., 2001). 
The temporal correlation in development of antibody with ADCC activity and 
decline in viraemia suggests that ADCC may play a role in control of viral 
replication in primary infection (Connick et al., 1996). Furthermore, it has been 
recently demonstrated that antibodies to the viral envelope present during 
primary infection can inactivate virus by triggering the activation of 
complement (Aasa-Chapman et al., 2005).
However studies in B cell-depleted animals suggested that antibody is unlikely 
to play a role in initial containment in acute viral replication in SIV infection, 
since in these antibody-deficient animals, a normal reduction in the level of 
viraemia was observed during the acute phase of infection (Schmitz et al.,
2003).
The reasons why the nAb response is delayed in primary HIV infection are 
unclear, but this may be partly attributed to deficits in the virus-specific CD4+ T 
cell response during HIV infection, associated with which there may be a lack 
of B cell activation. Paradoxically, it has been shown that in LCMV-infected 
mice the presence of CD4 help may in fact impair the induction of nAb 
responses due to excess polyclonal B cell activation (Recher et al., 2004). 
Another possibility is that B cells producing nAb may be destroyed by virus- 
specific CD8+ T cells, as it is conceivable that the virus could bind to surface 
immunoglobulin on specific B cells and be internalised, then infecting these 
cells. The destruction of B cells displaying viral peptides by CD8 T cells has 
also been described in LCMV infection (Battegay et al., 1993; Planz et al.,
1996).
HIV gp120, which mediates receptor binding, is the major target for nAbs. 
However, broadly neutralising antibodies are rare, especially those able to 
neutralise primary virus isolates. A number of structural features of the HIV 
envelope contribute to the characteristic resistance of HIV primary isolates to 
neutralisation (reviewed by (Pikora, 2004)).
i) The viral envelope is heavily glycosylated, with carbohydrate structures 
masking critical epitopes (Reitter et al., 1998). Neutralising antibody epitopes
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are contained in functionally conserved gp120 regions involved in binding to 
CD4 (CD4 binding site antibodies) or chemokine receptors (CD4-induced 
antibodies). However carbohydrates flank both of the receptor-binding regions 
on gp120, effectively shielding the virus from antibody-mediated neutralisation. 
In support of this, deletion of glycosylation sites which flank receptor-binding 
regions was shown to increase the sensitivity of primary virus to neutralisation 
by CD4 binding site antibodies and CD4-induced antibodies (Koch et al.,
2003). In SIV, elimination of N-glycosylation sites and a long deletion spanning 
variable loops V1 and V2 increased the sensitivity of the virus to neutralisation 
(Johnson et al., 2003). Also, in an SIV model of infection where rhesus 
monkeys were infected with mutant forms of the virus lacking N-glycosylation 
sites in the envelope glycoprotein, antibody binding and neutralising activity 
increased (Reitter etal., 1998).
ii) Overlapping hypervariable loops (such as V1 and V2) on the exposed 
surface of the viral envelope may also mask critical structural determinants 
(Parren et al., 1999). These hypervariable regions of the envelope protein are 
immunodominant regions which can easily escape neutralisation.
iii) Many antibodies are directed against gp160 decoy proteins in cell surface 
debris or the monomeric soluble form of the envelope. These react poorly with 
the envelope as it exists in its oligomeric form on the surface of the virus and 
infected cells, as they are often directed against gp120 regions that are buried 
within the trimeric complex (Wyatt et al., 1998).
iv) Neutralising antibodies may target regions of the envelope that are only 
transiently exposed at the time of virus entry, when the viral glycoprotein is 
ready to mediate fusion between viral and cellular membranes (Chan et al., 
1997; Weissenhorn et al., 1997), by which time conformational constraints 
restrict the access of antibody molecules to conserved co-receptor binding 
sites on gp120. This is evidenced by the greater neutralising ability of Fab 
fragments than intact antibodies (Labrijn et al., 2003).
When nAbs are raised in vivo, evidence suggests that they exert selective 
pressure on the virus as it continually and rapidly evolves to escape 
neutralisation. This accounts for some of the variation in the env gene 
observed in the early months after primary infection (Richman et al., 2003). 
The escape virus is thought to acquire mutations involving changes primarily 
in N-linked glycosylation sites, such that an evolving glycan shield can prevent 
nAb binding but not receptor binding (Wei et al., 2003). The emergence of
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neutralisation escape mutants has also been reported in SIV infection (Burns 
et al., 1993). Mutations in the gene encoding the surface glycoprotein with 
consequent nAb escape have also been observed in LCMV infection of mice. 
Here, the failure of the host to mount effective humoral responses against 
emerging neutralisation escape mutants correlated with the loss of CD4+ T cell 
responsiveness during the establishment of persistent LCMV infection (Ciurea 
et al., 2001), suggesting that impairment of CD4+ T cell responses in HIV 
infection could also prevent the mounting of effective nAb responses to 
escape mutants.
(b) The HIV-specific CD4+ T cell response
HIV-specific CD4+ T cells can have direct antiviral effects by releasing antiviral 
cytokines and chemokines (such as IFN-y, MIP-1a and MIP-1/?) (Abdelwahab 
et al., 2003; Lotti et al., 2002; Norris et al., 2001) or by directly killing infected 
cells (Littaua et al., 1992; Lotti et al., 2002; Norris et al., 2004; Norris et al.,
2001). However, it is probably more through their helper functions for the 
antibody and CD8 response that they contribute to immune control of HIV. 
That patients with stronger HIV-specific CD4 responses do better, as 
demonstrated by low viral loads, highlights the importance of CD4 cells in 
control of viral replication. Examples of patient groups in which strong CD4 
responses and low viral loads are observed are LTNPs (Rosenberg et al.,
1997) and HIV-2-infected subjects. Stronger virus-specific CD4 responses in 
HIV-2 compared to HIV-1 infection are associated with an undetectable viral 
load in the former infection (Berry et al., 1998).
It is generally agreed that CD4+ T cell function in blood is impaired early in 
infection. One study showed that HIV-specific CD4+ cell responses could be 
transiently detected in primary infection (by antigen-stimulated release of IFN- 
Y), but then disappeared in untreated patients (Oxenius et al., 2000) (probably 
due to the rapid destruction of activated CD4+ cells in the acute phase of 
infection). Another study found that HIV-specific CD4 responses were 
sustained in patients who contained primary viraemia efficiently (Gloster et al.,
2004), consistent with which, the minority of patients who exhibit good 
immunological control of the virus were found to have vigorous polyclonal HIV- 
specific proliferative responses in chronic infection (Rosenberg et al., 1997). 
Acutely infected patients treated with antiretroviral drugs also showed 
strong/preserved proliferative responses too (Harari et al., 2004; Lichterfeld et 
al., 2004; Rosenberg et al., 1997). The majority of untreated HIV-infected
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individuals exhibit poor CD4 proliferative responses to HIV and recall antigens 
in vitro (Clerici, 1989; Musey et al., 1999). Some reports suggest that HIV- 
specific CD4 cell responses can be detected by intracellular IFN-y staining 
after antigenic stimulation at all stages of infection (Pitcher et al., 1999). 
However, in keeping with the general consensus that the number of 
responding HIV-specific CD4 cells is low, the frequency of HIV-specific cells in 
the latter study was found to be much lower than the frequency of CMV- 
specific cells in the same subjects.
The early dysfunction of HIV-specific helper T cell activity has been shown to 
persist, and HIV-specific responses are weak in the majority of chronically 
infected patients. The early impairment of proliferative responses to mitogens, 
recall antigens and HIV antigens is followed by improvement of responses to 
phytohaemagluttinin (PHA) and recall antigens within 6-9 months, but HIV- 
specific proliferation remains undetectable (Musey et al., 1999). The lack of 
proliferative capacity of HIV-specific CD4+ T cells in chronic infection is 
associated with diminished IL-2 secretion by these cells (lyasere et al., 2003; 
Younes et al., 2003), suggesting a potential relevance of autocrine IL-2 
secretion for maintaining HIV-specific CD4+ T cell proliferative responses. In 
chronic infection HIV-specific CD4+ T cell responses are generally inversely 
correlated with viral load (with stronger recall responses also being positively 
correlated with low viral load). Frequencies are higher in those with non­
progressive disease (Pitcher et al., 1999), and loss of CD4 function in vitro 
predicts progression to AIDS (Dolan etal., 1995; Roos etal., 1995).
The weak HIV-specific CD4+ T cell response observed in the majority of HIV- 
infected individuals is likely due in large part to the destruction of HIV-specific 
CD4+ T cells. HIV-specific CD4+ T cells are ideal targets for infection by HIV, 
because they are activated as they respond to the virus. They may acquire 
infection from the APCs with which they interact during the activation process. 
Infected cells may either be destroyed by the lytic effects of replication or 
become targets for the CD8+ CTL response. Cells may also be killed via 
ADCC triggered by antibody complexed with gp120 expressed on the surface 
of infected cells (Jewett et al., 1997). There is also evidence that HIV 
selectively infects and eliminates HIV-specific CD4+ T cells (Douek et al.,
2002). Other factors may lead to loss of CD4+ cells besides that due to the 
direct cytopathic effects of the virus. Bystander killing may occur through Fas- 
mediated mechanisms during AICD or as a result of HIV proteins (e.g. Nef and
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Vpr) released from infected cells, or inactivated virions stimulating apoptosis in 
uninfected cells (Alimonti et al., 2003; Azad, 2000; Esser et al., 2001). With 
the increasing cytokine dysregulation that is seen in progressive infection, the 
overproduction of cytokines such as IL-10 and IL-4 increases susceptibility to 
AICD.
Suppression of HIV-specific CD4 responses may also be attributed to other 
mechanisms besides their physical elimination. Env-specific CD4 responses 
are particularly lacking in the vast majority of patients. It was shown that HIV 
may evade induction of Env-specific responses by exploiting antibodies to 
suppress the processing of envelope antigens. gp120 presentation to CD4+ T 
cells was inhibited by antibodies specific for the CD4 binding domain of gp120 
(Hioe et al., 2001); when gp120 was complexed to anti-CD4 binding domain 
antibodies, it was more resistant to proteolysis by lysosomal enzymes from 
APCs, and so peptide epitopes were not released and presented efficiently by 
MHC class II to gp 120-specific CD4 cells (Chien et al., 2004).
The activation and effector function of CD4+ cells may also be impaired by 
effects of HIV infection on APCs, MHC class ll-restricted antigen presentation 
and thus CD4+ T cell priming. HIV Nef has been shown to downregulate the 
expression of peptide-loaded MHC class II molecules (Stumptner-Cuvelette et 
al., 2001). Studies with other primate lentiviruses also show that Nef can 
modulate MHC class II expression on the cell surface (Schindler et al., 2003). 
Co-stimulatory defects may also impact upon the development of HIV-specific 
T cell immunity. When dendritic cells infiltrating lymphoid tissue in acutely 
infected patients were characterised, the upregulation of co-stimulatory 
molecules that was seen in primary EBV infection did not occur in primary HIV 
infection (Lore et al., 2002). Defects in the ability of APCs to present HIV 
antigens to T cell clones have also been suggested to be due to the binding of 
CD4 to APC-associated gp120, which may block/modulate the function of 
these cells (Fidler et al., 1996). It is also thought that envelope proteins free in 
the circulation and bound to the surface of CD4 cells can interact with non­
infected cells and have immunomodulatory effects on APCs. In addition, it is 
possible that infection and depletion of DCs may affect the stimulation of HIV- 
specific T cell proliferation (Donaghy et al., 2003).
There is also evidence that the HIV-specific CD4+ T cell responses that are 
present in HIV-infected individuals may be evaded by viral mutational escape. 
Variation in the envelope in viral isolates corresponding to regions that
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stimulate helper T cell responses has been observed (Meddows-Taylor et al.,
2004). It was shown that HIV variants have the capacity to affect the activation 
of virus-specific CD4+ cells (Harcourt et al., 1998). In a rhesus monkey model, 
envelope variant peptides were still able to bind MHC class II molecules, but 
failed to stimulate the proliferation or cytokine secretion of Env-specific CD4+ T 
cell lines (Lekutis & Letvin, 1998).
That HIV viraemia reduces the frequency of circulating HIV-specific CD4+ cells 
may impact upon other help-dependent responses. For example, failure of T 
cell help could affect the ability of the immune system to deal with evolving 
viruses which have mutated to escape CTL and antibody responses that exert 
selective pressure on the virus. A less adaptable immune system that is 
unable to generate CTL/antibodies of new specificities may contribute to 
decline in immune control of the virus as disease progresses.
(c) The HIV-specific CD8+ T cell response
CD8+ T cells play an important role in the clearance or control of many viral 
infections. CD8 cells are able to inhibit viral replication by both cytolytic and 
non-cytolytic means (Buseyne et al., 1996; Price et al., 1998). Lysis is 
mediated predominantly by calcium-dependent exocytosis of perforin and 
granzyme proteases (Gulzar & Copeland, 2004; Shankar et al., 1999; Smyth 
et al., 2001), although a minority of CTLs use FasL to trigger apoptosis in 
target cells that also express Fas (Hadida et al., 1999). HIV-specific CD8+ T 
cells can also produce cytokines and chemokines that can affect viral 
replication. IFN-y secreted from CD8 cells displays potent antiviral effects on 
HIV replication (Wells et al., 1991), acting at an early step in the viral life cycle 
to reduce the synthesis of viral DNA (Meylan et al., 1993). It is able to inhibit 
replication by affecting the expression or activity of cellular factors interacting 
with Tat, inhibiting Tat-induced transactivation of the HIV LTR (Emilie et al.,
1992). CC-chemokines such as MIP-1a, MIP-1/? and RANTES are also 
produced by CD8 T cells (Price et al., 1998; Wagner et al., 1998) and released 
from cytotoxic granules. These suppress HIV replication by competition for, or 
downregulation of, the CCR5 coreceptor, thereby interfering with viral entry 
(Cocchi et al., 1995). CD8 cells are also able to produce a soluble factor 
(CD8+ cell derived anti-HIV-1 inhibitory factor (CAF)) that interferes with viral 
transcription, thereby shutting off virus production (Barker, 1999; Copeland et
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al., 1995; Levy et al., 1996). Alpha-defensins are thought to account for much 
of the anti-HIV activity of CAF (Zhang et al., 2002a).
HIV has been shown to stimulate strong immune responses by CD8+ T cells 
(Plata et al., 1987; Walker et al., 1987). During acute infection large 
expansions of oligoclonal CD8+ T cells can be observed, with some reaching 
up to 40% of all T cells (Pantaleo et al., 1994). Epitope-specific CD8 
responses can be as large as 12% of CD8+ cells (Doisne et al., 2004). It has 
been estimated that to achieve this frequency starting from a naive cell at a 
frequency of less than 1 in 106 requires 17 divisions over 2-3 weeks 
(McMichael & Rowland-Jones, 2001), illustrating the massive expansion that 
occurs in response to infection.
The clonal expansion of HIV-specific CD8 cells in response to an increasing 
antigenic load in acute infection is temporally associated with the resolution of 
primary viraemia (Borrow et al., 1994; Koup et al., 1994). The expanded CD8 
population then partially contracts, as a consequence of apoptosis (Roos et 
al., 1994; Selin & Welsh, 1994).
In chronic infection, the expanded HIV-specific T cells are maintained at high 
frequencies, when CD8+ T cells targeting a dominant epitope can constitute 1- 
2% of all CD8+ T cells (Altman et al., 1996; Ogg et al., 1998). This high 
frequency is maintained by continued antigenic stimulation of HIV-specific 
cells by viral replication, for it has been observed that when this viraemia is 
suppressed in HAART-treated patients, levels of HIV-specific responses 
decline (Draenert et al., 2004a; Gray et al., 1999; Kalams et al., 1999a; Ogg et 
al., 1999). Similarly in SIV-infected macaques, following the disappearance of 
the response due to limited antigenic stimulation, rechallenge with SIV caused 
CTL frequency to increase again (Geretti etal., 1999).
During progression to AIDS, HIV-specific CTL responses deteriorate 
(Carmichael et al., 1993; Greenough et al., 1997; Hoffenbach et al., 1989; 
Klein et al., 1995), and this is typically paralleled by an increase in viral load.
In vitro studies have shown that HIV-specific CD8+ CTLs can eliminate virus- 
infected cells via cytotoxic mechanisms (Yang et al., 1996) and suppress viral 
replication by non-cytolytic mechanisms (Vella & Daniels, 2003). In addition to 
the observation that that HIV-specific CD8+ CTL activity is temporally 
associated with the decline of plasma viraemia during acute infection (Borrow 
et al., 1994; Koup et al., 1994), there are other lines of evidence which also
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suggest that HIV-specific CD8+ T cells make an important contribution to the 
control of viral replication in vivo. The most direct evidence for the in vivo 
importance of CD8 cells in the control of HIV replication comes from studies of 
CD8-depleted monkeys that were unable to control viral replication in primary 
SIV infection (Jin et al., 1999; Schmitz et al., 1999). Also the selection of viral 
variants able to escape CD8+ T cell recognition in both HIV infected individuals 
(Borrow etal., 1997; Goulder etal., 1997a; Price et al., 1997) and SIV infected 
macaques (Allen et al., 2000b; Evans et al., 1999) suggests that the CD8 
response is of in vivo importance and exerting a selective pressure on the 
virus. The inverse relationship between the CD8+ T cell response and viral 
load (Klein et al., 1995; Ogg et al., 1998), and the loss of HIV-specific CD8 T 
cell responses with disease progression (Carmichael et al., 1993; Klein et al., 
1995) also implicate CD8 cells with immunological control of HIV. The 
association between CD8 activity and a better disease status, with high levels 
of anti-HIV CD8 memory CTL in LTNPs (Greenough et al., 1994; Harrer et al., 
1994; Harrer et al., 1996; Rinaldo et al., 1995), which are sustained (Klein et 
al., 1995) also implies an important role for the CD8 response in controlling 
replication and preventing disease in such subjects. The influence of MHC 
genes on the course of infection (Kaslow et al., 1996), with HLA alleles such 
as B27 and B57 being associated with slow and B35 being associated with 
rapid disease progression (Carrington et al., 1999) also suggests that class I- 
restricted CD8 responses have an important influence. In addition, that 
resistant women who appear ‘resistant’ to infection despite repeated exposure 
to HIV show evidence of HIV-specific T cell responses further suggests that 
they may contribute to protection against infection (Fowke et al., 2000; Kaul et 
al., 2000; Rowland-Jones etal., 1995; Rowland-Jones etal., 1998).
1.7 Strategies used by HIV-1 to evade control by the HIV-specific CD8+ T 
cell response
Despite the activation of strong CD8 responses which can reduce the initial 
acute viral burst of replication, HIV is not completely eliminated and it is able 
to replicate at high levels in the majority of infected individuals. The following 
discussion focuses upon how the virus might evade the HIV-specific CD8+ 
response. The mechanisms involved fall into three categories as discussed in 
section 1.5.
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1.7.1 Avoidance of recognition by the host immune response
HIV is able to avoid detection by the host immune response by establishing a 
latent infection in resting memory CD4+ T cells and/or macrophages (and 
possibly other cell types) (Embretson et al., 1993). In this situation, the viral 
genome (as cDNA) is integrated into the host genome, but is transcriptionally 
silent in the absence of activation and the associated lack of transcription 
factors. In this state, the virus is able to lay dormant and escape immune 
surveillance until cellular activation induces viral gene expression at a later 
time. This constitutes a stable viral reservoir that is a major obstacle to the 
eradication of virus using antiretroviral drugs.
HIV is also able to hide from the cellular immune response by establishing 
infection in anatomical locations to which T cells normally have no access. 
Such immunologically privileged sites in which HIV can be sequestered are 
also typified by limited MHG expression and an immunoregulatory 
environment, and include the brain, testes and eye. The latency and 
sequestration of HIV in anatomical and cellular reservoirs and the implications 
for eradication by antiretroviral therapy is reviewed in (Hamer, 2004; Persaud 
et al., 2003; Saksena & Potter, 2003; Shearer, 1998; Wassef et al., 2003).
Since high levels of productive viral replication also take place in sites readily 
accessible to the immune response, other mechanisms must be involved in 
evasion of the CD8 response. One way is through the virus avoiding antigen 
presentation to and recognition by CD8 cells by downmodulation of MHC class 
I. Three HIV proteins are able to reduce the expression of MHC on the surface 
of infected cells (reviewed in (Kamp et al., 2000)).
Nef is able to cause selective internalisation of MHC molecules from the cell 
surface and thereby protect infected cells against CTL-mediated lysis (Collins 
et al., 1998). Newly-synthesised MHC molecules are recruited into clathrin- 
coated pits and diverted towards the endosomal pathway where they 
accumulate in the trans-Golgi network and are degraded as they leave 
(Greenberg et al., 1998; Le Gall et al., 1998; Piguet et al., 1998; Schwartz et 
al., 1996). This downregulation of MHC is selective for HLA-A and HLA-B, 
since these contain a critical tyrosine residue in their cytoplasmic domain 
which is a necessary determinant for being able to respond to Nef (Le Gall et 
al., 1998; Parham et al., 1995). As already mentioned, the downregulation of 
MHC leaves cells susceptible to attack by NK cells. Infected cells still 
expressing HLA-C and HLA-E are however able to evade NK cell-mediated
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destruction, since NK cells express receptors for HLA-C and HLA-E which 
inhibit NK cell activation (Cohen etal., 1999).
HIV Tat and Vpu are also able to downregulate MHC by other mechanisms 
which act prior to Nef-mediated internalisation of MHC. Tat is able decrease 
the promoter activity of the class I gene (Howcroft et al., 1993) by its 
interaction with a transcription factor (Weissman et al., 1998), whereas Vpu is 
able to interfere with an early step in the biosynthesis of MHC class I 
molecules and induce the rapid loss of newly-synthesised class I heavy chains 
in the ER (Kerkau et al., 1997).
Although in vitro studies show that a number of mechanisms act to reduce the 
expression of MHC class I, downregulation may not be complete. One in vitro 
study showed that although infection led to a 50% reduction in class I 
expression on the cell surface, lysis by CTL clones was unaffected (Yang et 
al., 1996). By contrast, other studies have shown that MHC class I 
downregulation can impact in the efficiency of CTL lysis (Collins et al., 1998). 
Therefore the extent of protection from CTL attack afforded by the 
downregulation of MHC class I molecules in infected cells in vivo is unclear.
One major way in which HIV can evade the virus-specific CD8 response is via 
antigenic variation. Mutational escape has been observed in other viral 
infections as a means of avoiding antibody or CTL recognition, but it seems to 
be particularly important in the case of HIV-1 (and SIV) infection.
It has been estimated that each time the 10kb genome of HIV is replicated, on 
average, one nucleotide substitution is introduced (Mansky & Temin, 1995). 
This is driven by two features of HIV replication which make the virus 
susceptible to mutational change: the high rate of viral replication, and the lack 
of proof-reading activity of the reverse transcriptase enzyme of this RNA virus. 
Any genetic change which results in a growth advantage will be rapidly 
selected for in vivo. In the face of the pressure exerted by the anti-viral CD8+ T 
cell response on viral replication, antigenic variants which can escape the CTL 
response will be selected for as they will have a replicative advantage. 
However, there are constraints on immune escape (Wagner et al., 1999). 
Mutations may arise that are in regions essential for replication, resulting in a 
virus that is unable to propagate itself (Nietfield et al., 1995). So even though 
the mutations that arise may abrogate CTL recognition, they may also strongly 
impair viral replication. For the mutant virus to outgrow in the viral 
quasispecies, the benefit to be gained must outweigh any deleterious costs to
88
viral fitness. The capacity for mutations to be selected for in functionally 
important, more conserved regions of the genome, is therefore more limited. 
The pressure exerted by the CD8+ T cell response on an individual epitope will 
depend on both the magnitude and the efficacy of the response. Factors which 
determine the effectiveness of an epitope-specific response (and therefore 
influence the likelihood that escape variants will be selected for) may include 
the functional capacity of the epitope-specific T cells, and the avidity of 
recognition of the epitope by the T cells (O'Connor et al., 2002). The timing of 
expression of the protein containing the epitope may also be important, for the 
kinetics of epitope expression may influence the effectiveness of HIV-specific 
CTL (van Baalen et al., 2002; Yang et al., 2003). Changes in dominant 
epitopes in early expressed proteins that elicit high avidity T cell responses 
may have a particularly great impact on immune control, and may thus be 
selected for rapidly.
Variation within a targeted epitope (or flanking residues) can confer escape 
from CTLs by altering epitope processing (Allen et al., 2004; Del Val et al., 
1991; Draenert et al., 2004b; Jones et al., 2004; Yokomaku et al., 2004), the 
ability of the epitope peptide to bind to MHC (Borrow et al., 1997; Couillin et 
al., 1994; Goulder et al., 1997a; Price et al., 1997; Rammensee & Monaco,
1994) or by altering the interaction of the MHC-peptide complex with the TCR 
(McAdam etal., 1995; Rammensee & Monaco, 1994; Reid etal., 1996).
Not only can the cytolytic activity of epitope-specific CD8 cells be impaired if a 
variant epitope fails to be recognised, for signalling through the TCR following 
antigen binding also results in chemokine release. Epitope variants that bound 
to HLA molecules but failed to stimulate cytolytic activity in CTLs were shown 
to also fail to stimulate chemokine release (Price et al., 1998). Therefore 
antigenic variation might not only allow escape but might contribute to 
propagation of infection by its knock-on effect of reducing the inhibition of HIV 
entry by chemokines.
Furthermore, antigenic variation can have other effects on the T cell response 
besides escaping recognition by CTL. Epitope variants can induce anergy in T 
cells, antagonising the response to the original epitope, such that the 
response to the wild type virus is also impaired (Klenerman et al., 1994). 
Altered interaction of the MHC-peptide complex with the TCR can also result 
in abnormal signalling, such that immunogenic variant peptides may induce 
the expansion of cells without effector function that are unable to control the 
mutant virus (McAdam et al., 1995).
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That CTL escape is a feature of HIV (and SIV) infection has been observed 
during various stages of infection. Escape from immunodominant CTL 
responses can occur very rapidly in acute/early infection (Borrow et al., 1997; 
Price et al., 1997). In primary HIV infection, the high virus turnover and large 
expansions of HIV-specific T cells may promote the rapid selection and 
fixation of escape mutants. Rapid CTL escape is also frequently seen in 
primary SIV infection (Allen et al., 2000b; Evans et al., 1999; O'Connor et al., 
2002; O'Connor et al., 2003).
Selection for CTL escape viral variants has also been observed during mid­
stage infection (Brander et al., 1998; Goulder et al., 1997b), but unlike during 
primary infection, mutations are frequently not selected for to completion 
within the viral quasispecies at this stage of infection.
Antigenic variation within an immunodominant epitope may shift responses to 
weaker epitopes. This may however weaken immune control over the virus 
because the subdominant CTL response may be less effective (Nowak et al.,
1995). Mutations can thus alter patterns of immunodominance. A complex 
picture of shifting hierarchies of immunodominance among CTL of different 
specificities and corresponding oscillations in the composition of the viral 
quasispecies emerges.
The frequency of occurrence of CTL escape during mid-stage infection may 
be lower than that in primary infection because of several factors:
i) The lower rate of viral replication at this stage, and a corresponding lower 
rate of mutation.
ii) The frequency of HIV-specific CD8 cells is lower than in primary infection, 
reducing the immune pressure exerted.
iii) Escape may be less common later on in infection as the CD8 T cell 
response may be broader than in primary infection (Draenert et al., 2004a), 
reducing the advantage to be gained from escaping from any one component 
of the response.
iv) Any mutations that arise may be associated with high costs to viral fitness 
or else they would have already been selected for during primary infection.
v) The humoral response comes into play to contribute to control of viral 
replication, and so the advantage to gained from evading the CD8 response is 
not as great.
The selection for mutant forms of virus which escape CTL responses has also 
been seen during late infection in association with progression to AIDS 
(Goulder etal., 1997a; Kelleher etal., 2001), and also during late SIV infection
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(Evans et al., 1999). Escape at this stage of infection may ultimately contribute 
to the loss of control of replication as a declining immune system is less able 
to make new responses to new epitopes which emerge. In support of this, the 
emergence of an escape mutation during late infection was coincident with re- 
emergence of viraemia (Feeney et al., 2004). However viral mutation may also 
be considered to be the result of increased viral replication. Mutations arising 
at this stage could be expected to be associated with high fitness costs to the 
virus. However, additional compensatory mutations can evolve over time to 
allow the outgrowth of the escape virus (Kelleher et al., 2001) (although 
reversion to wild type sequences may still occur on transmission to new hosts, 
suggesting that compensatory mechanisms may only be partial).
Therefore mutational escape may play a major role in undermining CTL 
control of virus replication and the ultimate ability of the host to control the 
infection. In support of this, associations have been observed between 
immunodominant responses that are not escaped and good control of 
replication, as seen for a B57-restricted epitope (Migueles et al., 2003). 
Furthermore, the limited emergence of escape viral variants in the context of 
good viral control compared to rapid selection for mutations in multiple 
epitopes in the setting of poor viral control has been reported (Jones et al., 
2004).
That CTL escape is common in HIV infection was demonstrated in a study of a 
large population of chronically infected patients, in which RT sequences from 
the study population were analysed (Moore et al., 2002). Polymorphisms were 
most evident at sites of least functional constraint and a number were found to 
be associated with particular MHC class I alleles and to lie within epitopes 
known to be presented by these alleles. These ‘footprints’ provided evidence 
of adaptation by the virus to HLA-restricted immune responses at a population 
level.
CTL escape could influence the evolution of the virus in the population as a 
whole as well as within an individual, as evidence suggests that CTL 
mutations in certain epitopes can be stable when transmitted and accumulate 
(Goulder et al., 2001b). In this study of the vertical transmission of virus 
encoding CTL escape variants in a dominant Gag epitope, an infected infant 
was found to target an otherwise subdominant B27-restricted epitope and 
failed to control replication. The escape variant remained stable without 
reversion in the absence of the pressure that originally selected for the 
mutation. Other studies, however, show that CTL escape variants may revert
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to the wild type sequence in vivo in a new host in the absence of the original 
selective pressure (Allen e ta l., 2004; Leslie etal., 2004). In one case, despite 
the reversion back to wild type of one escape mutant within an epitope, 
another epitope mutation within the same epitope in the same patient was 
maintained (Leslie et al., 2004). The costs to viral fitness exacted in escape 
may be an important factor which dictates reversion (Friedrich et al., 2004). 
Viral escape from CTL recognition may be a major limitation to CTL-based 
vaccines, as evidenced by the failure of an experimental AIDS vaccine as a 
result of escape from CTL recognition. Mutation within an immunodominant 
Gag epitope in animals vaccinated and then challenged with pathogenic 
simian-human immunodeficiency virus (SHIV) resulted in escape from the 
vaccine-induced response, a burst of viral replication and progression to AIDS 
(Barouch et al., 2002).
1.7.2 Induction of a sub-optimal host immune response 
Another explanation as to how HIV can persist in the face of the CD8 
response would be that the response may not possess all the characteristics 
of an effective anti-viral response.
Analysis of CD8+ T cell responses to many different viruses (e.g. LCMV, EBV, 
CMV and HCV) has suggested that effective CD8 responses are rapidly 
induced (Moskophidis et al., 1987a), strong (Callan et al., 1998b; Cooper et 
al., 1999; Lechner etal., 2000a; Murali-Krishna etal., 1998; Wills etal., 1996), 
broadly directed (Cooper et al., 1999), functional (Gruener et al., 2001; Zajac 
et al., 1998) and sustained (Cooper et al., 1999; Lechner et al., 2000a). There 
have been relatively few studies of the virus-specific CD8+ T cell response in 
acute/early HIV infection and it is currently unclear how well it conforms to 
these parameters. The following discussion reviews what is currently 
understood about various aspects of the nature of the HIV-specific CD8 
response which could impact upon the efficiency of control of viral replication.
A number of studies have been carried out to investigate the magnitude of the 
HIV-specific CD8+ T cell response in patients with different persisting viral 
loads to address whether this is one of the determinants of the efficiency of 
control of viral replication and disease prognosis. Different studies have come 
to different conclusions with regard to the relationship between the magnitude 
of the HIV-specific response and viral load. This may reflect the different 
methods used to quantitate HIV-specific cells, different patients cohorts used,
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the stage of infection when the response was studied, or differences in the 
proteins studied.
Some studies have found an inverse relationship between HIV-specific CTL 
frequency and viral load (Edwards etal., 2002; Greenough etal., 1997; Ogg et 
al., 1998; Rinaldo et al., 1995; van Baalen et al., 1997), supporting a role for 
HIV-specific CD8 responses in limiting replication. By contrast, several studies 
have found no relationship between the total magnitude of the HIV-specific 
CD8+ T cell response and the viral load at different stages of infection and do 
not agree that high frequency responses are associated with better 
containment (Addo et al., 2003; Betts et al., 2001; Cao et al., 2003; Dalod et 
al., 1999a; Draenert et al., 2004a; Gea-Banacloche et al., 2000). This 
suggests some other parameters of the response may differentiate patients 
who contain viral replication well.
Another aspect of the CD8 response which may be important in determining 
its effectiveness is the epitope breath of the response, and the extent to which 
the overall response is biased towards a limited number of immunodominant 
epitopes. CTL escape is favoured if a particularly immunodominant response 
is made towards an individual epitope, as it is highly advantageous to the virus 
to escape from this response. It follows that escape would not be favoured in 
the setting of a broadly directed, co-dominant response targeting multiple 
epitopes where the immune pressure is spread out over a greater proportion 
of the viral genome, as escape from any one component of the response 
would not be as advantageous. The breadth of the HIV-specific CD8 response 
could thus impact upon the likelihood of the occurrence of CTL escape, and 
consequently the efficiency of control of HIV replication. That expansion of a 
response of limited breadth was associated with poor control of early viral 
replication was shown by the analysis of distortion of the T cell repertoire 
during primary infection in patients who established different persisting viral 
loads (Pantaleo et al., 1997b). The implications of mounting responses of 
different breadths on CTL escape are also highlighted by a small study in 
which the breadth of the primary CTL response and extent of escape were 
compared in patients with differing persisting viral loads. It was found that 
escape was indeed restricted in a patient where there was a relatively broad, 
co-dominant distribution of CTL pressure, and that this was associated with 
establishment of a low persisting viral load (Jones et al., 2004). Further 
studies are required to determine whether highly immunodominant responses
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are more common in patients with poorer prognosis, and what factors 
contribute to the induction of a skewed response as opposed to a broad 
response.
Two studies have reported no relationship between the number of epitopes 
recognised and the viral load (Addo et al., 2003; Masemola et al., 2004) but 
these predominantly focused on chronically-infected patients, and neither 
addressed the relative dominance of epitope-specific responses in the study 
populations. Notably, one study suggested that that the primary response in 
many patients may be of limited specificity, as responses were detected to 
fewer epitopes in patients with primary infection compared to those with 
chronic infection (Dalod et al., 1999b), although it is possible that this was due 
to differences in the specificity of the response in primary compared to chronic 
infection (Goulder et al., 2001a), with the set of epitope peptides used to 
assess response breadth in the former study representing epitopes typically 
recognised in chronic rather than primary infection.
In support of the breadth of the response influencing the efficiency of control of 
viral replication are studies which link the degree of HLA heterozygosity with 
the rate of progression to AIDS (Carrington et al., 1999). Individuals with the 
greatest degree of heterozygosity at HLA A, B and C loci would be able to 
present a wider range of epitopes, and consequently elicit responses of 
greater diversity and breadth.
In addition to the breadth of the response in terms of the number of T cells of 
different specificities, the clonality of individual epitope-specific responses may 
also be important. Epitope-specific responses which are dominated by limited 
numbers of T cell clones have been associated with poorer control of 
replication, implying that clonal breadth may be important in influencing control 
(Kalams et al., 1994). Limited TCR diversity against an immunodominant 
epitope may limit recognition of virus variants with mutations in regions 
interacting with this TCR, thereby facilitating escape. The greater degree of 
clonality of the virus-specific CD8 response in HIV-2 infection may contribute 
to the better control of virus in HIV-2 infection compared to HIV-1 infection 
(Lopes et al., 2003). The relatively limited breadth of TCR usage of HIV-1 
epitope-specific CD8 cells was found to be associated with a less flexible 
response in terms of the ability to respond to amino acid substitutions within 
these epitopes. By contrast, the more diverse TCR usage of HIV-2-specific 
CD8 cells was associated with a greater ability to cross-recognise epitope 
variants and proliferate and produce IFN-y. Polyclonal responses may
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therefore have an enhanced capacity to tolerate mutations within epitopes. 
However, the preferential utilisation of specific TCRs may also be 
advantageous. For example a single TCR may be able to recognise multiple 
variants of an epitope, limiting the chances that viral mutation will lead to loss 
of CTL reactivity against the variant epitope (Dong et al., 2004).
TCR use may be also important in determining the avidity of interaction 
between CD8+ T cells and the APCs/targets cells; studies have suggested that 
TCR affinity may impact on the efficiency with which CD8+ T cells mediate 
control of viral replication (O'Connor et al., 2002; Yang et al., 2003).
The epitope specificity of the HIV-specific CD8 response may also be of 
importance in determining its efficacy. It is suggested that the timing of target 
cell recognition critically contributes to CTL effectiveness (Gruters et al., 2002) 
so direction of responses against epitopes in proteins expressed early in the 
viral lifecycle may be beneficial. Rapid epitope presentation on infected cells 
could allow infected cells to be detected by HIV-specific CD8 cells sooner, and 
allow a longer window of opportunity for CTL action before the release of viral 
progeny, and also before Nef-induced downregulation of MHC expression 
allows evasion of HIV-specific CTL. Proteins such as Rev, Tat and Nef are 
expressed early in the viral lifecycle, so CD8 responses directed epitopes 
within these proteins may be particularly efficacious. In vitro studies have 
supported this (van Baalen et al., 2002; Yang et al., 2003). Also, there is 
evidence for CTL responses directed against Tat being particularly effective in 
controlling in vivo virus replication. Reports of rapid escape from early protein- 
specific CTL during primary SIV infection (Allen et al., 2000b; O'Connor et al., 
2001) imply that Tat-specific CTLs may be significantly involved in controlling 
replication and may have a high in vivo efficacy. Various studies have also 
shown that vaccine-induced responses against early proteins are associated 
with more efficient control of viraemia (Cafaro et al., 1999; Maggiorella et al., 
2004; Stittelaar etal., 2002).
There is evidence that the high cost of escape to intrinsic viral fitness may 
restrict viral escape from CTL responses to particular epitopes (Jones et al., 
2004; Kelleher et al., 2001; Wagner et al., 1999). The epitope specificity of the 
HIV-specific CD8+ T cell response may thus also impact on the efficiency of 
control of virus replication in that responses which target functionally 
constrained regions of the genome (and hence are difficult for the virus to 
escape) may be advantageous.
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Another parameter that may affect the efficiency with which HIV-specific CD8+ 
T cells combat virus replication is their functional capacity. There have been 
questions raised about the functional capacity T cells for despite the induction 
of quantitatively large HIV-specific CD8+ T cell responses, they are unable to 
mediate complete control over viral replication. In one study, it was found that 
the majority of HIV-specific CD8 cells in the peripheral blood contained low 
levels of perforin, reflected by poor ex vivo killing, when compared to CMV- 
specific cells within the same individual, which expressed high levels of 
perforin and killed well (Appay et al., 2000). Low levels of perforin have also 
been reported in the CD8 cells in lymph nodes of infected patients (Andersson 
etal., 1999; Trimble & Lieberman, 1998).
The effector function of CD8+ T cells is related to their differentiation status, 
which is defined by the expression of specific cell surface markers. The 
perforin-deficient HIV-specific CD8+ cells were shown to have lost CD28 
expression but retain to CD27 expression. By contrast, CMV-specific cells lose 
the expression of both markers of cellular differentiation, marking them out as 
mature effectors (Hamann et al., 1997), whereas the HIV-specific cells may be 
pre-terminally differentiated cells. In agreement with this, other studies using 
different markers show that the phenotype of HIV-specific cells (CCR7' 
CD45RA') lies between that of immature CD8+ T cells (CCR7+ CD45RA+) and 
fully mature CD8 cells (CCR7' CD45RA+, the phenotype of CMV specific CD8 
cells) (Champagne et al., 2001). The altered differentiation status of HIV- 
specific cells may thus affect their effector function as well as homing 
properties. Other features of the HIV-specific CD8 response suggestive of 
incomplete maturation include low ex vivo IL-2 production and proliferative 
capacity (Migueles et al., 2002).
The reasons for inappropriate maturation of T cells and their dysfunction are 
not well understood, but may include impaired TCR signalling. CD3£ a 
signalling component of the TCR complex, was found to be downmodulated in 
HIV-specific CTL (Trimble & Lieberman, 1998). Its expression was shown to 
increase after culture in an IL-2-dependent manner, coincident with restoration 
of cytotoxic activity, suggesting that IL-2 is a co-factor necessary for proper 
activation of CD8 effector cells. In agreement with this, another study has 
shown that the deficits in effector function seen in SIV-specific CD8 cells in 
primary infection were reversible on extended incubation with IL-2 (Xiong et 
al., 2001).
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The failure of CD8 cells to mature could therefore be a consequence of 
impaired CD4 help, as CD4 T cells provide cytokines in addition to important 
cell-cell contact interactions with APCs needed for activation of CD8 cells. The 
positive correlation between levels of p24-specific proliferative responses and 
levels of Gag-specific CTL precursors (Kalams et al., 1999b) highlights the 
association between CTL and helper responses. Further evidence to link APC 
function with CD8 function is the finding that CD28 co-stimulation increases 
the non-cytotoxic suppression of HIV replication in CD4 cells by CD8 cells 
(Barker et al., 1997).
By affecting the function of CD4s and activation of APCs, and thus altering the 
pattern of cytokine production and engagement of cellular receptors, HIV may 
thus disrupt the signalling required for proper CD8 maturation. Improper TCR  
stimulation may promote the functional unresponsiveness of CD8 cells, and 
decrease the circulating pool of effector and memory CD8 cells able to combat 
infection.
Another consequence of impairment of CTL function is that it may result in 
higher rates of mutation owing to the higher level of viral replication due to 
poor control by dysfunctional cells. This may further favour the selection of 
escape variants and thus contribute to failure of immune control of viral 
replication.
1.7.3 Resistance to host effector mechanisms
HIV is also able to resist the effector mechanisms of HIV-specific cells. One 
way in which it does this is a consequence of the transition of the virus from 
the R5 type which utilises the CCR5 co-receptor, to the X4 type which uses 
the CXCR4 co-receptor during disease progression. A switch in co-receptor 
usage means that the virus will become insensitive to the effects to the CC 
chemokines released by activated CD8 cells, as they will no longer compete 
for the common receptor that they share.
The virus is also able to resist cytolysis by CD8 cells using a number of 
mechanisms. HIV is able to infect cells which may be inherently resistant to 
apoptosis, for example macrophages. It is thought that the differentiation of 
monocytes is accompanied by the upregulation of anti-apoptotic molecules 
and downregulation of pro-apoptotic molecules, resulting in the development 
of macrophages which are able to avoid destruction by CTL (Kedzierska & 
Crowe, 2002; Lum & Badley, 2003). HIV may also induce resistance to CTL in 
cells it infects. Studies of HIV proteins and their affects on apoptosis have
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suggested that Nef, Vpr and Tat have regulatory effects on apoptotic 
processes (Badley et al., 2000; Conti et al., 1998; Xu et al., 2001). Most 
notably, Nef has been shown to inhibit Fas and TNFR-1 signalling pathways 
through its interaction with ASK-1, a key signalling intermediate (Geleziunas et 
al., 2001) and inhibition of caspase 3 and 8 activation (Yoon et al., 2001). HIV 
Nef can also, via kinase activation, phosphorylate and inactivate bad, a pro- 
apoptotic molecule, and thereby block apoptosis in T cells (Wolf et al., 2001). 
Infected cells can also ‘fight back’ against CTL by promoting apoptosis of 
CD8+ CTL via the Fas pathway. Because HIV-specific CD8+ T cells almost all 
express Fas, this renders them highly susceptible to Fas-induced apoptosis if 
they come into contact with cells expressing FasL. HIV Nef can mediate 
upregulation of the expression of FasL on the surface of infected cells (Xu et 
al., 1997). This involves the interaction of Nef with the TCR zeta chain to form 
a signalling complex for the upregulation of FasL expression (Xu et al., 1999), 
and results in the Fas-mediated apoptosis of virus-specific CTL that come into 
contact with infected cells. Another mechanism by which CD8+ T cells can be 
triggered to undergo apoptosis is via TNF-induced death (Herbein et al.,
1998). The gp120 component of the HIV envelope can bind to CXCR4 on 
macrophages and induce the expression of TNF.
In summary, HIV is known to stimulate the induction of an innate response 
and virus-specific cell-mediated and humoral responses. Despite this, HIV is 
not cleared and is able to establish a persistent infection in the vast majority of 
infected individuals. This is likely due to multiple immune evasion mechanisms 
used by the virus. These may include weakened innate defence mechanisms, 
impairment, evasion and resistance to control by the humoral response, 
together with a variety of mechanisms for evading the anti-viral CD8+ T cell 
response as discussed in detail here. Among the factors contributing to the 
difference in persisting viral load established in different HIV-infected 
individuals are likely to be the nature of the early antiviral immune response, 
and the extent to which this is evaded. A better understanding of the 
mechanisms involved, including the impact that defects seen in the HIV- 
specific CD4+ T cell response during primary infection may have on the virus- 
specific CD8+ T cell response, will help to facilitate the design of successful 
therapeutic and prophylactic strategies to combat HIV-1 infection and perhaps 
other persistent virus infections.
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1.8 HIV-1 control, therapy and vaccine development
1.8.1 Control of transmission of HIV-1 infection
Several strategies to prevent HIV transmission are in use (reviewed in 
(Valdiserri et al., 2003)). Globally, most cases of transmission result from 
unprotected sexual intercourse. Ways to prevent sexual transmission include 
promoting the adoption of safer sexual practises, use of microbicides and 
improving diagnosis and treatment of other sexually transmitted infections 
among those who are at risk for acquiring HIV, since it is known that untreated 
sexually transmitted infections can facilitate the transmission and acquisition 
of HIV (Wasserheit, 1992).
The screening of donated blood (and blood products) has virtually eliminated 
the spread of transfusion-associated HIV. Parenteral transmission in health 
care settings, for example occupational needle stick injury, can be avoided if 
safe working practises are used, treating blood and other bodily fluids from all 
patients as potentially infectious. The promotion of behavioural risk reduction 
and access to sterile needles has prevented the spread of HIV among 
injecting drug users.
Vertical transmission of HIV is estimated to be responsible for more than 90% 
of infections in children and infants (Quinn, 1996). Without treatment the risk 
of vertical transmission is 25-30%. In the developed world, the use of HAART 
can fortunately prevent the perinatal transmission of HIV in nearly 99% of 
cases (Minkoff, 2003). To prevent the transmission of HIV through breast milk, 
particularly in the developing world, breast milk formulas can be used.
Although such preventative interventions have been effective, in varying 
degrees, in curbing the spread of HIV, millions around the world are infected 
and so therapeutic strategies have to be employed.
1.8.2 HIV-1 antiretroviral therapy
As a result of the development of therapy, HIV has now become a treatable, 
chronic infection in the developed world. Several drugs targeting different 
parts of the viral life cycle are currently in use (reviewed in (Pomerantz & 
Horn, 2003)).
Introduced in 1987, zidovudine (azidothymidine (AZT)) was the first drug to be 
widely used. This is a nucleoside analogue which inhibits the HIV reverse 
transcriptase enzyme, termed a NRTI (nucleoside reverse transcriptase 
inhibitor). To enable viral replication to proceed, the ss RNA HIV genome is 
converted to ds DNA by reverse transcriptase. NRTIs competitively inhibit
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reverse transcriptase by binding to the DNA chain and terminating its 
production, thus blocking viral replication.
Another class of drugs, the NNRTIs (non-nucleoside reverse transcriptase 
inhibitors) also target and inhibit the reverse transcriptase enzyme. These are 
a group of structurally diverse agents that, by binding at a distal position, 
induce conformational changes at the active site and effectively denature the 
enzyme.
Progress in drug development has led to the availability of new classes of 
drugs targeting different steps in the viral life cycle. The HIV Protease is 
responsible for the maturation of viral particles to infectious virions. Protease 
inhibitors bind to the active site of the enzyme and stop the protein cleavage 
events involved in the maturation of virions.
More recently fusion inhibitors were developed. These interfere with the fusion 
of the viral membrane with the cell membrane, thereby inhibiting viral entry. 
This involves preventing the full conformational changes in gp41 required for 
fusion.
Clinical trials are also underway to look at the clinical efficacy of integrase 
inhibitors and chemokine receptor entry inhibitors.
Initially the reverse transcriptase inhibitors were used as monotherapies. 
However, it was recognised that the effect of monotherapy was brief and 
limited. Although they did reduce viral load, their suppressive effect on viral 
replication was incomplete, and the high ongoing level of replication together 
with the selective pressure exerted by the drug enabled viral variants carrying 
mutations conferring drug resistance to emerge among the quasispecies 
(Concorde Coordinating Committee, 1994; Larder & Kemp, 1989; Volberding 
et al., 1995).
With the increased availability of a wider range of other agents, various 
combination therapies were introduced. The triple combination therapy, or 
HAART, in use today effectively suppresses viral replication (Hirsch et al.,
1999), giving a more robust durable reduction in viral load (often to below the 
level of detection) and consequently limits the emergence of drug resistant 
variants. Furthermore, long term use of HAART is associated with the 
restoration of immune function, with the regeneration of robust CD4 and CD8 
cellular responses to recall antigens (Autran et al., 1997; Li et al., 1998b). 
However, there are several drawbacks associated with the use of antiretroviral 
drugs. The side effects of the drugs involve metabolic complications, including 
lactic acidosis, diabetes mellitus, lipodystrophy and pancreatitis (Carr et al.,
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2000; Carr et al., 1999; Carr et al., 1998; Safrin & Grunfeld, 1999). The 
complicated regimens, requiring the intake of numerous tablets multiple times 
on a daily basis mean that there are adherence issues too. Poor adherence 
can result in an increase in viral replication, and facilitate the emergence of 
drug-resistant viral variants.
Despite the ability of HAART to reduce the plasma viral load to undetectable 
levels, obstacles to total eradication of the virus are presented by the low 
levels of replication that occur ‘cryptically’ in the presence of HAART 
(Dornadula et al., 2001; Dornadula et al., 1999) plus the existence of cellular 
reservoirs of latent infection, that can re-emerge after the withdrawal of 
therapy (Finzi et al., 1997; Wong et al., 1997). The timing of initiation of 
antiretroviral therapy is though to influence the level of residual viral reservoir, 
with early treatment found to result in a greater decline of HIV proviral DNA 
levels (Pires et al., 2004).
So although combination antiretroviral therapy has been successful in 
significantly reducing morbidity and mortality in the developed world, issues of 
drug resistance and viral reservoirs remain. Furthermore, the use of such 
therapy where it is much needed in the developing world is hindered by the 
high costs and lack of medical expertise and infrastructure required to 
implement it.
1.8.3 HIV-1 vaccine development
As already discussed, there is an urgent need to develop prophylactic 
vaccines to prevent the further spread of HIV infection. There is evidence that 
the host immune response may in some cases prevent HIV. The 
demonstration in individuals who are reported to be persistently exposed to 
HIV yet seronegative of HIV-specific T cell and antibody responses (Broliden 
et al., 2001; Devito et al., 2000; Devito et al., 2002; Kaul, 2001; Kebba et al., 
2004; Mazzoli et al., 1997; Rowland-Jones etal., 1995; Rowland-Jones et al., 
1998) suggests that vaccination might prevent or abort early infection. 
However despite intense efforts over the last twenty years, the development of 
an effective vaccine has proved difficult.
The majority of vaccines currently in use for protection against infection with 
different microorganisms work primarily through the induction of neutralising 
antibodies. However, the only HIV protein known to be a target for neutralising 
antibody is the HIV envelope and, as discussed earlier, the structure of the 
envelope makes it difficult for the host to generate antibodies capable of
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neutralising primary HIV-1 isolates. The ideal vaccine would be one that 
induces sterilising immunity. The only likely way to achieve that, however, is 
through the induction of an antibody response that prevents infection upon 
exposure to HIV, ideally by neutralising a diversity of isolates. Because of the 
problems of stimulating HIV-specific neutralising antibodies, a number of the 
vaccine approaches currently being pursued are aimed at stimulating T cell 
responses, instead of or in addition to antibody responses.
Vaccines designed to stimulate CD4 and CD8 T cell immunity have been 
shown to confer some degree of protection on macaques from challenge with 
the aggressive SHIV89.6P strain (Amara et al., 2001; Barouch et al., 2000; 
Belyakov et al., 2001; Rose et al., 2001; Shiver et al., 2002). Although the 
vaccinated macaques were infected, their viral load was dramatically reduced 
compared to that in unvaccinated controls.
Thus it is hoped that, although HIV-specific CD8+ CTL cannot prevent the 
initial infection of cells, the induction of a strong T cell response will control 
early infection, reducing primary viraemia. This would have two major 
beneficial consequences: a lower initial viral load setpoint would enable the 
immune system to cope better so that the progression to AIDS is delayed, and 
also with a lower viral burden there is a lower likelihood of transmitting the 
virus. In addition, the role of CD4 cells in supporting the development of 
effective CD8 T cell and antibody responses (for example, in mice CD4 help 
has been shown to be crucial for priming an effective memory CD8 response 
(Shedlock & Shen, 2003; Sun & Bevan, 2003)) calls for the induction of helper 
responses to be an important requirement for an effective vaccine.
The first approaches to vaccine design were based on traditional strategies 
that had proven successful in preventing infection with other viruses. These 
involved the use of live attenuated viruses, inactivated viruses and viral 
components as subunit vaccines.
Live attenuated viral vaccines are generally very good at simultaneously 
inducing several immune effector mechanisms, and are in use for preventing 
polio, measles and varicella. The infection of monkeys with an SIV isolate 
made non-pathogenic by deletion of the gene encoding Nef was reported to 
protect monkeys from subsequent infection with wild type pathogenic SIV 
(Almond & Stott, 1999; Daniel et al., 1992). However safety concerns about 
the long term stability of genetically altered viruses and the possible reversion 
to a pathogenic form, as seen in attenuated HIV (Greenough et al., 1999;
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Learmont et al., 1999) and SIV (Baba et al., 1995; Baba et al., 1999; 
Whatmore et al., 1995; Wyand et al., 1997) strains, have restricted the 
utilisation of live attenuated HIV vaccines. For example, the late development 
of AIDS despite many years of disease-free infection in an Australian cohort 
infected by a single source of contaminated blood products was shown to be 
attributable to the re-emergence of a pathogenic form of a virus initially 
containing a mutation in the nef gene (Deacon et al., 1995; Greenough et al., 
1999; Learmont etal., 1999).
Inactivated virus vaccines have been used to elicit immunity that prevents 
infection with poliovirus and influenza. Despite an initially encouraging result in 
which monkeys were protected from an SIV challenge using a formalin- 
inactivated virus vaccine (Murphey-Corb et al., 1989), this was later shown to 
be the result of induction of an immune response to antigens derived from the 
cells in which the virus was prepared (Stott, 1991). In light of this observation, 
the induction of allogeneic immune responses is being pursued as a possible 
approach to HIV vaccine design (Shearer et al., 1999).
A recombinant protein vaccine for HIV has been sought in the hope of 
following the success of a vaccine against hepatitis B based on such 
technology. The first Env immunogens to be evaluated were monomeric 
recombinant envelope subunit vaccines. These have been tested in both non­
human primate models (Berman et al., 1990; Lubeck et al., 1997) and in 
human volunteers (Cohen, 2003; Connor et al., 1998; Graham et al., 1998; 
Mascola et al., 1996; Montefiori & Evans, 1999). The finding that recombinant 
gp120 protected against challenge with a homologous HIV-1 in vaccinated 
chimpanzees was met with scepticism owing to the use of immunogen and 
challenge virus with identical sequences. Results of the assessment of 
monomeric gp120 in human trials have been disappointing, revealing 
elicitation of antibodies which do not neutralise patient primary HIV isolates 
(Mascola et al., 1996; Montefiori & Evans, 1999). Further, there were no 
benefits to the virological or clinical status of patients who were vaccinated 
with recombinant gp120 and subsequently became infected (Connor et al., 
1998). The first HIV vaccine candidate to progress to Phase III trials was a 
recombinant gp120 vaccine, and this failed to show any protective effect (see 
www.vaxqen.com).
Thus the application of traditional vaccine development strategies to HIV 
vaccine design has proved difficult. An important feature of inactivated viruses
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and recombinant monomeric protein immunogens is that they do not elicit T 
cell responses very efficiently. While live attenuated vaccines stimulate strong 
CD4 and CD8 responses and neutralising antibodies, inactivated virus or 
purified protein subunit vaccines are less efficient, as they are poor at 
stimulating CD8 T cell responses, and the antibody responses induced 
frequently have restricted neutralising ability. Consequently, novel strategies 
are now being pursued in the hope of designing an efficacious vaccine. 
Considerable efforts have been made to evaluate the potential use of live 
vector-based approaches and plasmid DNA immunogens. Genes encoding 
HIV proteins have been inserted into a variety of viral and bacterial vectors. 
Since their antigens are processed through the class I pathway, the immune 
responses to the HIV gene products include antibodies, helper T cells and 
CTL. For example, modified vaccinia Ankara (MVA), a poxvirus which has a 
number of large genetic deletions that attenuate its replicative potential in 
primate cells, is amenable to the insertion of HIV genes, which, when 
presented in this way have proved immunogenic (Barouch et al., 2001; Hirsch 
et al., 1996; Ourmanov et al., 2000; Seth et al., 2000). A variety of other viral 
(e.g. canarypox (Egan et al., 1995; Pialoux et al., 1995), Venezuelan equine 
encephalitis virus (Caley et al., 1997), Semliki Forest virus (Hanke et al., 2003; 
Mossman et al., 1996) (Nilsson et al., 2001) and adenovirus (Ferrari et al., 
1997; Shiver et al., 2002; Vinner et al., 2003)) and bacterial (e.g. BCG 
(Yasutomi et al., 1993) and salmonella (Fouts et al., 1995; Hone et al., 1996)) 
vectors are also being developed as recombinant HIV vaccines. However, one 
concern is that their effectiveness may be limited by pre-existing host 
immunity to the vector, such as may be the case for vectors based on 
common serotypes of adenovirus (Sumida et al., 2004).
DNA immunisation involves inoculation with plasmids encoding pathogen 
antigens. This results in protein production in local transfected cells as well as 
in directly transfected APC, which migrate to regional lymph nodes, eliciting 
both humoral and cellular responses to the specific immunising antigens.
The immunity elicited by DNA vaccines has demonstrated to be sufficient to 
reduce viral replication in monkeys subsequently challenged with SIV and 
SHIV (Barouch et al., 2000; Egan et al., 2000). Furthermore, monkeys 
immunised with DNA vaccines augmented by plasmid IL-2 constructs were 
protected against SHIV disease (Barouch et al., 2000). The use of genes 
coding for cytokines is one strategy employed to enhance the efficacy of 
plasmid DNA vaccination. Other ‘genetic adjuvants’ encoding chemokines or
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co-stimulatory molecules could also be useful. Inclusion of CpG motifs as a 
vaccine adjuvant to enhance the induction of immune responses has also 
been explored. Unmethylated CpG motifs in the DNA sequence have the 
capacity to mimic the ability of microbial DNA to stimulate innate responses 
which, in addition to limiting early viral spread, also promote the development 
of adaptive responses. Multiple delivery of the DNA vaccine and attempts to 
increase cellular uptake of DNA have also been explored as methods to boost 
responses (Estcourt et al., 2004).
The most effective means of augmenting responses induced by DNA vaccines 
has been their incorporation into heterologous prime-boost immunisation 
regimes, taking into consideration that plasmid DNA represents a good 
priming immunogen, but that DNA plasmids may require relatively large doses 
to be immunogenic.
Vaccine design has thus progressed onto the use of bimodal vaccine 
regimens in which one vector (often plasmid DNA) is used to prime the 
immune response and a second (often live recombinant vector) is later used to 
boost that immunity. The use of two different vaccine vectors encoding a 
common immunogen has been recognised as a highly effective method for the 
induction of CTL activity in many models, with responses to the common 
vaccine antigen(s) but not vector antigens being boosted after the subsequent 
immunisation (Hanke et al., 1998; Schneider et al., 1998). The ability of 
DNA/poxvirus combinations to induce enhanced levels of CD8 T cell mediated 
protection has been attributed to the relatively low levels of antigen expression 
from the DNA vector facilitating the induction of higher avidity T cells which are 
then expanded by the booster immunisation (Estcourt et al., 2002); and the 
induction of immune responses with enhanced IFN-y production phenotypes 
or Th1 bias due to the cytokines induced by the vectors at the time of 
immunisation (Ramshaw & Ramsay, 2000; Woodberry et al., 2003). 
Prime-boost regimes (particularly DNA immunisation followed by boosting with 
poxvirus vectors) have been shown to stimulate strong CD8 responses and 
confer significant protection against pathogenic challenge with SHIV in rhesus 
macaques (Allen et al., 2000a; Amara et al., 2001; Hanke et al., 1999; 
Robinson et al., 1999; Shiver et al., 2002). A number of Phase I and II trials 
involving prime-boost approaches are currently in progress.
Despite the current trend to pursue T cell-based vaccine approaches, 
research on ways to elicit HIV-specific neutralising antibody responses has not
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been abandoned. There are a number of encouraging results from studies 
carried out using antibodies showing that antibody-mediated protection is 
possible. Vaccines based on the viral envelope can protect non-human 
primates challenged with homologous virus (Berman et al., 1990; Emini et al., 
1992; Fultz, 1992; Girard etal., 1995; Girard etal., 1997; Lubeck etal., 1997). 
Five broadly cross-neutralising human monoclonal antibodies have been 
isolated (Moore et al., 2001). When passively transfused, these antibodies can 
protect severe combined immunodeficient (SCID) mice reconstituted with 
human lymphoid cells against challenge with HIV (Gauduin et al., 1997) and 
can also protect monkeys against challenge with SHIV (Hofmann-Lehmann et 
al., 2001a; Hofmann-Lehmann et al., 2001b; Mascola et al., 2000; Ruprecht et 
al., 2001). Thus, induction of HIV-specific neutralising antibodies is possible in 
principle.
As mentioned earlier, unlike viruses adapted to laboratory culture, primary HIV 
isolates from infected patients are often resistant to neutralisation (Moore et 
al., 1995). A number of approaches have been explored for engineering the 
structure of the HIV envelope with the aim of eliciting antibodies that may 
neutralise a variety of isolates. These approaches include the engineering of 
correctly folded and oligomerised Env immunogens that mimic the native 
structure of oligomeric Env (Binley et al., 2000; Earl et al., 1997; Earl et al., 
1994; Yang et al., 2002); removing N-linked glycosylation and variable loop 
structures that may be responsible for masking neutralising epitopes (Barnett 
et al., 2001; Binley et al., 1998; Jeffs et al., 1996; Quinones-Kochs et al., 
2002; Reitter et al., 1998; Wyatt et al., 1993); and triggering and stabilising 
conformational intermediates of gp120 and gp41 that arise during fusion, for 
example cryptic epitopes on gp120 that only become exposed after binding to 
CD4 (Fouts et al., 2000), and the pre-fusion intermediate of gp41 (LaCasse et 
al., 1999). However, none of these strategies have yet been successful in 
eliciting broadly neutralising antibody responses.
The antigenic opportunities for inducing CTL responses are not as limited as 
those for trying to elicit humoral responses, for the peptides recognised can 
originate from both surface proteins and inner structural and non-structural 
proteins, which may be relatively conserved, giving a greater number of 
protein targets.
Gag is usually included as an immunogen as seems to be very immunogenic 
in natural infection, contains important helper epitopes, and is also a relatively
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conserved protein (Addo et al., 2003; Betts et al., 2001). Although they are 
quite variable proteins, Nef and Env are also often included as part of vaccine 
constructs. Given the kinetics of expression of these proteins, responses 
targeting them may be particularly efficacious.
One of the problems which HIV vaccine design faces is the enormous 
variability of the virus. It has been estimated that in theory, there is only a 1 in 
3 chance that the T cell response stimulated by a vaccine of one clade will 
recognise the equivalent epitope from another clade (McMichael & Hanke, 
2003). Potential solutions may be to include a combination of immunogens, 
possibly representing consensus clade sequences. It not only at the clade 
level where variability exists, and it is important to stimulate a response that is 
broad enough to cope with variability within clades too. This may necessitate 
splitting a multi-specific vaccine up into separate components rather than 
including them as one long protein so that the immune response sees each as 
a separate antigen against which to react and the immunodominance of 
certain epitopes is minimised (Palmowski etal., 2002; Rodriguez etal., 2002). 
Another reason for eliciting a broad response is that, as discussed earlier, by 
avoiding a narrow response, the danger that an escape mutant may be 
selected for is minimised. It has been shown that vaccine-induced immune 
control can be escaped by mutation (Barouch et al., 2002).
Another important consideration in vaccine design is that high levels of 
immunity may need to be induced at mucosal sites to achieve protection 
against infection (Lehner et al., 1999). The demonstration of the presence of 
HIV-specific neutralising antibody and CD8 responses in mucosal sites in HIV- 
exposed, seronegative individuals (Broliden et al., 2001; Devito et al., 2000; 
Devito et al., 2002; Mazzoli et al., 1997) highlights the importance of mucosal 
immunity in protection against a virus transmitted predominantly across 
mucosal surfaces.
Therapeutic immunisation, whereby HIV components are delivered to 
individuals with established infection in the hope of enhancing their immune 
responses to HIV, is another attractive goal of HIV vaccine research. 
Therapeutic immunisation may prove even more difficult than prophylactic 
vaccination, for inducing immunity in the face of multiple immunological 
defects acquired throughout the course of infection may be a great challenge.
107
Evidence that enhancement of HIV-specific immunity is possible comes from 
studies involving structured treatment interruptions (STIs) (Autran et al., 1997; 
Autran et al., 1999). When therapy is stopped, there is a rise in the level of 
replicating virus which stimulates immune responses, effectively allowing for 
autovaccination using autologous virus. Early treatment followed by an 
interruption has been associated with increased humoral and cellular 
responses and control of viral replication (Lisziewicz et al., 1999; Ortiz et al., 
1999; Rosenberg et al., 2000). However, STIs are not ideal as each burst of 
viral replication is associated with infection of more CD4+ cells and 
undermining of the HIV-specific response. Hence, now attempts are being 
made to administer some of the vaccines discussed earlier in the context of 
HAART.
After many years of research, a number of HIV vaccine candidates are being 
evaluated in uninfected volunteers across the world (see www.iavi.org). These 
vaccine candidates (many of which primarily focus on the elicitation of cell- 
mediated immunity) present HIV immunogens in a number forms, including as 
recombinant proteins, inserts in viral vectors, plasmid DNA and synthetic 
peptides linked to lipid molecules, and are being tested in several 
combinations such as DNA serving as a prime for either protein or viral vector 
boosting. The majority of vaccine candidates are undergoing Phase I and II 
safety and immunogenicity trials, with one Phase III efficacy trial of a 
canarypox prime plus VaxGen gp120 boost in progress, results from which are 
not expected until 2008.
It is uncertain how responses observed in the primate models typically used 
for pre-clinical evaluation of potential vaccines will translate into actual 
protective efficacy in natural human infection. It is questionable as to whether 
they mimic human disease accurately, since the high dose challenges given to 
macaques to guarantee infection are probably far greater than the dose of HIV 
humans are exposed to during sexual contact. Immunisation strategies for 
eliciting strong, efficacious long term memory CD8 responses to vaccine 
antigens in humans need to be optimised; and strategies for eliciting nAb 
responses developed. Thus despite advances in the understanding of basic 
HIV biology and the host antiviral immune response, an effective protective 
vaccine still seems a distant prospect.
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1.9 Project aims
As reviewed above, HIV-1 infection represents a major health problem across 
the world today, already responsible for millions of deaths and continuing to 
spread at an alarming rate. Although antiretroviral drugs which help reduce the 
viral load and delay disease progression are available, they do not eliminate 
infection, and are too expensive for use by the majority of infected individuals. 
Improved immunotherapeutic strategies and a prophylactic vaccine are thus 
urgently needed to control the AIDS pandemic.
One of the factors hampering HIV vaccine development is the current 
incomplete understanding of why, despite the induction of HIV-specific 
immune responses, in particular an apparently vigorous HIV-specific CD8+ T 
cell response, the host is unable to eliminate the infection; and what kind of 
immune response vaccines should aim to elicit to provide good long-term 
control of virus replication.
The persisting viral load established during primary infection is thought to be 
an important prognostic indicator (Mellors et al., 1996). Virus-specific CD8+ T 
cell responses are induced in primary HIV infection (Borrow et al., 1994; Koup 
et al., 1994) and play an important role in control of early virus replication (Jin 
et al., 1999; Schmitz et al., 1999). The nature of the primary HIV-specific CD8+ 
T cell response may thus be among the factors that determine the persisting 
viral load established. Despite its importance, there have been relatively few 
studies of the CD8+ T cell response in acute and very early HIV-1 infection, 
and only limited information is available about its magnitude, kinetics, and 
epitope/clonal breadth or the phenotype and functional properties of the cells 
involved. Importantly, how these aspects of the response may differ between 
infected individuals - particularly individuals in whom primary viral replication is 
contained to differing setpoint persisting viral loads - is also unknown.
The aim of this project was therefore to characterise the primary HIV-specific 
CD8+ T cell response in a number of infected individuals, to gain insight into 
quantitative, kinetic and qualitative features of the response, and if possible to 
determine their relationship to the persisting viral load established in primary 
infection.
The approach taken was to study the primary HIV-specific CD8+ T cell 
response in patients from whom samples were available at sequential 
timepoints beginning prior to/during seroconversion and who did not receive 
antiretroviral therapy during acute/early infection. Important features of this
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approach which have been reproduced in very few other studies include the 
ability to perform a longitudinal analysis of the virus-specific CD8+ T cell 
response during acute and early infection, a critical period during which the 
virus-host dynamic is established; and the ability to analyse the relationship 
between features of the primary CD8 T cell response and the persisting viral 
load subsequently (naturally) established.
In chapter 3, I performed a "comprehensive” analysis of the epitope specificity 
of the CD8+ T cell response in early infection in thirteen patients. Objectives 
here were to gain insight into the number and location of epitopes recognised 
and relative immunodominance of responses to each in early infection and to 
address the hypothesis that there may be differences in the epitope breadth, 
specificity and/or degree of biasing of responses towards immunodominant 
epitopes in patients who controlled viral replication with differing efficiency.
In chapter 4, I addressed the relationship between the functional avidity and 
relative dominance of epitope-specific responses in primary HIV infection, and 
looked for potential viral epitopes which may be cross-recognised by HIV- 
specific CD8+ T cells. I also used murine models to investigate potential 
changes in the hierarchy of antiviral CD8 responses induced under conditions 
of limited CD4 help.
The aims here were to explore whether, when there is a paucity of CD4 help 
as occurs during primary HIV infection, responses involving T cells which are 
less affected by sub-optimal conditions of priming become particularly 
immunodominant in the primary virus-specific CD8 response. Such 
immunodominant responses were hypothesised to involve high avidity/affinity 
responses or memory cells cross-recognising epitopes from a heterologous 
virus.
In chapter 5, I used multimeric peptide-MHC complexes to identify HIV 
epitope-specific CD8+ T cells at sequential timepoints over the course of 
primary infection to follow the kinetics of expansion of, and to assess the 
magnitude of, different individual HIV-specific responses. I also co-stained 
tetramer- (or pentamer-) positive cells with antibodies specific for other cell 
surface and intracellular markers to enable the extent of V/? family usage by T 
cells involved in individual responses and the phenotype of HIV-specific CD8+ 
T cells to be followed over the course of primary infection.
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By using tetramers specific for both immunodominant and subdominant 
responses and studying responses in patients with differing persisting viral 
loads, results of these experiments would enable the hypothesis that there 
may be differences in the kinetics, magnitude, clonality or phenotype of cells 
responding to different viral epitopes and/or in patients who control primary 
viral replication with differing efficiency to be addressed.
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Chapter 2 
Materials & Methods
2.1 Materials
2.1.1 Biochemical Reagents
Reagent Supplier Catalogue number
Acetonitrile Sigma Aldrich Company Ltd, 
Poole, UK
A-3396
Agarose Promega UK, Southampton, UK V-3121
Ammonium sulphate BDH Lab Supplies, Poole, UK 100334C
Bovine Serum Albumin (BSA) Sigma Aldrich Company Ltd, 
Poole, UK
A4503
5’-Bromo-2’-Deoxyuridine
(BrDU)
ICN Biomedicals Inc., Ohio, USA 100171
Concanavalin A (Con A) Sigma Aldrich Company Ltd, 
Poole, UK
C-5275
Coomassie Plus 200 Perubio Science, Tattenhall, UK 23238
Crystal violet BDH Laboratory Supplies, Poole, 
UK
3420244K
Cytofix/Cytoperm™ solution Beckton Dickinson (BD) 
Biosciences Pharmingen, 
Oxford, UK
51-2090KZ
Dimethylsulphoxide (DMSO) Sigma Aldrich Company Ltd, 
Poole, UK
D2650
Ethylene diamine tetra acetic 
acid (EDTA)
BDH Laboratory Supplies, Poole, 
UK
100935V
Ethanol IAH Stores, Compton, UK
Ethanolamine Sigma Aldrich Company Ltd, 
Poole, UK
E9508
Formaldehyde BDH Laboratory Supplies, Poole, 
UK
101136C
Glacial acetic acid BDH Laboratory Supplies, Poole, 
UK
100015N
Heparin (Pump-Hep) Leo Laboratories Ltd, Princes 
Risborough, UK
PL0043/0149
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2-Mercaptoethanol Sigma Aldrich Company Ltd, 
Poole, UK
M-7522
Na51Cr04
(51Cr)
Amersham Pharmacia Biotech 
UK Ltd, Little Chalfont, UK
CJS11
Opti-Phase Supermix 
Scintillant
Wallac, Turku, Finland SC/9235/21
Paraformaldehyde Sigma Aldrich Company Ltd, 
Poole, UK
P6148
Perm/wash ™ buffer BD Biosciences Pharmingen, 
Oxford, UK
51-2091KZ
PHA Sigma Aldrich Company Ltd, 
Poole, UK
L-9132
Potassium chloride Sigma Aldrich Company Ltd, 
Poole, UK
P4504
Sodium carbonate anhydrous BDH Lab Supplies, Poole, UK 102405Y
Sodium hydrogen carbonate BDH Lab Supplies, Poole, UK 102475W
Triton-X-100 Sigma Aldrich Company Ltd, 
Poole, UK
T9284
Tween-20 Sigma Aldrich Company Ltd, 
Poole, UK
P7949
2.1.2 Kits
Kit Supplier Catalogue Number
Chromogenic alkaline BioRad Laboratories Ltd, Hemel 170-6432
phosphatase substrate kit Hempstead, UK
QIAamp DNA blood mini kit QIAGEN Ltd, Crawley, UK 51104
2.1.3 Plasticware
Product Supplier Catalogue Number
6 well plates Becton Dickinson Labwear, NJ, 
USA
353046
24 Well Plates Becton Dickinson Labwear, NJ, 
USA
353047
60mm cell culture dishes Corning Costar, High Wycombe, 
UK
430166
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100mm Petri dishes Fahrenheit Laboratory 
Supplies, Milton Keynes, UK
351029
15ml Falcon tubes Becton Dickinson Labwear, 
NJ, USA
352096
27G Needles Sigma Aldrich Company Ltd, 
Poole, UK
Z19238-4
50ml Falcon Tubes Becton Dickinson Labwear, 
NJ, USA
352070
96 flat bottom plates Corning Costar, High 
Wycombe, UK
3595
96 well round bottom plates Corning Costar, High 
Wycombe, UK
3799
Cell scrapers Becton Dickinson Labwear, 
NJ, USA
3036
Cell strainers (40pm) Becton Dickinson Labwear, 
NJ, USA
352340
Cluster tubes Abgene, Surrey, UK AB-0672
ELISPOT plates Millipore, Watford, UK MAHA S45 
MAIP S4510
Eppendorf tubes 0.5ml 
1.5ml
Tref Ag, Degersheim, 
Switzerland
96.4625.9.01
96.8160.9.02
FACS tubes (5ml round 
bottom polystyrene)
Becton Dickinson Labwear, 
NJ, USA
352054
Filters: 0.45pm Millipore, Bedford, USA 16555
Flasks T150 
T75 
T25
Helena Biosciences, 
Sunderland, UK
90151
9076
9026
Glasstic® Slide 10 
combination coverslip- 
microscope slides
Hycor Biomedical Ltd, 
Penicuik, UK
87144
Internal thread 1.8ml Nunc 
Cryovials
Life Technologies, Paisley, UK 377267
LD MACS columns Miltenyi Biotech, Bisely, UK 130-042-901
Microscope slides Merck Ltd, Lutterworth, UK 406/0184/04
Pasteur pipettes Jencons Scientific, Leighton 
Buzzard, UK
475-068
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Pipettes 5mI 
10ml 
25ml 
50ml
Bibby Sterilin, Stone, UK
Becton Dickinson Labwear, 
NJ, USA
40105
47110
18327
357550
Plate sealers Camlab Ltd, Cambridge, UK EC/005.SPN
Reagent reservoirs (100ml) Corning Inc, NY, USA 4873
Single edge blades TAAB Laboratories Equipment 
Ltd, Aldermaston, UK
B054
Slide-A-Lyzer (1000 MWCO) Pierce & Warriner UK Ltd, 6638122
Dialysis Cassettes Chester, UK
Syringes Scientific Laboratory Supplies, 
Nottingham, UK
SYR 6200
Tips 20ul Rainin Instruments Co Ltd, GPS25
200ul Woburn, USA GPS250
1000ul GPS1000
Universal tubes BDH Lab Supplies, Poole, UK 275/0460/04
2.1.4 Tissue Culture Reagents
Reagent Supplier Catalogue number
AIM V medium Invitrogen Life Technologies, 
Paisley, UK
12055-091
DMEM (Dulbecco’s MEM) with 
Glutamax medium
Invitrogen Life Technologies, 
Paisley,UK
31966-047
Foetal Calf Serum (FCS) 
(normal grade)
PAA Laboratories, Linz, 
Austria
A15-002 
(Lot: 083)
Foetal Calf Serum 
(high grade)
Invitrogen Life Technologies, 
Paisley, UK
10106-169 
(Lot: 40Q1282F)
Histopaque-1077 Sigma Aldrich Company Ltd, 
Poole, UK
H8889
Human Male AB serum Sigma Aldrich Company Ltd, 
Poole, UK
H-4522
M199 medium Invitrogen Life Technologies, 
Paisley, UK
21157-029
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MEM (Eagle’s) with Glutamax 
medium
Invitrogen Life Technologies, 
Paisley, UK
41090-028
Phosphate Buffered Saline 
(PBS)
Institute for Animal Health 
media supply
Penicillin & Streptomycin IAH Media Supplies, Compton, 
UK
Red cell lysis buffer Sigma Aldrich Company Ltd, 
Poole, UK
R7757
RPMI (Phenol-Red Free) 
Medium
Invitrogen Life Technologies, 
Paisley, UK
1835-030
RPMI 1640 with Glutamax 
medium
Invitrogen Life Technologies, 
Paisley, UK
72400-021
Saline Baxter Healthcare, Compton, 
UK
F7124
Trypsin-EDTA Invitrogen Life Technologies, 
Paisley, UK
45300-019
Tryptose phosphate broth Institute for Animal Health 
media supply
Water (Sterile) Institute for Animal Health 
media supply
2.1.5 Cell Lines
Cell Line Supplier Catalogue Number
BHK Laboratory stocks, originally 
obtained from ATCC
EBV-B-LCL (Patient BORI) Dr P. Borrow, Compton, UK
GK1.5 ATCC TIB-207
RMAS cells Shirley Ellis, Institute For 
Animal Health, Compton, UK
143TK- Laboratory stocks, originally 
obtained from ATCC
Vero Laboratory stocks, originally 
obtained from ATCC
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2.1.6 Cytokines
Cytokine Supplier Catalogue Number
Recombinant human IL-2 Roche Diagnostics, Lewes, 
UK
1011456
2.1.7 Antibodies
Antibody Supplier Catalogue
Number
Clone Isotype
Anti-human:
CCR7APC R & D Systems 
Europe Ltd, 
Abingdon, UK
FAB197A 150503 lgG2a
CD3 Harlan Sera Lab UK 
Ltd, Biscester, UK
Custom
produced
OKT3
CD3 FITC Serotec, Kidlington, 
UK
MCA463F UCHT1 IgGi
CD4 MACS Beads Miltenyi Biotech, 
Bisley, UK
130-045-101 SK3 igGi
CD8 MACS Beads Miltenyi Biotech, 
Bisley, UK
130-045-201 BW135/80 igG2a
CD8 PerCP BD Biosciences 
Pharmingen, Oxford, 
UK
345774 SK1 IgGi
CD25 APC BD Biosciences 
Pharmingen, Oxford, 
UK
555434 M-A251 \gG,
CD27 FITC BD Biosciences 
Pharmingen, Oxford, 
UK
555440 M-T271 igG1
CD28 APC BD Biosciences 
Pharmingen, Oxford, 
UK
559770 CD28.2 igGi
CD28 FITC BD Biosciences 
Pharmingen, Oxford, 
UK
555728 CD28.2 igG!
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CD45RA APC BD Biosciences 
Pharmingen, Oxford, 
UK
550855 HI100 igG2b
CD57 FITC BD Biosciences 
Pharmingen, Oxford, 
UK
555619 NK-1 IgM
IFNy (ELISPOT 
capture Ab)
MabTech AB, Nacka, 
Sweden
3420-3 1-D1K IgGi
IFNy-biotin 
(ELISPOT 
detection antibody)
MabTech AB, Nacka, 
Sweden
3420-6 7-B6-1 IgGi
IL7R-biotin R & D Systems BAF306 igG
Ki67 FITC BD Biosciences 
Pharmingen, Oxford, 
UK
556026 B56 igGi
Vp1 TCR FITC Serotec, Kidlington, 
UK
MCA1591F BL37.2 igGi
VJ32TCR FITC Serotec, Kidlington, 
UK
MCA1592F MPB2D5 IgGi
V(33 TCR FITC Serotec, Kidlington, 
UK
MCA1700F CH92 IgM
V05.1 TCR FITC Serotec, Kidlington, 
UK
MCA1699F IMMU 157 igG2a
VJ35.2TCR FITC Serotec, Kidlington, 
UK
MCA1611F 36213 igGi
Vp5.3 TCR Serotec, Kidlington, 
UK
MCA1698 3D11 igGi
V(36.7 TCR FITC Perbio Science UK 
Ltd, Northumberland, 
UK
TCR2657 OT145 igGi
V07TCR FITC Serotec, Kidlington, 
UK
MCA1594F ZOE igG2a
VP8.1/8.2 TCR 
FITC
Serotec, Kidlington, 
UK
MCA1696F 56C5 igG2a
V(39 TCR Serotec, Kidlington, 
UK
MCA1595 FIN9 igG2a
V(311 TCR FITC Serotec, Kidlington, 
UK
MCA1596F C21 igG2a
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VP12 TCR FITC Serotec, Kidlington, 
UK
MCA1597F VER2.32.1 lgG2a
Vp13.1 TCR FITC Serotec, Kidlington, 
UK
MCA1608F IMMU 222 igG2b
Vp13.2 TCR Gift from Dr Tao 
Dong, Oxford, UK
H132.8 igGi
Vp13.6 TCR FITC Serotec, Kidlington, 
UK
MCA1598F JU-74 igGi
Vp14 TCR FITC Serotec, Kidlington, 
UK
MCA1599F CAS 1.1.3 igGi
Vp16 TCR FITC Serotec, Kidlington, 
UK
MCA1600F TAMAYA 1.2 igGi
Vp17 TCR FITC Serotec, Kidlington, 
UK
MCA1697F E17.5F3 igGi
Vp18 TCR Serotec, Kidlington, 
UK
MCA1601 BA62 igGi
Vp20 TCR FITC Serotec, Kidlington, 
UK
MCA1602F ELL1.4 IgGi
Vp21.3 TCR FITC Serotec, Kidlington, 
UK
MCA1603F IG125 IgGza
Vp22 TCR FITC Serotec, Kidlington, 
UK
MCA1604F IMMU 546 IgGi
VP23 TCR Serotec, Kidlington, 
UK
MCA1605 AF-23 igGi
Anti-mouse:
CD3 APC BD Biosciences 
Pharmingen, Oxford, 
UK
553006 145-2C11 igGi
CD3 FITC BD Biosciences 
Pharmingen, Oxford, 
UK
553062 145-2C11 igGi
CD4 ascites Qbiogene, llkirch 
Cedex, France
CD4 PerCP BD Biosciences 
Pharmingen, Oxford, 
UK
553052 RM4-5 igG2a
CD8 Cy5 TCS Biologicals Ltd, 
Buckingham, UK
RM2211 CT-CD8a igG2a
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CD8 FITC BD Biosciences 
Pharmingen, Oxford, 
UK
553031 53-6.7 lgG2a
CD8 PerCP BD Biosciences 
Pharmingen, Oxford, 
UK
553036 53-6.7 igG2a
Fc y m/ll receptor BD Biosciences 553142 2.4G2 igG2b
block Pharmingen, Oxford,
(CD16/CD32) UK
H-2 DD FITC Serotec, Kidlington, 
UK
MCA1505F CTDd igG2a
H-2 Kd FITC Serotec, Kidlington, 
UK
MCA1503F CTKD igG2a
IFN-y (ELISPOT MabTech AB, Nacka, 3321-3-1000 AN 18 IgGi
capture antibody) Sweden
IFN-y ~ biotin MabTech AB, Nacka, 3321-6-1000 R46A2 IgGi
(ELISPOT Sweden
detection antibody)
IgG beads Dynal, Bromborough, 
UK
110.02
V(B TCR screening BD Biosciences 557004
panel Pharmingen, Oxford, 
UK
V(32 TCR FITC B20.6 igG2a
V03 TCR FITC KJ25 IgG 
(group 2)
V(34 TCR FITC KT4 igG2b
V05.1, 5.2 TCR MR9-4 igG1
FITC
V06 TCR FITC RR4-7 igG2b
V07 TCR FITC TR310 igG2b
V08.1, 8.2 TCR MR5-2 igG2a
FITC
V08.3 TCR FITC 1B3.3 IgG 
(group 3)
V09 TCR FITC MR10-2 Igci
V01Ob TCR FITC B21.5 lgG2a
V011 TCR FITC RR3-15 igG2b
V012TCR FITC MR11-1 IgG!
V013TCR FITC MR12-3 IgG!
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V014TCR FITC 
Vpi7aTCR FITC
14-2
KJ23
IgM
igG2a
Isotype control Supplier Catalogue Clone
antibodies Number
Mouse IgGi FITC BD Biosciences 
Pharmingen, 
Oxford, UK
550616 MOPC-31C
Mouse IgGi PE BD Biosciences 
Pharmingen, 
Oxford, UK
550617 MOPC-31C
Mouse lgG2a FITC BD Biosciences 
Pharmingen, 
Oxford, UK
554647 G155-178
Mouse lgG2b FITC BD Biosciences 
Pharmingen,
Oxford,
UK f
33804X 27-35
Rat IgM FITC BD Biosciences 
Pharmingen, 
Oxford, UK
553942 R4-22
Secondary step reagents Supplier Catalogue Number
Anti-biotin AP (alkaline 
phosphatase)
Vector laboratories, Inc., 
Orton Southgate, UK
SP-3020
Anti-mouse IgG/IgM (H+L)- 
FITC (Goat)
Stratech Scientific Ltd, 
Soham, UK
115-096-068
Anti-rat IgG beads Dynal, Bromborough, UK 110.08
Steptavidin-Alkaline
phosphatase
MabTech AB, Nacka, 
Sweden
3310-10
Streptavidin-APC
BD Biosciences 
Pharmingen, Oxford, UK
554067
Streptavidin-FITC
BD Biosciences, 
Pharmingen, Oxford, UK 13024D
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2.1.8 Viruses
Recombinant vaccinia viruses expressing HIV genes used for in vitro assays:
Virus Expresses Supplied by References
vSC8 Vaccinia strain WR 
encoding E.coli p- 
galactosidase (p-gal) gene 
under the control of the 
vaccinia P11 promotor.
Dr. B. Moss via the 
AIDS Research 
and Reference 
Reagent Program.
(Chakrabarti et al., 
1985)
vPE16 Vaccinia strain WR 
encoding the entire env 
gene of HIV-1 clone BH8 
under the control of the 
vaccinia P7.5 promotor, 
plus E.coli p-galactosidase 
gene under the control of 
the vaccinia P11 promotor.
Dr. B. Moss via the 
AIDS Research 
and Reference 
Reagent Program.
(Earl etal., 1990)
vTFNef2 Vaccinia strain WR 
encoding the complete 
ORF nef of HIV-1 strain 
NL43 under the control of 
the vaccinia P7.5 
promotor, plus E.coli p- 
galactosidase gene under 
the control of the vaccinia 
P11 promotor.
Dr. B. Moss via the 
AIDS Research 
and Reference 
Reagent Program.
(Koenig etal., 1990)
vTat Vaccinia strain WR 
encoding the tat gene of 
HIV-1 strain BH10 under 
the control of the vaccinia 
P7.5 promotor, plus E.coli 
p-galactosidase gene 
under the control of the 
vaccinia P11 promotor.
Dr. B. Moss via the 
AIDS Research 
and Reference 
Reagent Program.
(Falkner etal., 1988)
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vAbT-
141.5.1
Vaccinia strain NYCBH 
encoding the gag gene of 
HIV-1 strain BH10 under 
the control of the vaccinia 
P7.5 promotor, plus E.coli 
(3-galactosidase gene 
under the control of the 
vaccinia P11 promotor.
Dr. D. Panicali, 
Therion Biologies, 
Cambridge,
MA, USA
(Koup etal., 1989)
VP1288 Vaccinia virus strain WR Virogenetics Corp. (Goebel et al., 1990;
encoding the entire pol via the AIDS Gurgo etal., 1988;
gene of HIV-1 IIIB Research and Perkus etal., 1989;
contained within the Reference Reagent Ratner etal., 1985)
vaccinia K1L region. Program, Division
Purified by host range of AIDS, NIAID,
selection system. NIH
Viruses used for murine infections:
Virus Expresses Supplied by References
Influenza
virus
A/PR/8/34
Charles River 
SPAFAS, North 
Franklin, USA
LCMV
Armstrong
Dr. M.B.A. 
Oldstone, The 
Scripps Research 
Institute, La Jolla, 
USA
(Dutko & Oldstone, 
1983)
Pichinde 
virus (PV) 
(strain 
AN3739)
Dr. M. J. 
Buchmeier, The 
Scripps Research 
Institute, La Jolla, 
USA
(Buchmeier & Rawls, 
1977)
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wgplong Vaccinia strain WR
encoding the full-length GP 
gene of the Armstrong 
strain of LCMV under the 
control of the vaccinia P7.5 
promotor, plus E.coli B- 
galactosidase gene under 
the control of the vaccinia 
P11 promotor.
Dr. J. Lindsay 
Whitton, The 
Scripps Research 
Institute, La Jolla, 
USA
(Whitton etal., 1988)
vVNP Vaccinia strain WR
encoding the entire 
nucleoprotein (NP) gene of 
the Armstrong strain of 
LCMV under the control of 
the vaccinia P7.5 
promotor, plus E.coli B- 
galactosidase gene under 
the control of the vaccinia 
P11 promotor.
Dr. J. Lindsay 
Whitton, The 
Scripps Research 
Institute, La Jolla, 
USA
(Whitton etal., 1988)
2.1.9 MHC class l-peptide multimers
Multimer Fiuorphore Supplier
H-2 Dd FQPQNGQFI tetramer APC Prolmmune, Oxford, UK
H-2 Db KAVYNTAC tetramer APC Prolmmune, Oxford, UK
H-2 Dd WMHHNMLDI (Uty) 
tetramer
PE
Dr Liz Simpson, Hammersmith 
Hospital, London, UK
HLA -A*0101 GSEELRSLY 
tetramer
PE Beckman Coulter, San Diego, 
USA
HLA-A*0201 YTAFTIPSI 
pentamer
PE Prolmmune, Oxford, UK
HLA-A*0301 QIYAGIKVK 
tetramer
PE Prolmmune, Oxford, UK
HLA-A*0301 QVPLRPMTYK 
tetramer
PE Prolmmune, Oxford, UK
HLA-A*0301 RLRPGGKKK 
tetramer
PE Prolmmune, Oxford, UK
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HLA-A*1101 AAVDLSHFLK 
tetramer
PE Beckman Coulter, San Diego, 
USA
HLA-A*1101 VPLRPMTYK 
tetramer
PE Beckman Coulter, San Diego, 
USA
HLA-B*0702 IPRRIRQGL 
pentamer
PE Prolmmune, Oxford, UK
HLA-B*0702 RPQVPLRPMTY 
tetramer
PE Prolmmune, Oxford, UK
HLA-B*0702 TPGPGIRYPL 
pentamer
PE Prolmmune, Oxford, UK
HLA-B*0801 FLKEKGGL tetramer PE
Beckman Coulter, San Diego, 
USA
HLA-B*0801 GEIYKRWII tetramer PE
Beckman Coulter, San Diego, 
USA
HLA-B*3501 RPQVPLRPMTY 
tetramer PE
Beckman Coulter, San Diego, 
USA
HLA-B*5701 KAFSPEVIPMF 
tetramer
PE
Beckman Coulter, San Diego, 
USA
2.1.10 Peptides
Synthetic peptides were supplied by Chiron Mimotopes (Clayton, Australia) in 
a peptide-amine-acid format or were synthesised by Larry Hunt (IAH, 
Compton, UK) using Fmoc or TBoc chemistry. Lyophilised peptides were 
resuspended in either DMSO or an organic solvent, pH modifier and water and 
stored at -20°C.
2.1.11 Mice
Female C57BL/6 mice and IA knock-out (k/o) mice 8-12 weeks of age were 
obtained from the SPF animal unit (IAH, Compton, UK) and Charles River 
(Margate, UK).
2.2 Methods
2.2.1 Human study subjects
HIV-infected patients: The majority of samples were obtained from a cohort of 
HIV seroconverters attending clinics at the Mortimer Market Centre (MMC) 
(London, UK) as part of a collaboration with Dr Ian Williams (Royal Free and
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University College London Medical School, UK). The cohort consisted 
predominantly of Caucasian male homosexuals who reported to the clinic with 
acute retroviral symptoms (such as nausea, vomiting, headaches and fever) 
following a high risk exposure incident. Confirmation of the HIV status of the 
patient was made by enzyme-linked immunosorbent assay (ELISA). Samples 
from additional HIV seroconverters were obtained from Dr. George 
Panayiotakopoulos (St. George’s Hospital, London, UK) and Dr. George Shaw 
(University of Alabama at Birmingham, USA). Samples used from patients 
chronically infected with HIV were obtained from Dr. Ian Williams. Ethical 
approval for these studies was obtained from the local ethical review/human 
subjects committees, and written informed consent for participation in the 
study was obtained from all patients. Viral load data, CD4 cell counts and 
clinical histories of the patients were supplied by Drs Pippa Newton, Pierre 
Pellegrino and Ian Williams (Royal Free and University College London 
Medical School).
Peripheral blood samples were collected from acutely-infected patients at 
sequential timepoints during and after seroconversion (at weekly intervals for 
the first month following onset of symptoms, at weeks 6, 8 and 12, and then 
every three months until two years, at which point samples were taken every 
six months). Samples used in our studies were taken at timepoints during 
which the subjects were not receiving any ART. All samples were processed 
on the same day of venepuncture. PBMCs were isolated and frozen and 
stored in liquid nitrogen until use.
HIV-seronegative subjects: As a source of control HIV-negative PBMCs, cells 
isolated from buffy coat bags were used. These were obtained from the North 
London blood transfusion service (Collindale, London, UK) and had been 
screened to confirm HIV-seronegativity before release.
For cross-reactivity studies, fresh blood from Donor JSS, a subject who was 
previously found to respond to the B44 restricted EBV epitope EENLLDFVRF, 
was provided by Dr A. Carmichael (University of Cambridge, UK).
2.2.2 Isolation of PBMCs from peripheral human blood 
Peripheral blood was diluted with an equal volume of saline, underlayed with 
an equal volume of Histopaque-1077 and then centrifuged at 1600rpm for 30 
mins in a benchtop centrifuge (Beckman, High Wycombe, UK). The PBMC
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interface was harvested, washed three times with saline and the number of 
viable cells counted by trypan blue dye exclusion. The cells were frozen in 
high grade FCS with 10% DMSO initially at -80°C before transfer to liquid 
nitrogen for long term storage.
2.2.3 Determination of HLA types of study subjects
2.2.3 (a) Purification of genomic DNA from PBMCs for HLA typing
DNA was purified from frozen PBMCs from subjects of interest using a 
QIAamp® DNA blood mini kit according to the manufacturer’s instructions. 
Briefly, cells were thawed, washed twice in PBS and counted. 5x106 PBMCs 
were pelleted in a microfuge tube, then resuspended in 200pl PBS, and 20pl 
QIAGEN Protease plus 200pl buffer were added. After a 10 minute period of 
lysis at 56°C, 200pl ethanol was added per tube, mixed and the lysate loaded 
onto a spin column. The DNA in the sample was bound to the silica-gel 
membrane of the column during a brief centrifugation step at 6000 x g in a 
microfuge (Eppendorf, Hamburg, Germany), and the filtrate discarded. 
Residual contaminants were removed by the addition of two wash buffers, 
centrifugation and discarding the filtrates. Purified DNA was eluted from the 
columns by addition of 200pl water and centrifugation for 1 min at 6000 x g. 
The concentration of DNA in the eluate was determined by measuring the 
absorbance at 260nm on a GeneQuant Pro UV spectrophotometer 
(Amersham Pharmacia Biotech, Little Chalfont, UK). Samples were stored at 
4°C before sending off for HLA typing.
2.2.3 (b) HLA typing of DNA samples
High resolution class I typing was carried out using 10pg purified DNA by the 
Oxford Transplant Centre at the Churchill Hospital, Oxford, UK using 
phototyping (Bunce et al., 1995), a PCR based technique which uses 
sequence specific primers (PCR-SSP).
2.2.4 Removal of CD8+ cells from human PBMCs
CD8+ or CD4+ T cell subsets were depleted from PBMCs using MACS LD 
columns. PBMCs were thawed, washed twice in MACS buffer (RPMI 1640 
medium supplemented with 2% FCS and 2mM EDTA), and resuspended in 
80pl buffer per 107 cells. 40pl of MACS CD8 MicroBeads (or CD4 beads as a 
control) were added per 107 cells, mixed and incubated at 4°C for 15 mins. 
Cells were then washed twice and resuspended in a volume of 2ml of buffer
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(up to 5x108 cells in 2ml), ready for application to the columns. MACS LD 
columns were prepared by placing them onto a MACS magnetic separator and 
letting 2ml of buffer run through the column. 2ml of cell suspension was then 
applied to each column and the negative fraction allowed to pass through. The 
columns were next washed twice with 1 ml of buffer, and all negative fractions 
collected. Cells were passed over a second column to increase the purity of 
the magnetic separation. The CD8+ (or CD4+) cell depleted fractions were 
collected and counted before use in assays.
2.2.5 Human IFN-v Enzvme-linked immunospot (ELISPOT) assay 
IFN-y ELISPOT assays were carried out using a method based on that 
described by Larsson e ta l (Larsson et a/., 1999). Multiscreen 96-well filtration 
plates were coated with 50pl per well of capture antibody (anti-IFNy 
monoclonal antibody (mAb) clone 1-DIK diluted to 5ug/ml in 0.1M sodium 
bicarbonate buffer, pH9.6) overnight at 4°C. Plates were washed four times 
with filtered PBS and blocked with 50pl per well of filtered RPMI 1640 medium 
containing 10% heat inactivated pooled human serum for 1 hour at 37°C in a 
5% C 0 2 environment. Cells were thawed and washed three times in RPMI 
1640 supplemented with 15% high grade FCS, counted and resuspended to a 
concentration of 2x10ec/ml in RPMI with 10% human serum, and 100pl cells 
were added to each well. If recombinant vaccinia viruses were used to 
stimulate cells, viruses were added to wells at a multiplicity of infection (m.o.i.) 
of 2 plaque forming units (pfu) /cell. For consistency, all viruses were diluted to 
the same titre beforehand and added in an equal volume. If peptides were 
being used to stimulate cells, they were added in a 20pl volume so that the 
final concentration was 10'5M for screening assays, or at a range of 
concentrations for peptide titration assays. For a positive control, 20pl PHA 
was added to a final concentration of 10pg/ml. For negative control wells, cells 
received either a recombinant vaccina virus (rW ) expressing (3-galactosidase 
in the rW-stimulated assay, or medium only in the peptide-stimulated assay. 
All variables were assayed in duplicate or, where possible, triplicate. Plates 
were incubated at 37°C in a 5% C 0 2 environment for 1 hour, after which 
30pl/well filtered FCS (high grade) was added. Plates were incubated at 37°C 
in a 5% C 0 2 environment for two days for rW-stimulated assays (-45  hrs) or 
overnight (14-20hrs) for peptide-stimulated assays.
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To detect bound IFN-y, plates were washed four times with filtered PBS 
containing 0.05% Tween-20 before the addition of 50jjI detection antibody 
(biotin conjugated anti-IFNy mAb clone 7-B6-1 diluted to a final concentration 
of 1 Mg/ml) and incubation for 2 hrs at 37°C/5% C 0 2. Plates were washed as 
before then 1OOpI per well of anti-biotin alkaline phosphatase (AP) was added 
(final concentration Ipg/ml) and they were incubated for 1-2hr at room 
temperature. Plates were washed again and after the final wash, plates were 
taken apart to wash the back of the filters to remove trapped antibody. AP 
substrate was prepared by diluting a colour development buffer to a 1x 
solution in sterile water and adding 100pl AP colour reagents A and B per 
10ml of substrate solution required. 100pl substrate was added per well and 
plates were allowed to develop for 30 mins at room temperature. The reaction 
was stopped by discarding the substrate and rinsing the filters in tap water. 
Plates were allowed to dry overnight, then spots were counted using an AID 
automated image analysis system with AID ELISPOT version 2.3 software 
(Autoimmun Diagnostika GmbH, Stassberg, Germany).
Results are expressed as the mean (of values from duplicate or triplicate test 
wells) number of spot forming cells (SFC) per 106 PBMCs, and are generally 
shown with the background values (the mean number of spots counted in the 
negative control wells) subtracted (specific SFC per 106 PBMCs).
2.2.6 Comprehensive HIV CD8+ T cell epitope mapping 
A peptide pool matrix-based approach was used to comprehensively 
characterise the HIV-specific T cell response in thirteen HIV-1 seroconverters 
(Addo et a!., 2003). 310 synthetic peptides spanning the entire HIV-1 clade B 
consensus sequence (the sequences of which are shown in Table 2.1) were 
arranged in five different peptide matrix systems (as shown in Table 2.2). The 
peptides were 20 amino acids in length and overlapped by 10 amino acids. 
Overlapping peptides corresponding to sequences in Gag, Pol, Nef and Env 
were arranged as individual peptide matrices while Rev, Tat, Vif, Vpr and Vpu 
were pooled into a combined accessory and regulatory protein peptide matrix. 
Within a given protein matrix, each peptide was represented in two different 
peptide pools, allowing for the identification of an epitope-containing peptide 
by the patient’s cells responding to the two pools containing this peptide.
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Peptide number Matrix assignment Protein Sequence
1 gp160 1 gp160 1-20 MRVKGIRKNYQHLWRWGTML
2 gp1602 gp160 11-30 QHLWRWGTMLLGMLMICSAA
3 gp160 3 gp160 21-40 LGMLMICSAAEQLWVTVYYG
4 gp160 4 gp160 31-50 EQLWVTVYYGVPVWKEATTT
5 gp160 5 gp160 41-60 VPVWKEATTTLFCASDAKAY
6 gp160 6 gp160 51-70 LFCASDAKAYDTEVHNVWAT
7 gp160 7 gp160 61-80 DTEVHNVWATHACVPTDPNP
8 gp1608 gp160 71-90 HACVPTDPNPQEWLENVTE
9 gp160 9 gp160 81-100 QEWLENVTENFNMWKNNMV
10 gp160 10 gp160 91-110 NFNMWKNNMVEQMHEDIISL
11 gp160 11 gp160 101-120 EQMHEDIISLWDQSLKPCVK
12 gp160 12 gp160 111-130 WDQSLKPCVKLTPLCVTLNC
13 gp160 13 gp160 121-140 LTPLCVTLNCTDLNNNTNTT
14 gp160 14 gp160 131-150 TDLNNNTNTTSSSGEKMEKG
15 gp160 15 gp160 141-160 SSSGEKMEKGEIKNCSFNIT
16 gp160 16 gp160 151-170 EIKNCSFNITTSIRDKVQKE
17 gp160 17 gp160161-180 TSIRDKVQKEYALFYKLDW
18 gp160 18 gp160 171-190 YALFYKLDWPIDNDNTSYR
19 gp16019 gp160 181-200 PIDNDNTSYRLISCNTSVIT
20 gp160 20 gp160 191-210 LISCNTSVITQACPKVSFEP
21 gp160 21 gp160 201-220 QACPKVSFEPIPIHYCAPAG
22 gp160 22 gp160 211-230 IPIHYCAPAGFAILKCNDKK
23 gp160 23 gp160 221-240 FAILKCNDKKFNGTGPCTNV
24 gp160 24 gp160 231-250 FNGT G PCTN VSTVQCTHGIR
25 gp160 25 gp160 241-260 STVQCTHGIRPWSTQLLLN
26 gp160 26 gp160 251-270 PWSTQLLLNGSLAEEEWI
27 gp160 27 gp160 261-280 GSLAEEEWIRSENFTDNAK
28 gp160 28 gp160 271-290 RSENFTDNAKTIIVQLNESV
29 gp160 29 gp160 281-300 TIIVQLNESVEINCTRPNNN
30 gp160 30 gp160 291-310 EINCTRPNNNTRKSIHIGPG
31 gp160 31 gp160 301-320 TRKSIHIGPGRAFYTTGEII
32 gp160 32 gp160 311-330 RAFYTTGEIIGDIRQAHCNI
33 gp160 33 gp160 321-340 GDIRQAHCNISRAKWNNTLK
34 gp160 34 gp160 331-350 SRAKWNNTLKQIVIKLREQF
35 gp160 35 gp160 341-360 QIVIKLREQFGNKTIVFNQS
36 gp160 36 gp160 351-370 GNKTIVFNQSSGGDPEIVMH
37 gp160 37 gp160 361-380 SGGDPEIVMHSFNCGGEFFY
38 gp160 38 gp160 371-390 SFNCGGEFFYCNTTQLFNST
39 gp160 39 gp160 381-400 CNTT QLFNSTWNSTNTEGSN
40 gp160 40 gp160 391-410 WNSTNTEGSNNTDTITLPCR
41 gp160 41 gp160 401-420 NTDTITLPCRIKQIINMWQE
42 gp160 42 gp160 411-430 IKQIINMWQEVGKAMYAPPI
43 gp160 43 gp160 421-440 VGKAMYAPPIRGQIRCSSNI
44 gp160 44 gp160 431-450 RGQIRCSSNITGLLLTRDGG
45 gp160 45 gp160 441-460 TGLLLTRDGGNNNNTTEIFR
46 gp160 46 gp160 451-470 NNNNTTEIFRPGGGDMRDNW
47 gp160 47 gp160 461-480 PGGGDMRDNWRSELYKYKW
48 gp160 48 gp160 471-490 RSELYKYKWKIEPLGVAPT
49 gp160 49 gp160 481-500 KIEPLGVAPTKAKRRWQRE
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50 gp160 50 gp160 491-510
51 gp160 51 gp160 501-520
52 gp160 52 gp160 511-530
53 gp160 53 gp160 521-540
54 gp160 54 gp160 531-550
55 gp160 55 gp160 541-560
56 gp160 56 gp160 551-570
57 gp160 57 gp160 561-580
58 gp160 58 gp160 571-590
59 gp160 59 gp160 581-600
60 gp160 60 gp160 591-610
61 gp160 61 gp160 601-620
62 gp160 62 gp160 611-630
63 gp160 63 gp160 621-640
64 gp160 64 gp160 631-650
65 gp160 65 gp160 641-660
66 gp160 66 gp160 651-670
67 gp160 67 gp160 661-680
68 gp160 68 gp160 671-690
69 gp160 69 gp160 681-700
70 gp160 70 gp160 691-710
71 gp160 71 gp160 701-720
72 gp160 72 gp160 711-730
73 gp160 73 gp160 721-740
74 gp160 74 gp160 731-750
75 gp160 75 gp160 741-760
76 gp160 76 gp160 751-770
77 gp160 77 gp160 761-780
78 gp160 78 gp160 771-790
79 gp160 79 gp160 781-800
80 gp160 80 gp160 791-810
81 gp160 81 gp160 801-820
82 gp160 82 gp160 811-830
83 gp160 83 gp160 821-840
84 gp160 84 gp160 828-847
85 gag 1 gag p17 1-20
86 gag 2 gag p17 11-30
87 gag 3 gag p17 21-40
88 gag 4 gag p17 31-50
89 gag 5 gag p17 41-60
90 gag 6 gag p17 51-70
91 gag 7 gag p17 61-80
92 gag 8 gag p17 71-90
93 gag 9 gag p17 81-100
94 gag 10 gag p17 91-110
95 gag 11 gag p17 101-120
96 gag 12 gag p17 111-130
97 gag 13 gag p17 121-132/gag p24 1-8
98 gag 14 gag p17 131-132/gag p24 1-18
99 gag 15 gag p24 9-28
KAKRRWQREKRAVGIGAMF 
KRAVGIGAMFLGFLGAAGST 
LGFLGAAGSTMGAASMTLTV 
MG AASMTLTVQARQLLSGIV 
QARQLLSGIVQQQNN LLRAI 
QQQNNLLRAIEAQQHLLQLT 
EAQQHLLQLTVWGIKQLQAR 
VWGIKQLQARVLAVERYLKD 
VLAVERYLKDQQLLGIWGCS 
QQLLGIWGCSGKLICTTAVP 
GKLICTTAVPWNASWSNKSL 
WNASWSNKSLDQIWNNMTWM 
DQIWNNMTWMEWEREIDNYT 
EWEREIDNYTSLIYTLIEES 
SLIYTLIEESQNQQEKNEQE 
QNQQEKNEQELLELDKWASL 
LLELDKWASLWNWFDITNWL 
WNWFDITNWLWYIKIFIMIV 
WYIKIFIMIVGGLVGLRIVF 
GGLVGLRIVFAVLSIVNRVR 
AVLSIVN RVRQG Y S PLSFQT 
QGYSPLSFQTRLPAPRGPDR 
RLPAPRGPDRPEGIEEEGGE 
PEGIEEEGGERDRDRSGRLV 
RDRDRSGRLVDGFLALIWVD 
DGFLALIWVDLRSLCLFSYH 
LRSLCLFSYHRLRDLLLIVT 
RLRDLLLIVTRIVELLGRRG 
RIVELLGRRGWEALKYWWNL 
WEALKYWWNLLQYWSQELKN 
LQYWSQELKNSAVSLLNATA 
SAVSLLNATAIAVAEGTDRV 
IAVAEGTDRVIEWQRACRA 
IEWQRACRAILHIPRRIRQ 
CRAILHIPRRIRQGLERALL 
MGARASVLSGGELDRWEKIR 
GELDRWEKIRLRPGGKKKYK 
LRPGGKKKYKLKHIVWASRE 
LKHIVWASRELERFAVNPGL 
LERFAVNPGLLETSEGCRQI 
LETSEGCRQILGQLQPSLQT 
LGQLQPSLQT GSEELRSLYN 
GSEELRSLYNTVATLYCVHQ 
TVATLYCVHQRIEVKDTKEA 
RIEVKDTKEALEKIEEEQNK 
LEKIEEEQNKSKKKAQQAAA 
SKKKAQQAAADTGNSSQVSQ 
DTGNSSQVSQNYPIVQNLQG 
NYPIVQNLQGQMVHQAISPR 
QMVHQAISPRTLNAWVKWE
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100 gag 16 gag p24 19-38
101 gag 17 gag p24 29-48
102 gag 18 gagp24 39-58
103 gag 19 gag p24 49-68
104 gag 20 gag p24 59-78
105 gag 21 gag p24 69-88
106 gag 22 gag p24 79-98
107 gag 23 gag p24 89-108
108 gag 24 gag p24 99-118
109 gag 25 gag p24 109-128
110 gag 26 gag p24 119-138
111 gag 27 gag p24 129-148
112 gag 28 gag p24 139-158
113 gag 29 gag p24 149-168
114 gag 30 gag p24 159-178
115 gag 31 gag p24 169-188
116 gag 32 gag p24 179-198
117 gag 33 gag p24 189-208
118 gag 34 gag p24 199-218
119 gag 35 gag p24 209-228
120 gag 36 gag p24 219-231/gag p2p7p6p1 1-7
121 gag 37 gag p24 229-231/gag p2p7p6p1 1-17
122 gag 38 gag p2p7p1p6 8-27
123 gag 39 gag p2p7p1p6 18-37
124 gag 40 gag p2p7p1p6 28-47
125 gag 41 gag p2p7p1p6 38-57
126 gag 42 gag p2p7p1p6 48-67
127 gag 43 gag p2p7p1p6 58-77
128 gag 44 gag p2p7p1p6 68-87
129 gag 45 gag p2p7p1p6 78-97
130 gag 46 gag p2p7p1p6 88-107
131 gag 47 gag p2p7p1p6 98-117
132 gag 48 gag p2p7p1p6 108-127
133 gag 49 gag p2p7p1p6 118-137
134 pol 1 pol
135 pol 2 pol
136 pol 3 pol
137 pol 4 pol
138 pol 5 pol
139 pol 6 pol
140 pol 7 protease 5-24
141 pol 8 protease 15-34
142 pol 9 protease 25-44
143 pol 10 protease 35-54
144 pol 11 protease 45-64
145 pol 12 protease 55-74
146 pol 13 protease 65-84
147 pol 14 protease 75-94
148 pol 15 protease 85-99/RT 1-5
149 pol 16 protease 95-99/RT 1-15
TLNAWVKWEEKAFSPEVIP 
EKAFSPEVIPMFSALSEGAT 
MFSALSEGATPQDLNTMLNT 
PQDLNTMLNTVGGHQAAMQM 
VGGHQAAMQMLKETINEEAA 
LKETINEEAAEWDRLHPVHA 
EWDRLHPVHAGPIAPGQMRE 
GPIAPGQMREPRGSDIAGTT 
PRGSDIAGTTSTLQEQIGWM 
STLQEQIGWMTNNPPIPVGE 
TNNPPIPVGEIYKRWIILGL 
IYKRWIILGLNKIVRMYSPT 
NKIVRMYSPTSILDIRQGPK 
SILDIRQGPKEPFRDYVDRF 
EPFRDYVDRFYKTLRAEQAS 
YKTLRAEQASQEVKNWMTET 
QEVKNWMTETLLVQNANPDC 
LLVQNANPDCKTILKALGPA 
KTILKALGPAATLEEMMTAC 
ATLEEMMTACQGVGGPGHKA 
QGVGGPGHKARVLAEAMSQV 
RVLAEAMSQVTNSATIM MQ R 
TNSATIMMQRGNFRNQRKTV 
GNFRNQRKTVKCFNCGKEGH 
KCFNCGKEGHIAKNCRAPRK 
IAKNCRAPRKKGCWKCGKEG 
KGCWKCGKEGHQMKDCTERQ 
HQMKDCTERQANFLGKIWPS 
ANFLGKIWPSHKGRPGNFLQ 
HKGRPGNFLQSRPEPTAPPE 
SRPEPTAPPEESFRFGEETT 
ESFRFGEETTTPSQKQEPID 
TPSQKQEPIDKELYPLASLR 
KELYPLASLRSLFGNDPSSQ 
FFREDLAFPQGKAREFSSEQ 
GKAREFSSEQTRANSPTRRE 
TRANSPTRRELQVWGRDNNS 
LQVWGRDNNSLSEAGADRQG 
LSEAGADRQGTVSFSFPQIT 
TVSFSFPQITLWQRPLVTIK 
LWQRPLVTIKIGGQLKEALL 
IGGQLKEALLDTGADDTVLE 
DTGADDTVLEEMNLPGRWKP 
EMNLPGRWKPKMIGGIGGFI 
KMIGGIGGFIKVRQYDQILI 
KVRQYDQILIEICGHKAIGT 
EICGHKAIGTVLVGPTPVNI 
VLVGPTPVNIIGRNLLTQIG 
IGRNLLTQIGCTLNFPISPI 
CTLNFPISPIETVPVKLKPG
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150 pol 17 RT 6-25 ETVPVKLKPGMDGPKVKQWP
151 pol 18 RT 16-35 MDGPKVKQWPLTEEKIKALV
152 pol 19 RT 26-45 LTEEKIKALVEICTEMEKEG
153 pol 20 RT 36-55 EICTEMEKEGKISKIGPENP
154 pol 21 RT 46-65 KISKIGPENPYNTPVFAIKK
155 pol 22 RT 56-75 YNTPVFAIKKKDSTKWRKLV
156 pol 23 RT 66-85 KDSTKWRKLVDFRELNKRTQ
157 pol 24 RT 76-95 DFRELNKRTQDFWEVQLGIP
158 pol 25 RT 86-105 DFWEVQLGIPHPAGLKKKKS
159 pol 26 RT 96-115 H PAG LKKKKS VTVLD VG DAY
160 pol 27 RT 106-125 VTVLDVGDAYFSVPLDKDFR
161 pol 28 RT 116-135 FSVPLDKDFRKYTAFTIPSI
162 pol 29 RT 126-145 KYTAFTIPSINNETPGIRYQ
163 pol 30 RT 136-155 NNETPGIRYQYNVLPQGWKG
164 pol 31 RT 146-165 YNVLPQGWKGSPAIFQSSMT
165 pol 32 RT 156-175 SPAIFQSSMTKILEPFRKQN
166 pol 33 RT 166-185 KILEPFRKQNPDIVIYQYMD
167 pol 34 RT 176-195 PDIVIYQYMDDLYVGSDLEI
168 pol 35 RT 186-205 DLYVGSDLEIGQHRTKIEEL
169 pol 36 RT 196-215 GQHRTKIEELRQHLLRWGFT
170 pol 37 RT 206-225 RQHLLRWGFTTPDKKHQKEP
171 pol 38 RT 216-235 TPDKKHQKEPPFLWMGYELH
172 pol 39 RT 226-245 PFLWMGYELHPDKWTVQPIV
173 pol 40 RT 236-255 PDKWTVQPIVLPEKDSWTVN
174 pol 41 RT 246-265 LPEKDSWTVNDIQKLVGKLN
175 pol 42 RT 256-275 DIQKLVGKLNWASQIYAGIK
176 pol 43 RT 266-285 WASQIYAGIKVKQLCKLLRG
177 pol 44 RT 276-295 VKQLCKLLRGTKALTEVI PL
178 pol 45 RT286-305 TKALTEVIPLTEEAELELAE
179 pol 46 RT 296-315 TEEAELELAENREILKEPVH
180 pol 47 RT 306-325 NREILKEPVHGVYYDPSKDL
181 pol 48 RT 316-335 GVYYDPSKDLIAEIQKQGQG
182 pol 49 RT 326-345 IAEIQKQGQGQWTYQIYQEP
183 pol 50 RT 336-355 QWTYQIYQEPFKNLKTGKYA
184 pol 51 RT 346-365 FKNLKTGKYARMRGAHTNDV
185 pol 52 RT 356-375 RM RG AHTN DVKQLTE AVQKI
186 pol 53 RT 366-385 KQLTEAVQKIATESIVIWGK
187 pol 54 RT 376-395 ATESIVIWGKTPKFKLPIQK
188 pol 55 RT 386-405 TPKFKLPIQKETWEAWWTEY
189 pol 56 RT 396-415 ETWEAWWTEYWQATWIPEWE
190 pol 57 RT 406-425 WQATWIPEWEFVNTPPLVKL
191 pol 58 RT 416-435 FVNTPPLVKLWYQLEKEPIV
192 pol 59 RT 426-445 WYQLEKEPIVGAETFYVDGA
193 pol 60 RT 436-455 GAETFYVDGAANRETKLGKA
194 pol 61 RT 446-465 ANRETKLGKAGYVTDRGRQK
195 pol 62 RT 456-475 GYVTDRGRQKWSLTDTTNQ
196 pol 63 RT 466-485 WSLTDTTNQKTELQAIHLA
197 pol 64 RT 476-495 KTELQAIHLALQDSGLEVNI
198 pol 65 RT486-505 LQDSGLEVNIVTDSQYALGI
199 pol 66 RT 496-515 VTDSQYALGIIQAQPDKSES
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200 pol 67 RT 506-525 IQAQPDKSESELVSQIIEQL
201 pol 68 RT 516-535 ELVSQIIEQLIKKEKVYLAW
202 pol 69 RT 526-545 IKKEKVYLAWVPAHKGIGGN
203 pol 70 RT 536-555 VPAHKGIGGNEQVDKLVSAG
204 pol 71 RT 546-560/integrase 1-5 EQVDKLVSAGIRKVLFLDGI
205 pol 72 RT 556-560/integrase 1-15 IRKVLFLDGIDKAQEEHEKY
206 pol 73 integrase 6-25 DKAQEEHEKYHSNWRAMASD
207 pol 74 integrase 16-35 HSNWRAMASDFNLPPWAKE
208 pol 75 integrase 26-45 FNLPPWAKEIVASCDKCQL
209 pol 76 integrase 36-55 IVASCDKCQLKGEAMHGQVD
210 pol 77 integrase 46-65 KGEAMHGQVDCSPGIWQLDC
211 pol 78 integrase 56-75 CSPGIWQLDCTHLEGKIILV
212 pol 79 integrase 66-85 THLEGKIILVAVHVASGYIE
213 pol 80 integrase 76-95 AVHVASGYIEAEVIPAETGQ
214 pol 81 integrase 86-105 AEVIPAET GQETAYFLLKLA
215 pol 82 integrase 96-115 ETAYFLLKLAGRWPVKTIHT
216 pol 83 ntegrase 106-125 GRWPVKTIHTDNGSNFTSTT
217 pol 84 ntegrase 116-135 DNGSNFTSTTVKAACWWAGI
218 pol 85 ntegrase 126-145 VKAACWWAGIKQEFGIPYNP
219 pol 86 ntegrase 136-155 KQEFGIPYNPQSQGWESMN
220 pol 87 ntegrase 146-165 QSQGWESMNKELKKIIGQV
221 pol 88 ntegrase 156-175 KELKKIIGQVRDQAEHLKTA
222 pol 89 ntegrase 166-185 RDQAEHLKTAVQMAVFIHNF
223 pol 90 ntegrase 176-195 VQMAVFIHNFKRKGGIGGYS
224 pol 91 ntegrase 186-205 KRKGGIGGYSAGERIVDIIA
225 pol 92 ntegrase 196-215 AGERIVDIIATDIQTKELQK
226 pol 93 ntegrase 206-225 TDIQTKELQKQITKIQNFRV
227 pol 94 ntegrase 216-235 QITKIQNFRVYYRDSRDPLW
228 pol 95 ntegrase 226-245 YYRDSRDPLWKGPAKLLWKG
229 pol 96 ntegrase 236-255 KGPAKLLWKGEGAWIQDNS
230 pol 97 ntegrase 246-265 EGAWIQDNSDIKWPRRKA
231 pol 98 ntegrase 256-275 DIKWPRRKAKIIRDYGKQM
232 pol 99 ntegrase 266-285 KIIRDYGKQMAGDDCVASRQ
233 pol 100 ntegrase 269-288 RDYGKQMAGDDCVASRQDED
234 nef 1 nef 1-20 MGGKWSKRSWGWPTVRERM
235 nef 2 nef11-30 VGWPTVRERMRRAEPAADGV
236 nef 3 nef 21-40 RRAEPAADGVGAVSRDLEKH
237 nef 4 nef 31-50 GAVSRDLEKHGAITSSNTAA
238 nef 5 nef 41-60 GAITSSNTAANNADCAWLEA
239 nef 6 nef 51-70 NNADCAWLEAQEEEEVGFPV
240 nef 7 nef 61-80 QEEEEVGFPVRPQVPLRPMT
241 nef 8 nef71-90 RPQVPLRPMTYKAAVDLSHF
242 nef 9 nef 81-100 YKAAVDLSHFLKEKGGLEGL
243 nef 10 nef 91-110 LKEKGGLEGLIYSQKRQDIL
244 nef 11 nef 101-120 IYSQKRQDILDLW VYHTQG Y
245 nef 12 nef 111-130 D LWVYHT QGYFPDWQNYTPG
246 nef 13 nef 121-140 FPDWQNYTPGPGIRYPLTFG
247 nef 14 nef 131-150 PGIRYPLTFGWCFKLVPVEP
248 nef 15 nef 141-160 WCFKLVPVEPEKVEEANEGE
249 nef 16 nef 151-170 EKVEEANEGENNSLLHPMSL
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250 nef 17 nef 161-180 NNSLLHPMSLHGMDDPEREV
251 nef 18 nef 171-190 HGMDDPEREVLVWKFDSRLA
252 nef 19 nef181-200 LVWKFDSRLAFHHMARELHP
253 nef 20 nef 187-206 SRLAFHHMARELHPEYYKDC
254 rev 1 rev 1-20 MAGRSGDSDEELLKTVRLIK
255 rev 2 rev 11-30 ELLKTVRLIKFLYQSNPPPS
256 rev 3 rev 21-40 FLYQSNPPPSPEGTRQARRN
257 rev 4 rev 31-50 PEGTRQARRNRRRRWRERQR
258 rev 5 rev 41-60 RRRRWRERQRQIRSISEWIL
259 rev 6 rev 51-70 QIRSISEWILSTYLGRPAEP
260 rev 7 rev 61-80 STYLGRPAEPVPLQLPPLER
261 rev 8 rev 71-90 VPLQLPPLERLTLDCNEDCG
262 rev 9 rev 81-100 LTLDCNEDCGTSGTQGVGSP
263 rev 10 rev 91-110 TSGTQGVGSPQILVESPAVL
264 rev 11 rev 97-116 VGSPQILVESPAVLESGTKE
265 tat 1 tat 1-20 MEPVDPRLEPWKHPGSQPKT
266 tat 2 tat 11-30 WKHPGSQPKTACTNCYCKKC
267 tat 3 tat 21-40 ACTNCYCKKCCFHCQVCFIT
268 tat 4 tat 31-50 CFHCQVCFITKGLGISYGRK
269 tat 5 tat 41-60 KGLGISYGRKKRRQRRRAPQ
270 tat 6 tat 51-70 KRRQRRRAPQDSQTHQVSLS
271 tat 7 tat 61-80 DSQTHQVSLSKQPASQPRGD
272 tat 8 tat 71-90 KQPASQPRGDPT GPKESKKK
273 tat 9 tat 81-100 PT G PKESKKKVERETETDPV
274 tat 10 tat 82-101 TGPKESKKKVERETETDPVD
275 vif 1 vif 1-20 MENRWQVMIVWQVDRMRIRT
276 vif 2 vif 11-30 WQVDRMRIRTWKSLVKHHMY
277 vif 3 vif 21-40 WKSLVKHHMYISRKAKGWFY
278 vif 4 vif 31-50 ISRKAKGWFYRHHYESTHPR
279 vif 5 vif 41-60 RHHYESTHPRISSEVHIPLG
280 vif 6 vif 51-70 ISSEVHIPLGDARLVITTYW
281 vif 7 vif 61-80 DARLVITTYWGLHTGERDWH
282 vif 8 vif 71-90 GLHTGERDWHLGQGVSIEWR
283 vif 9 vif 81-100 LGQGVSIEWRKKRYSTQVDP
284 vif 10 vif 91-110 KKRYSTQVDPDLADQLIHLY
285 vif 11 vif 101-120 DLADQLIHLYYFDCFSESAI
286 vif 12 vif 111-130 YFDCFSESAIRNAILGHIVS
287 vif 13 vif 121-140 RNAILGHIVSPRCEYQAGHN
288 vif 14 vif 131-150 PRCEYQAGHNKVGSLQYLAL
289 vif 15 vif 141-160 KVGSLQYLALAALITPKKIK
290 vif 16 vif 151-170 AALITPKKIKPPLPSVTKLT
291 vif 17 vif 161-180 PPLPSVTKLTEDRWNKPQKT
292 vif 18 vif 171-190 EDRWNKPQKTKGHRGSHTMN
293 vif 19 vif 173-192 RWNKPQKTKGHRGSHTMNGH
294 vpr 1 vpr 1-20 MEQAPEDQGPQREPYNEWTL
295 vpr 2 vpr11-30 QREPYNEWTLELLEELKSEA
296 vpr 3 vpr 21-40 ELLEELKSEAVRHFPRIWLH
297 vpr 4 vpr31-50 VRHFPRIWLHGLGQHIYETY
298 vpr 5 vpr 41-60 GLGQHIYETYGDTWAGVEAI
299 vpr 6 vpr 51-70 GDTWAGVEAIIRILQQLLFI
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300 vpr 7 vpr 61-80 IRILQQLLFIHFRIGCQHSR
301 vpr 8 vpr 71-90 HFRIGCQHSRIGITRQRRAR
302 vpr 9 vpr 77-96 QHSRIGITRQRRARNG ASRS
303 vpu 1 vpu 1-20 MQSLQILAIVALWAAIIAI
304 vpu 2 vpu 11-30 ALWAAIIAIWWSIVFIEY
305 vpu 3 vpu 21-40 WWSIVFIEYRKILRQRKID
306 vpu 4 vpu 31-50 RKILRQRKIDRLIDRIRERA
307 vpu 5 vpu 41-60 RLIDRIRERAEDSGNESEGD
308 vpu 6 vpu 51-70 EDSGNESEGDQEELSALVEM
309 vpu 7 vpu 61-80 QEELSALVEMGHHAPWDVDD
310 vpu 8 vpu 62-81 EELSALVEMGHHAPWDVDDL
Table 2.1. Sequences of long peptides spanning the entire HIV-1 clade B 
consensus sequence used for comprehensive mapping of HIV epitopes. The
sequences of all 310 overlapping peptides (based on a recent clade B consensus 
sequence http://www.hiv.lanl.gov/content/hiv-db/CONSENSUS/M_GROUP/2002- 
Aug.html), their designation in the peptide pool matrices in Table 2.2 and the 
protein/amino acid position within the HIV-1 genome they correspond to are shown.
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Matrix setup for gp160 peptides:
Pool A PoolB Pool C Pool D Pool E Pool F Pool G Pool H Pool Pool J
POOlK gp160-1 gp 160-2 gp160-3 gp160-4 gp160-5 gp160-6 gp160-7 gp160-8 gp160-9 gp160-10
Pool L gp160-11 gp160-12 gp160-13 gp160-14 gp160-15 gp160-16 gp160-17 gp160-18 gp160-19 gp160-20
Pool M gp160-21 gp160-22 gp160-23 gp160-24 gp160-25 gp160-26 gp160-27 gp160-28 gp160-29 gp 160-30
Pool N gp160-31 gp160-32 gp160-33 gp160-34 gp160-35 gp160-36 gp160-37 gp160-38 gp 160-39 gp160-40
Pool 0 gp160-41 gp160-42 gp 160-43 gp160-44 gp160-45 gp160-46 gp160-47 gp 160-48 gp 160-49 gp160-50
Pool P gp160-51 gp160-52 gp 160-53 gp160-54 gp 160-55 gp160-56 gp 160-57 gp160-58 gp160-59 gp 160-60
Pool Q gp160-61 gp160-62 gp160-63 gp160-64 gp160-65 gp160-66 gp 160-67 gp160-68 gp 160-69 gp160-70
PooIR gp160-71 gp160-72 gp160-73 gp160-74 gp160-75 gp160-76 gp160-77 gp160-78 gp160-79 gp160-80
PoolS gp160-81 gp160-82 gp 160-83 gp160-84
Matrix setup for gag peptides:
Pool A Pool B Pool C Pool D Pool E Pool F Pool G
Pool H gag-1 gag-2 gag-3 gag-4 gag-5 gag-6 gag-7
Pool I gag-8 gag-9 gag-10 gag-11 gag-12 gag-13 gag-14
Pool J gag-15 gag-16 gag-17 gag-18 gag-19 gag-20 gag-21
Pool K gag-22 gag-23 gag-24 gag-25 gag-26 gag-27 gag-28
Pool L gag-29 gag-30 gag-31 gag-32 gag-33 gag-34 gag-35
Pool M gag-36 gag-37 gag-38 gag-39 gag-40 gag-41 gag-42
Pool N gag-43 gag-44 gag-45 gag-46 gag-47 gag-48 gag-49
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Matrix setup for pol peptides:
Pool A Pool B Pool C Pool D Pool E Pool F PoolG Pool H Pool I Pool J
Pool K pol-1 pol-2 pol-3 pol-4 pol-5 pol-6 pol-7 pol-8 pol-9 pol-10
Pool L pol-11 pol-12 pol-13 pol-14 pol-15 pol-16 pol-17 pol-18 pol-19 pol-20
Pool M pol-21 pol-22 pol-23 pol-24 pol-25 pol-26 pol-27 pol-28 pol-29 pol-30
Pool N pol-31 pol-32 pol-33 pol-34 pol-35 pol-36 pol-37 pol-38 pol-39 pol-40
Pool 0 pol-41 pol-42 pol-43 pol-44 pol-45 pol-46 pol-47 pol-48 pol-49 pol-50
Pool P pol-51 pol-52 pol-53 pol-54 pol-55 pol-56 pol-57 pol-58 pol-59 pol-60
Pool Q pol-61 pol-62 pol-63 pol-65 pol-65 pol-66 pol-67 pol-68 pol-69 pol-70
Pool R pol-71 pol-72 pol-73 pol-74 pol-75 pol-76 pol-77 pol-7 8 pol-79 pol-80
Pool S pol-81 pol-82 pol-83 pol-84 pol-85 pol-86 pol-87 pol-88 pol-89 pol- 90
Pool T pol-91 pol-92 pol-93 pol-94 pol-95 pol-96 pol-97 pol-98 pol-99 pol-100
Matrix setup for nef peptides:
Pool A Pool B Pool C Pool D
POOI E nef-1 nef-2 nef-3 nef-4
Pool F nef-5 nef-6 nef-7 nef-8
PoolG nef-9 nef-10 nef-11 nef-12
Pool H nef-13 nef-14 nef-15 nef-16
Pool I nef-17 nef-18 nef-19 nef-20
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Matrix setup for accessory and regulatory proteins:
Pool A Pool B Pool C Pool D Pool E Pool F Pool G Pool H
Pool I rev-1 rev-2 rev-3 rev-4 rev-5 rev-6 rev-7 rev-8
Pool J rev-9 rev-10 rev-11 tat-1 tat-2 tat-3 tat-4 tat-5
Pool K tat-6 tat-7 tat-8 tat-9 tat-10 vif-1 vif-2 vif-3
Pool L vif-4 vif-5 vif-6 vif-7 vif-8 vif-9 vif-10 vif-11
Pool M vif-12 vif-13 vif-14 vif-15 vif-16 vif-17 vif-18 vif-19
POOlN vpr-1 vpr-2 vpr-3 vpr-4 vpr-5 vpr-6 vpr-7 vpr-8
Pool 0 vpr-9 vpu-1 vpu-2 vpu-3 vpu-4 vpu-5 vpu-6 vpu-7
Pool P vpu-8
Table 2.2. Arrangement of peptides corresponding to the entire HIV-1 clade B 
consensus sequence into peptide pools according to a matrix system. A panel of 310 
overlapping peptides, 20 amino acids in length overlapping by 10 amino acids, was arranged 
into 78 peptide pools as shown in the matrices above, where each peptide is represented in 
two separate pools. Peptides spanning HIV gp160, gag, pol and nef were combined into 
separate individual matrices, and peptides spanning rev, tat, vif, vpr and vpu were arranged in 
a combined accessory/regulatory protein matrix. Each peptide was assigned a peptide 
number, for example the 84 peptides spanning gp160 were named gp160-1 to gp160-84. The 
amino acid sequences of each peptide are given in Table 2.1.
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Cryopreserved patient PBMCs were screened for responses to all peptide 
pools by IFN-y ELISPOT assay. To enable determination of specific 
responses over background levels of IFN-y production, control wells 
containing cells stimulated with medium only were included on each plate. 
From the matrices, a ranked list of potential epitope-containing peptides was 
made (in accordance with which peptide pools stimulated the largest 
responses), and the top 25-30 peptides most likely to contain an epitope were 
re-tested individually in a second IFN-y ELISPOT assay. In the second assay 
to confirm which peptides corresponded to epitopic regions, only those which 
stimulated a response which was greater than three times a background value 
(the mean of the values of the IFN-y spot numbers counted in the wells 
containing cells stimulated with medium alone) and at least 50 SFC per 106 
PBMC were considered to be genuine, positive responses.
The number of epitopic regions recognised, and the relative magnitude of the 
response to each region were calculated for each patient. In order to avoid 
overestimation of the number of epitopes recognised, responses to two 
adjacent overlapping peptides were counted as a response to one epitope, 
since some epitopes could be located in the overlapping region of two 
adjacent peptides, resulting in responses to both overlapping peptides. Only 
the higher of the responses observed to two adjacent overlapping peptides 
were considered for final calculations of the overall magnitude of the HIV- 
specific T cell response.
2.2.7 Statistical analysis
Statistical analysis of data was performed using Graphpad Prism version 4.00 
software. Pearson’s correlation test was used to estimate the degree of 
association between the concurrent viral load and the different parameters of 
the early HIV-specific CD8+ T cell response studied in chapter 3; between the 
breadth and magnitude of total HIV-specific CD8+ T cell responses; between 
the functional avidity and relative dominance of HIV epitope-specific 
responses; and between the kinetics of expansion and magnitude of HIV 
epitope-specific responses. Linear regression analysis was used to fit a line 
through data points plotted on scatter graphs and determine the slope. 
Two-tailed t-tests were used to assess whether the differences between the 
means of groups of observations (e.g. antigen-specific responses made by
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animals in different groups or the functional avidities of responses of different 
dominance) were statistically significant.
One-way analysis of variance (ANOVA) was used to compare the means of 
groups of observations recorded in three or more groups of subjects (e.g. 
features of the HIV-specific response made in patient who established 
different persisting viral loads, or antigen-specific responses made by mice 
receiving different treatments) to see if the difference across the groups was 
significant. Tukey’s multiple comparison tests were subsequently carried out to 
compare pairs of group means.
2.2.8 Staining human PBMCs with antibodies to cell surface markers and 
tetramers (or pentamers)
In 96-well plates, 5x105-106 PBMCs per well were stained with a tetramer or 
pentamer in a 50pl volume and incubated according to pre-optimised 
conditions. (Each tetramer or pentamer had been tested on cells from a 
patient known to have a response to the epitope plus a HLA-matched HIV 
seronegative donor as a control using different concentrations, temperatures 
and incubation times to determine the minimum concentration and 
combination of conditions which gave the brightest specific staining and lowest 
background staining.) Cells were washed three times in PBS supplemented 
with 10% FCS, and then potential Fc receptor-mediated binding of antibodies 
blocked by incubating the cells for 15 mins at 4°C in PBS supplemented with 
10% FCS and 10% human serum. Cells were pelleted and relevant 
monoclonal antibodies (mAbs) to cell surface markers added in a 50pl volume 
and incubated for 15 mins at 4°C. Cells were then washed three times and 
either fixed using 200pl 4% paraformaldehyde or further staining (and blocking 
if necessary) steps performed. Some samples were stained with a single 
antibody only (without staining with a tetramer); for these samples, a pre­
blocking step with FCS was not necessary. The proportion of cells expressing 
the marker(s) of interest was determined by fluorescence-activated cell sorting 
(FACS): samples were run on a FACS Calibur (Beckton Dickinson, Oxford, 
UK) and data was analysed using Cell Quest Pro software.
2.2.9 Staining human PBMCs with antibodies against intracellular markers 
Cell were permeabilised by incubating with 100pl BD cytofix/perm solution for 
20 mins at 4°C, followed by three washes with BD perm/wash buffer. Potential 
FcR-mediated binding of antibodies was prevented by blocking with
141
perm/wash buffer containing 10% human serum. Antibodies to intracellular 
markers were added to pelleted cells and incubated for 15 mins at 4°C. Cells 
were washed three times in perm/wash buffer and then fixed using 4% 
paraformaldehyde. Samples were run on a FACS Calibur and data was 
analysed using Cell Quest Pro software.
2.2.10 Analysis of VB family usage bv HIV-specific CD8* cells
Vp family usage by HIV-specific CD8+ cells was assessed by co-staining 
tetramer- or pentamer-labelled cells with Vp family-specific antibodies (either, 
as indicated in the materials, directly conjugated to a flurorchrome or detected 
using secondary reagents). Staining was carried out by the same method 
employed for analysis of cell surface markers on HIV-specific CD8+ T cells, 
described in section 2.2.8. The percentage of tetramer-stained cells utilising 
each Vp family was subsequently determined by FACS analysis, using Cell 
Quest Pro software.
2.2.11 Stimulation and expansion of polyclonal CTL from HIV-infected 
individuals
Frozen PBMCs were thawed quickly at 37°C and then washed once in T cell 
growth medium (RPMI 1640 supplemented with 10% high grade FCS, 50U/ml 
penicillin, 50pg/ml streptomycin, 10U/ml IL-2 and 50pM 2-mercaptoethanol). 
Cells were counted and -4-5x105 PBMCs were plated in a 1ml volume into 
wells of a 24 well plate. To each well, 1ml of medium containing 5x105 
irradiated allogeneic feeder cells and 0.8pg/ml anti-CD3 antibody was added. 
Cells were incubated at 37°C for 8 days with changes in the medium made 
every 3 days. The resulting polyclonal T cells were assayed for HIV-specific 
CTL activity using a 51 Cr release assay.
2.2.12 51 Cr release assay
51 Cr release assays were performed as described by Borrow et al (Borrow et 
a/., 1994). Autologous EBV-B-LCL (EBV-transformed B lymphoblastoid cell 
line) to be used as target cells were counted and 2x106c pelleted and labelled 
with 100pCi NaCr04 for 1 hour at 37°C. 51Cr-labelled cells were then washed 
four times in CTL assay medium (RPMI without phenol red supplemented with 
10% high grade FCS), and then resuspended at 3x105c/ml and added to 
assay wells in 50pl (1.5x104 target cells/well). Effector CTL were harvested 
from 24 well plates, pelleted and resuspended in CTL assay medium at an
142
appropriate concentration so that 100pl could be added to test wells to give an 
effectontarget (E:T) ratio of at least 50:1. To assay the recognition of synthetic 
peptides, peptide was added in 50pl at 4x the desired concentration. Controls 
were included to indicate the spontaneous release o f51 Cr from the target cells 
(measured by adding target cells and medium alone in a total volume of 
200|jl/well) and the maximal lysis (measured by adding target cells in a 100pl 
volume and 100pl of 2% (v/v) Triton-X-100 per well). All variables were 
assayed in triplicate.
Assays were incubated at 37°C for 5 hours. 40pl of supernatant was then 
harvested from each well into a counting plate and 100pl scintillant (Opti- 
phase supermix) was added. The plates were sealed with adhesive lids and 
left overnight for the scintillant and sample to become homogeneously mixed 
before they were then counted on a Beta-plate reader (Microbeta Trilux, 
Wallac, Turku, Finland). The percent specific 51 Cr release was calculated as 
detailed below:
(mean test counts - mean spontaneous counts) x 100 = % specific 51 Cr release 
(mean maximum counts - mean spontaneous counts)
2.2.13 Assay to determine the relative affinity of binding of peptides to MHC 
alleles
The relative affinity of binding of peptides to murine H-2 alleles was 
determined using a MHC stabilisation assay (Gairin et al., 1995). Test 
peptides were serially diluted in AIM V medium across 96 well plates from an 
initial starting concentration of 2mM, down to 0.2nM. Peptides were prepared 
in a 100pl volume at twice the desired final concentration as they were to be 
diluted by the addition of an equal volume of cells. Dilutions of positive 
reference (LCMV NP396 for Db assay; 2c Syng for Kb assay) and negative 
control (HIV Nef 82-90) peptides were also prepared in the same way. A no 
peptide control was also included.
RMA-S cells (endogenously expressing Kb and Db molecules) previously 
cultured overnight at 26°C to induce stable MHC expression on the cell 
surface were washed, counted and 2.5x106 cells in a 100pl volume added to 
all wells. The cells were incubated with the peptides for one hour at 26°C to 
allow stable peptide-MHC complexes to form, and then incubated for 3 hrs at 
37°C, a temperature at which, "empty” MHC-(32m complexes dissociate and
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disappear from the cell surface. The level of surface MHC expression (and 
hence the relative affinity of binding of the stabilising peptide) was then 
assessed by staining the cells with FITC-conjugated anti-class I H-2Kb or H- 
2Db antibody (or isotype control antibodies) for one hour at 4°C. Cells were 
washed twice in FACS buffer and fixed with 4% paraformaldehyde, after which 
they were stored at 4°C in the dark before running the samples on a FACS 
Calibur.
The fluorescence intensity of each sample was analysed using CellQuest 
software. Results are expressed as fluorescence index (FI) values. These 
were calculated according to the following formula:
mean fluorescence intensity (MFI) of test peptide - MFI of no peptide isotype control 
MFI of no peptide class l-stained control -  MFI of no peptide isotype control
The half-maximal binding level (BL50), which is the peptide concentration 
yielding the half-maximal FI of the reference peptide in each assay, was 
calculated using ED50 plus v1.0 software.
2.2.14 Propagation of viruses
2.2.14 (a) Growth of working stocks
• Recombinant vaccinia viruses 
143 TK' cells were set up in flasks at 107 cells/flask in a volume of -30ml 
medium (Eagle’s MEM supplemented with 7% normal grade FCS and 
BrDU at a final concentration of 25pg/ml) and grown overnight at 37°C in a 
5% C 0 2 environment. The following day a master stock of a virus in a 3ml 
volume per flask was added to near confluent cells at a m.o.i. of 0.1 
pfu/cell. After a one hour infection period at 37°C/ 5% C 0 2, 30ml of 
medium was added to each flask and then incubated as before for 2-3 
days. After this time the cells were collected and a virus-containing lysate 
prepared by three cycles of sonication and freeze/thawing, followed by a 
trypsin digestion. Aliquots of the resulting virus working stock were then 
made and stored at -80°C. The virus titre of the stock was determined by 
titration on 143 TK' cells as described below.
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•  Arenaviruses
BHK cells were set up in flasks at -5x106 cells/flask in a volume of ~30ml 
medium (Dulbecco’s MEM supplemented with 7% normal grade FCS and 
10% tryptose phosphate broth) and grown at 37°C in a 5% C 0 2 
environment until -  40% confluent (typically overnight). Cells were infected 
with a master stock of virus at a m.oi of 0.1 pfu/cell in a 4ml volume per 
flask. After a one hour infection period at 37°C/ 5% C 0 2, 30ml of medium 
was added to each flask and then incubated as before for 2 days. After this 
time the virus-containing supernatant was harvested, and any cell debris 
removed by centrifugation. Aliquots of the resulting virus working stock 
were then made and stored at -80°C. The virus titre of the stock was 
determined by titration on Vero cells as described below.
2.2.14 (b) Plaque assay
• Recombinant vaccinia viruses
143 TK' cells were plated out into 6 well plates at 3x105 cells per well in 
a 3ml volume and grown overnight at 37°C in a 5% C 0 2 environment. 
The following day cells were checked to ensure they had formed a just 
confluent monolayer, the medium removed from the cells, and 500pl 
per well of one of a series of dilutions of a virus stock to be titrated 
(typically 1/103 down to 1/107) added to each well. One well, to which 
medium alone was added, was kept as a negative control. The cells 
were incubated with the virus for one hour at 37°C/5% C 0 2 to allow 
infection to take place, and then overlayed with 4ml per well of a 1:1 
mixture of 1% agarose in water and 2x 199 medium supplemented with 
10% high grade FCS. The plates were then incubated at 37°C in a 5% 
C 0 2 environment. After three days the cell monolayers were fixed by 
adding ~3ml per well of 9.25% formalin (1 in 4 dilution of a 37% stock 
in PBS) and leaving for one hour at room temperature. The plaques in 
the monolayers were visualised by discarding the agarose overlay and 
adding 2ml of a 1 in 10 dilution of a stock solution of 1% crystal violet 
to each well, and allowing the cells to uptake the dye before rinsing 
away excess dye. The plaques were counted and the titre of the virus 
stock calculated in pfu/ml as the number of plaques x dilution factor x 
2 .
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•  Arenaviruses
Vero cells were plated out into 6 well plates at 3x105 cells per well in 3ml 
medium (Eagle’s MEM supplemented with 7% normal grade FCS) and 
grown overnight at 37°C in a 5% C 0 2 environment. The medium was 
removed from the cells, and 500pl per well of one of a series of dilutions of 
a virus stock to be titrated (typically 1/103 down to 1/107) added to each 
well. One well, to which medium alone was added, was kept as a negative 
control. The cells were incubated with the virus for one hour at 37°C/5%  
C 0 2 to allow infection to take place, and then overlayed with 4ml per well 
of a 1:1 mixture of 1% agarose in water and 2x 199 medium supplemented 
with 10% high grade FCS. The plates were then incubated for six days at 
37°C in a 5% C 0 2 environment. The cell monolayers were then fixed for 
one hour at room temperature using ~3ml per well of 9.25% formalin (1 in 
4 dilution of a 37% stock in PBS), after which they were stained by 
discarding the agarose overlay and adding 2ml of a 1 in 10 dilution of a 
stock solution of 1% crystal violet to each well. The cells were allowed to 
uptake the dye before rinsing away excess dye. The plaques were counted 
and the titre of the virus stock calculated in pfu/ml as the number of 
plaques x dilution factor x 2.
2.2.15 Preparation of anti-CD4 antibody used for murine in vivo depletion 
experiments
Immunoglobulins were enriched and concentrated from ascites fluid containing 
monoclonal antibody GK1.5 by ammonium sulphate precipitation. One volume 
of cold saturated ammonium sulphate solution was added dropwise to 2 
volumes of ascites fluid on ice whilst stirring. The mixture was allowed to stand 
on ice for 15 mins, and then centrifuged at 2200rpm/1 OOOOg on a Sorvall RT7 
Plus benchtop centrifuge (DuPont Ltd, Stevenage, UK) at 4°C. The sediment 
was dissolved in a small volume of PBS, injected into a dialysis cassette and 
dialysed against PBS with constant stirring at 4°C for ~ 24 hrs, with several 
changes of PBS. The antibody was harvested from the cassette, its 
concentration determined by protein assay as described below, and then it 
was stored at -20°C until use.
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2.2.16 Determination of antibody concentration in ammonium sulphate
precipitated ascites fluid
The concentration of antibody was determined using a Coomasie Plus 200 
Protein assay in conjunction with BSA standards. The standard microplate 
protocol (working range 100-1500pg/ml) was followed as described below.
Protein standards were prepared by diluting a 2mg/ml BSA stock with PBS to 
concentrations ranging between 0 and 2mg/ml. 10pl of standard or 
appropriately diluted unknown sample was added to micoplate wells in 
duplicate. 300pl of the Coomasie Plus reagent were added to each well, and 
mixed for 30 secs before reading the absorbance at 595nm using a 
Spectramax 340 plate reader (Molecular Devices, Winnersh, UK). The 
average reading from the blank replicates (Opg/ml) was subtracted from the 
average readings of all other standards and unknowns and a standard curve 
prepared using SOFT max PRO version 3.1.2 software. The protein 
concentration in the antibody preparation was determined using the plotted 
standard curve.
2.2.17 Experiments in murine model systems -  immunisaton protocols:
• Epitope hierarchy of the LCMV-specific CD8+ response induced following 
LCMV infection of CD4 depleted C57BL/6 mice
On day -1 and 2 mice were inoculated by an intravenous (i.v.) route with 1mg 
anti-CD4 antibody in a 200pl volume. On day 0, the CD4-depleted mice plus a 
control group which had not received any depleting antibody were infected 
with 2x105 pfu LCMV Armstrong by an intraperitoneal (i.p.) route in a 200pl 
volume. On day 8 mice were bled from a tail vein and then sacrificed, and their 
spleens removed for experimental analysis.
• Epitope hierarchy of the LCMV-specific CD8+ response induced following 
W -LC M V  infection of control C57BL/6 and IA k-o mice
Normal C57BL/6 mice and IA k/o mice (also on a C57BL/6 background) were 
infected i.p. with a mixture of 106 pfu w N P  and 106 pfu wGPIong in a total 
volume of 200pl. 8 days later the mice were sacrificed and their spleens 
removed for experimental analysis.
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•  Epitope hierarchy of the influenza-specific CD8+ response induced 
following i.p. infection of control C57BL/6 and IA k/o mice
Normal C57BL/6 mice and IA k/o mice (also on a C57BL/6 background) were 
infected i.p. with 600 haemagglutinating units of influenza PR8 virus. 8 days 
later the mice were sacrificed and their spleens removed for experimental 
analysis.
•  Expansion of cross-reactive memory cells in Pichinde virus-immune mice 
in the response to LCMV infection induced under conditions where CD4 
help is limiting
Five groups of C57BL/6 mice were used in this experiment, each receiving 
one or more viruses ± anti-CD4 antibody. Each mouse in groups 1-3 were 
each infected with 2x105 pfu Pichinde virus i.p in a 200pl volume. Four weeks 
later, on day -1, groups 3 and 5 were transiently depleted of CD4+ cells by i.p. 
injection of 1mg anti-CD4 antibody. On day 0 groups 2-5 were challenged with 
2x105 pfu LCMV Armstrong given i.p. in a 200pl volume. A further inoculation 
of anti-CD4 antibody was given as before to mice in groups 3 and 5 on day 2. 
On day 8 all mice were sacrificed and their spleens removed for experimental 
analysis.
•  Expansion of memory cells versus naive cells in the help-dependent CD8+ 
T cell response to the male antigen H-Y
Five groups of female C57BL/6 mice were used in this experiment. Mice in 
groups 1-3 were each given an inoculation of 5x106 cells from a splenocyte 
suspension prepared from male C57BL/6 mice. Mice in groups 4 and 5 were 
not initially primed. Four weeks later on day -1, mice in groups 2 and 5 were 
given an inoculation of 1mg anti-CD4 antibody i.v. in a 200pl volume. On day 
0, mice in all groups except for those in group 3 were given a primary or 
boosting inoculation of 5x106 cells from a splenocyte suspension prepared 
from male C57BL/6 mice. Mice in groups 2 and 5 were kept CD4 cell-deficient 
by further inoculations of anti-CD4 antibody as before on days 2 and 7. All 
mice were sacrificed, and their spleens removed for experimental analysis on 
day 13.
2.2.18 Murine IFN-v ELISPOT assay
Multiscreen 96-well filtration plates were coated overnight at 4°C with 100pl 
per well of capture antibody (purified anti-IFN-y mAb clone R4-6A2) diluted to
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5|jg/ml in 0.1 M sodium bicarbonate buffer, pH9.6). Plates were washed three 
times with filtered PBS and blocked by the addition of 200|jl per well RPMI 
1640 supplemented with 10% normal grade FCS for at least 2 hrs at 37°C in a 
5% C 0 2 environment. Plates were washed again before the addition of cells.
Single cell suspensions were prepared from the spleens of experimental mice 
by a process involving mechanical disruption of splenic tissue, removal of red 
cells using red cell lysis buffer and removal of clumps by passing the 
suspensions through cells sieves. Cells were washed three times in RPMI 
1640 supplemented with 2% FCS, counted, resuspended to 107c/ml, and 
diluted so between 2x105 and 2x103 cells could be added per well in a 1 OOjjI 
volume. An aliquot of each suspension (~106 cells) was stained with a 
fluorochrome-conjugated anti-CD8 antibody, and the percentage of CD8+ T 
cells determined by flow cytometry so that ELISPOT results could be 
expressed as SFC per 106 CD8+ T cells. Feeder ceils were prepared from the 
spleens of control mice in a similar way, irradiated at 3000 Rads using a 
Gammacell 1000 Elite irradiator (Nordion International Inc.), washed and 
resuspended to a concentration of 2x106c/ml so that 105 feeder cells could be 
added per well in a 50pl volume. Recombinant human IL-2 was also added at 
10IU/well. Peptides were added in a 50pl volume to give a final concentration 
of lO^M. Positive and negative control wells were included in all assays; in 
these wells con A (final concentration 2.5pg/ml) or medium only were added in 
place of peptide. All variables were assayed in duplicate. Plates were 
incubated overnight at 37°C in a 5% C 0 2 environment.
To detect bound IFN- y, plates were washed three times with filtered PBS and 
three times with PBS containing 0.05% Tween-20 before the addition of 100pl 
secondary antibody (biotinylated anti-IFNy mAb clone XMG1.2 diluted to a 
final concentration of 1pg/ml). They were then incubated overnight at 4°C. 
Plates were washed five times with PBS-Tween, then 100pl per well of anti­
biotin AP was added (final concentration 1pg/ml) and the plates were 
incubated for 4hrs at 37°C. Plates were washed four times with PBS-Tween 
and four times with PBS. After the final wash, plates were taken apart to wash 
the back of the filters to remove trapped antibody. Alkaline phosphatase 
substrate was prepared by diluting a colour development buffer to a 1x 
solution in sterile water and adding 100pl AP colour reagents A and B per 
10ml. 100pl substrate was added per well and plates were allowed to develop
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for 30 mins at room temperature. The reaction was stopped by discarding the 
substrate and rinsing the filters under tap water. Plates were allowed to dry 
overnight and spots counted using an AID automated image analysis system 
with AID ELISPOT version 2.3 software.
Results were calculated from spot values obtained at the most appropriate cell 
density and are expressed as the mean number of SFC per 106 CD8+ cells. 
This was calculated by finding the mean of replicate wells and deducting the 
mean number of spots counted in the negative control wells, then scaling up 
based on the percentage of CD8+ cells in the sample and number of cells per 
well.
2.2.19 Staining murine splenocvtes with antibodies to cell surface markers 
In 96-well plates, ~105 cells per sample were pelleted and relevant mAbs to 
cell surface markers added in a 50pl volume and incubated for 15 mins at 4°C. 
Cells were then washed three times and fixed using 200pl 4%  
paraformaldehyde. Samples were run on a FACS Calibur (Beckton Dickinson, 
Oxford, UK) and data was analysed using Cell Quest Pro software.
2.2.20 H-Y tetramer staining of murine splenocvtes
Splenocyte suspensions were prepared as described above, washed and the 
cells pelleted. To remove B cells, 100pl/spleen of sheep anti-mouse IgG Ab 
Dynalbeads were added, mixed and left at room temperature for 30 mins. 5ml 
of PBS supplemented with 2% FCS was then added to each sample, and 
labelled B cells were removed by magnetic separation. The negative fraction 
was collected, washed and counted. 106 cells in 50pl were stained with 1pl Db- 
Uty-PE tetramer for 20 mins at room temperature. Cells were then stained with 
CD8-Cy5 antibody for 20 mins on ice, washed twice and resuspended in 
PBC/2% FCS without fixing. Samples were run on a FACS Calibur and data 
was analysed using Cell Quest Pro software.
2.2.21 Combined LCMV tetramer and TCR VB region staining of murine blood 
lymphocytes
Blood samples were collected from mice by making an incision in a tail vein, 
and collecting 6-8 drops of blood into a tube containing 200pl blood buffer 
(10mM EDTA and 100IU heparin/ml in PBS). Red cells were removed by the 
addition of 1ml red cell lysis buffer per sample and incubation for 15 mins at
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room temperature, followed by centrifugation, to leave a white pellet of 
lymphocytes. To reduce FcR-mediated binding of antibodies, 2pl Fc block was 
added to the pellet for 10 mins on ice. Cells were then resuspended in an 
appropriate volume of FACS buffer (PBS supplemented with 2% BSA), and 
transferred to wells of a 96 well round bottomed plate, with cells in a volume of 
50pl per well. Cells were then co-stained with optimised quantities of 
fluorescently labelled tetramer, anti-CD8 antibody and one of a panel of V(3- 
specific antibodies. (Each tetramer had been tested on cells using different 
concentrations, temperatures and incubation times to determine the minimum 
concentration and combination of conditions which gave the brightest specific 
staining and lowest background staining.) Staining was carried out for 45 mins 
at room temperature, after which cells were washed twice in FACS buffer and 
fixed in 4% paraformaldehyde. Samples were run on a FACS Calibur and data 
was analysed using Cell Quest Pro software.
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Chapter 3
Characterisation of the breadth and specificity of the virus-specific CD8+ 
response in primary HIV-1 infection
3.1 Introduction
As reviewed in chapter 1, it is known that the virus-specific CD8+ T cell 
response plays an important role in control of viral replication during early HIV- 
1 infection although, at least in the vast majority of infected individuals, it fails 
to contain viral replication completely. A better understanding of the nature of 
the CD8+ response mounted to HIV-1 during the early stages of infection may 
help to explain why this response is not more effective in controlling viral 
replication. However, there have been relatively few studies of the HIV-specific 
CD8+ T cell response during primary infection (Appay, 2002; Appay et al., 
2002; Borrow et al., 1994; Borrow et al., 1997; Cao et al., 2003; Dalod et al., 
1999b; Doisne et al., 2004; Goulder et al., 2001a; Koup et al., 1994; Musey et 
al., 1997; Papagno et al., 2004; Price et al., 1997; Safrit et al., 1994; Wilson et 
al., 2000). The overall magnitude, breadth and kinetics of expansion of the 
response thus remain poorly characterised, and whether/how these 
parameters may vary in different infected individuals is not well understood. 
The aim of this study was to explore such features of the primary HIV-specific 
CD8+ T cell response in a panel of HIV seroconverters who naturally (in the 
absence of early antiretroviral therapy) established differing persisting viral 
loads (see section 3.2), and to determine whether there was any association 
between the magnitude, breadth and/or specificity of the response and the 
persisting viral load established.
Traditionally, CD8+ T cell responses were detected using lytic assays, which 
measure the ability of populations of cells (either ex vivo cells or those 
expanded during a period of in vitro culture) to lyse radiolabelled, antigen- 
pulsed, HLA-matched target cells. Limiting dilution assays were employed to 
obtain more quantitative results: here CTL precursor frequencies were 
calculated after measuring the antigen-specific lytic potential of cells expanded 
in limiting dilution cultures. However, these assays have a number of 
drawbacks, including not being very quantitative or sensitive, problems 
associated with in vitro culture of cells and being relatively time-consuming to 
perform. Newer improved assays now allow for easier, more sensitive and 
accurate assessment of antigen-specific CD8+ responses (Doherty, 1998; 
McMichael & O'Callaghan, 1998). These include assays which detect
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responding T cells on the basis of cytokine production following antigenic 
stimulation (such as ELISPOT assays or intracellular cytokine staining (ICS) 
assays) and those which involve staining cells with fluorescently tagged 
multimeric complexes of an antigenic peptide and MHC allele. ELISPOT 
assays and ICS can both be used to screen rapidly for responses to different 
proteins/peptides and have the added advantage that no prior information 
about the precise epitopes or their MHC restriction is needed. However, 
because they employ a functional readout to detect responding cells, they do 
not reveal the exact magnitude of responses made as they cannot detect cells 
that are unable to mount the response being measured (e.g. produce a 
particular cytokine) following antigenic stimulation. The use of tetramers to 
detect antigen-specific CD8+ T cells allows for a more precise measurement of 
the magnitude of responses, but has the drawback that the epitope and its 
MHC restriction have to be known, plus the cost of purchasing tetramers limits 
the number of epitopes that can be feasibly studied.
Here it was initially chosen to use ELISPOT assays to assess patients’ CD8+ T 
cell responses, first studying responses to whole HIV proteins which were 
presented by a viral vector, and then assessing responses to overlapping 
synthetic 20-mer peptides corresponding to the entire HIV-1 clade B 
consensus sequence. These assays allowed rapid screening of responses to 
different HIV proteins, such that information about the specificity and breath of 
the HIV-specific CD8+ T cell response in multiple patients could be obtained. 
As described in chapter 5, I subsequently went on to characterise individual 
epitope-specific responses identified using the ELISPOT assays more 
comprehensively, using tetramer staining. This enabled the magnitude of 
specific responses to be followed over a series of timepoints, and when used 
in combination with staining with other fluorescently labelled antibodies, the 
breadth of TCR V/? family usage in individual epitope-specific responses and 
the phenotype of the T cells could be explored.
In summary, in this chapter I used ELISPOT assays to analyse the epitope 
breadth and specificity of the HIV-specific CD8+ T cell response raised during 
primary infection in a number of patients. Also included at the end of the 
chapter is some analysis of the TCR V/? family usage by epitope-specific T 
cells, which I carried out to try and gain some insight into the clonal breadth, 
as well as the epitope breadth, of the HIV-specific CD8+ T cell response in 
primary infection. The main objectives of this work were to learn more about 
the nature of the primary HIV-specific CD8+ T cell response and to determine
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whether/how the nature of the response may differ in patients who control viral 
replication with differing efficiency, establishing different persisting viral loads.
3.2 HIV seroconverter cohort
The PBMC samples used in this study were obtained from a cohort of HIV 
seroconverters recruited by Dr Ian Williams from the Mortimer Market Centre 
(London, UK), with the exception of samples from patient SC1 (obtained from 
Dr George Panayiotakopoulos, St George’s Hospital Medical School, London) 
(patients from the latter two sources are collectively referred to as the London 
cohort of patients) and SUMA (obtained from Dr. George Shaw, University of 
Alabama at Birmingham, USA). The clinicians concerned provided details of 
each patient’s clinical history and disease course, together with sequential 
viral load and CD4 count measurements. Clinical tests suggested that all 
subjects were infected with the clade B subtype of HIV-1. All patients 
presented with symptomatic primary HIV infection, with symptoms such as 
nausea, vomiting, headaches, fever, sore throat, rash and lymphadenopathy. 
Peripheral blood samples were collected from patients at sequential 
timepoints after diagnosis, and were assigned a timepoint in accordance with 
the number of days following onset of symptoms (DFOSx) that the sample 
was taken. Although others may define the various phases of HIV infection 
differently, throughout this thesis the following definitions are used: acute 
infection - the time at which the burst of acute viral replication occurs, before 
detection of HIV-1 antibodies by ELISA or Western immunoblot (typically 0-2 
weeks FOSx); subacute infection - when the acute viral burst starts to be 
contained, and during which the patient is antibody indeterminant (typically 3-4 
weeks FOSx); early infection -  after full serocoversion (typically between 5 
weeks FOSx and approximately 6 months FOSx); and chronic infection - any 
time thereafter. Primary infection is used to define the period encompassing 
the acute, subacute and early phases of infection. Because the day of 
symptom onset is based on patient histories and may not be completely 
accurate in all cases, the viral load may provide a better indicator of the time 
within primary infection at which sample collection was begun. For some 
patients, samples were obtained coincident with the peak of viral replication, 
but for many patients, sample collection began after the acute burst of viral 
replication, more coincident with the early phase of infection onwards.
A list of the patients studied and some relevant clinical data is shown in Table 
3.1. Their HLA types are given in Table 3.2. The patients have been divided
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Table 3.1 Clinical profiles of the patients used for T cell studies in chapter 3.
Viral load 
quartile1
Patient Persisting viral load 
established (RNA 
copies/m l)2
Subsequent disease 
course
High MM24 170,200 at 198 DFOSx Has maintained a stable 
CD4 cell count for the 
duration of follow-up (>2.5 
years)
MM23 117,600 at 204 DFOSx Maintained a stable CD4 cell 
count until lost to follow up 
( -1 8  months FOSx)
MM25 71,100 at 185 DFOSx Maintained a stable CD4 cell 
count until lost to follow up 
(~ 22 months FOSx)
SC1 67,075 at 7 months 
FOSx
Has maintained a stable 
CD4 cell count for the 
duration of follow-up (>1.5 
years)
MM26 44,600 at 169 DFOSx Maintained a stable CD4 cell 
count until lost to follow up 
(~ 17 months FOSx)
Intermediate-
high
MM12 34,900 at 230 DFOSx CD4 cell count fell to 200 x 
106 cells/i by 899 DFOSx; 
patient subsequently 
received HAART at 908 
DFOSx. Viral load has been 
maintained at <50 RNA 
copies/ml since initiation of 
therapy.
MM9 30,900 at 189 DFOSx CD4 cell count fell to <200 x 
106 cells/l by 876 DFOSx; 
patient subsequently 
received HAART. Viral load 
has been maintained at <50 
RNA copies/ml and CD4 cell 
counts >200 x 106 cells/l 
since initiation of therapy.
MM4 30,200 at 206 DFOSx CD4 cell count fell to 390 x 
106 cells/l by the time which 
the patient was 
subsequently lost to follow- 
up (-4  years)
MM27 28,800 at 202 DFOSx Has maintained a stable 
CD4 cell count for the 
duration of follow-up (~2 
years)
MM14 27,200 at 179 DFOSx Has maintained a stable 
CD4 cell count for the 
duration of follow-up (> 3 
years)
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MM19 13,900 at 192 DFOSx Diagnosed with acute 
Hepatitis C virus infection at 
95 DFOSx. Subsequently 
received IFN and ribavirin 
treatment. Hepatitis C virus 
undetectable by 287 
DFOSx. Stable CD4 counts 
maintained throughout.
Low-
intermediate
MM35 9,600 at 192 DFOSx Has maintained a stable 
CD4 cell count for the 
duration of follow-up (>1 
year)
MM13 8,200 at 196 DFOSx Has maintained a stable 
CD4 cell count for the 
duration of follow-up (>3 
years)
MM28 5,600 at 198 DFOSx Has maintained a stable 
CD4 cell count for the 
duration of follow-up (>2 
_years)
Low SUMA 2,268 at 278 DFOSx Maintained a stable CD4 cell 
count for >7 years; patient 
subsequently lost to follow-
UP .. ... ...
N .D .J MM22 N.D.J
Last recorded viral load 
before commencement 
of therapy -  3,249,700 
at 25 DFOSx
Received HAART for a 6 
month period from 26-196 
DFOSx. Has maintained a 
stable CD4 cell count since 
coming off therapy for the 
subsequent duration of 
follow-up (>1.5 years).
MM18 N .D /
Last recorded viral load 
-  680,500 at 57 DFOSx
Patient lost to follow-up after 
~ 8 months FOSx.
MM11 N .D /
Last recorded viral load 
before commencement 
of therapy -  355,700 at 
25 DFOSx
Received HAART from 29- 
426 DFOSx; then resumed 
therapy again after 990 
DFOSx.
N.A * DO N.A * This patient consented to
3,200 at 27 months post­ giving samples at three
diagnosis timepoints during chronic
infection (~ 2-4 years after
diagnosis) and was not
monitored over the course of
primary infection.
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1 Patients are listed according to the “’setpoint” persisting viral load, i.e. the persisting viral 
load they established by ~6 months FOSx (the viral load measurement of the sample taken 
nearest to 180 DFOSx). This column indicates which of the four viral load quartiles identified 
in a study by Mellors et al (Mellors et al., 1996) the patients fall into: low (<4531 RNA 
copies/ml plasma), low-intermediate (4,531-13,020 RNA copies/ml plasma), intermediate-high 
(13,020-36,270 RNA copies/ml plasma), or high (> 36,270 RNA copies/ml plasma) persisting 
viral load.
2 Plasma viral RNA load at ~6 months FOSx (the viral load measurement of the sample taken 
nearest to 180 DFOSx). The timepoint at which the viral load given was recorded is also 
indicated.
3 N.D. Not determined, as these patient went onto antiretroviral therapy before 6 months.
4 N.A. Not applicable. This patient was not followed over the period of seroconversion through 
to the time of establishment of the persisting viral load, and so has not been categorised as 
the other patients have been.
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Table 3.2. HLA types of patients used for T cell studies in chapter 3.
Viral load quartile1 Patient HLA type2
High MM22 A*02
A*24
B*15
B*51
Cw*03
Cw*16
MM18 A*02
A*02
B*08
B*44
Cw*05
Cw*07
MM11 N.D. N.D. N.D.
MM24 A*01
A*02
B*08
B*51
Cw*01
Cw*07
MM23 A*02
A*23
B*44
B*49
Cw*05
Cw*07
MM25 A*11
A*03
B*07
N.D.
Cw*07
N.D.
SC1 A*01
A*02
B*08
B*44
Cw*05
Cw*07
MM26 A*02
A*68
B*51
B*35
Cw*15
Cw*04
Intermediate-high MM12 A*03
A*68
B*07
B*44
Cw*07
Cw*07
MM9 A*01
A*66
B*41
B*08
Cw*07
Cw*17
MM4 A* 02 
A*29
B‘ 44
B*58
Cw*07
Cw*16
MM27 A*02
A*03
B*07
B*44
Cw*05
Cw*07
MM14 A*02
A*01
B*27
B*08
Cw*02
Cw*07
MM19
t- 
00 
O 
CO
< 
<
B*44
B*57
Cw*06
Cw*07
Low-intermediate MM35 A*01
A*24
B*35
B*39
Cw*12 
Cw*11
MM13 A*01
A*01
B*08
B*57
Cw*06
Cw*07
MM28 A*11 
A*30
B*13
B*35
Cw*04
Cw*06
Low SUMA A*11 
A*24
B*14
B*15
Cw*08
Cw*12
N.D. Not determined
1 Patients are grouped according to the viral load they established at ~6 
months FOSx (see Table 3.1)
2 The MHC class I types of all patients studied was determined by the 
Oxford Transplant Centre, UK, using a PCR based technique.
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into four groups according to the viral load that they established at around six 
months FOSx, with patients being defined as having either a low (<4531 RNA 
copies/ml plasma), low-intermediate (4,531-13,020 RNA copies/ml plasma), 
intermediate-high (13,020-36,270 RNA copies/ml plasma), or high (> 36,270 
RNA copies/ml plasma) setpoint viral load. These viral load ranges are taken 
from a study by Mellors et al in which the relationship between the persisting 
viral load established by -s ix  months post-infection and the subsequent 
disease course was addressed in a cohort of 180 HIV-infected individuals in 
the USA (Mellors et al., 1996). In this cohort, these viral load ranges divided 
the patients into four quartiles. The time to development of AIDS and death of 
patients in these viral load quartiles was shown to differ, with each group 
having a different median survival time (see Figure 1.5). The patients within 
the cohort I studied were not evenly distributed between the four groups, with 
the majority establishing persisting viral loads which were high or 
intermediate-high: this is discussed further at the end of the chapter.
3.3 Experiments to investigate the suitability of a recombinant vaccinia 
virus-stimulated IFN-y ELISPOT assay for analysis o f HIV-specific CD8+ T 
cell responses
To give an overview of the breadth of the functional HIV-specific CD8+ T cell 
response at the protein level, and the relative immunodominance of responses 
to different proteins I initially used rW -stimulated IFN-y ELISPOT assays 
(based on a method by Larsson et al (Larsson et al., 1999)) to assess T cell 
responses to five different HIV proteins (gp160, Gag, Pol, Tat and Nef - all 
derived from laboratory isolates of HIV-1). In this assay PBMCs are infected 
with recombinant vaccinia viruses containing HIV-1 genes. During a 48-hour 
incubation period, cells within the PBMC population (predominantly 
monocytes) are infected by the vaccinia viruses and the HIV proteins they 
encode are expressed within these cells. HIV proteins are then processed and 
presented for recognition with MHC class I molecules at the cell surface and 
HIV-specific CD8+ T cells within the PBMC population which recognise these 
peptide-MHC complexes are stimulated to produce IFN-y, which is detected in 
a standard ELISPOT assay.
Figure 3.1 shows results from a representative rW -stimulated IFN-y ELISPOT 
assay. Both the data initially obtained and its final representation (with the 
background - the level of IFN-y production seen when cells were stimulated 
with a control vaccinia virus - deducted) are shown to explain how the final
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Figure 3.1. Determination of the responses made by patient MM23 to different HIV-1 proteins using a recombinant 
vaccinia virus-stimulated ELISPOT assay. PBMCs cryopreserved from patient MM23 at 9 DFOSx were thawed and tested 
for responses to recombinant vaccinia viruses expressing HIV proteins (or a control protein): vSC8 - /?-gal only, vPE16 - HIV 
gp160, vAbT -  HIV Gag, vP1288 -  HIV Pol, vTat -  HIV Tat and vTFNef2 -  HIV Nef. Cells were infected with recombinant 
vaccinia viruses at a moi of 2 pfu/cell and 48hrs later, the frequency of IFN-y spot forming cells (SFC) was measured by 
ELISPOT assay. The graph on the left shows the average (of duplicate or triplicate wells) number of spots per well following 
stimulation of 2x105 PBMC with the different recombinant vaccinia viruses. The graph on the right shows the results after the 
background value (average number of spots per well when cells were stimulated with a control vaccinia virus expressing /?-gal 
only) was deducted from the data on the left, and values scaled up to express the data as the number of specific SFC per 106 
PBMC. The error bars indicate 1 SD above the mean. All subsequent data from rW-stimulated ELISPOT assays are 
expressed in this way.
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results were calculated from the raw data. In subsequent figures, all results 
are shown with the background values deducted. The background values that 
have been subtracted are given in the figure legends to enable comparison of 
the magnitude of each response in relation to the background level of 
response. Although the background values were variable between patients 
and even within the same patient when cells from different timepoints were 
used, backgrounds were generally low (in the range of 10-625 SFC per 106 
PBMC). If the background was very high using cells from a particular patient 
or timepoint (greater than 700 SFC per 106 PBMC), then the data was 
considered to be unreliable and was excluded from the analysis. High 
backgrounds may have been due to non-specific secretion of IFN-y or pre­
existing immunity to the vaccinia vector.
Prior to use of rW-stimulated ELISPOT assays for assessment of HIV-specific 
CD8+ T cell responses, experiments were carried out to confirm that the HIV- 
specific IFN-y responses detected using this assay were mediated by CD8+ T 
cells, and also to investigate the reproducibility of results obtained using this 
assay method.
Larsson et al showed that the responses they detected in HIV-infected 
individuals using the rW-stimulated ELISPOT assay were indeed mediated by 
CD8+ T cells (Larsson et al., 1999). Further, previous results from our group 
have shown that it is difficult to detect HIV-specific CD4+ T cell responses in 
typical HIV-infected individuals using cryopreserved cells in ELISPOT assays 
(Gloster et al., 2004), again suggesting that the majority of responses detected 
in rW-stimulated ELISPOT assays would be mediated by the CD8+ T cell 
subset. To confirm this, CD8-depleted PBMC were tested in parallel with total 
PBMC for responses to the five rW s  to verify the phenotype of the responding 
population of cells. CD4-depleted PBMC were also tested as a control to show 
that if responses were abrogated by removal of CD8+ cells, this wasn’t just due 
to alteration of the cells that had been subjected to magnetic separation. In 
Figure 3.2 it can be seen that patient MM4 predominantly made responses to 
HIV gp160, Pol and Tat, plus low-level responses to Gag and Nef. Depletion 
of CD8+ cells reduced the response detected to all proteins, with any residual 
response in most cases being below twice the background level. By contrast, 
CD4+ cell depletion had little or no effect on the response observed to most 
proteins, the one exception being the response to gp160. Whilst this could 
mean that a proportion of this response was mediated by CD4+ T cells, the 
fact that CD8 depletion also very strongly reduced this response suggests that
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Figure 3.2. Investigation of the phenotype of the T cells mediating the 
HIV-specific IFN-y response in rW-stimulated ELISPOT assays.
Cryopreserved PBMC from patient MM4 (pooled cells from 1058 and 1222 
DFOSx) were thawed and either CD8+ or CD4+ cells removed using 
magnetic beads. The efficiency of the depletions was assessed by staining 
total, CD8-depleted and CD4-depleted cells with anti-CD8 APC and anti CD4 
PerCP monoclonal antibodies. Flow cytometric analysis of the stained cells 
revealed that the CD8+ cells in the CD8-depleted cell sample had been 
reduced by 99% and the CD4+ cells in the CD4-depleted cell sample by 83% 
(top two panels). Total, CD8-depleted and CD4-depleted cells were then 
tested in parallel for responses to recombinant vaccinia viruses expressing 
HIV proteins (or a control protein): vPE16 - HIV gp160, vAbT -  HIV Gag, 
vP1288 -  HIV Pol, vTat -  HIV Tat and vTFNef2 -  HIV Nef and vSC8 - 0-gal 
only. Cells were infected with recombinant vaccinia viruses at a moi of 2 
pfu/cell and 48hrs later, the frequency of IFN-y spot forming cells (SFC) was 
measured by ELISPOT assay. Results are expressed as the mean (of 
duplicate wells) number of SFC per 106 PBMC after deduction of the 
background value (mean number of SFC generated when cells were infected 
with the control rW ). The background values were 60, 60 and 15 SFC/106 
PBMC for the total, CD8-depleted and CD4-depleted cells respectively. The 
results shown are representative of findings made in two independent 
experiments.
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this was not a CD4-mediated response. Altogether, the results from this 
experiment suggested that the T cells producing IFN-k in this assay were 
predominantly CD8+ T cells.
Further experiments were carried out to investigate the reproducibility of 
results obtained using the rW-stimulated ELISPOT assay. In Figure 3.3 the 
results from two assays carried out on separate days using two separate vials 
of cells cryopreserved from the same patient at the same timepoint (both 
cryopreserved at the same time) and aliquots of the same virus stocks are 
shown. The magnitudes of the responses to all of the viruses were markedly 
higher in assay two. Variability in the magnitude of the response observed in 
repeated rW-stimulated ELISPOT assays was also seen in experiments 
carried out with cells from other patients too, although this is an extreme 
example. This variability may reflect differences in the viability of vials of 
cryopreserved patient cells (although these were not apparent on thawing), 
and/or differential survival of cells during the two day culture period in different 
assays. Notably, despite the inter-assay variability in the responses observed 
in rW-stimulated ELISPOT assays, replicate wells in a single experiment 
were much less prone to variability. However, although there were 
inconsistencies in the magnitude of the protein-specific responses recorded in 
repeat assays, the hierarchy of responses to different proteins always 
remained the same. For example, in the two assays shown in Figure 3.3, the 
most dominant response was to gp160 and the weakest responses were to 
Gag and Nef. In the light of these observations, it was concluded that rW - 
stimulated ELISPOT assays could not reliably be used for comparison of the 
magnitudes of HIV protein-specific responses at different timepoints and/or in 
different patients. However these assays could be used to address the 
hierarchy of responses to different proteins in different patients and at different 
timepoints within a given patient. To try to reduce the impact of inter-assay 
variability on responses observed in each patient it was decided to test cells 
cryopreserved from a given patient at a series of timepoints together in a 
single assay.
3.4 Longitudinal analysis o f the HIV-specific CD8+ T cell response by 
rW -stim utated IFN-y ELISPOT assay in patients who controlled early 
viral replication with differing efficiency
rW-stimulated IFN-k ELISPOT assays were used to give an overview of the 
relative magnitude of the T cell response to different HIV-1 proteins during
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Figure 3.3. Extent of assay-to-assay variability between rW-stimulated
IFN-y ELISPOT assays. Cryopreserved PBMCs from patient MM4 (pooled 
cells from 1058 and 1222 DFOSx) were stimulated for 48 hours with 
recombinant vaccinia viruses encoding HIV-1 proteins (vPE16 - HIV gp160, 
vAbT -  HIV Gag, vP1288 -  HIV Pol, vTat -  HIV Tat and vTFNef2 -  HIV Nef) 
at a m.o.i. of 2 pfu/cell. The number of cells stimulated to produce IFN-y was 
then enumerated by ELISPOT assay and is expressed as the mean (of 
duplicate or triplicate wells) number of SFC per 106 PBMC after deduction of 
background values (the number of cells found to produce IFN-y following 
stimulation with a recombinant vaccinia virus encoding /?-gal only). The 
background values were 60 and 290 SFC per 106 PBMC for assays 1 and 2 
respectively. The red and blue bars represent results of two independent 
experiments using cells cryopreserved from the same patient/timepoint, and 
the viruses diluted from the same stocks. The error bars indicate 1 SD above 
and below the mean.
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primary infection in different HIV-infected individuals. The number of cells 
producing IFN-y in response to stimulation by vaccinia viruses encoding HIV 
gp160, Gag, Pol, Nef and Tat was determined at sequential timepoints over 
the course of acute, subacute (where samples were available), and early 
infection and at later timepoints in two patients who established high persisting 
viral loads (Figure 3.4), four patients who established intermediate-high viral 
persisting loads (Figure 3.5), three patients who established low-intermediate 
persisting viral loads (Figure 3.6) and one patient who established a low 
persisting viral load (Figure 3.7). Some patients went onto antiretroviral 
therapy by early infection, but all data shown is from experiments using cells 
cryopreserved at timepoints when patients were not on therapy. Viral load 
data are shown for each patient and, as mentioned before, are the best 
indicator of the stage of infection. For a number of the patients here, samples 
from timepoints coincident with the acute viral burst were not available, and 
the samples are from timepoints corresponding to subacute/early infection 
onwards. All graphs show the number of IFN-y spot forming cells per 106 
PBMC after deduction of background values (IFN-y production by cells 
stimulated with a recombinant vaccinia virus expressing /?-gal only). The y-axis 
scales used on different graphs are different because, as discussed in section 
3.3, due to potential variation in the magnitude of the response seen in 
different assays, reliable conclusions cannot be drawn from this data about the 
absolute magnitude of responses and how this may differ in one patient 
compared to another.
In every patient, HIV-specific T cell responses were detected from the earliest 
timepoint available for testing, which in several patients was at/near the peak 
in acute viral replication and in patient SUMA was as early as 4 DFOSx. This 
demonstrates that HIV-specific CD8+ T cell responses start to be induced very 
rapidly after infection. The kinetics of expansion of protein-specific responses 
could not be reliably determined using this assay, but it was notable that in 
several patients (e.g. MM22, MM19, MM9 and MM27) the responses detected 
at the earliest timepoint(s) tested appeared much weaker than those observed 
subsequently. This could potentially reflect poor in vitro survival of cells highly 
activated in vivo in the presence of a high antigenic load; and/or relatively 
delayed expansion of HIV-specific CD8+ T cell responses in these individuals 
(who, notably, all established high or intermediate-high persisting viral loads). 
This issue is addressed in more depth in chapter 5.
In the majority of patients tested, the response observed was heavily biased
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Figure 3.4. Analysis of HIV-specific T cell responses by recombinant 
vaccinia-stimulated IFN-y ELISPOT assay during primary infection in HIV- 
infected individuals who established high setpoint viral loads. PBMCs 
cryopreserved from patients MM22 and MM18 at sequential timepoints during 
infection were stimulated in duplicate or triplicate wells for 48 hours with 
recombinant vaccinia viruses expressing HIV proteins (gp160, Gag, Pol, Tat 
and Nef) or a control protein (/?-gal), and the number of cells that produced IFN- 
Y was assessed by ELISPOT assay. Frequencies are expressed as the mean 
(of duplicate or triplicate wells) number of spot forming cells per 106 PBMC after 
deduction of background values (the number of cells found to produce IFN-y 
following stimulation with a recombinant vaccinia virus encoding /?-gal only). 
Figures in brackets indicate the background values (expressed as the number 
of spot forming cells per 106 PBMC) at each timepoint. The error bars indicate 1 
SD above the mean. The viral load values shown (HIV RNA copies/ml) were 
provided by Dr. I. Williams (Mortimer Market Centre, UK).
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Figure 3.5. Analysis of HIV-specific T cell responses by recombinant 
vaccinia-stimulated IFN-y ELISPOT assay during primary infection in HIV- 
infected individuals who established intermediate-high setpoint viral 
loads. PBMCs cryopreserved from patients MM9, MM27, MM 19 and MM 14 at 
sequential timepoints during infection were stimulated in duplicate or triplicate 
wells for 48 hours with recombinant vaccinia viruses expressing HIV proteins 
(gp160, Gag, Pol, Tat and Nef) or a control protein (y?-gal), and the number of 
cells that produced IFN-y was assessed by ELISPOT assay. Frequencies are 
expressed as the mean (of duplicate or triplicate wells) number of spot forming 
cells per 106 PBMC after deduction of background values (the number of cells 
found to produce IFN-y following stimulation with a recombinant vaccinia virus 
encoding jS-ga) only). Figures in brackets indicate the background values 
(expressed as the number of spot forming cells per 106 PBMC) at each 
timepoint. The error bars indicate 1 SD above the mean. The viral load values 
shown (HIV RNA copies/ml) were provided by Dr. I. Williams (Mortimer Market 
Centre, UK).
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Figure 3.6. Analysis of HIV-specific T cell responses by recombinant vaccinia- 
stimulated IFN-y ELISPOT assay during primary infection in HIV-infected 
individuals who established low-intermediate setpoint viral loads. PBMCs 
cryopreserved from patients MM35, MM13, and MM28 at sequential timepoints 
during infection were stimulated in duplicate or triplicate wells for 48 hours with 
recombinant vaccinia viruses expressing HIV proteins (gp160, Gag, Pol, Tat and 
Nef) or a control protein (J3-gal), and the number of cells that produced IFN-k was 
assessed by ELISPOT assay. Frequencies are expressed as the mean (of duplicate 
or triplicate wells) number of spot forming cells per 106 PBMC after deduction of 
background values (the number of cells found to produce IFN-k following stimulation 
with a recombinant vaccinia virus encoding /?-gal only). Figures in brackets indicate 
the background values (expressed as the number of spot forming cells per 106 
PBMC) at each timepoint. The error bars indicate 1 SD above the mean. The viral 
load values shown (HIV RNA copies/ml) were provided by Dr. I. Williams (Mortimer 
Market Centre, UK).
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Figure 3.7. Analysis of HIV-specific T cell responses by recombinant 
vaccinia-stimulated IFN-y ELISPOT assay during primary infection in an 
HIV-infected individual who established a low setpoint viral load.
PBMCs cryopreserved from patient SUMA at sequential timepoints during 
infection were stimulated in duplicate or triplicate wells for 48 hours with 
recombinant vaccinia viruses expressing HIV proteins (gp160, Gag, Pol, Tat 
and Nef) or a control protein (/?-gal), and the number of cells that produced 
IFN-y was assessed by ELISPOT assay. Frequencies are expressed as the 
mean (of duplicate or triplicate wells) number of spot forming cells per 106 
PBMC after deduction of background values (the number of cells found to 
produce IFN-y following stimulation with a recombinant vaccinia virus 
encoding /?-gal only). The error bars indicate 1 SD above the mean. N.D. 
indicates that PBMC were not available for testing at this timepoint. The viral 
load values shown (HIV RNA copies/ml) were provided by Dr. G.M. Shaw 
(University of Alabama at Birmingham, USA).
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towards epitope(s) in a limited number (one or two) of the proteins tested. In 
only two patients (MM13 who established an intermediate-low viral load and 
patient SUMA who established a low viral load) were broad, co-dominant 
responses observed to multiple viral proteins from the earliest timepoint tested 
onwards. In the other patients, the response was more restricted, with fewer 
viral proteins recognised, and the response to one or two proteins being much 
more dominant than the others. The proteins to which the response was 
biased were different for different patients, for example patient MM9 mounted 
a response very biased towards Pol, but patient MM35 focused his response 
on gp160 and Gag.
The conclusions that can be drawn from these data are limited. Responses 
were assessed to only five HIV proteins, which did not correspond to the 
patients’ autologous viral sequences, and responses observed to a given 
protein could potentially represent recognition of one or many viral epitopes. 
Nonetheless, these results provided suggestive evidence that there may be 
some difference in the breadth of the HIV-specific CD8+ T cell response 
expanded in primary infection in different patients. Further experiments were 
thus designed to explore this more thoroughly.
3.5 "Comprehensive" epitope mapping using peptide-stimulated IFN-y 
ELISPOT assays in patients who controlled early viral replication with 
differing efficiency
The rW-stimulated IFN-y ELISPOT assays initially used gave a limited 
overview of the HIV-specific CD8+ T cell response mounted during primary 
infection. To extend the observations made using this assay, I moved on to 
more comprehensive mapping of the ‘entire’ HIV-specific CD8+ T cell response 
in a number of patients, to give more detailed information on the breadth and 
specificity of the response.
In "comprehensive" mapping experiments, responses made by patient PBMCs 
to peptides corresponding to the entire HIV-1 clade B consensus sequence 
were identified. By using peptides corresponding to the consensus sequence, 
this made mapping the HIV-specific CD8+ T cell response in a large number of 
patients more feasible than if peptides corresponding to each patient’s 
autologous virus sequence were used. However, it also meant that responses 
to some epitopes, particularly in more variable regions of the HIV genome, 
could be missed due to differences between the consensus sequence and 
autologous sequence.
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In total, I used 310 overlapping peptides (20 amino acids in length, 
overlapping by 10 amino acids) corresponding to the entire HIV-1 clade B 
consensus sequence (the sequences of which are shown in Table 2.1). To 
enable fewer cells to be used for mapping and to make the approach more 
feasible, the 310 peptides were not all tested individually, but were arranged in 
pools of peptides according to peptide matrices (Table 2.2), and the peptide 
pools were tested for recognition in an initial IFN-y ELISPOT assay. The 
peptides which a patient’s cells responded to were deduced from the matrices. 
A list was then made of the 25-30 peptides most likely to contain an epitope 
(in accordance with which peptide pools stimulated the largest responses) and 
these peptides were re-tested individually in a second IFN-y ELISPOT assay. 
Although it was possible that a greater number of epitopes could be 
recognised by a patient, only this number of peptides was chosen for re­
testing as the number of cells available was limited. In a similar study by Addo 
et al, only 3 out of 57 patients tested had responses to more than 30 epitopic 
regions, and all three of these patients were chronically infected with HIV 
(Addo et al., 2003). Given that responses in primary infection are reported to 
be narrower than those in chronic infection (Altfeld et al., 2001a; Cao et al., 
2003; Dalod et al., 1999b), it was decided that 25-30 peptides was a 
reasonable number to re-test. In the second assay to confirm which peptides 
contained epitopic regions, only those which stimulated a response which was 
greater than three times the background value (the mean of the values of the 
IFN-y spot numbers counted in the wells containing cells stimulated with 
medium alone) were considered to be genuine responses.
To begin with, some preliminary experiments were carried out to verify that 
this peptide pool-stimulated assay approach was suitable for detecting HIV- 
specific CD8+ T cell responses. First, to confirm that a response to an 
individual peptide could be detected when the peptide was included in a pool 
with other peptides, PBMCs from a patient chronically infected with HIV were 
screened for responses to the peptide pools containing peptides 
corresponding to HIV Gag in parallel with all of the individual Gag peptides. 
The results obtained (Figure 3.8) show that when the peptides were tested 
individually, peptides 110 and 117 stimulated responses greater than three 
times the background value, indicating that these peptides contained HIV 
epitope(s) targeted by this patient’s T cell response. From the matrix, it can be 
seen that if these two peptides did indeed contain epitopes, the patient should
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Figure 3.8. Comparison of the use of individual peptides and peptide pools for analysis of HIV-specific responses in IFN-y 
ELISPOT assays. 49 overlapping peptides spanning HIV Gag (numbered 85-133) were used either individually or in pools of 7 peptides per 
pool (A-N) to stimulate PBMC from patient DO (cells taken during chronic infection) in an IFN-y ELISPOT assay. Responses considered 
positive were those which stimulated IFN-y production above the threshold value of three times above the background level, represented by 
the black arrow (the average number of SFC per 106 PBMC produced when cells were stimulated with medium only). The matrix shows how 
the individual Gag peptides were arranged into pools, and the pools which patient DO responded to are highlighted. From the matrix, it can 
be seen that recognition of peptides 110 and 117 would give rise to positive responses to these pools.
also respond to peptide pools E, K and L, which was in fact what was 
observed in the assay. What is more, the magnitudes of the responses made 
to the peptide pools reflect the magnitudes of the responses observed to the 
individual constituent peptides: the largest response is to pool E as it is made 
up of responses to both peptides 110 and 117, and pool L stimulates a larger 
response than pool K because the individual epitopic region that it contains 
(peptide 117) stimulates a larger response than the epitopic region that pool K 
contains (peptide 110). These results show that the epitopic regions to which 
responses were detected in this patient using the peptide pools would be the 
same as those that would be detected using individual peptides.
Further experiments were carried out to address whether the responses seen 
were mediated by CD8+ T cells and to investigate the reproducibility of results 
between assays.
To investigate the phenotype of the responding cells in peptide-stimulated 
IFN-y ELISPOT assays, total PBMC, CD8-depleted PBMC and CD4-depleted 
PBMC were tested in parallel for responses to peptide pools that a particular 
patient’s cells had previously been shown to exhibit responses to. Figure 3.9 
shows the responses made by cells from patient MM11 when three peptide 
pools from HIV Gag were used to stimulate the three different cell populations. 
It can be seen that CD8 depletion of the PBMCs resulted in almost a complete 
loss of the responses to the three peptide pools, compared to just a slight 
reduction in the magnitude of the response caused by CD4 depletion of the 
PBMCs (the latter suggesting that cell viability may have been affected to a 
small extent by depletion). Altogether, this provided strong evidence that the 
cells making the HIV-specific IFN-y response in this assay were CD8+ cells.
To investigate the reproducibility of results obtained in peptide pool-stimulated 
ELISPOT assays, two assays addressing responses to the gp160 peptide 
matrix were carried out on separate days using different vials of the same 
patient’s cells cryopreserved at the same time, and the same stocks of the 
peptide pools. As shown in Figure 3.10, the two assays gave very similar 
results. Interestingly, in these assays, which were carried out with PBMC 
cryopreserved from a patient during chronic HIV infection, responses were 
seen towards a high proportion of the gp160 peptide pools, with >65% of the 
pools tested giving a positive response (three times background) in both 
assays. Most importantly, the responses seen to the different peptide pools 
were of a similar hierarchy in the two assays, so the ranked list of long
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Figure 3.9. Investigation of the phenotype of the T cells mediating the HIV- 
specific IFN-y response in peptide pool-stimulated ELISPOT assays. PBMCs 
cryopreserved from patient MM11 (25 DFOSx) were depleted of either CD8+ or CD4+ 
cells using magnetic beads. The efficiency of the depletions was assessed by staining 
total, CD8-depleted and CD4-depleted cells with anti-CD8 FITC and anti CD4 PE-Cy5 
monoclonal antibodies. Flow cytometric analysis of the stained cells revealed that the 
CD8+ cells in the CD8-depleted cell sample had been reduced by 91% and the CD4+ 
cells in the CD4-depleted cell sample by 78% (top two panels).The three populations of 
cells were then tested in parallel for responses to three Gag peptide pools that the 
patient was known to respond to. Cells were stimulated overnight with the peptide pools 
at a final concentration of 10‘5M (or with medium only) and the number of cells 
stimulated to produce IFN-y was measured by ELISPOT assay. The results are 
expressed as the mean (of duplicate wells) number of SFC per 106 PBMC after 
deduction of the background value (mean number of SFC generated when cells were 
incubated with medium alone). The error bars indicate 1 SD above and below the 
mean. The background values were 65, 25 and 15 SFC/106 PBMC for the total, CD8- 
depleted and CD4-depleted cells respectively. The results shown are representative of 
observations made in two independent experiments.
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Figure 3.10. Analysis of the extent of assay-to-assay variability between peptide-stimulated IFN-k ELISPOT 
assays. PBMC cryopreserved from patient MM4 at 574 DFOSx were stimulated with pools of peptides corresponding to 
the HIV-1 gp160 clade B consensus sequence at a final peptide concentration of 10'5M. The number of cells stimulated 
to produce IFN-k was enumerated by ELISPOT assay and is expressed as the mean (of duplicate or triplicate wells) 
number of SFC per 106 PBMC after deduction of background values (response observed when cells were stimulated 
with medium alone - the background in assay 1 was 70 SFC per 106 PBMC and in assay 2 was 105 SFC per 106 
PBMC). The red and green bars represent results of two independent experiments using cells cryopreserved from the 
same patient/timepoints, and the same peptide pool stocks. The error bars indicate 1 SD above and below the mean.
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peptides to be re-tested that would be indicated by results from the two 
replicate assays were very similar (with the peptide pools stimulating the 
strongest responses being the same in both cases). The variation in the 
magnitude of responses between replicate wells was also found to be lower in 
the peptide-stimulated assays than in the rW-stimulated assays. This could 
reflect differences in the nature of in vitro stimulation of the cells in the two 
assays, the longer incubation period with a virus possibly having a more 
detrimental effect on cell survival in the recombinant vaccinia virus-stimulated 
assay. These results, and similar observations made in duplicate assays using 
cells from other patients, indicate that the peptide pool-stimulated IFN-y 
ELISPOT assays provide a reproducible means of identifying the majority of 
epitopic regions recognised by the T cell response in a given patient.
Having verified that this approach was suitable for identifying HIV-specific 
CD8+ T cell responses, this methodology was used to investigate the nature of 
the early CD8+ response in 13 HIV-1 infected individuals. The first objective 
was to “comprehensively” identify the epitopic regions recognised by each 
patient’s primary HIV-specific CD8+ T cell response. This was done by initially 
screening patient cells for responses to the peptide pools, and then re-testing 
peptides that the initial screen indicated might contain an epitopic region as 
discussed earlier. All responses were identified using cells cryopreserved at 
timepoints in early infection (generally between approximately 45 and 100 
DFOSx, with the exception of patient SC1 where cells from -seven months 
FOSx were used) in IFN-y ELISPOT assays. The 13 patients studied 
established different persisting viral loads by -six months FOSx, falling into 
three of the four viral load quartiles defined by Mellors et al (Mellors et al., 
1996): data is shown from five patients who established high viral loads in 
Figure 3.11, five patients who established intermediate-high viral loads in 
Figure 3.12, and three patients who established low-intermediate viral loads in 
Figure 3.13.
Part (i) of each figure summarises the long peptides containing epitopic 
regions that each patient was found to exhibit a response to, and the relative 
magnitude of the response to each long peptide. In some cases, responses 
were observed to two or more overlapping peptides. If responses to two 
adjacent overlapping peptides were seen, in subsequent calculations of the 
number of epitopic regions recognised (section 3.6), this was counted as a
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(a) Patient MM24
(i) 44-51 DFOSx
■  22 IPIHYCAPAGFAILKCNDKK
□  1D TN N P P IP VGEIYKRWIILGL
□  244 IYSQKRQDILDLWVYHTQGY 
■  256 F LYQSN PPPSPEG TRQARRN
B 284 KKRYSTQVD P D LADQLIH LY
(ii) 211 DFOSx
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude of 
response 
(SFC per 106 
PBMC)
22 CAPAGFAIL gp i60 B51 1309
(aa 216-224)
110 EIYKRWII gag p24 B8 3320
(aa 128-135)
(GEIYKRW IIL) B8 (2424)
(GEIYKRW II) B8 (2930)
244 (KRQ)DILDLW VY nef Cw07 2647 (3812)
(aa 105-115)
244/245 YFPDW Q NYT nef A1 2534
(aa 120-128)
284 LADQLIHLYY vif A1 379
(aa 102-111)
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(b) Patient MM23
(i) 37-113 DFOSx
■  216GR\APVKTIHTDNGSNFTSTT
■  240 QEEEEW3FPVRPQVPLRPMT
□  242YKAAVDLSHFLKB<GGLEGL
□  2 4 4 IYSQKRQDILDLVWYHTQGY
■  247 PGIRYPLTFGWCFKLVPVEP
■  256 FLYQSNPPPSPEGTRQARRN
■  259 QIRSISBMLSTYLGRPAEP
□  2 7 8 ISRKAKGWFYRHHYESTHPR
i
(ii) 113 DFOSx
Magnitude of
Long
peptide
Epitope peptide Location MHC restriction response 
(SFC per 106 
PBMC)
242 FLKEKGGLEGL nef 
(aa 90-100)
A2 1952
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(c) Patient MM25
(i) 38-94 DFOSx
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(ii) 94 DFOSx
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude of 
response 
(SFC per 106 
PBMC)
86 RLRPGGKKK(Y) gag p17 
(aa 20-29)
A3 2588 (2291)
241 RPQVPLRPM TY nef 
(aa 71-81)
B7 1196
241/242 (A)AVDLSHFLK nef 
(aa 83-92)
A3/A11 308 (451)
244 RQDILDLW VY nef
(aa 106-115)
B7 2341
KRQDILDLW VY nef
(aa 105-115)
Cw07 2731
■  10NFNMWKNNMVEQMHEDIISL
■  14 TDLNNNTNTTSSSGEKMEKG
□  86GB.DRWB<IRLRPGGKKKYK
■  219KQEFQPYNPQSQGW ESMN  
Q 240QEESVGFPVRPQVPLRPMT
■  241RPCN/PLRPMTYKAAVDLSHF
■  244 IYSQKRQDILDLW iAHTQGY
□  256 FLYOSNPPPSPEGTRQARRN
■  2 8 0 ISSB/HIPLGDARLVITTYW
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(d) Patient SC1
(i) -  7 months post-infection
4000 -i
■  80LQYWSQaKNSAVSLLNATA
■  87LRPGGKKKYKLKHIWUASRE
□  89 LERFAVNPGLLETSEGCRQI
■  HOTNNPPIPVG0YKRWIILGL
□  115 YKTLRAEQASQEVKNVWITET
■  117LLVQNANPDCKTILKALGPA
■  161FSVPLDKDFRKYrAFTlPSI
□  195 GWTDRGRQKV^LTDTTMQ
■  2«GRW PVKT1HTDNGSNI=TSrr
□  242 YKAAVDLSHFLKEKGGLBGL 
P  284KKRYSTQVDPDLADQLIHLY
■  296B .LE .K SEA VR H FPR IW LH
(ii) -  10 months post-infection
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude 
of response 
(SFC per 106 
PBMC)
80 ELKSAVSL gpi60  
(aa 797-805)
B8 2700
87 GGKKKYKL gag p17 
(aa 24-31)
B8 1253
110 GEIYKRW II gag p24 
(aa 127-135)
B8 883
115 AEQASQEVKNW gag p24 
(aa 174-184)
B44 1070
161 YTAFTIPSI R.T.
(aa 127-135)
A2 1050
216 HTDNGSNF in teg rase 
(aa 114-121)
A1 3079
242 FLKEKGGL nef 
(aa 90-97)
B8 3160
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(i) 44 DFOSx
(e) Patient MM26
6000 -
5000 -
4000
o  3000
O  2000 -
■ 54 Q^RQLLSGIVQQQNNLLRAI
■ 151FSVPLDKDFRKYTAFTPSI
□ 239 NNADCAWLEAQEEEEVGFPV
□ 241RPCVPLRPMTYKAAVDLSHF
■ 246 FPDV\QNYTPGPGIRYPLTFG 
O 250 NNSLLHPMSLHGMDDPEREV
■ 251HGMDDPEREVLWVKFDSRLA
□ 253 SRLAFHHM ARELHPEYYKDC
■ 256 FLYQSN P P PSP EGTRQA RRN
■ 259QIRSISEWLSTYLGRPAEP
□ 261VPLQLPPLERLTLDCNEDCG
■ 272 KQPASQPRGDPTGPKESKKK
■ 275 M ENRWQVMIWVQVDRM RIRT
■ 277 V\KSLVKHHM YISRKAKGVVFY
■ 280ISSEVH IP LGDA RLVnTYW
■ 296 ELLEELKSEAVRHFPRWLH
■ 299GDTV\AGVEAIIRLQQLLFI
(ii) 111 DFOSx
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude of 
response 
(SFC per 106 
PBMC)
161 (K)YTAFTIPSI R.T.
(aa 126-135)
A2 2367 (2467)
TAFTIPSI R.T.
(aa 128-135)
A2/B51 2279
241 QVPLRPMTYK nef 
(aa 73-82)
A2/B35 2087
RPQVPLRPMTY nef 
(aa 71-81)
B35/B51 1872
VPLRPMTY nef 
(aa 74-81)
B35 1887
246 LTFGWCFKLV nef
(aa 137-146)
A2 1124
246 TPGPGIRYPL nef
(aa 128-137)
B35 2309
253 AFHHMAREL nef
(aa 190-198)
A2 919
277 LVKHHMYISR vif
(aa 24-33)
A68 1059
280 EVHIPLGDAR vif
(aa 54-63)
A68 1004
296 EAVRHFPRI vpr 
(aa 29-37)
B51 737
299 RILQQLLFI vpr 
(aa 62-70)
A2 962
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Figure 3.11. Analysis of the specificity of the early T cell response in patients 
who established high persisting viral loads.
(i) Pools of overlapping peptides corresponding to the entire HIV-1 clade B 
consensus sequence were screened in IFN-y ELISPOT assays for recognition by 
PBMC cryopreserved at the indicated timepoints from patients (a) MM24, (b) MM23, 
(c) MM25, (d) SC1 and (e) MM26. Long peptides against which responses were 
identified in this initial screen were then re-tested in a second assay. Those peptides 
to which responses above the threshold value of three times the mean background 
response (the response made by cells stimulated with medium alone) were seen are 
shown in this figure. The magnitude of the response to each long peptide is given. 
The results are expressed as the mean number of specific SFC per 106 PBMC (i.e. 
the number of SFC after subtraction of background values), ±1 SD.
(ii) The epitopes recognised within some of the long peptides to which responses 
were identified in (i) were more precisely mapped by testing short peptides 
corresponding to epitopes known or predicted to be presented by the patient’s HLA 
alleles within the long peptides for recognition by patient PBMC. The sequences 
shown are those peptides which stimulated levels of IFN-y production greater than 
three times the background response stimulated by medium alone. Where the 
precise length of the optimal epitope is not known, the additional amino acids of the 
longer potential epitope are given in brackets. The magnitudes of responses in 
brackets correspond to the longer peptides which include the additional amino acids. 
The timepoints at which the cells used for each assay were cryopreserved are 
indicated in each panel.
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(a) Patient MM12
(i) 40-104 DFOSx
B 4 EQLWV7VYYGVFVWKEATTT 
B 84 CRAILHIPRRIRQGLERALL 
B 176 WASQIYAGIKVKQLCKLLRG 
B 240 QEEEEV GFFV RFQV PLRPMT 
□ 241 RPQV PLRPMTY KA A V DLSHF
(ii) 230 DFOSx
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude of 
response 
(SFC per 106 
PBMC)
84 IPRRIRQGL gp i60  
(aa 834-842)
B7 803
176 QIYAGIKVK R.T.
(aa 269-277)
A3 535
240 FPVRPQVPL(R) nef 
(aa 68-77)
B7 578 (633)
241 QVPLRPM TYK nef 
(aa 73-82)
A3 1408
RPQVPLRPM TY nef 
(aa 71-81)
B7 1385
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(b) Patient MM9
(i)40-105 DFOSx
1400 -
“  1000
°  800 -
a- 600
W 400
□ 127 HQMKDCTERQA NFLGKIWPS
■ 174 LPB<DSWTVNDIQKLVGKLN
□ 193 GAETFYVDGAANRETKLGKA
■ 222 RDQABHLKTAVQMAVFIHNF
■ 234 MGGKWSKRSVV GWFTVRBRM
□ 242 Y KAAV DLSHFLKB<GGLEGL
■ 244 IY SQKRQDILDLWVY HTQGY
(ii) 273 DFOSx
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude of 
response 
(SFC per 106 
PBMC)
242 FLKEKGGL nef 
(aa 90-97)
B8 619
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(c) Patient MM27
(i) 53 DFOSx
■  86 GELDRWEKIRLRPGGKKKYK
■  -B1FSVPLDKDFRKYTAFTIPSI
□  246 FPDW QNYTPGPGIRYPLTFG
(ii) 109-299 DFOSx
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude of 
response 
(SFC per 106 
PBMC)
86 RPGGKKKYKL gag p17 
(aa 22-31)
B7/A3 347
(RLRPGGKKK) gag p17 
(aa 20-28)
A3 N.D.
161 (K)YTAFTIPSI R.T.
(aa 126-135)
A2 1457 (1647)
246 TPGPGIRYPL nef
(aa 128-137)
B7 1795
N.D. Not determined by ELISPOT but sequence subsequently confirmed as an 
epitope using tetramer staining.
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(d) Patient MM14
(i) 40 DFOSx
o
2
CDQ.
<0
<
4000 - 
3500 J 
3000 J 
2500 -
2000 J
g. 1500
O
L L</> 1000
500
0 i
■  84 CRAILHIPRRIRQGLERALL
■  tDTNNPPIPVGEIYKRWllLGL
□  « 5  GYVTDRGRQKW SLTDTTNQ
□  242 YKA A VDLSH F LKEKGGLEGL
■  277 WKSLVKHHM YISRKAKGWFY
(ii) 111-259 DFOSx
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude of 
response  
(SFC per 106 
PBMC)
84 RRIRQGLERALL gp i60  
(aa 836-847)
B8 2108
110 GEIYKRW IIL gag p24 
(aa 127-136)
B8 3101
195 R G R Q K W S L R.T.
(aa 461-469)
B8 1823
242 FLKEKGGL nef 
(aa 90-97)
B8 2086
242 AAVDLSHFL nef 
(aa 83-91)
A2 686
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(e) Patient MM19
(i) 65-102 DFOSx
2500 -
0  2000 -
1CQ
£  1500 - < o
O 10 0 0  -
a
o
fc 500 - i
■  92 GSEELRSLYNTVATLYCVHQ
■ "D1EKAFSPEVIPM FSALSEGAT
□  t)5  LKETINEEAAEWDRLHPVHA
□  t)8  P RGSDIA GTT ST LQEQIGWM
■  ItllYKRWIILGLNKIVRMYSPT
B tBYKTLRAEQASQEVKNWMTET  
B tB ATLEEM MTACQGVGGPGHKA
□  122 TNSATIM M QRGNFRNQRKTV  
B 125 IAKNCRAPRKKGCWKCGKEG 
B 173 PDKWTVQPIVLPEKDSVVrVN
□  234 M GGKWSKRSWGWPTVRERM  
B 245 DLWVYHTQGYFPDWQNYTPG
(ii) 65-102 DFOSx
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude of 
response 
(SFC per 106 
PBMC)
92 GSEELRSLY gag p17 
(aa 71-79)
A1 911
101 KAFSPEVIPMF gag p24 
(aa 30-40)
B57 N.D.
108 TSTLQEQIGW gag p24 
(aa 108-117)
B57 N.D.
234 W G W P T V R E R nef 
(aa 10-19)
A68 1861
N.D. Not determined by ELISPOT but sequence subsequently confirmed as an 
epitope using tetramer staining.
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Figure 3.12. Analysis of the specificity of the early T cell response in 
patients who established intermediate - high persisting viral loads.
(i) Pools of overlapping peptides corresponding to the entire HIV-1 clade B 
consensus sequence were screened in IFN-y ELISPOT assays for recognition by 
PBMC cryopreserved at the indicated timepoints from patients (a) MM12, (b) 
MM9, (c) MM27, (d) MM14 and (e) MM19. Long peptides against which 
responses were identified in this initial screen were then re-tested in a second 
assay. Those peptides to which responses above the threshold value of three 
times the mean background response (the response made by cells stimulated 
with medium alone) were seen are shown in this figure. The magnitude of the 
response to each long peptide is given. The results are expressed as the mean 
number of specific SFC per 106 PBMC (i.e. the number of SFC after subtraction of 
background values), ±1 SD.
(ii) The epitopes recognised within some of the long peptides to which responses 
were identified in (i) were more precisely mapped by testing short peptides 
corresponding to epitopes known or predicted to be presented by the patient’s 
HLA alleles within the long peptides for recognition by patient PBMC. The 
sequences shown are those peptides which stimulated levels of IFN-y production 
greater than three times the background response stimulated by medium alone. 
Where the precise length of the optimal epitope is not known, the additional amino 
acids of the longer potential epitope are given in brackets. The magnitudes of 
responses in brackets correspond to the longer peptides which include the 
additional amino acids.
The timepoints at which the cells used for each assay were cryopreserved are 
indicated in each panel.
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(a) Patient MM35
(i) 45-74 DFOSx
4000
00 3000
<° 2500
2000
O 1500
■  5 VP VWKEATTTLFC ASD A KAY
■  8 H AC VPTDPNPQEW LENVTE
□  99QM  VHQAISPRTLNAW VKWE
□  117 LLVQNANPDCKTILKALGPA
■  121RVLAEAM SQVTNSATIM M QR
□  132TPSQKQEPIDKELYPLASLR
■  234 M GGKWSKRSWGWPTVRERM  
Q 247 PGIRYPLTFGWCFKLVPVEP
■  259 QIRSISEWILSTYLGRPAEP
■  261VPLQLPPLERLTLDCNEDCG
(ii) 192 DFOSx
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude of 
response 
(SFC per 106 
PBMC)
5 LFCASDAKAY gp i60  
(aa 51-60)
A24 1078
8 D P N P Q E W L gp160 
(aa 77-85)
B35 1360
117 NPDCKTIL gag p24 
(aa 195-202)
B35 565
246/247 NYTPG PG IRY nef
(aa 126-135)
A24 1203
247 RYPLTFGW (CF) nef
(aa 134-143)
A24 697 (872)
247 YPLTFG W CF nef
(aa 135-143)
B35 502
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(b) Patient M M 13
(i) 45-98 DFOSx 
3000 i
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o
m 2000Q.
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■ 1MRVKGJRKNYQH.WRWGTML
■  92 GSEELRSLY NTVATLYCV HQ 
D 101EKAFSPEVIPM FSALSEGAT
□  110 TNNPPIPVGEIYKRWIILGL
■  117 LLVQNANPDCKTILKALGPA
□ 186 KQLTEAVQK1ATESIVIWGK
■  242 YKAAVDLSHFLKEKGGLEGL
□  245 DLWVYKTQGYFPDWQNYTPG
■  282 GU-fTGERDWH-GOGVSIEWR
(ii) 275 DFOSx
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude of 
response 
(SFC per 106 
PBMC)
92 GSEELRSLY gag p17 
(aa 71-79)
A1 274
101 KAFSPEVIPMF gag p24 
(aa 30-40)
B57 948
110 (G)EIYKRWII gag p24 
(aa 127-135)
B8 (288)333
242 FLKEKGGL nef 
(aa 90-97)
B8 547
245 HTQYFPDWQ nef
(aa 116-124)
B57 1362
245 YFPDWQNYT nef
(aa 120-128)
A1 204
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(c) Patient MM28
(i) 34-93 DFOSx
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0  1400 
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m 1200
£L
? 1000
0
1  800a>
O 600
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0
(ii) 365 DFOSx
Long
peptide
Epitope peptide Location MHC
restriction
Magnitude of 
response 
(SFC per 106 
PBMC)
84 IPRRIRQGL gp i60  
(aa 834-842)
B35 399
84 RRIRQGLERALL gp160 
(aa 836-847)
A30 915
86 RLRPGGKKKY gag p17 
(aa 20-29)
A30 893
241 VPLRPMTYK nef 
(aa 74-82)
A11 3239
241 RPQVPLRPM TYK nef 
(aa 71-82)
B35 2827
241 AAVDLSHFLK nef 
(aa 83-92)
A11 442
278 ISRKAKGW FY vif
(aa 31-40)
B35 382
■  31TRKSIHIGPGRAFYTT GEII
■  54 QA RQLLSGIVQQQN N LLR AI
■  84 CRAILHIPRRIRQGLERALL
□  86 GE LD R WE KIR LR P GGKKKYK
■  241RPQVPLRPMTVKAAVDLSHF
■  254 M AGRSGDSDEELLKTVRLIK
□  278 ISRKAKGWFYRHHYESTHPR
■  280 ISSEVH IP LGDA RLVUTYW
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Figure 3.13. Analysis of the specificity of the early T cell response in 
patients who established low-intermediate persisting viral loads.
(i) Pools of overlapping peptides corresponding to the entire HIV-1 clade B 
consensus sequence were screened in IFN-y ELISPOT assays for recognition by 
PBMC cryopreserved at the indicated timepoints from patients (a) MM35, (b) 
MM13 and (c) MM28. Long peptides against which responses were identified in 
this initial screen were then re-tested in a second assay. Those peptides to which 
responses above the threshold value of three times the mean background 
response (the response made by cells stimulated with medium alone) were seen 
are shown in this figure. The magnitude of the response to each long peptide is 
given. The results are expressed as the mean number of specific SFC per 106 
PBMC (i.e. the number of SFC after subtraction of background values), ±1 SD.
(ii) The epitopes recognised within some of the long peptides to which responses 
were identified in (i) were more precisely mapped by testing short peptides 
corresponding to epitopes known or predicted to be presented by the patient’s 
HLA alleles within the long peptides for recognition by patient PBMC. The 
sequences shown are those peptides which stimulated levels of IFN-y production 
greater than three times the background response stimulated by medium alone. 
Where the precise length of the optimal epitope is not known, the additional amino 
acids of the longer potential epitope are given in brackets. The magnitudes of 
responses in brackets correspond to the longer peptides which include the 
additional amino acids.
The timepoints at which the cells used for each assay were cryopreserved are 
indicated in each panel.
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response to one epitopic region, since a single epitope could be located in the 
overlapping region of two adjacent peptides. Further, when calculating the 
total magnitude of the CD8+ T cell response detected during early infection, 
only the higher of the responses seen to two adjacent overlapping peptides 
was included in the final calculation. If responses to three overlapping 
peptides were seen, the two largest responses were taken. Overall, responses 
to between 3 (for patient MM27) and 17 (for patient MM26) epitope-containing 
regions were identified in different patients. The epitope-containing regions 
identified were located within all HIV protein subunits, with the exception of 
Protease and Vpu. The magnitude of the total response detected in different 
patients ranged from around 1,500 up to 21,000 SFC per 106 PBMC. A more 
detailed analysis of the data is presented in section 3.6.
The optimal sequence and the MHC restriction of the epitopes recognised 
within some of the regions targeted by each patient’s T cell response were 
then further identified. This was done for two purposes: so that tetramers 
could be obtained (corresponding to one or two immunodominant and 
subdominant epitopes for selected patients) to enable study of responses to 
certain epitopes in more detail later on in chapter 5; and to enable the 
relationship between immunodominance and avidity of T cell responses to be 
investigated for some patients (in chapter 4). Prediction of optimal epitopes 
was carried out using information taken from the HIV molecular immunology 
database (httD://www.hiv.lanl.qov/content/hiv-db) on previously described CTL 
epitopes restricted by the patient’s HLA alleles in the long peptide sequences 
recognised by each patient. If a CTL epitope within a long peptide of interest 
could not be successfully predicted in this way, then computer algorithms 
(SYFPEITHI (http://www.svfDeithi.de/) and BIMAS
(http://bimas.dcrt.nih.aov/molbio/hla bind/)) were used to search for all 
possible 8, 9 or 10mer peptide sequences within the long peptide predicted to 
bind to any of the patient’s HLA alleles. If this gave no suggestions as to 
potential epitopes, in some cases a more empirical approach was taken and 
nested sets of peptides were tested for recognition by patient PBMC in an 
IFN-k ELISPOT assay, and the optimal epitope deduced from the results. 
Synthetic peptides corresponding to the optimal epitope peptides predicted or 
deduced to be recognised by each patient were then tested for recognition by 
patient cells (not necessarily at timepoints during early infection, but rather 
where cell availability permitted) to confirm that they were epitopes. As
194
mentioned before, one aim was to obtain tetramers for the identification of T 
cells responding to selected epitopes within each patient’s response. Since 
tetramer synthesis is not readily possible for all HLA alleles, for most patients 
only those epitope peptides which were presented by alleles for which 
tetramers could be readily obtained were tested. The optimal epitopes to 
which responses were identified in each patient and their MHC restriction are 
shown in part (ii) of Figures 3.11-3.13.
3.6 Comparison o f features o f the early HIV-specific CD8+ T cell response 
in patients who controlled early viral replication with differing efficiency
The data shown in Figures 3.11 to 3.13 was then analysed in a variety of 
ways, to give insight into quantitative and qualitative features of the early HIV- 
specific CD8+ T cell response and whether/how these may differ in patients 
who subsequently established different persisting viral loads.
However, none of the patients in the London cohort I had available for study 
established persisting viral loads in the lowest viral load quartile as defined by 
Mellors et al (Mellors et al., 1996). Unfortunately, there were not sufficient cells 
available from the one patient studied in section 3.4 (SUMA, who was not part 
of the London cohort) who did establish a very low persisting viral load to 
enable him to be included in this analysis. This patient’s entire primary HIV- 
specific CD8+ T cell response had already been mapped ((Jones et al., 2004) 
and Jones et al unpublished data), however this analysis was carried out 
using reagents corresponding to the patient’s autologous sequence, rather 
than the clade B consensus sequence peptides. Since the methods used 
previously to study SUMA’s response were different to those used here, data 
from this patient could not be included in the inter-group comparisons that 
follow.
Magnitude
After all epitopic regions recognised by each subject had been identified, the 
total number of specific spot forming cells per million PBMC to all epitopic 
regions was calculated as a measure of the magnitude of the entire early 
response. A wide range in the total magnitude of the response was seen in the 
different patients, from around 1,500 SFC per 106 PBMC up to over 21,000 
SFC per 106 PBMC. 21,000 SFC per 106 PBMC is equivalent to 2.1% of 
PBMC. Given that CD8+ T cells can constitute 50% of PBMC during primary 
HIV infection, this equates to up to 4.2% of CD8+ T cells being HIV-specific.
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For reasons covered in the discussion, this is likely to be an underestimate of 
the total percentage of HIV-specific CD8+T cells in the blood.
In Figure 3.14, the magnitude of each patient’s response is plotted against 
their viral load at the timepoint at which the cells used for this analysis were 
taken. Looking at the patient group as a whole, there is no relationship 
between the magnitude of the response and the antigenic load (p=0.539).
A comparison of the magnitude of the response in patients grouped according 
to the persisting viral load they established by -six months post-infection is 
shown in Figure 3.15. It can be seen that there was a trend for the patients 
who established the highest persisting viral loads to have the highest 
magnitude responses and that this was statistically significant (as revealed by 
Tukey’s pairwise comparison) when the patients with the high and mid-high 
persisting viral loads were compared (p<0.05), but not when those with high 
and low-mid persisting viral loads were compared (p>0.05).
Overall, the majority of patients exhibited very high magnitude HIV-specific 
CD8+ T cell responses during early infection. The magnitude of the response 
did not appear to be related to the antigenic load at the time the analysis was 
carried out; although there was perhaps some tendency for higher magnitude 
responses to be observed during early infection in patients who went on to 
establish high persisting viral loads.
Breadth
The number of epitopic regions targeted by the early HIV-specific response 
was calculated as one measure of the breadth of the response in each 
subject. In this patient cohort, between 3 and 17 epitopic regions were 
recognised. Overall, responses were detected during early infection to 
approximately a fifth of the HIV genome, with 64 out of 310 long peptides 
being recognised by at least one of the 13 subjects. When the breadth of the 
response as measured by number of epitopic regions recognised was plotted 
against the viral load of each subject at the time of analysis (Figure 3.16), 
there was no correlation between breadth and the level of viraemia in this 
group of patients (p=0.359). There was also no difference in the breadth of the 
response in patients who subsequently established persisting viral loads in the 
three different viral load quartiles (Figure 3.17). There was, however, a 
significant correlation between the number of epitopic regions recognised and 
the magnitude of the response in the 13 subjects (p=0.0072) (Figure 3.18).
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p=0.539
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Total magnitude of early HIV-specific CD8+T cell response 
(SFC per 106 PBMC)
Figure 3.14. Relationship between the viral load and total magnitude of 
HIV-specific CD8* T cell responses of patients during early infection.
Epitopic regions recognised by the early HIV-specific CD8+ T cell response of 13 
subjects were identified as described in the text. The sum of the number of 
specific spot forming cells per million PBMC raised to all epitopic regions 
identified as being recognised by a patient’s early HIV-specific response was 
used as a measure of the magnitude of the subject’s entire response.
In the graph above, the total magnitude of the response for each patient (in SFC 
per 10 PBMC) is plotted against the viral load of the patient at the timepoint at 
which cells were taken for analysis (or the mean of the viral loads measured at 
different timepoints if pooled cells from more than one timepoint were used). A 
linear regression line is shown, and the p value given was determined using 
Pearson’s correlation test.
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Figure 3.15. Comparison of the total magnitude of the early HIV-specific T cell 
response detected by IFN-y ELISPOT assay in patients who established 
different persisting viral loads. The magnitude of the total HIV-specific CD8* T cell 
response during early infection was determined for 13 infected individuals by 
calculating the total number of specific spot forming cells per million PBMC to all 
epitopic regions identified as being recognised by their early HIV-specific response 
(see text).
In the graph above, patients are divided into three groups according to the persisting 
viral load they established at around 180 DFOSx, as explained in the text: low-mid, 
mid-high, or high. Each symbol represents the total magnitude of the response 
detected in early infection in a single patient; the mean values for each group are 
indicated by the horizontal bars. A one-way ANOVA test with Tukey’s multiple 
comparison post tests were performed to assess whether there was a significant 
difference between patient groups; only p values which are <0.05 are shown.
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Figure 3.16 Relationship between the viral load at the time of analysis 
and the breadth of the HIV-specific CD8+ T cell response during early 
infection in HIV-1 infected subjects. The number of epitopic regions 
recognised during the early response was determined for 13 infected 
individuals using IFN-y ELISPOT assays as described in the text. For each 
patient, the number of epitopic regions recognised is plotted against the viral 
load at the timepoint at which cells were taken for analysis (or the mean of the 
viral loads measured at different timepoints if cells from more than one 
timepoint were used). A linear regression line is shown, and the p value given 
was determined using Pearson’s correlation test.
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Figure 3.17. Comparison of the number of epitopic regions within 
the HIV genome targeted by the early T cell response of patients 
who established different persisting viral loads. The number of 
epitopic regions recognised during the early response was determined 
for 13 patients using IFN-y ELISPOT assays as described in the text. 
Each symbol represents the number of epitopic regions to which 
responses were detected during early infection in a single patient. 
Patients are divided into three groups according to the persisting viral 
load they established at around 180 DFOSx as explained in the text: low- 
mid, mid-high or high viral load, and the mean values for each group are 
indicated by horizontal bars. Statistical analysis (one-way ANOVA) 
revealed that there was no significant difference in the number of 
epitopic regions recognised between different patient groups.
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Figure 3.18. Relationship between the total magnitude and breadth 
of the early HIV-specific CD8+ T ceil response. The number of epitopic 
regions recognised and the total magnitude of the response were 
determined for 13 infected individuals as explained in the text. The 
number of epitopic regions recognised is plotted against the magnitude of 
the response for each patient. A regression line is fitted through the data 
points and a p value (as calculated using Pearson’s correlation test) is 
given. The p value of 0.0072 indicates that there is a significant positive 
association between the magnitude and breadth of the early HIV-specific 
CD8+ T cell response.
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Another measure of breadth is the number of protein subunits targeted by the 
early HIV-specific CD8+ T cell response. The number of protein subunits 
recognised by a patient was defined as the number of subunits out of a 
maximum of 14 (gp120, gp41, p17, p24, p2p7p6p1, Protease, Reverse 
Transcriptase, Integrase, Nef, Rev, Tat, Vif, Vpr and Vpu) in which 
response(s) to one or more epitopic regions were detected. Between 3 and 8 
subunits were found to be recognised in different patients. Analysis of the 
mean number of protein subunits recognised by groups of patients who 
established different persisting viral loads revealed that this was highest in the 
group of patients who established high persisting viral loads, although the 
difference between the breadth of the response in this patient group was not 
statistically significant from that in patients who established mid-high or low- 
mid persisting viral loads at the 0.05 confidence limit (Figure 3.19).
Altogether, these results show that the number of epitopic regions targeted by 
the CD8 response in early HIV-1 infection in this group of patients was related 
neither to the antigen load at the time of analysis nor to the persisting viral 
load established by -six months post-infection. There was however a 
tendency for those patients who made large magnitude responses to also 
target more epitopes.
Specificity
The specificity of the early HIV-specific CD8+ T cell response was explored in 
a number of ways, to identify immunologically important proteins/protein 
subunits. In addition to establishing which subunits were recognised, the 
cumulative magnitude of the response made towards them by all subjects and 
the proportion of each subject’s response targeting specific proteins/protein 
subunits were also calculated.
Looking at the London patient cohort as a whole, it was observed that most 
protein subunits could serve as targets for the early HIV-specific immune 
response, with the detection of responses to one or more epitopic regions 
within all HIV protein subunits with the exception of Protease and Vpu which 
were not recognised by any of the 13 subjects.
The frequency of recognition of each protein subunit was determined by 
calculating the percentage of subjects recognising at least one epitopic region 
within the subunit. As can be seen in Figure 3.20, the most frequently 
recognised protein subunit was Nef, with 100% recognition, i.e. all 13 subjects 
recognised one or more epitopic regions within this protein. Furthermore, the
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Figure 3.19. Comparison of the number of HIV protein subunits targeted 
by the early T cell response in patients who established different 
persisting viral loads. The epitopic regions recognised by the early HIV- 
specific CD8+ T cell response of each of 13 patients were identified using 
IFN-y ELI SPOT assays as described in the text. The number of protein 
subunits recognised (out of a total of 14: gp120, gp41, p17, p24, p2p7p6p1, 
Protease, Reverse Transcriptase, Integrase, Nef, Rev, Tat, Vif, Vpr and Vpu) 
was determined for each patient. Recognition of one or more peptides within 
a protein subunit was counted as recognition of that particular protein subunit. 
Each symbol represents the number of protein subunits recognised in early 
infection by a single patient. Patients are divided into three groups according 
to the persisting viral load they established at around 180 DFOSx as 
explained in the text, and the mean values for each group are indicated by 
horizontal bars. Statistical analysis (one-way ANOVA) revealed that there 
was no significant difference in the number of protein subunits recognised 
between different patient groups.
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Figure 3.20. Frequency of recognition of individual HIV-1 protein subunits. The
epitopic regions within the HIV-1 proteome recognised during early infection by PBMC 
from 13 HIV-infected individuals were determined as described in the text. The 
frequency of recognition of each protein subunit by the patient cohort was determined 
by calculating the percentage of patients with a response to at least one epitopic region 
within the subunit. The amino acid-adjusted score represents the frequency of 
recognition of each subunit divided by the subunit length in amino acids.
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most frequently targeted long peptide (YKAAVDLSHFLKEKGGLEGL) was 
located in Nef, with 6 out of 13 patients responding to it. The next most 
recognised proteins were RT and Vif. However when the results were adjusted 
to take into consideration the size of the subunits, although Nef was still the 
most immunogenic subunit, in this case Rev and Gag p17 were the next most 
frequently recognised (Figure 3.20). A similar analysis was carried out to 
explore the size of the response targeted at different proteins, since even a 
quantitatively small response would be counted as recognition of a subunit in 
the analysis of protein subunit recognition in Figure 3.20, which hence may not 
reflect the true immunogenicity of the protein subunits. The total magnitudes of 
responses made to each subunit were calculated by finding the total number 
of SFC per 106 PBMCs raised to each subunit in all patients responding to that 
particular subunit. The results are shown in Figure 3.21, where the protein 
subunits have been ranked in order of the magnitude of the responses they 
stimulate. Taking into account the size of the subunits, the distribution of SFC 
frequencies per amino acid length was also determined (Figure 3.21). Looking 
at the amino-acid adjusted scores, overall the greatest response was to 
epitopes within Nef, followed by Rev. As well as being the most frequently 
recognised subunit, Nef was therefore also the subunit against which the 
highest total response was targeted in this patient cohort.
Another aspect of the specificity of the early response of interest was whether 
it is related to the persisting viral load established later. To address this, for 
each subject the proportion of their entire early HIV-specific CD8 response 
targeting each of four major viral protein regions (Env, Gag, Pol and Nef) (i.e. 
the total number of SFC per 106 PBMC directed towards all epitopic regions 
recognised within a certain protein expressed as a percentage of the total 
magnitude (SFC per 106 PBMC) of the patient’s early response) was plotted 
against the persisting viral load as shown in Figure 3.22. Statistical analysis 
revealed that there was no association between the total proportion of the 
response directed towards the protein and the persisting viral load for any of 
the proteins studied in this way (p=0.914, 0.473, 0.844 and 0.585 for Env, 
Gag, Pol and Nef respectively), i.e. there was no evidence to suggest that 
there is preferential targeting of a specific protein by patients with higher or 
lower viral loads.
It has been shown that CD8+ T cell responses which target epitopes within 
proteins that are expressed early during the viral lifecycle (such as Nef, Tat 
and Rev) control viral replication in vitro more effectively than responses which
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Figure 3.21. Total magnitudes of responses detected to HIV-1 protein subunits in 
IFN-k ELISPOT assays in 13 infected subjects. The specificity and magnitude of the 
early HIV-specific CD8+ T cell response in 13 subjects were determined as described in 
the text. The total magnitude of responses made to each HIV protein subunit was 
determined by calculating the total SFC per 106 PBMC made by the study group to all 
peptides corresponding to the subunit as shown in chart (a).The different sizes of the 
protein subunits were taken into account in (b) by dividing the total magnitude as 
indicated in (a) by the length of the subunit. Both the total magnitude of the responses 
made to each subunit and the amino acid-adjusted scores are represented in the 
graphs in a hierarchy from highest to lowest recognition.
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Figure 3.22. Relationship between specificity of the early HIV-specific CD8+ T cell response and the persisting viral 
load established by HIV-infected subjects. The proportion of the early HIV-specific CD8+ T cell response directed against 
HIV Env, Gag, Pol and Nef was determined for each of 13 HIV-1 infected individuals by calculating the total magnitude of 
responses to all peptides corresponding to the HIV protein as a proportion of the total HIV-specific response (the total 
magnitude of the response raised to all epitopic regions found to be targeted by the patient’s early response, determined as 
explained in the text). Each point represents the proportion of the early response specific for a particular HIV protein in one 
individual and is plotted against the persisting viral load they established by -180 DFOSx. Linear regression lines are shown 
in each panel; the p values given were determined using Pearson’s correlation tests.
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target epitopes within proteins which are expressed later in the lifecycle (van 
Baalen et a!., 2002; Yang et al., 2003). The proportion of the response 
targeting early proteins was determined for each patient by calculating the 
sum of the magnitude of all responses made to epitopic regions within Nef, Tat 
and Rev as a percentage of the total magnitude of all the responses made by 
the subject. This ranged from 11 % of the response in one patient up to as 
much as 70% of the response in another patient. To see if there was any 
association between responses mounted towards epitopes within early viral 
proteins and a more favourable disease course, the proportion of the response 
targeting early proteins was compared for patients within different viral load 
groups. In Figure 3.23 it can be seen that the early-protein specific response 
was quite variable for patients within one group, and that there was no 
evidence that early proteins were targeted any more or less by patients with 
different disease prognoses (p>0.05 for all inter-group comparisons).
Biasing o f the response
Earlier in this chapter, results from rW -stim ulated ELISPOT assays 
addressing the response to five HIV proteins suggested that in the majority of 
the subjects the response towards these proteins was unevenly distributed, 
with skewing of the response towards one or two proteins in many cases. To 
confirm and expand upon this observation, analysis was carried out using data 
from the comprehensive epitope mapping studies to see if there was biasing 
of the response towards certain regions of the HIV genome firstly at the 
protein level, and secondly, at the epitope level.
The percentage of the response directed towards each protein was calculated 
(i.e. the sum of the responses to epitopic regions recognised by a patient 
within a given protein divided by the total magnitude of the response, 
multiplied by 100), and the two most immunodominant proteins identified. The 
sum of the magnitudes of the responses towards these two proteins was 
calculated as a percentage of the magnitude of the total response for each 
patient and is shown in Figure 3.24, where patients have been divided up into 
three groups depending on the persisting viral load established by ~six months 
FOSx. In all 13 patients, greater than 55% of the total early response was 
directed against just two viral proteins, confirming earlier observations made 
using rW -stim ulated ELISPOT assays that the primary HIV-specific CD8+ T 
cell response is biased towards a small number of immunodominant proteins. 
The extent of biasing was greatest in patients who established mid-high
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Figure 3.23. Comparison of the proportion of the early HIV-specific T cell 
response targeted against proteins expressed early in the viral life cycle in 
HIV-infected individuals who established different persisting viral loads. The
epitopic regions recognised by the early CD8+ T cell response in 13 patients and the 
magnitude of the response to each region were identified as described in the text. 
The percentage of the early HIV-specific T cell response directed towards proteins 
expressed early in the viral life cycle (Rev, Tat and Nef) was determined for each 
individual by calculating the sum of the magnitude of the responses directed towards 
epitopic regions in Rev, Tat and Nef as a percentage of the total magnitude of the 
response. Each symbol represents the percentage of the early response targeting 
early proteins in a single patient. Patients are divided into three groups according to 
the persisting viral load they established at around 180 DFOSx (as explained in the 
text): low-mid, mid-high or high viral load, and the mean values for each group are 
indicated by horizontal bars. Statistical analysis (one-way ANOVA) revealed that 
there was no significant difference in the in proportion of the response targeted 
against proteins expressed early in the viral life cycle between different patient 
groups.
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Figure 3.24. Comparison of the extent of biasing of the early HIV- 
specific T cell response towards the two most immunodominant 
proteins in patients who established different persisting viral loads. The
epitopic regions within the HIV-1 proteome recognised by the early HIV- 
specific CD8+ T cell response (and the magnitude of the response to each 
region) were identified for each of 13 patients as described in the text. The 
two proteins to which the highest percentages of the total response were 
directed were identified for each individual, and the percentage of the early 
HIV-specific T cell response directed towards these two proteins was 
calculated by expressing the sum of the magnitude of the response to them 
as a percentage of the total magnitude of the patient’s response. Each 
symbol represents the percentage of the response focused on the two most 
dominant proteins during early infection in a single patient. Patients are 
divided into three groups according to the persisting viral load they 
established at around 180 DFOSx (as explained in the text): low-mid, mid- 
high or high viral load. The mean values for each group are indicated by 
horizontal bars. A one-way ANOVA test with Tukey’s multiple comparison 
post tests were performed to assess whether there was a significant 
difference between patient groups; only those p values resulting from inter­
group comparisons which are <0.05 are shown.
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persisting viral loads (and statistical analysis revealed that this was 
significantly greater compared to those who established high persisting viral 
loads (p<0.01), although the reasons for this are unclear).
In order to study the extent of biasing of the response at the epitope level, the 
four most dominant epitopes (i.e. the four which elicited the largest responses) 
within the response of each patient were determined and the sum of the 
magnitudes of the responses towards them were calculated as a percentage 
of the total magnitude of the patient’s response. In Figure 3.25 it can be seen 
that for all patients, greater than 50% of their entire response was targeted 
towards the most immunodominant epitopes. Hence at the epitope level, there 
was also a high degree of biasing of the response towards a small number of 
immunodominant regions of the proteome in all patients studied. Comparing 
patients in different viral load quartiles, although the extent of biasing of the 
response towards the most dominant epitopes appeared to be greater for the 
patients with mid-high and high than that for patients with low-mid persisting 
viral loads, this was not significantly significant (p>0.05 for all inter-group 
comparisons).
These results confirmed that the early HIV-specific T cell response in most 
patients is highly biased towards a small number of viral proteins (an 
observation made earlier using rW-stimulated ELISPOT assays) and a small 
number of epitopic regions within the viral proteome. Earlier results suggested 
that there may potentially be somewhat less bias in the response of those 
patients establishing the lowest persisting viral loads; here no patients 
establishing low persisting viral loads were available for study, so whether 
their response differed in the extent of biasing from that of other patients could 
not be addressed.
3.7 Analysis o f TCR Vp usage by H IV  epitope-specific T cells in patients 
who established different persisting viral loads
In the previous section, the breadth of the HIV-specific CD8+T cell response in 
different patients was described in terms of either the number of HIV proteins 
or the number of epitopic regions the patient recognised in IFN-k ELISPOT 
assays. Another aspect of the breadth of a response is the number of different 
clones of T cells involved -  the clonal breadth. T cell clones can be 
distinguished on the basis of their TCR use. The TCR is a membrane bound 
heterodimer made up of an a and a /? chain. Each chain is encoded by a 
series of variable (V), diversity (D), joining (J) and constant (C) segments. The
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Figure 3.25. Comparison of the extent of biasing of the early HIV- 
specific T cell response towards the four most dominant epitopic 
regions in patients who established different persisting viral loads. The
epitopic regions recognised by the early HIV-specific CD8+ T cell response 
(and the magnitude of the response to each region) were identified for each 
of 13 patients as described in the text. The four epitopic regions towards 
which the highest magnitude responses were directed were determined for 
each patient, and the percentage of the early HIV-specific T cell response 
directed towards these four epitopic regions was calculated by expressing 
the sum of the magnitude of the response to them as a percentage of the 
total magnitude of the patient’s response. Each symbol represents the 
percentage of the response focused on the four most dominant epitopes 
during early infection in a single patient. Patients are divided into three 
groups according to the persisting viral load they established at around 180 
DFOSx (as explained in the text): low-mid, mid-high or high viral load. The 
mean values for each group are indicated by horizontal bars. Statistical 
analysis (one-way ANOVA test) revealed that there was no significant 
difference in the extent of biasing of the response towards the four most 
dominant epitopic regions between different patient groups.
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broad diversity of the TCR repertoire results from the numerous possible 
combinations of V, D and J segments, from random mutations or nucleotide 
additions and from the random pairing of a  and p  chains. There are a variety 
of techniques for assessing the repertoire of T cell clones involved in an 
immune response, including TCR heteroduplex analysis and CDR3 length 
spectratyping. I chose to assess the pattern of V/? family usage by T cells 
responding to individual HIV epitopes in different patients by co-staining 
patient PBMCs with tetrameric peptide-MHC complexes (details of which are 
given in chapter 5) and antibodies specific for different TCR V/? families. 
Although this does not allow quantitation of the number of individual T cell 
clones involved in a response (as within a given VJ3 family, more than one 
clone of cells may be involved), it gives an overview of the diversity of TCR V/? 
families used in a given response, allowing this to be compared between 
responses in different patients.
In experiments described in chapter 5, tetrameric peptide-MHC complexes 
were obtained to allow identification of T cells responding to dominant and 
subdominant epitopes in different patients, and the kinetics of expansion of 
epitope-specific responses were characterised. Here, the tetramers were used 
to analyse V/? family usage by T cells responding to a dominant epitope in four 
patients (one patient in each of the four different viral load quartiles) at the 
peak of the epitope-specific response (determined in chapter 5). The epitopes 
and patients studied were as follows: A3 RLRPGGKKK in MM25, a patient 
who established a high persisting viral load; A3 QIYAGIKVK in MM12, a 
patient who established an intermediate-high persisting viral load; B8 
FLKEKGGL in MM13, a patient who established a low-intermediate persisting 
viral load and B15 MTKGLGISY in SUMA, a patient who established a low 
persisting viral load. PBMC taken from a timepoint at or close to the peak of 
each response were then co-stained with a HIV tetramer, antibodies to CD3 
and CD8, plus one of a panel of V£ family-specific antibodies. Flow cytometric 
analysis of samples revealed the percentage of tetramer positive cells using 
each V/? family, the results of which are shown in Figure 3.26. The A3 
RLRPGGKKK -specific CD8+ T cells in MM25’s response used only 3 out of 22 
Vp families tested, with a strong bias towards the use of VP 2 (-50%  tetramer 
positive cells using V/? 2). By comparison the A3 QIYAGIKVK-specific CD8 
cells in patient MM12 used a broader range of Vp families (10/22), with a slight 
bias towards V£ 2 and V0 5.3. Although the B8 FLKEKGGL-specific response 
in MM13 used a moderate number of VP families (6/22), there was particularly
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Figure 3.26. Clonal breadth of individual HIV epitope-specific responses in patients who established different 
persisting viral loads. The Vp families used by the T cell receptors of cells responding to one HIV epitope at or near 
the peak of the epitope-specific response were determined for four patients: the A3 RLRPGGKKK response at 31 
DFOSx for MM25, a patient who established a high persisting viral load; the A3 QIYAGIKVK response at 40 DFOSx 
for MM12, a patient who established an intermediate-high persisting viral load; the B8 FLKEKGGL response at 16 
DFOSx for MM13, a patient who established a low-intermediate persisting viral load and the B15 MTKGLGISY 
response at 8-15 DFOSx for SUMA, a patient who established a low persisting viral load. Cryopreserved PBMC were 
co-stained with an MHC class I tetramer corresponding to the epitope being studied within the patient’s early HIV- 
specific CD8 response, antibodies against CD3 and CD8 and an antibody specific to one of 22 different TCR Vp 
families (or an isotype control antibody). The percentage of tetramer positive cells using each V/? family was 
determined by flow c^ometry, and is shown in the bar charts above, with frequencies <1% regarded as background 
staining and therefore not shown. The percentage of the entire tetramer positive population detected by staining using 
the available Vp family antibodies was 56% (A3 RLRPGGKKK), 57% (A3 QIYAGIKVK), 74% (B8 FLKEKGGL) and 
43% (B15 MTYKGLGISY).
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strong biasing of the response towards one family, with almost 60% of 
tetramer positive cells using Vp 22. The broadest and most evenly distributed 
Vp usage was seen with the B15 MTKGLGISY response in patient SUMA, 
with 12 out of 22 families used, and none of the families accounting for greater 
than 10% of the total tetramer positive population. It should be taken into 
consideration however that the percentage of all tetramer positive cells 
detected by the available Vp family-specific antibodies only came to between 
43 and 74% of the total number of cells responding to each epitope. The 
breadth of V/? family usage by the remaining cells is not known.
To gain further insight into TCR usage by HIV-specific T cells in patients who 
established different persisting viral loads, this analysis was extended to look 
at responses to more than one epitope per patient. PBMC were stained with 
other MHC class I tetramers (again at a timepoint near the peak of the 
epitope-specific response), and in each case, the minimum number of Vp 
families involved in the response was determined. Given that in no case were 
100% of tetramer positive cells detected by the available Vp family-specific 
antibodies, the minimum number of families was taken to be the number 
detected plus one, as there must be at least one more involved in each case. 
The results obtained are shown in Figure 3.27 and indicate that there was not 
a marked difference in the mean minimum number of Vp families used in 
epitope-specific responses in different patients. Although the broadest usage 
of Vp families was observed in the patient who established a low persisting 
viral load, responses made by patients in each viral load group exhibited 
restricted TCR usage, and a two-tailed t-test revealed that overall there was 
no significant difference in the breadth of TCR usage in the patient who 
established a low persisting viral load compared to patients who established 
low-mid, mid-high plus high persisting viral loads (observations from three 
patient groups combined) (p=0.073). Had patient/tetramer availability 
permitted, this analysis would ideally have been extended to larger numbers of 
epitopes in more patients, so that more reliable conclusions could be drawn 
from the results.
3.8 Discussion
The prognostic importance of the persisting viral load established within the 
first -six months following infection with HIV-1 (Mellors et al., 1996) indicates 
that events taking place during the initial stages of this infection are critical 
determinants of the subsequent disease course. Nonetheless, this phase of
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Figure 3.27. Comparison of the breadth of V£ family usage by the T cell 
receptors of HIV-specific CD8+ T cells in patients who established different 
persisting viral loads. V/3 family usage by T cells responding to different HIV 
epitopes was analysed as described in the legend to Figure 3.26 in patients who 
established differing persisting viral loads. All responses were identified as being part 
of the patient’s early HIV-specific CD8+ T cell response as described in the text, and 
clonal breadth analysis was carried out at a timepoint at or near the peak of the 
epitope-specific response (determined in chapter 5). The A3 RLRPGGKKK-specific 
response (A3 RK9) at 31 DFOSx was analysed in MM25, a patient who established 
a high persisting viral load; the A3 QIYAGIKVK-specific response (A3 QK9) at 40 
DFOSx and the B7 IPRRIRQGL-specific response (B7 IL9) at 139 DFOSx in MM 12, 
a patient who established an intermediate-high persisting viral load; the B8 
FLKEKGGL-specific response (B8 FL8) at 16 DFOSx and B57 KAFSPEVIPMF- 
specific response (B57 KF11) at 1125 DFOSx in MM13, a patient who established a 
low-intermediate persisting viral load; and the B15 MTKGLGISY-specific response 
(B15 MY9) at 8-15 DFOSx and B14 ERYLKDQQL-specific response (B14 EL9) at 22 
DFOSx in SUMA, a patient who established a low persisting viral load. An estimate of 
the minimum number of V0 families involved in each individual epitope-specific 
response was made based on the actual number of V/? families used by the TCRs, 
with the addition of one more family for every response where <100% of tetramer- 
positive cells were identified using the available TCR V/? family-specific antibodies. 
Each symbol represents the minimum number of V/? families used by the TCRs of 
cells of one epitope specificity. The percentages of the tetramer positive population 
stained using the V/? family-specific antibodies available are indicated. Patients are 
divided into four groups according to the persisting viral load they established at 
around 180 DFOSx. The mean values for each group are indicated by horizontal 
bars. Statistical analysis (a two-tailed t-test) revealed that there was no significant 
difference in the in breadth of V0 family usage by the T cell receptors of HIV-specific 
CD8+ T cells in the patient with a low persisting viral load compared to patients in 
other groups.
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infection remains poorly characterised and the factor(s) determining the 
setpoint viral load have yet to be defined.
The HIV-specific CD8+ T cell response is known to play an important role in 
control of early virus replication (Borrow et a i,  1997; Jin et a i,  1999; Price et 
al., 1997; Schmitz et a i, 1999). However kinetic, quantitative and qualitative 
aspects of the primary HIV-specific CD8+ T cell response are all incompletely 
characterised, and whether/how they may impact on the setpoint viral load 
remains unclear. The main goal of this study was thus to characterise the 
primary HIV-specific CD8+ T cell response in a cohort of HIV-1 infected 
individuals, in order to gain insight into why this response fails to contain viral 
replication more completely, plus potentially identify aspects of the response 
that may differ in patients who subsequently establish different persisting viral 
loads.
The primary HIV-specific CD8+ T cell response was studied using PBMC 
samples cryopreserved at a series of timepoints from patients recruited 
following presentation with symptomatic primary HIV-1 infection. All patients 
were HIV seronegative or indeterminate at the time of presentation. Each 
sample was assigned a timepoint according to the number of DFOSx at which 
it was collected, although the viral load and HIV serostatus typically provide a 
better means of comparing the time during primary infection at which patients 
were first sampled. In this study, I defined the acute phase of infection as the 
time during which the acute burst of viral replication occurred, prior to 
seroconversion; subacute infection as the period when seroconversion was 
taking place, and the viral load was typically declining; subsequent timepoints 
when viraemia was reduced and full seroconversion had occurred as early 
infection. This definition of acute infection is more stringent than that used in 
many other studies, in which any timepoints during the first few months post­
infection have been considered as "acute” (Altfeld et a i, 2001a; Goulder et 
a i, 2001a; Papagno etal., 2004).
Sequential PBMC samples were available from acute, subacute or early 
infection onwards in a total of 16 patients recruited from clinics in London. Of 
these, two commenced combination ART during primary infection. In addition, 
limited samples were available from one patient recruited from a US clinic. 
This patient did not receive any ART and samples were obtained at timepoints 
from acute infection onwards. rW-stimulated ELISPOT assays were carried 
out using samples from sequential timepoints during acute and/or early
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infection for ten of these patients. Although these included some individuals 
who went onto receive ART, only timepoints prior to the commencement of 
therapy were studied. 13 of the patients were selected for more in-depth 
studies of the primary HIV-specific CD8+ T cell response. These patients were 
chosen because they had remained ART-naive throughout the course of 
infection and because sufficient samples were available for study at timepoints 
over the course of early (plus subacute and acute where possible) infection. 
Unfortunately sample availability was more limited in the one patient recruited 
from the US clinic and only allowed limited analysis to be performed for this 
patient. Much of the work in this chapter focused on characterisation of the 
HIV-specific CD8 response during early infection in different infected 
individuals, with follow-on studies in chapter 5 addressing the kinetics and 
phenotype of epitope-specific components of the response during acute, 
subacute and early infection.
The patients were divided into groups according to the viral load established at 
around six months post-infection. The viral load boundaries on which this 
categorisation was based corresponded to those defined by Mellors et al 
(Mellors et al., 1996) as the quartile values taken from the frequency 
distribution of plasma viral load measurements in a cohort of 180 US patients 
whose plasma viral loads were measured within the first six months of 
infection. It was notable that the persisting viral loads established in the cohort 
of London patients I studied were heavily biased towards the upper viral load 
quartiles from the study by Mellors et al, and no patients fell into the lowest 
quartile (although I was able to carry out limited studies on samples from one 
patient (in fact recruited from a US clinic) who did establish a persisting viral 
load in the lowest quartile). It is possible that differences in the locally 
circulating virus strains and/or ethnicity or socioeconomic circumstances of the 
US cohort studied by Mellors et al and the London patients I studied 
contributed to the differences in the distribution of persisting viral loads 
established by -s ix  months post-infection.
Examination of the composition of the two patient cohorts revealed that both 
cohorts largely consisted of Caucasian male homosexuals who were 
predominantly infected with clade B HIV-1 strains. However an important 
difference between the cohorts that likely made a major contribution to the 
difference in the persisting viral loads established by the two groups of 
subjects was in the way they were recruited. The cohort studied by Mellors et 
al was identified by repeated screening of a population of high-risk individuals
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for HIV seroconversion, whereas the patients in the London cohort were 
recruited following clinical presentation with symptoms (e.g. fever, 
lymphadenopathy, nausea, rash and/or headaches) consistent with acute viral 
infection following a high risk HIV exposure incident. A highly symptomatic 
seroconversion illness may well be indicative of a high initial level of viral 
replication, which may be associated with strong cytokine responses involving 
for example type I IFNs and IL-1, that are responsible for many of the 
symptoms characteristic of acute viral infections. If the subjects in this cohort 
did experience particularly high-level early virus replication, this may have also 
been associated with the establishment of relatively high persisting viral loads. 
Indeed, there is evidence in the literature to suggest that individuals 
experiencing highly symptomatic primary infection do have a poor disease 
prognosis (Henrard et al., 1995; Pedersen et al., 1989; Vanhems et al., 2000; 
Vanhems et al., 1998).
Notably, the London patient cohort is biased not only in terms of the 
distribution of persisting viral loads they established, but also in their HLA 
types, with HLA alleles that are associated with rapid disease progression, 
such as HLA-B3502/03 (Gao et al., 2001; Jin et al., 2002) and HLA-B8 
(Candore et al., 1998; Kaslow et al., 1990; McNeil et al., 1996) being present 
at higher than the normal frequency. For example, while the frequency of HLA- 
B8 in the USA Caucasian population is -10%  (HLA 1991) the frequency of this 
allele in this patient cohort was 38% (5/13 subjects expressed HLA-B8). This 
may have contributed to the relatively high viral loads in this patient cohort. It 
may also influence the repertoire of epitopes that responses were observed 
against.
Ideally, the 13 patients for which detailed analysis of the primary HIV-specific 
CD8 response was carried out would have been evenly distributed over the 
four viral load quartiles defined by Mellors et al (Mellors et al., 1996) (which 
are probably more representative of the spectrum of persisting viral loads 
established by clade B-infected individuals in the US/Europe than the viral 
loads established by the London patient cohort). As no patients in the lowest 
viral load quartile were available for study, it was not possible to address what 
type of response is associated with good control of early viral replication; the 
nature of the response and whether/how this may differ in patients could only 
be studied/compared for patients in the three uppermost viral load quartiles. 
Limited sample availability meant that in-depth analysis of the one patient
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available who established a persisting viral load in the lowest viral load quartile 
could not be carried out. In addition, one patient in the lowest viral load 
quartile would not have permitted statistical analysis of any differences 
observed between that group compared to the other three to be performed, 
and so I could not hope to make anything other than anecdotal observations.
As reviewed in the introduction to this chapter, a variety of assays are 
available for analysis of virus-specific CD8 T cell responses. They vary with 
regard to the antigenic stimulus used, employing entire viral proteins 
(delivered intracellularly), long (overlapping) peptides corresponding to viral 
protein sequences, or short peptides comprising individual epitope sequences. 
The latter only gives information about selected components of the response; 
the former two approaches are better for obtaining a picture of the overall 
response. Different assays also vary with respect to the methodology by which 
antigen-specific responses are detected. Many assays use a functional read­
out, but the relatively recent advent of flurorescently-labelled MHC multimers 
allows for detection of epitope-specific T cells independently of function. In this 
chapter I used rW - and overlapping peptide-stimulated IFN-y ELISPOT 
assays to obtain an overall picture of the primary HIV-specific CD8+ T cell 
response in the patient cohort under study.
Initially rW-stimulated IFN-y ELISPOT assays were used to assess the HIV- 
specific CD8+ T cell response. This provided a simple and rapid means of 
determining responses to five major viral proteins over time in a number of 
patients. However, the rW-stimulated IFN-y ELISPOT assays had a number 
of drawbacks:
Firstly, the information that can be gained from the results of this somewhat 
crude assay is limited: because the assay only enables the detection of 
responses to a limited number of non-autologous viral proteins, an incomplete 
picture of the total response is obtained; also, because it does not reveal 
whether the response to a protein is made up of the responses to several 
epitopes within that protein, it gives no information about the number of 
epitopes recognised in a patient’s response.
Secondly, the assay depends on the processing of HIV proteins delivered into 
APCs into epitopic peptides that are presented to CD8+ T cells. However, at 
very early timepoints there may be a limited frequency of APCs in the PBMC 
population as this is a time where major expansions of HIV-specific CD8+ cells 
are occurring (Pantaleo et al., 1994). This may account for the weak
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responses seen at acute/early timepoints for some patients (e.g. MM19 and 
MM27) which could be interpreted as an apparent delay in kinetics of 
expansion of HIV-specific CD8+ responses.
Thirdly, because the rW-stimulated ELISPOT assay employs a functional 
read-out, it is only able to detect cells making IFN-y (this may not be the case 
for all T cells (Goepfert et al., 2000; Kostense et al., 2001; Shankar et al., 
2000)) and perhaps more importantly, only enumerates cells capable of 
cytokine production on In vitro restimulation. In acute HIV infection when cells 
are highly activated, they may undergo spontaneous apoptosis in vitro (Roos 
et al., 1994), and so it is particularly likely that responses will be 
underestimated at this time; this again could have contributed to the weak 
responses observed at early timepoints in some patients.
Fourthly, in experiments carried out to assess the suitability of this method for 
assessment of T cell responses, it was found that the magnitude of responses 
detected using this assay were not always very reproducible. This could be 
due to the two day incubation period with a recombinant vaccinia virus, which 
may have a negative influence on the in vitro survival of the cells in some 
experiments. In an attempt to address this problem, for each patient, cells 
from all timepoints of interest were assayed in the same experiment. 
Nonetheless, all results needed to be interpreted with caution and no 
conclusions could be drawn about the relative magnitudes of responses in 
different patients from rW-stimulated ELISPOT data.
Given the many drawbacks to this assay method, the conclusions that can be 
drawn from the results I obtained are relatively limited. However, using this 
technique I did confirm (Borrow et al., 1994; Koup et al., 1994) that HIV- 
specific CD8 responses could be detected in all patients studied from the 
earliest timepoint tested (which in some cases was even prior to the peak in 
acute viral replication). The development of the nAb response during primary 
HIV infection has also been studied in some of these patients, in which the 
CD8+ T cell response was detected at least two months earlier than nAb 
activity (Aasa-Chapman et al., 2005). As CD8 responses begin to be induced 
as acute-phase viral replication occurs, the nature of this initial response could 
potentially have a big impact on the efficiency of control of primary viral 
replication.
In several patients there was evidence that responses may be of relatively low 
magnitude at the earliest timepoints studied. As discussed earlier, there are a 
number of potential explanations for this observation (including a paucity of
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APCs in the PBMC population and/or the apoptotic tendency of CD8+ T cells 
at these timepoints). However these observations could potentially reflect 
relatively slow expansion of HIV-specific CD8 responses in these patients. 
The kinetics of expansion of epitope-specific T cell responses in primary HIV 
infection is addressed further in chapter 5.
In addition, the results from these assays highlighted that the virus-specific 
CD8 response in most patients was not evenly distributed across the five 
proteins studied, but was frequently concentrated on one or two proteins. 
There was also some evidence to suggest that the response was more 
broadly and evenly directed in patients with lower persisting viral loads, 
although the scope and size of this analysis did not permit definitive 
conclusions to be drawn about this.
To study HIV-specific CD8+ T cell responses in more detail, ELISPOT assays 
in which cells were stimulated with overlapping peptides corresponding to the 
entire HIV-1 clade B consensus sequence were used for further work. This 
approach shares some of the disadvantages of the rW-stimulated ELISPOT 
assay - notably, both are functional assays that only detect cells able to 
produce IFN-y and thus do not allow determination of the full magnitude of an 
epitope-specific T cell response (particularly during acute infection when, as 
discussed above, many of the responding T cells are highly activated and 
prone to undergo apoptosis in vitro). However it has many advantages 
compared to the rW-stimulated ELISPOT assay approach. By screening for 
responses to peptides spanning the whole HIV genome a more 
comprehensive approach was taken to study the entire HIV-specific response 
rather than just focusing upon a limited selection of viral proteins. Another 
advantage of the use of peptide-stimulated assays is that they do not have the 
same issues associated with antigen presentation as with rW-stimulated 
assays since the HIV antigens do not require such extensive processing and 
can potentially be presented by any MHC class l-expressing cell type, plus 
there is no potential competition for presentation by vaccinia viral antigens. 
Importantly, I also found that the magnitude of responses detected in peptide- 
stimulated ELISPOT assays was much more reproducible than that in rW -  
stimulated ELISPOT assays.
I could have chosen to evaluate peptide-stimulated T cell production of IFN-y 
by ICS rather than ELISPOT assay. ICS offers the option of confirming the 
phenotype (CD8+ versus CD4+) of responding T cells. However, as discussed
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below, it was expected that the vast majority of responses detected would be 
CD8+ T cell-mediated. Further, ELISPOT assays are more straightforward to 
carry out, and are typically more sensitive than ICS assays.
In this study, peptides based upon the clade B consensus sequence, 20 
amino acids in length with an overlap of 10 amino acids, were used. This was 
thought to be a suitable length and degree of peptide overlap to use following 
results from a study comparing different sets of overlapping peptides varying 
in length and overlap for their ability to detect CD8 responses (Draenert et al., 
2003). This showed that peptides ranging from 15 to 20 amino acids and in 
overlap from 10 to 11 amino acids yield similar results (in terms of the breadth 
and magnitude of responses detected in the entire cohort) in IFN-y ELISPOT 
assays (although there may be intra-individual differences in terms of the 
detection of responses using the different peptide sets). Using 20mer peptides 
overlapping by 10 amino acids should have enabled detection of responses to 
all T cell epitopes of 11 amino acids long or less.
The peptides were arranged into pools in matrices for screening in IFN-y 
ELISPOT assays. By initially using a peptide pool matrix-based system of 
screening for patient responses, patients could be rapidly screened for 
responses to the entire HIV genome using a relatively small number of cells - 
around 3x107 PBMC (not including cells needed for confirmation of positive 
responses), the number which might easily be obtained from 50ml blood 
(compared to 12 x 107 PBMC required if all individual peptides in the panel 
had been tested individually).
This approach was validated in a study by Addo et al (Addo et al., 2003), 
which showed that no HIV-specific T cell responses were detected in 10 HIV-1 
negative subjects when using peptide pools or individuals peptides to 
stimulate cells; T cell responses to individual peptides detected using peptide 
matrices correlated well with responses detected by use of individual peptides 
in 20 subjects tested (verifying that when peptides are included in a pool with 
other peptides there is no interaction or competition between the peptides 
which prevents their presentation and ability to elicit a response); and that the 
responses seen were CD8+ T cell dependent. Due to limited sample 
availability, these validation experiments were not extensively repeated; 
however I did check in a small number of patients that the responses to 
individual peptides were also detected when they were included within a pool 
of peptides, and that the responses were CD8 T cell-mediated. The issue of
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whether responses could be detected to HIV peptides in seronegative 
individuals is discussed further in chapter 4.
The sequence of the peptides used for the comprehensive epitope mapping 
corresponded to the HIV-1 clade B consensus sequence, not patient 
autologous viral sequences. By using non-autologous peptides that did not 
initially stimulate the responses in vivo, there is a risk of biasing the results 
towards the detection of more conserved epitopes, whilst missing any 
epitopes in any variable parts of the genome, where the differences between 
the autologous virus sequence and non-autologous sequence are likely to be 
the greatest (reducing the likelihood of cross-recognition of the consensus 
sequence). It is unclear just what proportion of the response was likely to have 
been missed by the use of non-autologous peptides in ELISPOT assays. This 
would clearly vary between patients, depending on both the relatedness of 
their autologous virus sequence to the clade B consensus sequence, and the 
ability of epitope-specific T cells to cross-recognise non-autologous versions 
of the epitope peptide. In one patient studied in our laboratory, whose 
response was originally mapped using peptides corresponding to the 
autologous acute stage virus sequence, subsequent comparison of the 
recognition of the autologous sequence, consensus sequence and a 
laboratory adapted virus sequence of the epitope peptides by patient PBMC 
showed that by using either of the non-autologous sequences, only 3 out of 39 
epitopes would have been missed (Jones et al, unpublished data). However, 
this may have been a reflection of the flexibility of this particular subject’s 
response to recognise potential epitope variants. Other studies have 
suggested that sequence variability does have an important impact upon the 
frequency of recognition of responses, with HIV-specific CD8 responses being 
observed to cluster within more conserved regions of the virus (Yusim et al., 
2002). Similarly, comprehensive epitope mapping studies have reported that 
proteins like Vif, Vpr, Tat, Rev and Vpu were less frequently recognised (Addo 
et al., 2003; Masemola et al., 2004), possibly reflecting more variability in 
these genes. By contrast, a study of T cell responses in the SIV macaque 
model where peptide sequences based on the infecting virus were used found 
that variable proteins like Tat were frequently targeted (Allen et al., 2000b). 
Moreover, it has been confirmed that responses to the more variable 
regulatory and accessory proteins are underestimated when consensus-based 
peptides, rather than peptides based on autologous virus are used (Altfeld et 
al., 2003).
224
In the analysis of results to determine the epitopic regions targeted by the HIV- 
specific response, it was decided that the positive responses would be defined 
as those which were greater than three times the background level of IFN-y 
production (i.e. that stimulated by medium alone) and greater than 50 SFC per 
106 PBMC. These are the same criteria as used by most other similar studies 
(Addo et al., 2003; Altfeld et al., 2003; Edwards et al., 2002), but not all. For 
example, others have defined positive responses as those greater than twice 
the response of negative control wells (cells incubated with either no peptide 
or a pool of irrelevant peptides) (Cao et al., 2003) (although this did not raise 
the number of responses seen relative to other studies); or those which 
exceed the mean of negative control wells plus three standard deviations 
(Frahm et al., 2004). In one study, the background level of response was 
determined using a panel of HIV seronegative subjects to define the spread of 
negative responses to each peptide pool, and the mean value plus four 
standard deviations used as the threshold for positive responses.
A further decision I made was that when establishing the epitopic regions 
recognised by each subject, the responses seen to two overlapping adjacent 
peptides would be counted as one response. Because of this, the number of 
epitopes recognised is likely to have been underestimated (also, more than 
one epitope may be contained within one epitopic region). However, a more 
conservative approach was thought to be better than overestimating 
responses. Such differences in analysis of data and how a positive response 
is defined may influence the conclusions made from studies carried out by 
different groups.
The total magnitude of the early response (as detected by IFN-y ELISPOT 
assay) in the 13 patients studied was found to range between 1,500 and 
21,000 SFC per 106 PBMC, with a mean of around 10,800 SFC per 106 
PBMC. The upper end of this range was similar to that found in a similar study 
by Addo et al (Addo et al., 2003) which comprehensively mapped the epitopic 
regions recognised by 57 HIV-infected subjects at different stages of infection 
using IFN-y ELISPOT assays (although in this study, the strongest response 
was observed in an untreated patient with chronic non-progressive infection). 
However the largest response observed another study by Cao et al (Cao et 
al., 2003) (where like my study, responses were evaluated during acute and 
early infection) was much lower (around 3000 SFC per 106 PBMC). 10,800 
SFC/106 PBMC corresponds to -1%  of PBMC (or 2-5% of peripheral blood
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CD8+ T cells). Further, for the many technical reasons discussed above, this is 
likely to be an underestimate of the true magnitude of the HIV-specific CD8 
response. These results thus suggest that HIV-specific CD8 T cell responses 
are typically of extremely high magnitude during early infection.
No correlation was found between the magnitude of the response and the 
concurrent viral load in this study, suggesting that the frequency of HIV- 
specific CD8 cells is not a reflection of antigenic load. This is in agreement the 
findings of some groups (Addo et al., 2003; Frahm et al., 2004; Gea- 
Banacloche et al., 2000; Novitsky et al., 2003), but not others, who have found 
there to be a positive (Betts et al., 2001; Buseyne et al., 2002; Masemola et 
al., 2004) or inverse correlation (Edwards etal., 2002; Greenough etal., 1997; 
Ogg et al., 1998) between the frequency of HIV-specific responses and viral 
load in chronically infected individuals.
From the inter-group analysis, there was a suggestion that there may be a 
relationship between the magnitude of the early HIV-specific CD8 response 
and the persisting viral load established by -six months post-infection, 
although a significant difference was only seen when comparing the 
intermediate to high with the high viral load patients but not the low to 
intermediate and high viral load patients, giving some ambiguity over the 
results. Overall, there was no evidence for the magnitude of the virus-specific 
CD8 T cell response in early infection being a key determinant of the efficiency 
of viral control.
It would have been interesting to have been able to measure the magnitude of 
the response during acute and/or subacute infection to see whether the size of 
the response at this stage is more critical. It should also be taken into 
consideration that it is possible that responses may not be expanded with the 
same kinetics in different patients. The kinetics of expansion of epitope- 
specific components of the primary HIV-specific CD8 response is explored in 
chapter 5.
Looking at the breadth of the responses detected, the number of epitopic 
regions found to be recognised by the patients in this study ranged between 3 
and 17. This was much lower than the largest number of responses detected 
in the study by Addo et al (42) (Addo et al., 2003). Although the maximum that 
could have been detected in this study was 30 due to the limit put on the 
number of peptides re-tested following the initial testing of peptide pools, none 
of the subjects had responses reaching this number. That my study did not 
detect as many responses as others is also evidenced by the finding that only
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20% of the genome was found to be immunogenic as compared to 63% 
peptides being targeted in the study of Addo et al. Similarly, the breadth of the 
response in terms of the number of protein subunits recognised was also 
found to be lower here (up to 8 subunits out of 14 recognised) than in the 
Addo study (13). However, it is notable that the study of Addo et al included 
chronically-infected individuals in addition to acutely-infected individuals, and 
the broadest responses were observed in the context of untreated chronic 
infection. Likewise other studies have indicated that the epitope breadth of the 
CD8 T cell response in primary HIV infection may be more limited than that in 
chronic infection (Altfeld et al., 2001a; Dalod et al., 1999b), e.g. a mean of 2.3 
epitopes (range 0-6) were recognised by patients in primary infection in the 
study of Cao et al (Cao et al., 2003). A narrowly directed response was also 
found in the context of primary infection in the study of Yu et al (Yu et al., 
2002), where virus specific T cell responses in one patient were found to be 
narrowly directed against two epitopic regions, illustrating that initial high-level 
viraemia does not necessarily induce broadly directed responses. Responses 
may be typically narrower in the primary compared to during the chronic stage 
of infection. Defects in antigen presentation/CD4 help in primary infection may 
limit the number of responses that can expand during this stage of infection 
(this idea is explored in chapter 4). The broadening of the response over time 
may parallel increases in viral diversity as a result of the error-prone RT 
enzyme. Broadening of the T cell repertoire may also reflect responses of the 
immune system to viral escape from responses that are immunodominant 
during acute and early infection.
No correlation was observed for the 13 patients studied here between the 
breadth of the HIV-specific CD8 response in early infection and the viral load 
(either concurrent or persisting). Other studies (some in chronically-infected 
individuals) have also found no correlation between the breadth of the 
response and the concurrent viral load (Addo et al., 2003; Cao et al., 2003; 
Dalod etal., 1999a; Frahm etal., 2004; Masemola etal., 2004). However, this 
is again a subject of debate since others report that the breadth of the total 
response is inversely associated with the concurrent viral load (Edwards et al., 
2002; Altfeld et al., 2001a). The breadth of the response in acute infection 
(which is influenced by the kinetics of expansion of different epitope-specific 
responses) may be much more critical than the breadth in early infection.
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This study did however find there to be significant positive correlation between 
the breadth and magnitude of the response in accordance with the findings of 
others (Cao et al., 2003; Addo et al., 2003). The latter study found that a 
broader and stronger response was observed in the context of continuous 
exposure to antigen, with the strongest and broadest responses observed in 
those with untreated chronic infection, and lower and more narrowly directed 
responses detected in those treated during primary infection.
As this discussion has highlighted, there is much conflict in the literature about 
the relationship between HIV-specific CD8+ T cell responses with plasma 
viraemia. Such disagreement may be attributed to differences in the way the 
studies were performed. Whilst more recent studies have used peptides 
corresponding to the consensus sequence of the entire HIV genome, many 
earlier studies have used single peptides, restricted panels of optimal epitopes 
or a limited selection of proteins to assess responses. The use of different 
techniques for assessing responses may also have an impact, for example, 
ICS may utilise co-stimulatory molecules that are not used in ELISPOT assays 
and this may mask in vivo immune response differences that may exist among 
subjects. A major reason for the discrepancies is also likely to be the use of 
different study populations. Some studies but not others utilise patients on 
treatment; there may be differences in the frequencies of HLA alleles within 
populations (leading to potential differences in immune responses among 
subjects with different HLA types); and the subjects involved may be at 
different stages of infection.
The findings discussed above suggest that neither the magnitude nor epitope 
breadth of the HIV-specific CD8+ T cell response in early infection correlate 
with the degree of virus containment, and so it is possible that the magnitude, 
breadth and/or kinetics of the response in acute infection (or perhaps 
qualitative aspects of the response) may be of more importance.
Out of 14 HIV protein subunits tested, all but Protease and Vpu were found to 
be recognised by at least one subject in the study population. Another study 
also did not detect any Vpu-specific responses in a cohort of acutely-infected 
patients (Cao et al., 2003), although others have observed that all proteins 
serve as targets for the HIV-specific response (Addo et al., 2003; Betts et al., 
2001; Masemola et al., 2004). The general consensus among most studies is 
that Nef is the most frequently recognised subunit, with responses to Vpu 
being the least frequently detected, so the lack of Vpu-specific responses
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seen in this study and that by Cao et aI may reflect the relatively low frequency 
of responses to Vpu, and the low number of subjects in which responses were 
studied.
The area of the genome found in this study to be most frequently targeted was 
in Nef: YKAAVDLSHFLKEKGGLEGL. Similarly, the most immunodominant 
peptide in the study by Addo et al (Addo et al., 2003) was 
TYKAAVDLSHFLKEK. In terms of the total magnitudes of responses induced 
to each protein subunit among the entire study population here, Nef was also 
found to induce the highest cumulative magnitude response, highlighting the 
dominance of Nef-specific responses within this cohort. That Nef was found to 
be a dominant target for CD8 responses was perhaps not surprising, since 
many epitopes have been defined in this protein, and it has a high density of 
epitopes per peptide length (HIV Molecular Immunology Database, 2003). 
That Rev induced the second highest cumulative magnitude response overall 
argues against the idea that the relative levels of sequence conservation in 
different parts of the genome dictate the prominence with which they are 
observed to be recognised in infected individuals.
The preferential targeting of Gag was found to be significantly associated with 
viral control in one study of a cohort of chronically infected patients (Masemola 
et al., 2004). Others have also reported an association between higher 
magnitude (and broader) anti-Gag p24-specific T cell responses and lower 
plasma viral loads during chronic infection (Edwards et al., 2002; Novitsky et 
al., 2003). This however was not found to be true for this study population 
when then the proportion of the early response targeting Gag (or Env, Pol or 
Nef) in the 13 patients was plotted against their persisting viral load.
One explanation for the reported association between Gag-specific responses 
and better viral control may be that Gag p24 has functional constraints which 
mean it does not readily accommodate new mutations and remains relatively 
conserved, making it difficult for the virus to escape from Gag-specific 
responses (Goulder & Watkins, 2004). This would allow for control of virus by 
the induction of a Gag p24-specific response.
Some studies have also reported an association between Nef-specific 
responses and poorer viral control, with preferential targeting of Nef in those 
with higher viral loads (Masemola et al., 2004) or higher Nef-specific T cell 
responses being associated with a higher viral load (Novitsky et al., 2003). 
Even though the proportion of the Nef-specific response was not found to be 
correlated with the persisting viral load in my study, the domineering nature of
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anti-Nef responses in terms of frequency of recognition and cumulative 
responses at early stages of infection may be noteworthy in this context. Nef is 
quite a variable protein, so it could be speculated that viral escape from 
immune recognition may more easily occur in epitopes within Nef. If early 
immune responses targeting Nef do not serve to efficiently control replication 
due to the more rapid viral escape from these responses, this in turn may 
impact upon long term viral control.
Comparisons of the protein/epitope specificity of HIV-specific CD8 responses 
in chronic compared to primary infection have been made. Differences have 
been observed both in the pattern of protein recognition (initial preferential 
targeting of Nef during primary infection, followed by an increased contribution 
of other proteins in the chronic phase, with Gag p24-specific responses 
becoming dominant (Addo et al., 2003)) and in the specific epitopes 
recognised (Goulder et al., 2001a). These finding are consistent with there 
being early escape from initially dominant (e.g. Nef-specific) responses, 
followed by expansion of responses of other specificities (including certain 
Gag epitopes).
CD8+ T cell responses which target epitopes within proteins that are 
expressed early during the viral lifecycle (such as Nef, Tat and Rev) have 
been reported to control viral replication in vitro more effectively than 
responses which target epitopes within proteins which are expressed later in 
the lifecycle (van Baalen et al., 2002). The in vivo importance of this may be 
that CD8+ T cells specific for early proteins may have a longer window of 
opportunity to recognise and kill the infected cell before new viral progeny are 
made and released, and also that epitopes may be presented before immune 
evasion mechanisms are active, e.g. downregulation of MHC class I 
molecules. Indeed, there is also evidence to suggest that CD8+ T cell 
responses directed at epitopes in early viral proteins may be particularly 
efficacious in vivo too, with observations of slower disease progression in HIV- 
1 infected patients who exhibited strong CTL responses to early proteins (van 
Baalen et al., 1997).
In the light of this, the relationship between responses targeting early proteins 
and the efficiency of early viral control was investigated. When the proportion 
of the early response targeting epitopic regions within Nef, Tat and Rev was 
calculated for each patient, the results were quite variable within the subjects 
in the same viral load group; and the mean percentage of the response
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targeting early proteins was not significantly different between the three 
patient groups. The low frequency of recognition of epitopes within Tat in 
Figure 3.21 may suggest that potential responses to the variable Tat protein 
could be overlooked by using peptides based on the consensus sequence for 
assessment of T cell responses; in turn this could influence the observations 
made on responses to early expressed proteins.
The analysis of the breadth of the response using rW-stimulated ELISPOT 
assays suggested that there was biasing of the response towards epitopes in 
one or two immunodominant proteins. That the primary HIV-specific response 
tends to be focused on a few immunodominant regions of the HIV genome 
was confirmed in the peptide-stimulated ELISPOT assays, firstly at the protein 
level and then the epitope level. A high proportion of the response (>50%) was 
found to be focused upon a small number or proteins (2) or epitopes (4) in all 
patients.
Another measure of the breadth of the HIV-specific response, the repertoire of 
T cell clones used in epitope-specific responses, was also studied, by 
assessing the usage of different V/? families by the TCRs of tetramer-stained 
cells using V/? family-specific antibodies. This analysis revealed that there was 
no association between the number of V/? families used in HIV epitope-specific 
responses and the persisting viral load established by the patient. However, 
the conclusions which can be drawn from these results are limited, for a 
number of reasons. First, not all T cells involved in each response could be 
detected using this technique, due to the lack of antibodies specific to certain 
V/? families. The proportion of the response that was unaccounted for varied 
for different responses studied, from 2% to 57%; V/? family usage by 
remaining T cells was unknown, and could have had a significant impact on 
the results. Second, this technique does not reveal the total number of T cell 
clones participating in a response, since more than one clone of cells may be 
involved in the response in a given V£ family. The full extent of the use of 
different T cell clones could have been assessed by more complex 
techniques, such as TCR heteroduplex analysis or TCR sequencing of sorted 
tetramer-positive cells (Kalams et al., 1994; Lopes et al., 2003; Turner et al., 
2005). Also, the number of patients and epitopes studied here was very 
limited, so this type of analysis would need to be extended to more patients 
and epitopes to enable meaningful conclusions to be drawn from the results.
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Prior studies in the literature provide support for a relationship between the 
breadth of T cell clones involved in the HIV-specific CD8 T cell response and 
the efficiency of control of virus replication. Pantaleo et al observed 
monoclonal/oligoclonal expansions of TCR V/? families in primary infection in 
patients who went on to establish high but not low persisting viral loads 
(Pantaleo et al., 1994; Pantaleo et al., 1997b). This suggests that the primary 
T cell response in patients who controlled viral replication well involved more 
synchronous expansion of multiple T cell clones, i.e. was more polyclonal 
and/or directed against more viral epitopes. Further support for more 
polyclonal responses being associated with good control of viral replication 
comes from Lopes et al (Lopes et al., 2003), who showed that epitope-specific 
CD8 T cell responses in HIV-2 infected patients (who typically control viral 
replication well) were typically more polyclonal than those in HIV-1 infected 
patients. Although it is not clear whether these associations are a 
consequence and/or a cause of the good control of viral replication, polyclonal 
responses could contribute to efficient containment of viral replication by 
giving potential for recognition of multiple variants of the epitope peptide and 
thus helping to restrict escape (although there are examples of responses of 
restricted clonality that are very functionally flexible (Dong et al., 2004)).
One reason why no associations between the persisting viral load and any 
single parameter studied were seen could potentially be because there was 
not enough of a spectrum of viral loads represented in the patient cohort. Had 
there been a number of patients available in the lowest viral load quartile 
defined by Mellors et al (Mellors et al., 1996), then perhaps more differences 
would have been apparent. It may be that the majority of patients make a 
similar type of response, and it is only the ones who control early viral 
replication particularly well (perhaps only the 10-20% of infected individuals 
who go on to become LNTPs) who have a qualitatively or quantitatively 
different primary HIV-specific CD8 response. Previous observations made in 
one patient (SUMA) who did establish a persisting viral load in the lowest 
quartile lend some support to this hypothesis. In patient SUMA a broad, non­
biased response was seen in the rW-stimulated ELISPOT assay (Figure 3.7). 
This was reflected by the finding, when his response was more finely mapped, 
of a response that was broad and co-dominant, targeting over 40 epitopes 
((Jones et al., 2004) and unpublished data of Jones et al). However these 
results were obtained from experiments using reagents corresponding to the
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patient’s autologous viral sequence, and so cannot be directly compared to 
the results obtained here.
The results from this study were obtained using cells cryopreserved during 
early infection. As indicated earlier in the discussion, one question of critical 
importance is how the HIV-specific CD8+ response might evolve over the 
course of primary infection. In a study by Cao et al (Cao et al., 2003), cross 
sectional analysis of patients showed that the number of epitopes recognised 
in primary infection was small, but increased with the duration of infection. 
Another study reporting a kinetic analysis of responses to epitopes in three 
viral proteins in three infected individuals again suggested that the HIV- 
specific CD8 response was highly biased towards a small number of 
immunodominant epitopes in acute infection, and increased in breadth/co­
dominance over time (Jones et al., 2004). It is thus possible there are 
important differences in CD8 responses in acute infection between patients 
that are no longer apparent by early infection. There have not been any 
studies that have addressed the evolution of the entire response from acute to 
subacute, through to early infection in many different patients, so the range of 
variation in magnitude and epitope breadth of the response and kinetics of 
evolution of these parameters and whether/how they may relate to the 
persisting viral load subsequently established is not known.
In summary, characterisation of the nature of the early HIV-specific CD8+ T 
cell response in patients who establish low-intermediate up to high persisting 
viral loads using IFN-y ELISPOT assays indicated that a high magnitude 
response is typically present in this phase of infection, but revealed little 
difference in the magnitude and/or breadth of response among the patients 
available for study here. Although this does not support the idea that the 
nature of the early response is related to the efficiency of viral control, had 
analysis of the response at the peak of infection and/or using patients with 
very low persisting viral loads been feasible, this may have revealed 
otherwise. Questions about other aspects of the response remain, such as 
how the kinetics of expansion of different responses in different patients 
compare, and whether other qualitative aspects of the response differ. Some 
of these are addressed in chapter 5.
The analysis in this chapter also revealed that the majority of patients make a 
virus-specific CD8 response that is focused upon a limited number of viral 
proteins/epitopes in early infection. The reasons for this, and the possible
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consequences of making a restricted response, are the subject of experiments 
and discussion in the next chapter.
234
Chapter 4
Investigation of mechanisms that may account for the biasing of the 
primary virus-specific CD8+ T cell response in the majority of HIV-1 
infected patients towards a small number of immunodominant epitopes
4.1 Introduction
As reviewed in the main introduction to this thesis and discussed in chapter 3, 
current data give a very incomplete picture of the expansion of the HIV- 
specific CD8+ T cell response in primary infection. A number of the studies 
have shown that the response starts to be induced in the acute phase of 
infection (Borrow et al., 1994; Koup et al., 1994), an observation that I also 
confirmed in chapter 3. However, the number of viral epitopes to which 
responses are induced in acute/subacute infection and the relative kinetics 
with which different epitope-specific responses expand, plus how these 
parameters may vary in different individuals are relatively poorly understood. 
Pantaleo et al (Pantaleo et al., 1994; Pantaleo et al., 1997b) observed 
monoclonal/oligoclonal TCR V/? family expansions during acute/subacute 
infection in patients who subsequently controlled viral replication poorly, but 
not those who went on to establish low persisting viral loads, suggesting that 
responses of limited clonality to a very small number of viral epitopes were 
rapidly expanded during primary infection in the former individuals, whereas 
the response mounted in the latter patients was broader (at the clonal and 
likely also the epitope level) from the start. In line with this idea, in-depth 
studies carried out in three infected individuals (Borrow et al., 1997; Jones et 
al., 2004) indicated that in acute/subacute infection the virus-specific CD8+ T 
cell response in the two patients who went on to establish high persisting viral 
loads was highly focused on a limited number of viral epitopes, with delayed 
expansion of responses of additional specificities, whilst responses to a 
broader range of viral epitopes were apparent from acute infection onwards in 
the patient who controlled early viraemia more efficiently. These limited 
studies (which are extended in chapter 5) suggest that in many HIV-infected 
individuals there may be preferential expansion of responses to a small 
number of immunodominant viral epitopes in acute/subacute infection, with 
delayed expansion of responses of additional specificities over time. The 
observations I made in chapter 3, where I found that in a panel of infected 
individuals, all of whom established moderate or high persisting viral loads, a 
mean of only 8 epitopic regions were recognised (range 3-17) in early
235
infection, and a high proportion of the response (>50%) was focused on 1-4 
immunodominant epitopes; plus results from other studies that have indicated 
that the epitope breadth of the virus-specific CD8+ T cell response in primary 
HIV infection is more restricted than that in chronically-infected individuals 
(Altfeld et al., 2001a; Cao et al., 2003; Dalod et al., 1999b), would fit with this 
hypothesis.
Building upon these observations, in this chapter I went on to explore 
mechanisms that may account for there being preferential expansion of CD8+ 
T cell responses to a limited number of immunodominant viral epitopes during 
primary HIV infection, and why a broader response may be observed in 
patients controlling the acute viral burst more efficiently.
A number of factors influence the epitopes against which T cell responses are 
generated and the immunodominance of individual epitopes within the CD8+ T 
cell response made to a virus (reviewed by (Chen et al., 2000)). These include 
(i) factors that influence the array of epitope peptides bound to MHC class I 
molecules on the surface of the APCs involved in priming the CD8+ T cell 
response; (ii) factors affecting the interaction between epitope-specific T cells 
and APCs and (iii) factors that dictate the pre-existing T cell repertoire 
(including the number and properties of epitope-specific T cells).
The peptides which have the potential to act as T cell epitopes and the 
abundance with which each is generated and presented with MHC class I on 
the APC surface will be dictated by the host MHC haplotype, the abundance 
with which viral proteins are produced and their availability for 
processing/presentation, the efficiency with which particular peptides are 
generated by antigen processing pathways, and competition between viral 
(and host) peptides for binding to MHC (in which the affinity of epitope binding 
to MHC plays an important role).
In addition, the number and T cell stimulatory capacity of APCs are also 
important determinants of epitope presentation. Properties of APCs which 
determine how immunostimulatory they are include the amount of MHC class I 
and co-stimulatory molecules they express, plus their ability to produce 
soluble factors.
Finally, features of the pre-existing host T cell repertoire can also influence the 
immunodominance of responses. The generation an epitope-specific response 
depends on the existence of epitope-specific T cells within the repertoire. 
Their frequency, affinity for peptide-MHC complexes and ease of activation
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may influence which T cell clones can respond strongly/more rapidly. The 
presence of competing T cells specific for other epitopes may also be of 
importance, since they could suppress the response by physically excluding 
other T cells from contacting their antigen or co-stimulatory ligands, or 
competing for soluble factors produced by APCs. Competing T cells could 
even actively suppress the response of other T cells by secreting 
immunomodulatory cytokines or by destroying APCs, thereby preventing 
competitor T cell activation.
In primary HIV infection APC numbers and/or function may be compromised 
(Pacanowski et al., 2001). This could be due to direct or indirect effects of the 
virus on APCs and/or due to impairment of HIV-specific CD4 responses, which 
may limit the help available for APC activation.
So, under these conditions, is the competition between T cells for APCs more 
fierce and is there more biasing of responses towards epitopes which are able 
to be presented particularly well and/or are recognised by T cell clones that 
can outgrow their competitors? In patients who are more efficient in controlling 
early viral replication, APC function may not be as adversely affected. This 
may mean that there is less competition between T cells of different 
specificities, and consequently more opportunity for the expansion of a 
broader response. This may explain the differences in the breadth of the 
response expanded in patients who control viral replication with differing 
efficiency (Jones etal., 2004; Pantaleo etal., 1997b).
In the setting of limited availability of activated APCs and a deficit in T cell help 
envisaged to exist in many patients during primary HIV-1 infection, there may 
be particularly prominent expansion of responses to peptides which bind with 
high affinity to MHC molecules and/or which are recognised by high affinity T 
cell receptors, as these factors may potentially favour T cell activation under 
suboptimal conditions. In support of this idea, there is evidence that CD8+ T 
cell responses to high affinity epitopes are less dependent on help for their 
expansion than responses to lower affinity epitopes (Franco et al., 2000).
In addition, there may be prominent expansion of responses to epitopes that 
can be cross-recognised by pre-existing memory T cells. There is evidence in 
the literature for cross-recognition of epitopes in different viruses by CD8+ T 
cells (Selin et al., 1994; Selin et al., 1998; Wedemeyer et al., 2001; Yang et 
al., 1989), and in mouse models this has been shown to affect the relative
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dominance of epitope-specific responses to subsequent virus infections 
(Brehm et al., 2002) (discussed in more detail later). It might be envisaged that 
cross-reactive memory T cells, being present at higher frequencies and being 
in a more highly activated state than naive T cells, would have a particularly 
marked expansion advantage under conditions where APC functions are 
limiting.
In this chapter, the relationship between the immunodominance and functional 
avidity of HIV-specific T cell responses was explored, and whether there was 
greater biasing towards high avidity responses in patients with the highest viral 
loads (those in which APC stimulatory capacity is likely to be affected the 
most) was investigated. Mouse models were also used to investigate whether 
the response to virus infection was biased to high affinity epitopes when help 
for APC activation was limited. To explore the possibility of cross-reactive 
immunity being one of the mechanisms contributing to the extreme 
immunodominance of responses to certain HIV epitopes in acute/subacute 
infection, responses that were particularly immunodominant in primary HIV 
infection were studied to see if they may represent expansion of cross-reactive 
memory responses. Mouse models were also used to look at whether cross­
reactive memory responses are preferentially expanded in response to a 
secondary virus infection if the response is induced when help is limiting.
4.2 Investigation of the relationship between the immunodominance and 
functional avidity of CD8+ T cell responses
As explained in section 4.1, it was hypothesised that the relative 
immunodominance of epitope-specific responses within the primary HIV- 
specific CD8+ T cell response may be influenced by the affinity of the epitope 
for the presenting HLA allele and/or the affinity of the receptors of responding 
T cells for the peptide-MHC complex. To test this hypothesis, it was decided to 
compare the epitope and/or TCR affinity of responses identified in chapter 3 
as being dominant and subdominant in early HIV infection in different patients. 
Ideally, it would have been preferable to perform a comparison of the epitope- 
specific responses that expanded first in acute infection and later-expanding 
responses, but as data on the relative kinetics of expansion of epitope-specific 
responses within each patient was not available, it was assumed that the 
relative immunodominance of responses in early infection would provide a
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reasonable view of their ‘’competitiveness” in the primary HIV-specific CD8+ T 
cell response.
There are a number of assays that can be used to measure the binding affinity 
of an epitope peptide to its MHC restriction element, including competitive 
binding assays (Gairin et al., 1995; van der Most et al., 1998) and assays 
based on stabilisation of empty MHC molecules on the surface of a TAP- 
deficient cell line (Gairin et al., 1995; Hudrisier et al., 1996). The affinity of 
TCR binding to peptide-MHC can also be explored, e.g. by measuring the 
dissociation of bound tetrameric peptide-MHC complexes (Kerry et al., 2003; 
Reichstetter et al., 2000; Savage et al., 1999), or using surface plasmon 
resonance in BIAcore analysis (Kerry et al., 2003; Khilko et al., 1993; Tissot 
et al., 2000). However, because there were many different HIV-specific 
responses made by this cohort of patients, involving a diverse range of HLA 
alleles, measurement of the affinity of MHC binding of each epitope and 
affinity of the responding TCR(s) for peptide-MHC was not feasible. Instead, it 
was decided that the relative functional avidity of the T cell response to each 
epitope (which could be gauged by determining the concentration of peptide 
required to stimulate a half-maximal response by epitope-specific T cells) 
would be studied, and the relationship between the functional avidity of 
responses and their relative immundominance within the whole HIV-specific 
CD8+ T cell response explored. The functional avidity of an epitope-specific 
CD8+ T cell response is influenced by both the affinity of the peptide for its 
restricting MHC molecule and the avidity of the interaction between the 
responding T cells and stimulating cells.
In Figures 4 .1 -  4.3 (uppermost panels) the results of experiments measuring 
the functional avidity of the T cell response to different epitopes shown in 
chapter 3 to be recognised in early HIV infection in patients who established 
high (Figure 4.1), intermediate-high (Figure 4.2) and low-intermediate (Figure 
4.3) persisting viral loads are shown. In each patient only those responses for 
which the optimal epitope sequence had been determined (Figures 3.11-3.13) 
were studied, and the cells used were from a timepoint in early infection (in the 
majority of cases between 3 and 9 months FOSx), so as to minimise the 
skewing of results due to changes in the affinity of TCRs of T cells involved in 
epitope-specific responses over time.
In the lowermost panels of each figure, the functional avidities of each epitope- 
specific response (calculated from the results of the peptide titrations) are 
summarised, and the relative immunodominance of the response within the
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Figure 4.1. Relative immunodominance and avidity of T cell responses made to HIV 
epitope peptides by patients with high persisting viral loads. In chapter 3, HIV-1 peptides 
against which CD8+ T cell responses could be detected during early infection in patients 
MM24 and MM26 were identified, and the relative immunodominance of the response to 
each peptide was determined by IFN-y ELISPOT assay (data in Figures 3.11(a) (MM24) 
and 3.11(e) (MM26)). The optimal epitopes recognised within some of the peptides against 
which responses were directed were also identified. In the uppermost panel of each page, 
the relative avidity of the T cell response to each of these epitopes was determined, by 
stimulating patient PBMC (cryopreserved at the timepoints indicated) with peptide 
concentrations between 10'5M and 10'12M, and determining the magnitude of the response 
elicited by IFN-y ELISPOT assay. The results shown are expressed as the mean (of 
duplicate wells) number of specific SFC per 106 PBMC (i.e. background values from 
medium only wells have been subtracted) ±1 SD. The table in the lowermost panel of each 
page summarises the relative immunodominance of the response to each epitope peptide 
in early infection (i.e. magnitude of the response to this epitope expressed as a percentage 
of the total response to all peptides to which responses were detected in this patient) and 
the relative avidity of each response (concentration of peptide required to stimulate a half- 
maximal response, calculated from the results of the peptide titrations).
241
SF
C 
pe
r 
10
A6 
PB
M
C
MM12
230-321 DFOSx
QIYAGIKVK
QVPLRPMTYK
FFVRPQVPLR
IPRRIRQGL
Epitope peptide Relative 
immunodominance 
of epitope-specific 
response in early 
infection (%)
Concentration of 
peptide required 
to stimulate half 
maximum 
response
QIYAGIKVK 42.9 10'7M
QVPLRPMTYK 27.0 10'6M
FPVRPQVPLR 7.8 10'7M
IPRRIRQGL 9.3 10'9M
1600 -
1400
1200 -
1000  -
800
600 ‘
400
200
\
peptide
242
MM27
81 and 299 DFSOx combined
2000
1800 ^  
Q 1600 -
§  1400 ]
£ 1200 4
o  1000 |
«  800 -
O 600 £
w 400 -
200 J
Jo
■ KYTAFTIPSI 
• TPGPGIRYPL
Peptide concentration
Epitope peptide Relative Concentration of peptide
immunodominance of required to stimulate half
epitope-specific response 
in early infection (%)
maximum response
KYTAFTIPSI 50.6 10'SM
TPGPGIRYPL 16.3 10'8M
243
M M14
111- 477 DFOSx combined
o
2
COo.
<0
<o
0)a
o
IL</>
Epitope peptide Relative 
immunodominance of 
epitope-specific response 
in early infection (%)
Concentration of peptide 
required to stimulate half 
maximum response
AAVDLSHFL 11.1 10'bM/10'6M
RGRQKVVSL 4.8 10'7M
GEIYKRWIIL 12.8 10‘7M
RRIRQGERALL 53.2 10‘7M
FLKEKGGL 11.1 10'7M
Figure 4.2. Relative immunodominance and avidity of T cell responses made to HIV 
epitope peptides by patients with intermediate-high persisting viral loads.
In chapter 3, HIV-1 peptides against which CD8+ T cell responses could be detected 
during early infection in patients MM12, MM27 and MM14 were identified, and the relative 
immunodominance of the response to each peptide was determined by IFN-y ELISPOT 
assay (data in Figures 3.12(a) (MM12), 3.12(c) (MM27) and 3.12(d) (MM14)). The optimal 
epitopes recognised within some of the peptides against which responses were directed 
were also identified. In the uppermost panel of each page, the relative avidity of the T cell 
response to each of these epitopes was determined, by stimulating patient PBMC 
(cryopreserved at the timepoints indicated) with peptide concentrations between 10'5M and 
10‘12M, and determining the magnitude of the response elicited by IFN-y ELISPOT assay. 
The results shown are expressed as the mean (of duplicate wells) number of specific SFC 
per 106 PBMC (i.e. background values from medium only wells have been subtracted) ±1 
SD. The table in the lowermost panel of each page summarises the relative 
immunodominance of the response to each epitope peptide in early infection (i.e. 
magnitude of the response to this epitope expressed as a percentage of the total response 
to all peptides to which responses were detected in this patient) and the relative avidity of 
each response (concentration of peptide required to stimulate a half-maximal response, 
calculated from the results of the peptide titrations).
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Figure 4.3. Relative immunodominance and avidity of T cell responses made to HIV 
epitope peptides by patients with low-intermediate persisting viral loads.
In chapter 3, HIV-1 peptides against which CD8+ T cell responses could be detected 
during early infection in patients MM13 and MM28 were identified, and the relative 
immunodominance of the response to each peptide was determined by IFN-y 
ELISPOT assay (data in Figures 3.13(b) (MM13) and 3.13(c) (MM28)). The optimal 
epitopes recognised within some of the peptides against which responses were 
directed were also identified. In the uppermost panel of each page, the relative avidity 
of the T cell response to each of these epitopes was determined, by stimulating 
patient PBMC (cryopreserved at the timepoints indicated) with peptide concentrations 
between 10'5M and 10'12M, and determining the magnitude of the response elicited by 
IFN-y ELISPOT assay. The results shown are expressed as the mean (of duplicate 
wells) number of specific SFC per 106 PBMC (i.e. background values from medium 
only wells have been subtracted) ±1 SD. The table in the lowermost panel of each 
page summarises the relative immunodominance of the response to each epitope 
peptide in early infection (i.e. magnitude of the response to this epitope expressed as 
a percentage of the total response to all peptides to which responses were detected 
in this patient) and the relative avidity of each response (concentration of peptide 
required to stimulate a half-maximal response, calculated from the results of the 
peptide titrations).
peptide
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patient’s early HIV-specific T cell response (determined by calculating the 
magnitude of the response to the epitopic region containing the epitope as a 
percentage of the total response to all peptides to which responses were 
detected in the patient) is also shown.
The results of this analysis show that there is not an absolute relationship 
between functional avidity and relative immunodominance. For example whilst 
for the two responses studied in patient MM27, the higher avidity response 
was also the more dominant of the two (the response which required only 
10'9M peptide to stimulate half the maximal response constituted over 50% of 
the entire early response whilst the one with a functional avidity of 10'8M 
constituted only 16%), the same pattern was not observed for responses 
studied in other patients, e.g. the highest avidity response (10"1°M) in patient 
MM24 was the least dominant response (13%) of the three studied. Analysis 
of the relationship between functional avidity and relative dominance of all the 
responses studied in the seven patients in which this analysis was carried out 
revealed that there was a trend towards a positive correlation between the 
functional avidity and relative immunodominance of responses in early HIV 
infection, although this was not statistically significant (p=0.139) (Figure 4.4). 
Comparison of the functional avidities of the most dominant responses (those 
individual responses which constituted >25% of the entire early response) with 
those of the more subdominant responses (Figure 4.5) revealed that there 
was a trend towards the dominant responses being of higher avidity, although 
this was not statistically significant (p=0.149). Notably however, only 1 of the 9 
highly dominant responses had a functional avidity of <10'7M, whereas 11 of 
the 25 more subdominant responses had functional avidities which were 
<10'7M. Hence having a moderate or high functional avidity appears to be 
almost a pre-requisite for a response to become highly immunodominant, 
although not all high avidity responses are immunodominant.
To see if the avidity-dominance relationship was any more apparent in 
patients with higher or lower persisting viral loads, the relative avidities of all 
dominant responses in the different patient groups were plotted separately. As 
shown in Figure 4.6, there was a trend towards the dominant responses in the 
patients with high persisting viral loads being of higher functional avidity than 
those in the other patients; statistical analysis showed this difference not to be 
of significance (p>0.05) (likely because the number of responses studied in 
each patient group was very low).
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Functional avidity 
(log molar peptide concentration)
Figure 4.4. Relationship between the functional avidity and relative dominance of HIV-specific CD8+ T cell 
responses. The functional avidity of selected epitope-specific responses found to be part of the early response of 
seven HIV-1 infected patients was determined as described in Figures 4.1-4.3. The relative dominance of each 
response was defined as the magnitude of the response made to the epitope-containing long peptide (determined 
in experiments described in section 3.5) as a proportion of the total magnitude of the early response (i.e. that to all 
epitopic regions found to be recognised by the patient). The functional avidities (expressed as the log concentration 
of epitope peptide required to simulate a half maximal response by early patient PBMC) and relative 
immunodominance (expressed as a percentage of the total early response) of epitope-specific responses mapped 
in patients MM24, MM26, MM12, MM27, MM14, MM13 and MM28 are plotted above. A linear regression line is 
shown and the p value shown was calculated using Pearson’s correlation test.
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Figure 4.5. Comparison of the functional avidity of responses of relative high 
and low dominance. The functional avidity and relative dominance in early 
infection of selected epitope-specific responses mapped in seven HIV-infected 
subjects (MM24, MM26, MM12, MM27, MM14, MM13 and MM28) was determined 
as described in Figures 4.1-4.3. Each symbol represents the functional avidity of 
an individual epitope-specific response. Responses were split into two groups on 
the basis of the percentage of the total response (i.e. that to all epitopic regions 
found to be recognised by the patient) constituted by the response to the epitope- 
containing long peptide being considered. Responses were considered of high 
dominance if they contributed to greater than 25% of the total response; all other 
responses were considered to be of low dominance. The mean functional avidity 
of each group of responses is indicated by the horizontal bar. Statistical analysis 
(a two-tailed t-test) showed that there was not a significant difference between the 
functional avidities of responses of low and high dominance.
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Figure 4.6. Comparison of the functional avidities of dominant 
responses in patients with different persisting viral loads. The
functional avidity and dominance of selected epitope-specific responses 
found to be part of the early HIV-specific CD8+ T cell response in seven HIV- 
infected subjects were determined as described in the legend in Figures 4.1- 
4.3. Individual responses which constituted over 25% of a patient’s entire 
early response were considered to be highly dominant. The avidities of 
these dominant responses are shown above and have been grouped on the 
basis of the persisting viral load established by the patient in which the 
epitope was mapped. This analysis was carried out for patients MM24 and 
MM26 (patients with high persisting viral loads); MM12, MM27 and MM14 
(patients with intermediate-high persisting viral loads) and MM13 and MM28 
(patients with low-intermediate persisting viral loads). Each data point 
represents the avidity of an individual dominant response, with the mean 
avidity of the dominant responses in each patient group indicated by the 
horizontal line. Statistical analysis (one-way ANOVA) showed that there was 
not a significant difference between the functional avidities of dominant 
responses in patients with different persisting viral loads.
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It should be mentioned that this data may be affected by the fact that some 
epitope-specific responses within a patient’s whole response were not 
represented in the analysis (the optimal epitopes were not mapped for all 
epitopic regions within a patient’s entire early response), and if/how they 
would have made any difference to the overall picture is not known. Also the 
functional avidities were not determined at precisely the same timepoints at 
which the relative magnitudes of the responses to the different epitopic 
regions were measured. These limitations are considered further in the 
discussion.
In summary, in this investigation of the relationship between the relative avidity 
and dominance of HIV-specific responses in early infection, an absolute 
relationship between the two parameters was not found. However, there was a 
weak positive association, with dominant responses tending to have a higher 
functional avidity than subdominant responses and very few dominant 
responses being of low avidity. The relationship may also be more apparent in 
particular patients, since the dominant responses in patients with higher 
persisting viral loads tended to be of higher functional avidity. These data 
suggest that the avidity of a response is one of the factors that influences its 
immunodominance. The relationship is not absolute however, and so other 
factors (such as repertoire-related factors) must also contribute to the 
immunodominance of responses.
4.3 Analysis of the effect of lack of CD4* T cell help at the time of priming 
of a virus-specific CD8+ T cell response on the epitope hierarchy of the 
response induced
The analysis above provided evidence for a weak association between the 
relative immunodominance and functional avidity of responses in early HIV-1 
infection. However, because there were not many patients with lower 
persisting viral loads available for comparison, the question of whether there 
was a greater dominance of high avidity responses in patients with the highest 
viral loads could not be fully addressed. Even had a full analysis been 
feasible, and a difference observed, this would not have revealed anything 
about the mechanisms involved. Because of the limitations of the human 
studies, murine models were used to assess more directly the question of 
whether defects in T cell help/APC activation at the time of induction of a 
virus-specific immune response leads to preferential expansion of high avidity 
responses.
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The CD8 T cell response made to LCMV in H-2b mice was the first model 
used. In this infection, the virus induces a high frequency CD8+ T cell 
response to a number of well defined epitopes in a reproducible hierarchy 
(Murali-Krishna et al., 1998; van der Most et al., 2003; van der Most et al., 
1998). The sequences of the principal epitopes (4 Db and 2 Kb restricted 
epitopes) known to be targeted by the LCMV-specific CD8+ T cell response 
are shown in Table 4.1. As summarised in this table, prior studies addressing 
the relative immunodominance of the response to these epitopes have 
indicated that the epitopes to which the highest magnitude responses are 
mounted in primary LCMV infection are the NP396 and GP33 epitopes, with 
the responses to other epitopes being of lower magnitude, and the response 
to the GP92 epitope being particularly subdominant. The binding affinity of 
these epitopes to their MHC restriction elements has also previously been 
determined; the epitope which has the highest affinity binding for its MHC 
restriction element is NP396 (Table 4.1). The NP396-specific response also 
has the highest functional avidity (Table 4.1). The data indicate that, with the 
exception of the GP33 epitope, there is a good correlation between the affinity 
and immunodominance of epitopes targeted in natural LCMV infection with a 
very high affinity epitope being particularly prominent in the virus-specific T 
cell response. The question of whether there would be greater bias towards 
the highest affinity response(s) if help was limiting at the time the response 
was induced was addressed.
CD4 help for the expansion of the LCMV-specific CD8+ T cell response was 
removed by the administration of a CD4-depleting antibody to mice just prior 
to infection with LCMV. CD4-depleted and control, non-depleted mice were 
infected with LCMV, and splenocytes were taken at day 8 after infection (when 
expansion of virus-specific cells is maximal), and the response to different 
LCMV epitopes was measured by IFN-y ELISPOT assay. The responses to 
only five peptides were tested since, due to the overlap between the GP33 
and GP34 epitopes, only the response to the GP33 (9mer) sequence, and not 
the response to the GP34 epitope, was tested. Figure 4.7 shows the average 
responses made to the five LCMV epitope peptides tested by mice in the two 
experimental groups. In the control mice, the GP33, NP396 and NP205 
peptides all stimulated high magnitude responses, in excess of 20,000 SFC 
per 106 CD8+ cells; the GP276-specific response was more subdominant, and 
the GP92-specific response very minor by comparison. It was noteworthy that 
the hierarchy of the response was not the same as that previously reported by
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Epitope Sequence MHC
restriction
Relative immunodominance in 
primary response 
(% CD8+T cells)
MHC binding affinity 
IC50 [nM] m  /  SC50 [nM] (<v)
Functional avidity1 
EDso [nM]
C (!) a ( i) a  w e  (no T (IU) g wo g m n W «w
NP396 FQPQNGQFI Db 28 19 8.7 4.4 N.D. 20 50 10 7 0.0002
GP33 KAVYNFATC(GI)a Db 19 20 8.3 5429 (776) 5429 (395) 615 344 21 (51) 470 (477) 0.26
GP276 SGVENPGGYCL Db 7 5.6 1.9 52 N.D. 37 42 26 51 1.9
NP205 YTVKYPNL Kb 8 5.9 3.2 170 N.D. N.D. N.D. N.D. N.D. N.D.
GP92 CSANNSHHYI Db 0.7 0.5 N.D. 470 N.D. N.D. N.D. 9 44 N.D.
GP34 AVYNFATCGI Kb N.D. N.D. 4.8 N.D. 22 N.D. N.D. N.D. N.D. N.D.
Table 4.1 LCMV CD8+ T cell epitopes in H-2b mice. The sequence, MHC restriction, proportion of the response elicited, 
relative affinity of binding to MHC and functional avidity of six epitopes targeted by the virus-specific CD8+ T cell response in 
primary LCMV infection of H-2b mice are given in the table above. Data from more than one study are given for comparison in 
some cases.
N.D. means that measurements for these peptides were not determined.
a Two possible sequences, a 9-mer and an 11-mer, have been shown to be the optimal epitope, the results varying on the 
method used to evaluate the response.
c Data from (Murali-Krishna et al., 1998) 
d Data from (van der Most et al., 2003)
(i) intracellular IFN-y staining (li) tetramer staining
e Data from (van der Most et al., 1998) 
f Data from (Puglielli etal., 2001)
9 Data from (Gairin et al., 1995) 
h Data from (Hudrisier et al., 1996)
(lli) competition assay: IC50 - concentration of competitor peptide that inhibits 50% of the specific binding of bound radio-labelled 
probe on T2 cells.
{iv) stabilization assay: SC50 - concentration of peptide that induces half maximal stabilization of H-2Db on RMA-S cells incubated 
at 37°C in the presence of increasing concentrations of peptide.
j Data from (Gairin et al., 1995). Cytotoxicity assay: ED50 - peptide concentration required to induce half maximal lysis of radio­
labelled peptide-pulsed target cells by LCMV-specific CTL clones/bulk splenocytes.
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Figure 4.7. Analysis of the magnitude of CD8+ T cell responses to different 
LCMV epitopes in CD4+ cell-depleted mice and control C57BL/6 mice 
infected with LCMV. Control and CD4-depleted C57BL/6 mice were infected 
i.p. with 2x105 pfu LCMV Armstrong. The CD4-depleted mice were given 1mg of 
anti-CD4 monoclonal antibody GK1.5 i.v. one day prior to and then 2 days after 
LCMV infection to remove CD4 T cell help for the induction of the LCMV- 
specific CD8+ T cell response. 8 days later the frequencies of splenic CD8+ T 
cells specific for different LCMV epitopes were determined by incubating 
splenocytes with synthetic peptides corresponding to LCMV CD8+ T cell 
epitopes (final concentration 10'6 M), and measuring the number of cells 
stimulated to produce IFN-y by ELISPOT assay. The percentage of CD8+ T cells 
in each splenocyte preparation was also analysed (by antibody staining and 
FACS), so that epitope-specific cell frequencies within the CD8+ T cell 
compartment could be calculated. The data shown represent the mean of 
results obtained in groups of four mice, and are expressed as the average 
number of specific spot forming cells (SFC) per 106 CD8+ T cells (i.e. with 
background values from medium only wells subtracted), +1 SE. Staining of 
splenocyte samples with an antibody against CD4 showed that the depletion 
had reduced the number of splenic CD4+ cells to <0.3% of the number found in 
control mice. This is one representative example of three experiments carried 
out, which all gave similar results.
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other groups (Murali-Krishna et al., 1998; van der Most et al., 2003; van der 
Most et al., 1998): the strongest response was that towards the GP33 peptide, 
and a larger than expected response was made to the normally subdominant 
NP205 epitope. Potential reasons for these discrepancies are considered in 
the discussion. In the CD4-depleted mice, the overall magnitude of the 
response was slightly reduced compared to the control group, but 
nonetheless, a strong response was still seen. In the representative 
experiment depicted in Figure 4.7, although the magnitude of the responses to 
the three most dominant epitopes was diminished in CD4-depleted mice, the 
responses to the more subdominant epitopes appeared to be preserved. 
Importantly however, CD4 depletion did not induce a major change in the 
immunodominance hierarchy: responses were still ranked in the order 
GP33>NP396>NP205>GP276>GP92. Thus there was no evidence in this 
experimental system to suggest that there was more of a bias to high affinity 
epitopes when the CD8 response was induced in the absence of CD4 help. 
Previous studies have shown that in LCMV-infected mice, the widespread 
virus replication in lymphoid tissues can substitute for CD4+ T cell help in the 
induction of the virus-specific CD8+ T cell response (Christensen et al., 1994; 
Janssen et al., 2003; Leist et al., 1987; Moskophidis et al., 1987b); in line with 
this, CD4 depletion had only a minor effect on the magnitude of the CD8 
response induced following infection of mice with LCMV in the experiment 
described above (a two-tailed t-test showed that the total magnitudes of the 
LCMV-specific responses were not significantly different between mice in the 
two groups). Therefore LCMV infection of CD4-depleted mice was perhaps not 
the most suitable model to use to mimic the limited availability of fully activated 
APCs hypothesised to be present in primary HIV infection (where, unlike in 
this model of acute LCMV infection, there are thought to be direct effects of 
the virus on APC function in addition to indirect effects due to limited 
availability of CD4 help). It was thus decided to use infection of mice with 
recombinant vaccinia viruses encoding the NP and GP genes of LCMV 
Armstrong (W -N P  and W -G P ) as an alternative model system. Here, 
responses to the LCMV epitopes could still be studied; however, because 
vaccinia virus (unlike LCMV) does not replicate extensively in lymphoid 
tissues, it was hoped that there would be less infection-associated APC 
activation, and so CD4 help would be more critical for induction of the virus- 
specific CD8+ T cell response in this situation.
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Control C57BL/6 mice and IA k/o mice which lack MHC class ll-restricted CD4 
helper T cells (because their APCs do not express MHC class II molecules) 
were infected with a mixture of W -N P  and W -G P , and eight days later the 
splenic LCMV-specific CD8 response was assessed using an IFN-y ELISPOT 
assay. IA k/o mice were used rather than CD4 depleted mice, as this was a 
better way of ensuring that the mice were completely CD4 cell deficient.
In Figure 4.8 it can be seen that the magnitude of the overall response to the 
LCMV epitopes was approximately 10-fold lower in the recombinant vaccinia- 
LCMV-infected mice than that seen in LCMV-infected mice in Figure 4.7. 
Similar observations have been made in previous studies (Hassett et al., 
2000; von Herrath et al., 1996); the difference is thought to be due in large 
part to the relative amounts of LCMV antigen generated in the two infections.
In the control mice, the GP33-specific response was clearly the most dominant 
in this experiment; the GP276 and NP396-specific responses were the next 
most dominant, followed by a small response to NP205, and the response to 
GP92 was below the limit of detection of the assay. In the IA k/o mice, 
responses were seen to the same four epitopes, with the magnitude of the 
response being diminished compared to the control mice for all but the high 
affinity NP396 epitope, the response to which was actually higher than that in 
control mice (however, this difference was not statistically significant as judged 
by a two-tailed t-test (p=0.246), which may be due to the small sample size in 
the experiment). The hierarchy of the response immunodominance in control 
and IA k/o mice thus differed: in the control mice it was in the order GP33 > 
GP276 «N P396 > NP205 > GP92, whereas in the IA k/o mice it was GP33 *  
NP296 > GP276 ==NP205 > GP92. These results lend some support to the 
idea that there may be better priming of the response to the highest affinity 
epitope when CD4 help is absent.
Given that relatively high magnitude responses were still raised against the 
recombinant vaccinia-LCMV viruses in the IA k/o mice, the virus-specific CD8 
response in this infection also appeared to be largely independent of CD4 help 
(again, statistical analysis (a two-tailed t-test) showed that the total 
magnitudes of the virus-specific responses were not significantly different for 
mice in the two groups). A further series of experiments were thus carried out 
using a different model, involving infection of mice with influenza virus via the 
i.p. route. Productive infection by influenza A virus is essentially limited to the 
lung because a protease required to cleave the influenza virus haemagglutinin 
molecule is restricted in distribution to the respiratory epithelium (Rott et al.,
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Figure 4.8. Analysis of the magnitude of CD8+ T cell responses to 
different LCMV epitopes in IA k/o mice and control C57BL/6 mice 
infected with W -LCM V. Control and IA k/o mice were infected i.p. with a 
mixture of two recombinant vaccinia viruses: one expressing the NP gene of 
LCMV Armstrong and the other expressing the GP gene (106 pfu of each 
virus used). 8 days later, mice were culled and the frequencies of splenic 
CD8+ T cells specific for different LCMV epitopes were determined by 
incubating splenocytes with synthetic peptides corresponding to LCMV CD8+ 
T cell epitopes (final concentration 10'6 M), and measuring the number of cells 
stimulated to produce IFN-y by ELI SPOT assay. The percentage of CD8+ T 
cells in each splenocyte preparation was also analysed (by antibody staining 
and FACS), so that epitope-specific cell frequencies within the CD8+ T cell 
compartment could be calculated. The data shown represent the mean of 
results obtained in groups of four mice, and are expressed as the average 
number of specific spot forming cells (SFC) per 106 CD8+ T cells (i.e. with 
background values from medium only wells subtracted), +1 SE. These results 
are representative of two independent experiments, in which similar results 
were obtained.
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1995; Walker et al., 1992). By delivering the virus by an i.p. route, viral 
antigens can be presented but without virus replication occurring. It was hoped 
that induction of a CD8 T cell response to viral epitopes would be more 
dependent on CD4 help in this system.
Influenza A virus is a negative-stranded RNA virus whose genome consists of 
8 RNA segments that encode 11 protein products, the majority of which serve 
as targets for T cell recognition. A number of H-2b-restricted CD8+ T cell 
epitopes have been defined for influenza (Table 4.2), but the relative 
immunodominance and relative affinity of MHC binding is not known for all of 
the epitopes. To gain a more complete picture of the relative MHC binding 
affinities of the different H-2b-restricted influenza epitopes, binding of the 
epitope peptides to Db/Kb was determined experimentally using an MHC 
stabilisation assay (Gairin et al., 1995; Hudrisier et al., 1996). RMA-S cells are 
a TAP-deficient mutant cell line which have empty MHC molecules that 
accumulate on the cell surface when the cells are grown at 26°C, but are 
unstable and disappear from the cell surface when the cells are incubated at 
37°C. Surface expression of MHC molecules can be stabilised by addition of 
peptides that bind to the empty MHC molecules. The ability of a peptide to 
stabilise MHC molecules on the cell surface correlates with the peptide’s 
affinity for the MHC. Stable complexes remain at the surface when the cells 
are incubated at 37°C and can be detected by staining with fluorescently 
labelled anti-MHC class I antibodies. By measuring the concentration of an 
epitope peptide required to stabilise MHC expression on the cell surface for 
several epitope peptides, their relative binding affinities can be compared.
In Figure 4.9, the stabilisation of Kb expression by Kb-binding influenza 
epitopes PB1 703, PB2 198, NS2 114, Ml 128 and the stabilisation of Db 
expression by Db-binding influenza epitopes PA 224, NP 366, DAMP 62 is 
shown, together with that of positive control peptides known to bind with high 
affinity to Kb/D b. Three peptides (PB2 198, NS2 114 and PA 224) stabilised 
moderate/high levels of MHC expression in a dose-dependent fashion. The 
fluorescence data obtained was used to calculate pBL50 values (the negative 
log of the peptide concentration yielding the half-maximal fluorescence 
intensity of the reference peptide) for each peptide; the pBL50 values for PB2 
198, NS2 114 and PA 224 were -7.6, -2.6 and -13.3, respectively, indicating 
that that PA224 had a particularly high MHC binding affinity. The other 
influenza peptides did not exhibit dose-dependent stabilisation of sufficiently 
high levels of MHC expression to enable pBL50 values to be calculated,
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Epitope Sequence MHC restriction Immunodominance
rank3
MHC binding affinity
SD50 value (nM)D IC50 value (nM)c PBL50 value0
PA 224 SSLENFRAYV Db 1 72.2 n.d. -13.3
NP 366 ASNENMETM Db 2 15.2 24 b.n.d.
DAMP 62 LSLRNPILV Db 3 n.d. n.d. n.d.
PB1 703 SSYRRPVGI Kb 4 47.4 n.d. b.n.d.
PB2 198 ISPLMVAYM Kb 5 n.d. n.d. -7.6
NS2 114 RTFSFQLI Kb 6 500-15000 9.7 -2.6
M1 128 MGLIYNRM Kb 7 188.3 4.6 b.n.d.
Table 4.2. Peptides in Influenza A PR8 virus recognised by virus-specific CD8* T cells in H-2b mice.
The sequence, MHC restriction, rank according to the magnitude of the CD8  response elicited to the 
epitope in primary influenza infection in H-2b mice and relative affinity of binding to MHC of seven peptides 
recognised by influenza virus-specific CD8 + T cells are given in the table above, n.d. means that affinity 
measurements for these peptides were not determined, b.n.d. means that binding was not detected.
3 Data from (Chen et al., 2002)
b Data from (Zhong et al., 2003)
c Data from (Vitello et al., 1996)
d Calculated from data in Figure 4.9
Explanations for calculation of SD50 and IC50 values are given in Table 4.1; pBL50 values were calculated 
as explained in the text.
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Figure 4.9. Determination of the relative binding affinities of influenza epitope 
peptides to H-2 alleles using a MHC stabilisation assay. RMA-S cells were cultured at 
37°C in the presence of a series of dilutions (1mM to 0.1 nM) of peptides corresponding to 
influenza epitopes. The relative affinity of binding of the peptides to MHC was assessed by 
their ability to stabilise expression of Kb or Db molecules on the cell surface, and was 
measured by staining the cells with FITC-conjugated anti-class I H-2Kb or H-2Db (or isotope 
control) antibodies. The mean fluorescence intensity (MFI) of each sample was determined 
by flow cytometry and results are expressed as fluorescence index (FI) values [FI = (MFI of 
test peptide - MFI of no peptide isotype control)/ (MFI of no-peptide class I -stained control - 
MFI of no peptide isotype control)]. The stabilisation of Kb expression by Kb-binding 
influenza epitopes PB1 703, PB2 198, NS2 114, M1 128 is shown in (a), and the 
stabilisation of Db expression by Db-binding influenza epitopes PA 224, NP 366, DAMP 62 
is shown in (b). No peptide, positive (2c Syng for Kb assay and LCMV NP396 for Db assay) 
and negative (HIV Nef 82-9 0 ) control peptides were also included in the assay. These data 
are representative of results obtained in two independent experiments.
PA 224 
— NP 366 
—A—  DAMP 62
—• —  LCMV NP396 (positive control) 
HIV Nef (negative control)
No peptide
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suggesting that their MHC binding affinities were too low to be assessed by 
this approach. As indicated in Table 4.2, there are discrepancies among the 
results obtained by other groups who have addressed the affinity of binding of 
these influenza virus peptides to MHC, and between the results obtained here 
and the different sets of published data; possible reasons for this are 
discussed later.
The hierarchy of responses induced to this panel of influenza virus epitope 
peptides when control and IA k/o mice were infected i.p. with influenza PR8 
virus was then investigated. Mice were sacrificed on day 8 post-infection, and 
the epitope-specificity of splenic CD8+ cells assessed in an IFN-y ELISPOT 
assay. In Figure 4.10 it can be seen that the control mice made dominant 
responses to the NP 366, PB2 198 and PA 224 epitopes, with the response to 
DAMP 62 being of slightly lower magnitude, and then smaller responses being 
made to the NS2 114, M1 128 and PB1 703 epitopes. In the IA k/o mice 
responses to all peptides were lower in magnitude than those in the control 
mice, and the hierarchy of the responses was slightly different; but there was 
no evidence to support the idea that there may be preferential induction of 
responses to high affinity epitopes when CD4 help was absent. However it 
was notable that despite efforts to choose a system which it was thought might 
be more dependent on help for priming a virus-specific CD8+ T cell response, 
the IA k/o mice were still able to make reasonable responses to the virus 
(once again, the total magnitudes of the virus-specific responses were not 
significantly different for mice in the two groups, as judged by a two-tailed t- 
test). Hence again, it was not possible to rigorously address the effects of 
incomplete APC activation on the hierarchy of responses primed to different 
viral epitopes using this system.
4.4 Analysis of the effect of lack of CD4* T cell help at the time of priming 
of a virus-specific CD8* T cell response on the clonality of the response 
induced
In experiments described above, the absence of CD4 T cell help at the time 
of priming of a virus-specific response was not found to have a great influence 
on the epitope hierarchy of the CD8+ T cell response induced. However it was 
possible that alterations were induced in the clonal composition of the 
response (e.g. there may be selective expansion of T cells with high affinity 
TCRs). To gain an overview of the TCR usage by virus-specific T cells 
induced in control and CD4-dep!eted mice infected with LCMV, TCR V£ family
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Figure 4.10. Analysis of the magnitude of CD8+ T cell responses to different 
influenza epitopes in IA k/o mice and control C57BL/6 mice infected with 
influenza virus. Control and IA k/o mice were infected with 600 hemagglutinating 
units of influenza virus PR8 i.p. Eight days later, the mice were culled and the 
frequencies of splenic CD8+ T cells specific for different influenza epitopes were 
determined by incubating splenocytes with synthetic peptides corresponding to 
influenza CD8+ T cell epitopes (final concentration 10'6 M), and measuring the number 
of cells stimulated to produce IFN-y by ELISPOT assay. The percentage of CD8+ T 
cells in each splenocyte preparation was also analysed (by antibody staining and 
FACS), so that epitope-specific cell frequencies within the CD8+ T cell compartment 
could be calculated. The data shown represent the mean of results obtained in 
groups of four mice, and are expressed as the average number of specific spot 
forming cells (SFC) per 106 CD8+ T cells (i.e. with background values from medium 
only wells subtracted), +1SE. This experiment is representative of results obtained in 
two independent experiments.
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usage by cells responding to two LCMV epitopes was assessed by staining 
with antibodies specific for different TCR V/? families. Peripheral blood pooled 
from groups of four control or CD4-depleted LCMV-infected mice (bled on day 
8 post-infection) was stained with tetramers of one of two specificities (NP396 
or GP33), an anti-CD8 antibody, plus one of a panel of antibodies specific for 
different TCR V£ families. The usage of different TCR V£ families by the 
antigen-specific cells was then assessed by flow cytometry. The TCR V£ 
families used (and proportion of cells using each family), by both the NP396 
and GP33-specific cells in the control mice and IA k/o mice are shown in 
Figure 4.11. Despite the fact that antibodies were not available to detect all 
TCR V/? families, the V/? staining detected all of the antigen-specific cells, 
suggesting that the panel of antibodies used covered all of the major TCR Vp 
families involved in each response.
The NP396-specific CD8 cells in the control mice exhibited very restricted 
TCR V/? family usage, with almost 90% of the epitope-specific cells using V/?8+ 
or V/? 8.1/8.2+ TCRs. Slightly more diversity in TCR V/? use was seen in the 
GP33-specific population in the control mice, with V/?s 7 and 8.3 being used in 
addition to Vp 8 and VP 8.1/8.2. TCR Vp family usage by NP396 and GP33- 
specific cells from IA k/o mice was very similar to that in control animals. 
There did not therefore seem to be any major difference in the repertoire of 
TCR V/? families used in the LCMV-specific response when CD4 help was 
limiting. However, as discussed above, APC activation may not have been 
appreciably compromised in these animals despite the lack of CD4 help.
In summary, the series of experiments described in sections 4.3 and 4.4 
showed that deficiency of CD4+ T cell help during an acute virus infection does 
not dramatically affect the hierarchy of epitope or clonal immunodominance in 
the primary virus-specific CD8+ T cell response. However the model systems 
used here did not allow the effects of deficits in APC numbers/activation state 
in addition to paucity of CD4+ T cell help on the nature of the primary virus- 
specific CD8 response to be explored properly.
4.5 Search for epitope-specific CD8+ T cell responses induced to viruses 
other than HIV that are able to cross-recognise HIV epitopes and may 
rapidly expand in acute HIV infection to become an immunodominant 
component of the primary HIV-specific CD8 T cell response
A second potential hypothesis to explain the strong responses made to single 
(or small numbers of) immunodominant epitopes in some patients undergoing
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Figure 4.11. Analysis of TCR V/? family usage by NP396 and GP33-specific peripheral blood T cells in control and 
CD4-depleted mice acutely infected with LCMV. Control C57BL/6 and CD4-depleted C57BL/6 mice were infected i.p. with 
2x105 pfu LCMV Armstrong. Depletion of CD4+ cells was achieved by the administration of 1mg anti-CD4 monoclonal 
antibody GK1.5 one day prior to and then 2 days after LCMV infection. Eight days later, mice were culled and blood 
lymphocytes pooled from groups of four mice were co-stained with anti-CD8 mAb, LCMV NP396 or LCMV GP33 tetramer, 
and a panel of TCR V/?-specific mAbs. The results shown are the percentage of tetramer positive cells for each epitope 
stained with each TCR V/? family-specific mAb in control and CD4-depleted mice. Values less than 2% were regarded as 
background staining and are not shown on the graph. The efficiency of the CD4 depletion was also checked by staining 
splenocytes with an anti-CD4 mAb. This showed that the number of splenic CD4+ cells in the depleted mice had been 
reduced to <0.3% of the number seen in the control mice.
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primary HIV-1 infection is that the cells used to make these responses may be 
cross-reactive memory cells which are triggered to expand upon recognition of 
HIV antigens more rapidly than naive cells (due to their high frequency and 
ease of re-activation). Such cross-reactive memory cells may also be less 
dependent on help/full APC activation for their expansion than naive cells.
One example of an epitope-specific response that was particularly 
immunodominant in primary HIV infection was that made by patient WEAU to 
a HI_A-B44-restricted epitope (AENLWVTVY(Y)) in gp160 (Borrow et al., 
1997). During acute infection, >40% of peripheral blood T cells in this patient 
may have been directed towards this epitope (Pantaleo et al., 1994), whilst 
responses to other epitopes were very low at this time (Borrow et al., 1997). 
Did this response arise as a consequence of rapid expansion of memory cells 
generated as a result of a previous infection that were able to cross-recognise 
this gp160 epitope? To examine this possibility, potentially cross-reactive 
epitopes were looked for. An initial search was made for known HLA-B44*03- 
restricted epitopes in other viruses that had similarity to the HIV 
immunodominant AENLWVTVY(Y) epitope. EBV was found to have a HLA- 
B44*03-restricted epitope (EENLLDFVRF) sharing several amino acids with 
the HIV epitope, and having chemically similar residues at other positions. The 
ability of peptides corresponding to the two viral epitopes to sensitise 
autologous target cells for lysis by polyclonal CTL derived from PBMC 
cryopreserved from WEAU was compared using a 51 Cr release assay. The 
AENLWVTVYY peptide was able to induce around 40% specific lysis, but no 
lysis of target cells pulsed with the EENLLDFVRF peptide was seen (data not 
shown - experiment carried out by Dr N. A. Jones). This result suggested that 
it was unlikely that this EBV epitope had primed the cells that may have later 
cross-recognised HIV AENLWVTVY(Y).
The possibility of cross-recognition of the immunodominant HIV epitope 
AENLWVTVYY by individuals who had a response to the EBV epitope 
EENLLDFVRF was further explored using cells from subject JSS, a HLA- 
B44*03+ HIV seronegative donor known to respond to the EBV epitope. Cells 
obtained from this subject were stimulated with a range of concentrations of 
both the EBV and HIV peptides, and the frequency of cells stimulated to 
produce IFN-y was assessed by ELISPOT assay. The results in Figure 4.12 
show that the subject’s cells made a dose-dependent response to the EBV 
peptide, but no response to the HIV epitope was seen at even the highest 
concentration of peptide used to stimulate the cells. Attempts were also made
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Figure 4.12. Analysis of the response of EBV+, HIV'subject JSS to the EBV 
epitope peptide EENLLDFVRF and the HIV epitope peptide AENLWVTVY.
PBMCs cryopreserved from subject JSS were stimulated for 24 hours with 
synthetic peptides representing B44-restricted EBV and HIV epitopes at 
concentrations between 10'5M and 10'9M. The number of cells stimulated to 
produce IFN-y was quantified by ELISPOT assay and is expressed as the mean 
(of values from duplicate wells) number of specific spot forming cells (SFC) per 
106 PBMCs (i.e. background values from medium only control wells have been 
subtracted). The error bars indicate one S.D. above and below the mean.
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to expand out a population of HIV-specific CD8+ T cells by in vitro culture of 
PBMCs from subject JSS with the HIV peptide, but this was not successful. 
Thus there was no evidence of the EBV-specific cells being able to cross- 
recognise the HIV epitope.
It remained possible that the HIV AENLWVTVY(Y) response had been 
expanded from memory cells responding to another HLA-B44*03-restricted 
epitope. To investigate this possibility, the predicted amino acid sequences of 
the entire proteome of eight common human viruses (influenza virus, EBV, 
adenovirus, CMV, measles, mumps, VZV and HSV) were screened by Darren 
Flower (Bioinformatics group, EJIVR, Compton) to identify peptides 9 amino 
acids in length that conformed to the HLA-B44*03 HLA binding motif 
(glutamate at position 2 and a hydrophobic residue at the C-terminus 
(http://www.svfDeithi.de/11. and had chemical similarity to the residues in the 
HIV AENLW VTVY(Y) epitope, that may have triggered a cross-reactive 
response. The peptides were ordered according to their chemical similarity to 
the AENLW TVY peptide, and the top 64 of these, which are listed in Figure 
4.13(a), were synthesised, grouped into pools of two, and tested for 
recognition by cryopreserved PBMCs from WEAU in an IFN-y ELISPOT 
assay. As shown in Figure 4.13, a strong response was stimulated by the HIV 
epitope, but the patient’s cells did not cross-recognise any of the test peptides. 
Observations made in a second HIV-infected individual, BORI, were initially 
supportive of the idea that a cross-reactive response could help prime a 
dominant HIV-specific response. This patient made a dominant response to 
the HLA-A*29 restricted HIV epitope SFEPIPIHY during acute infection (Jones 
et al., 2004). Using a similar approach as for that used for WEAU and the HIV 
AENLW VTVY(Y) epitope to look for possible sequences in other human 
viruses which could have primed this response, a panel of peptides were 
tested for cross-recognition by PBMC from BORI in an IFN-y ELISPOT assay 
(listed in Figure 4.14(a)). Strong responses were observed towards two 
sequences derived from the proteome of HSV-2 (Figure 4.14(b)): 
RLEARLGHL and HFEPAAEPV. However, when the recognition of the HIV 
and HSV-2 sequences were compared at lower peptide concentrations (by 
looking at the ability of polyclonally restimulated patient PBMC to lyse target 
cells pulsed with a range of dilutions of each peptide in a chromium release 
assay), it was apparent that the two HSV-2 sequences were recognised only 
at high peptide concentrations (whereas the functional avidity of the response 
to the SFEPIPIHY peptide was extremely high (10'11-10'12M) (Figure 4.14(c)).
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Peptide Pool Peptide A sequence Peptide B sequence Peptide Pool Peptide A sequence Peptide B sequence
P1 EEDLRVFGE EEDLRVFGE P17 TELLWHAHP PEDGWVKVH
P2 RELVWWFYA GENLVTAVS P18 DENLGVLDR EENLEGVRR
P3 LEDLSHSVF TENLMHCVK P19 DENFYLLVT PENIWVPW
P4 AEDLRVLEV SENLMWDIL P20 RENLERRGA TENLGGLSG
P5 YENLVYLYL ELRSRYWAL P21 KENLRRPW AEQYWRRW
P6 GEISPLPSL KEHVIQNAF P22 NENPEKDVL CEDLEGRVS
P7 NEGCGWAGW VEITPYKP7W P23 EEELWEAVF PENLUIIP
P8 FEDLRVLSF EGGVGWRHW P24 FENLIPPEI YENLLRELY
P9 LENLLSRYE AENIRGLNE P25 REDPWLDGA REILWAAYA
P10 MENLRRVYK AENLISNGI P26 GENLYVHAD NEDLYSDMM
P11 LENLRRVLD TENLRNALQ P27 NENPYHARR IESLWVGVY
P12 AENLLLVAL RENLLTLGQ P28 PEQPWIAAV AENLKGVWP
P13 PENPGSRAY RENLLSGDT P29 EEIPWVRVY EELLWFIRG
P14 QENLIEALA LENLSITEL P30 AENLPGLLF GENLKTLRL
P15 WENLLSKAK AENLSDVTQ P31 AENLPGLLV TENLPELWT
P16 YELLYFLVL KECLWVLSD P32 LENLKLKLG EENYYVTVL
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Figure 4.13. Testing peptides representing putative HLA-B44*03-restricted 
epitopes in unrelated viruses for recognition by PBMCs from patient WEAU using 
an IFN-k ELISPOT assay.
A. The predicted amino acid sequences of the entire proteome of eight common human 
viruses (EBV, CMV, VZV, HSV, measles, mumps, influenza and adenovirus) were 
screened by Dr Darren Flower (Bioinformatics Group, EJIVR) to identify peptides 9 
amino acids in length that were predicted to bind to HLA- B44*03. These were ranked 
on the basis of chemical similarity of their constituent amino acids to the HIV epitope 
AENLW VTVY, and the top 64 were synthesized and combined into pools of two for 
screening. The amino acid sequences of the peptides in each pool are shown.
B. PBMCs cryopreserved from patient WEAU (20 DFOSx) were stimulated for 24 hours 
with the indicated synthetic peptides (each peptide at 3x10'5M): either the 
immunodominant HIV AENLW VTVY epitope peptide or the peptide pools detailed in
(A). The number of cells stimulated to produce IFN-y was quantified by ELISPOT assay 
and is expressed as the mean (of values from duplicate wells) number of specific spot 
forming cells (SFC) per 106 PBMCs (i.e. background values from medium only control 
wells have been subtracted). The error bars indicate one S.D. above and below the 
mean.
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I(A) Peptide Sequence Peptide number Sequence Peptide number Sequence
Index SFEPIPIHY 10 SVEACGNHV 20 NFTPIYIHT
1 TLEPEKNHP 11 GFEAAALHV 21 AFETNQTHD
2 NIEPTYPHG 12 GFEPGTYRL 22 AFEPEVPTP
3 NIEAFLAHL 13 QFEPMLPRV 23 LFNTINFHY
4 DYEPVPRKF 14 GFQPPVTHP 24 NFHPELKKY
5 RLEARLGHL 15 IFETLALRL 25 SFEGDVARV
6 EIEPGVLKV 16 LFHAIPFHM 26 EFEGDFARY
7 PVEPTRPHV 17 RFNPPKMHP 27 RFTPRPQHD
8 DIEGHASHY 18 VFDPAQIHT 28 HFEPAAEPV
9 EYEPEDGEY 19 YFQAHQMHL 29 LFEHLAAHG
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Figure 4.14. Testing peptides representing putative A29-restricted ‘SFEPIPIHY-like’ viral epitopes for 
recognition by PBMCs from patient BORI.
(A) Putative A29-restricted viral epitopes which resembled the HIV SFEPIPIHY epitope were predicted in a similar 
manner as described for the prediction of putative B44-restricted viral epitopes resembling HIV AENLWVTVY in 
Figure 4.13. The top 29 of these (based upon chemical similarity of their constituent amino acids to the HIV 
epitope sequence) are listed here.
(B) Synthetic peptides corresponding to the 29 predicted sequences in (A) were synthesized and screened for 
recognition (along with the immunodominant HIV SFEPIPIHY epitope peptide for comparison) by PBMCs 
cryopreserved from Datient BORI (28 DFOSx). Cells were stimulated for 24 hours with the synthetic peptides 
(each peptide at 10' M), and the number of cells stimulated to produce IFN-y was quantified by ELISPOT assay. 
The results shown are expressed as the mean (of values from duplicate or triplicate wells) number of specific spot 
forming cells (SFC) per 106 PBMCs (i.e. background values from medium only control wells have been 
subtracted). The error bars indicate one S.D. above the mean.
(C) The relative recognition of the HIV SFEPIPIHY epitope and HSV-2 derived RLEARLGHL and HFEPAAEPV 
sequences by PBMCs from patient BORI were determined by 51Cr release assay. PBMC cryopreserved from 
patient BORI (21 DFOSx) were polyclonally restimulated in vitro for 8 days with an anti-CD3 antibody and 
irradiated allogeneic feeder cells. Their ability to lyse autologous B-LCL target cells pulsed with 10 fold dilutions of 
the peptides of interest was determined using a standard 51Cr release assay. The results shown are the % 
specific 51Cr release from the target cells at an E:T of 50:1
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This suggested that it was more likely that the HIV-specific CD8 cells were 
cross recognising the HSV-2 sequences, rather than that HSV-2-specific 
memory cells had expanded to generate the response to the HIV epitope.
A further question of interest was how commonly cross-reactive responses to 
HIV-1 epitope peptides are observed in HIV seronegative donors. To gain 
some insight into this, PBMCs from 10 different HIV seronegative blood 
donors were stimulated with pools of overlapping peptides that spanned the 
HIV Gag p24 sequence (listed in Table 4.3) and IFN-y ELISPOT assays were 
used to detect responses to the peptides. As shown in Figure 4.15, none of 
the donors tested made responses to these peptides above the background 
level of IFN-y production (that produced by cells incubated with medium 
alone). To enable more definitive conclusions to be drawn about cross­
recognition of HIV sequences by T cells in HIV seronegative individuals, 
similar studies should ideally have been extended to a large proportion of the 
HIV-1 proteome and a larger number of subjects, but unfortunately, time and 
resources did not permit this.
In summary, experiments to identify examples of cross-recognition of HIV 
epitopes by pre-existing memory T cells of other specificities proved 
unsuccessful. However it still remained possible that cross-reactivity between 
HIV and other viral epitopes may influence the nature of the primary HIV- 
specific CD8+ T cell response. This hypothesis was explored further using 
murine models.
4.6 Analysis of the relative dependence of naive and memory CD8* T 
cells specific for an H-Y epitope on CD4 help for their expansion
The first aim of experiments in murine models was to test whether, as 
predicted, memory CD8+ T cells were less dependent on CD4 help for their 
expansion than naive CD8+ T cells. This was done by looking at responses to 
male cells expressing the histocompatibility-Y (H-Y) antigen, as it is known 
that the primary CD8+ T cell response to this antigen is highly dependent on 
CD4 help (Simpson & Gordon, 1977). Could expansion of a memory H-Y 
response occur independently of CD4 help (unlike priming of naive cells to 
make a H-Y-specific response)?
In this experiment five groups of four female H-2b mice were used. The first 
group were primed with male splenocytes i.p. then 4 weeks later boosted with 
another inoculation of male splenocytes. A second group of mice were treated 
in a similar manner as for mice in group 1, but were also given an anti-CD4
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Peptide pools
P1 MLKETINEEAAEWDRLHPVH AEWDRLHPVHAGPIAPGQMR
P2 AGPIAPGQMREPRGSDIAGT EPRGSDIAGTTSTLQEQIAW
P3 TSTLQEQIAWMTNNPPIPVG MTNNPPIPVGEIYKRWIILG
P4 EIYKRWIILGLNKIVRMYSP LNKIVRMYSPVSILDIRQGP
P5 VSILDIRQGPKEPFRDYVDR KEPFRDYVDRFYKTLRAEQA
P6 FYKTLRAEQATQEVKNWMTE TQEVKNWMTETLLVQNANPD
P7 TLLVQNANPDCKTILKALGP CKTILKALGPGATLEDMMTA
P8 GATLEDMMTACQGVGGPGHK CQGVGGPGHKARVLAEAMSQ
P9 ARVLAEAMSQVTNTATMMMQ VTNTATMMMQRGNFRSPRKT
P10 RGNFRSPRKTIKCFNCGKEG IKCFNCGKEGHIARNCRAPR
P11 HIARNCRAPRKKGC WKCGQE KKGCWKCGQEGHQMKDCTER
P12 GHQMKDCTERQANFLGKIWS QANFLGKIWSSQKGRPGNFP
P13 SQKGRPGNFPQSRLEPTAPP QSRLEPTAPPEESFRFREET
P14 EESFRFREETTTPSQKQEPI TTPSQKQEPIDKELYPLTSL
P15 DKELYPLTSLKSLFGNDPSS KELYPLTSLKSLFGNDPSSQ
Table 4.3. Sequences of overlapping synthetic peptides spanning the HIV-1 Gag 
p24 sequence. Peptides spanning HIV-1 Gag (based upon the clade B consensus 
sequence) were used in pools of two in IFN-y ELISPOT assays (described in Figure 
4.15) at a final concentration of 10"5M each.
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Figure 4.15. Screening PBMCs from HIV-seronegative donors for responses to overlapping synthetic peptides 
corresponding to the HIV-1 Gag p24 sequence. PBMCs cryopreserved from 10 HIV-seronegative donors (A-J) were 
incubated for 24 hours with pools of overlapping peptides corresponding to the HIV-1 clade B consensus sequence Gag p24 
sequence (Table 4.3) (each at a final concentration of 10'5M) or PHA or medium alone. The number of cells stimulated to 
produce IFNy was quantified by ELISPOT assay and is expressed as the mean (of triplicate test wells) number of spots per test 
well containing 2x105 PBMCs. The error bars indicate one S.D. above and below the mean. N.B. Peptide pools 6 & 9 were in 
short supply and not included in this experiment.
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antibody around the time of the boost, so that help was limiting as the memory 
cells were expanding in response to the boost. In order to check the memory 
level of H-Y specific cells at ~6 weeks post-priming, mice in a third group only 
received the initial prime. The fourth group of mice were not initially primed, 
but were given male splenocytes at the same time as when groups 1 and 2 
were boosted, to look at the primary H-Y specific response in intact mice. Mice 
in group 5 were treated as mice in group 4, but also CD4+ cell-depleted using 
an anti-CD4 antibody so that CD4 help was limiting as the primary response 
was being induced. Spleens were taken from mice in all groups on day 13 
(post-boost) and H-Y-specific CD8+ T cell responses were assessed for each 
individual animal by tetramer staining using a H-Y-specific tetramer 
(Db/W MHHNMLDI), the results of which are shown in Figure 4.16.
The mean level of tetramer positive cells of mice in groups 4 (primary H-Y- 
specific response) and 5 (help absent at the time of induction of the primary H- 
Y-specific response) were 6.3% and 0.7% of CD8+ cells respectively, 
confirming that this response is a help-dependent one. The mean level of the 
memory response at 6 weeks post-priming in non-boosted mice (group 3) was 
found to be 2.1%. In comparison, the response in CD4-depleted and boosted 
mice (group 2) was higher (5.7%) and was similar to that in non-CD4-depleted 
boosted mice (group 1 -  4.6%), suggesting that memory cells had expanded 
efficiently. However, because CD4 T cells were not depleted altogether by the 
antibody administered, the data do not prove that memory cells can expand in 
the total absence of help. However, the results obtained here do support the 
idea that under conditions where CD4 help is limiting, the expansion of a large 
population of antigen-specific cells from a pre-primed repertoire (group 2) can 
occur, unlike when starting from a naive repertoire (group 5), where a similar 
large expansion was not achieved.
4.7 Investigation o f the consequences o f the presence o f Pichinde virus- 
primed, LCM V-cross reactive m em ory cells on the CD8+ T cell response 
made to LC M V  under conditions o f CD4+ T cell deficiency
To address the idea that immunodominant HIV-specific responses may be the 
result of expansion of cross-reactive memory cells, we looked to see how a 
known cross-reactive memory response could influence the epitope hierarchy 
in an antiviral immune response being induced under conditions of limited 
CD4+ T cell help. LCMV and Pichinde virus (PV) are two members of the 
Arenaviridae family, but are genetically and antigenically distinct. The primary
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Figure 4.16. Analysis of the relative dependence of naive and memory CD8*T cells specific for an H-Y epitope on CD4 
help for their expansion. Three groups of female C57BL/6 mice were immunised i.p. with 5x106 splenocytes prepared from 
male C57BL/6 mice. Groups 1 and 2 were boosted 4 weeks later with a similar inoculation of male splenocytes. Mice in group 3 
received no other treatments. Mice in group 2 were also given 1mg anti-CD4 monoclonal antibody GK1.5 i.v. on days -2 , 2 and 
7 with respect to the day of boosting. A further two groups of mice were not primed initially, but given male splenocytes at the 
time when groups 1 and 2 were boosted. Mice in group 5 were given a CD4+cell-depleting antibody as for mice in group 2. The 
frequency of H-Y-specific cells was determined for all mice on day 13 by staining of B cell-depleted splenocyte suspensions 
using the Db/WMHHNMLDI tetramer. Each group consisted of 4 mice (labelled A-D). The percentage of tetramer positive CD8+ 
cells in (a) individual mice and (b) the mean value for each group are shown above. The efficiency of the CD4 depletion was 
also checked by staining splenocytes with an anti-CD4 mAb. This showed that the number of splenic CD4+ cells in the depleted 
mice had been reduced to -48%  of the number seen in the control mice. This experiment was carried out twice, with similar 
results being obtained each time.
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response to each in H-2b mice is known to only weakly cross-recognise the 
other virus. However, it has been shown that if mice are already immune to PV 
the response they make to LCMV then includes a strong PV cross-reactive 
component due to the outgrowth of cross-reactive clones (Selin et a/., 1994). A 
cross-recognised viral epitope has been identified in the NP205-212 region in 
both viruses (Brehm et al., 2002). This peptide sequence is highly conserved 
between LCMV and PV, with variations at only two amino acid residues.
An experiment was carried out to investigate whether mice immune to PV, 
when CD4 depleted and infected with LCMV, now make an LCMV-specific 
response that is highly biased towards the PV cross-reactive NP205 epitope 
(cells responsive to which, being in the memory pool, should be able to 
expand more efficiently than the naive LCMV-specific cells). By exploring this, 
it was hoped to address the question of whether cross-reactive memory T 
cells have a selective advantage during the establishment of 
immunodominance when CD4 help is absent.
In Figure 4.17, it can be seen that in this experiment, the primary response to 
LCMV had the same hierarchy as in the experiment shown earlier in Figure 
4.7, with the most dominant responses being towards the GP33 followed by 
the NP396 epitope, with the NP205 response being the next largest. The mice 
that had previously been infected with PV and subsequently infected with 
LCMV, made a slightly lower overall response to LCMV. This could perhaps 
be due to cross-reactive antibodies in PV-immune mice limiting the amount of 
LCMV replication and hence antigen. Although the overall response was 
lower, an enhanced response was made to the NP205 epitope, consistent with 
previous reports indicating that this could be cross-recognised by PV-specific 
memory cells. This is reflected by the relative ratios of the magnitude of the 
response to each epitope in naive mice and PV-immune mice: for the NP205 
epitope, this ratio was greater than one. In primary LCMV infection of CD4- 
depleted mice, the responses to all epitopes were lower than those in control, 
undepleted mice, but the epitope hierarchy remained unchanged, as was 
found in the experiment described in Figure 4.7. In PV-immune, CD4-depleted 
mice, the response to LCMV reflected that seen in the equivalent non-CD4 
depleted group: responses to most epitopes were lower, but that to the cross­
recognised NP205 epitope was enhanced. However, the relative ratio of the 
responses to this epitope in naive and PV-immune, CD4-depleted mice was 
very similar to that in the non CD4-depleted groups (1.2 and 1.3 respectively). 
Thus there was preferential expansion of cross-reactive memory cells when a
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Figure 4.17. Experiment to address whether cross-reactive T cells in the memory pool 
become particularly immunodominant in the immune response to LCMV in CD4-depleted 
mice. As illustrated in (A), three groups of 4 C57BL/6 mice were infected with PV (2x105 pfu 
i.p.). Four weeks later, groups 2 and 3 received 2x105 pfu LCMV Armstrong i.p., group 3 having 
received 1mg anti-CD4 monoclonal antibody GK1.5 on one day prior to and then 2 days after 
LCMV infection. An additional two groups of mice were infected with LCMV Armstrong only (2 x 
105 pfu i.p) at this time, one of the two groups having received 1mg anti-CD4 monoclonal 
antibody GK1.5 one day prior to and then 2 days after LCMV infection. Administration of the 
antibody resulted in a reduction in the number of splenic CD4+ cells to <0.2% of the number 
found in control mice. Eight days after the last LCMV challenge, all groups of mice were culled 
and splenocytes were incubated with synthetic peptides (at a final concentration of 10'6M) 
corresponding to LCMV epitopes. The number of cells stimulated to produce IFN-y was 
enumerated by ELISPOT assay and was expressed as the mean (of duplicate test wells) 
number of specific spot forming cells (SFC) per 106 CD8+ T cells (i.e. background values from 
medium only control wells have been subtracted). The results shown in (B) are the mean 
responses made to each LCMV peptide by groups of four mice, +1SE. The table in (C) shows 
the relative magnitude of responses to each LCMV epitope in mice with and without prior 
immunity to PV, i.e. the mean magnitude of the response in PV-immune mice / the mean 
magnitude of the response in naive mice. These data are representative of results obtained in 
three independent experiments.
LCMV-infection Primary response UCMV infection 
of PV-immune to LCM V in CD4- of CD4-depleted 
mice depleted mice mice with prior PV
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CD8 response was induced to a heterologous virus, but this was not 
enhanced when CD4 help was absent. One drawback to this experiment was 
that it has the same problem as that experienced earlier using LCMV infection, 
in that the virus inherently induces extensive APC activation. Had time 
permitted, this experiment could have been repeated using recombinant 
vaccinia viruses encoding the LCMV NP and GP sequences, to try and make 
the response more help-dependent.
4.8 Discussion
Evidence suggests that in primary HIV infection, there may be preferential 
expansion of CD8+ T cells to a limited number of immunodominant viral 
epitopes, especially in those patients who do not control early virus replication 
well. Pantaleo et al showed that there was a difference in the nature of the 
CD8 response expanded in different patients during acute HIV infection: 
monoclonal/oligoclonal TCR V/? family expansions were observed during 
acute infection in patients who subsequently controlled viral replication poorly, 
whereas polyclonal TCR V/? family expansions were observed in those who 
controlled virus replication well (Pantaleo et al., 1997b). There is also 
evidence to suggest that there may be differences in the breadth of the HIV- 
specific CD8+ T cell response expanded during acute infection in patients who 
control early viral replication with differing efficiency at the epitope level, with 
those exhibiting poor viral control mounting responses of limited epitope 
breadth compared to those with good viral control (Jones et al., 2004). In 
chapter 3, I also found that the primary HIV-specific CD8+ T cell response in 
patients with moderate-high persisting viral loads tended to be biased towards 
a limited number of highly immunodominant epitopes.
The work in this chapter focused on investigation of why the primary HIV- 
specific CD8+ T cell response in patients who establish moderate or high 
persisting viral loads may be so biased towards a limited number of 
immunodominant epitopes, exploring mechanisms that may potentially 
contribute to the preferential expansion of particular epitope-specific T cell 
responses.
As mentioned in section 4.1, a number of factors influence the epitopes 
against which CD8+ T cell responses are induced in different individuals and 
their hierarchy of immunodominance. These include different the HLA alleles 
an individual possesses (which in turn dictate the specific epitopes and
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diversity of those epitopes which are able to be presented to T cells), the 
efficiency of epitope processing and affinity of epitope binding to MHC, the 
number and stimulatory capacity of APCs and the repertoire of responding T 
cells.
The HLA alleles an individual possesses play a key role in dictating which 
peptides (and the total number of peptides) can potentially be presented to T 
cells. HLA alleles vary in the diversity of peptides they can present, e.g. HLA-B 
alleles bind a greater diversity of peptides than HLA-A alleles (Marsh et al., 
2000); and a recent study of CD8+ T cell responses in a cohort of HIV-infected 
individuals from southern Africa found that a greater number of responses 
were HLA-B restricted than HLA-A restricted (Kiepiela et al., 2004). The 
particular HLA alleles expressed by a given individual, and the extent of 
heterozygosity at HLA loci may thus be one of the factors that dictates the 
epitope breadth and relative immunodominance of responses within the 
primary HIV-specific CD8+ T cell response. Importantly, there is good evidence 
to show that the HLA type of an individual has an important impact on the 
outcome of HIV infection. Certain alleles are associated with good (HLA-B57 
(Gillespie et al., 2002; Goulder et al., 1996; Migueles et al., 2000; Tang et al., 
2002) and HLA-B27 (den Uyl et al., 2004; Goulder et al., 2001b; Goulder et 
al., 1997a; McNeil et al., 1996; O’Brien et al., 2001)) or poor (HLA-B35-02/03 
(Gao et al., 2001; Jin et al., 2002), HLA-B8 (Candore et al., 1998; Kaslow et 
al., 1990; McNeil et al., 1996)) ability to restrict viral replication and disease 
prognosis. Also, HLA heterozygosity in HIV-1 infected individuals is 
advantageous, with those heterozygous at HLA class I A, B and C loci having 
a better disease prognosis than those individuals who are homozygous for 
one or more loci, who progress to AIDS more rapidly (Carrington etal., 1999). 
There are a number of possible explanations for these associations. The 
‘good’ alleles for example may present immunodominant epitopes which are 
associated with responses of particularly high efficacy: the responses may 
target epitopes within proteins that are expressed early in the viral life cycle; or 
the responses involved may be those for which viral escape is restricted by 
high costs to viral fitness, as has been suggested in the case of HLA-B57- and 
HLA-B27-restricted epitopes (Goulder & Watkins, 2004). It is also possible that 
the T  cells involved in the response to certain peptide-HLA combinations may 
use ‘better’ TCRs, which recognise the epitopes with high avidity and/or have 
high functional flexibility.
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However these associations may also relate in part to the number of epitopes 
that the HLA alleles are able to present (Nelson et al., 1997). Broader HIV- 
specific responses have been shown to be induced in the context of the ’good’ 
alleles, with responses induced to more viral epitopes (perhaps more T cell 
clones are involved in the response to each epitope too). This evidence would 
fit with the idea that presentation of a large number of epitopes (as would be 
allowed for by HLA heterozygosity) is beneficial. Based on these observations, 
it is therefore possible that the biasing of the response towards a limited 
number of dominant epitopes in patients who established high persisting viral 
loads may be explained at least in part, by the influence of HLA type. It is 
notable that 5 out of the 13 patients in the cohort studied here expressed HLA- 
B8. Since the frequency of this allele reported in Caucasian populations is 
10% (HLA 1991), this allele is over-represented in this patient cohort, which 
may explain the association of this group with a bad prognosis overall.
However, HLA type is not the only factor which could influence the array of 
epitope peptides bound to MHC class I molecules on the surface of APCs and 
specificity of the CD8+ T cell response subsequently primed. The relative 
quantities that are produced of different viral proteins can affect the relative 
abundance of different peptide-MHC complexes, e.g. Tsomides et al found 
that the abundance of complexes of HLA-A2 with a Gag and a RT-derived 
epitope was -4 0 0  and -1 2  molecules per HIV-infected Jurkat-A2 cell 
respectively, an observation attributed to the relatively low levels of RT 
produced in HIV-infected cells (Tsomides et al., 1994). Host antigen 
processing pathways may also dictate whether particular epitope peptides are 
generated during an infection, e.g. in mice infected with AKV/MCF type murine 
leukaemia virus (MLV), an epitope in the p15E transmembrane viral envelope 
protein constitutes the immunodominant sequence recognised by virus- 
specific CTL; however the corresponding sequence in 
Friend/Moloney/Rauscher type MLV, which differs by just a single amino acid 
residue, does not induce a CTL response, because the amino acid difference 
causes epitope destruction by specific proteasomal cleavage (Ossendorp et 
al., 1996). In addition, the affinity of binding of epitope peptides to their 
restricting MHC alleles influences their presentation. Peptides that have a high 
MHC binding affinity are likely to compete efficiently with both other viral 
peptides and host peptides for presentation and be represented at relatively 
high levels on the host cell surface. Peptides with extremely high MHC binding
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affinities have been shown to block the expansion of T cell responses to other 
epitopes presented by the same MHC molecule both in vitro and in vivo (von 
Herrath e ta l., 1998).
In addition to the factors discussed above, which all affect the array of epitope 
peptides presented to CD8+ T cells, the epitope specificity and 
immunodominance hierarchy of a virus-specific CD8+ T cell response is also 
affected by the repertoire of host T  cells available to participate in the 
response. The host T cell repertoire is initially shaped by positive and negative 
selection in the thymus and is subsequently modified by selective forces in the 
periphery. Negative selection may result in no response (or only a weak 
response) being mounted to certain viral epitopes that resemble epitopes 
derived from self proteins, as demonstrated using transgenic models (von 
Herrath et al., 1994). The host T cell repertoire can be selected for during an 
infection, and then be further modulated as a result of encounter with the 
same or new pathogens (Lin et al., 2000). For example, acute LCMV infection 
elicits a virus-specific CD8+ T cell response which substantially alters the 
host’s T cell repertoire (Butz & Bevan, 1998; Murali-Krishna et al., 1998; Selin 
et al., 1999; Welsh et al., 1997); this repertoire is preserved into the memory 
state such that it remains skewed after the virus has been cleared (Murali- 
Krishna et al., 1998; Selin et al., 1999). Further selection of the memory T cell 
repertoire can occur upon secondary infection with a homologous virus. This 
may involve affinity maturation (Busch & Pamer, 1999; Busch et al., 1998) and 
changes in the diversity of the secondary T cell repertoire (Busch et al., 1998; 
Maryanski et al., 1996). The existing T cell repertoire can also be perturbed by 
encounter with heterologous viruses which can quantitatively reduce and 
qualitatively alter the CD8+ T cell memory to previously encountered 
pathogens. Loss of memory T cells specific for previously encountered 
pathogens may occur following subsequent viral infections due to competition 
for space in the memory pool to accommodate the entry of new T cell 
populations (Selin et al., 1996; Selin et al., 1999). Subsequent heterologous 
viral infections may also result in alteration of the hierarchy of a T cell 
repertoire, as both distantly related and unrelated viruses are able to 
reactivate virus-specific memory T cells through cross-reactivity, as shown by 
LCMV, PV, W  and MCMV infection of mice (Brehm et al., 2002; Selin et al.,
1996; Selin eta /., 1999).
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Because cells in the memory pool are present at higher frequencies and are 
also more readily triggered to expand on antigenic exposure, this allows them 
to mount accelerated responses to recognised/cross-recognised pathogens. 
This not only has a positive effect on the response to an epitope that is 
recognised/cross-recognised by cells in the memory pool but can also have a 
negative effect on responses to other viral epitopes, for example IFN-y 
produced by the rapidly responding cells can suppress expansion of 
responses of other specificities (Rodriguez et al., 2002).
The number and stimulatory capacity of the APCs present at the time a 
response is primed may also have an important impact on the breadth of 
epitopes to which responses are induced and their relative 
immunodominance. During primary HIV infection APC function may be 
impaired. Possible reasons for this may be direct or indirect effects of the virus 
on APC numbers or activity, or effects secondary to lack of CD4 help for the 
activation of APCs. This may result in defects in antigen capture, processing 
and presentation, and T cell activation (reviewed in (Lore & Larsson, 2003)). 
Under conditions where CD4+ T cell help and the number and/or functional 
capacity of APCs are limited the epitope and clonal breadth of the CD8+ T cell 
response induced may be restricted, with a tendency for responses that 
require the least help/co-stimulation to be particularly competitive and hence 
to be preferentially expanded. As discussed below, these may include 
responses to high affinity epitopes and/or responses involving high avidity T 
cell-APC interactions; and responses mediated by T cells in the memory pool. 
The first issue explored in this chapter was whether high avidity responses 
were particularly dominant during the primary HIV-specific CD8+ T cell 
response.
A study by Franco et al suggested that the binding affinity of a peptide epitope 
for its class I restriction element is a key factor in determining helper 
independence (Franco et al., 2000). Immunogens that bound MHC class I with 
high affinity were found not to require help for priming of antigen-specific CTL, 
but for those with intermediate MHC binding affinity a source of help (provided 
by either a class II MHC-restricted T helper cell epitope or administration of 
antibody to CD40) was required to obtain significant CTL priming. A possible 
explanation for this association is that the concentration of an epitope on the 
surface of an APC and/or length of time that the epitope is expressed above
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some threshold concentration (both of which may be increased if an epitope 
interacts with MHC with high affinity) may be critical factors in determining 
need for help. If a sufficiently strong and/or sustained antigenic signal is 
provided, then help may not be required. In addition to this, the TCR affinity for 
the peptide-MHC complex is likely to be important too.
I chose to measure the functional avidity of epitope-specific CD8+ T cell 
responses (as this would give insight into the combined effects of peptide 
affinity and TCR affinity), and to explore how this was related to their 
immunodominance in the primary HIV-specific CD8+ T cell response. For this 
analysis, both the functional avidity and the magnitude of epitope-specific 
CD8+ T cell responses should have been measured at timepoints in 
acute/subacute infection, and the relationship between functional avidity and 
relative immunodominance calculated from this data. However, due to 
limitations on sample availability, studies were instead carried out using cells 
cryopreserved at timepoints in early infection. Data presented in Jones et al 
(Jones et al., 2004) indicate that by early infection, the HIV-specific CD8+ T 
cell response typically becomes less biased towards the epitopes that were 
highly immunodominant in acute/subacute infection, with subdominant 
responses becoming more apparent, but that dominant responses are still 
observed to those epitopes that stimulated the strongest responses in acute 
infection. Analysis of the functional avidity of responses that were dominant at 
this time should thus provide a reasonable picture of those responses that 
were immunodominant in acute/subacute infection.
Efforts were made to measure the functional avidity of epitope-specific 
responses (defined as the concentration of peptide required to stimulate half a 
maximal response when titrated concentrations of epitope peptide were used 
to stimulate patient PBMC in IFN-y ELISPOT assays) using cells 
cryopreserved as early as possible in infection (preferably at the same 
timepoints at which the relative magnitude of different epitope-specific 
responses was analysed in chapter 3). However in some cases it was 
necessary to use cells from slightly later timepoints for this analysis. As 
different clones of T cells may be used in an epitope-specific response over 
the course of infection, there is potential for the avidity of the response to 
change (how the avidity of a T cell response may alter during the course of 
infection is explored in chapter 5), and so measurements of functional avidity 
made at a later timepoint may not reflect that at earlier timepoints.
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Despite drawbacks to this analysis, this analysis revealed there was a trend 
towards an association between the functional avidity and relative dominance 
of epitope-specific responses in early HIV infection, with the more dominant T 
cell responses tending to display higher functional avidities than less dominant 
responses. Also, when the functional avidities of the dominant responses in 
patients who subsequently established different persisting viral loads were 
compared, the responses of the highest viral load group appeared to display 
the highest functional avidities (although this part of the analysis was limited 
by the small number of patients studied). It would also have been of greater 
interest to address the functional avidity of dominant CD8+ T cell responses in 
patients who established very low persisting viral loads (in whom help/APC 
activation may be best preserved), but unfortunately no such patients were 
available for study. These results suggest that in this cohort of HIV-infected 
individuals there is a relationship (although not absolute) between 
immunodominance and avidity; and more importantly provide suggestive 
evidence for dominant responses being of particularly high functional avidity in 
patients who established high persisting viral loads (where APC functions may 
be most compromised). Interestingly, Cao et al (Cao et al., 2003) did not 
observe a relationship between the avidity of epitope-specific responses and 
the overall frequency of the cells recognising the epitope in patients studied 
during primary HIV-1 infection. The reason(s) for this are not clear, but could 
relate to the fact that this study addressed the relationship between the avidity 
and the absolute magnitude (rather than the relative dominance) of responses, 
and as different subjects were studied during acute, subacute or early 
infection (a time-frame over which response dynamics alter rapidly), no overall 
relationship between response magnitude and functional avidity was apparent. 
Is there a relationship between immunodominance and functional avidity in 
CD8+ T cell responses to other viruses? Results from analysis of the antiviral 
CTL response elicited in BALB/c mice following i.n. infection with Simian Virus 
5 (SV5) suggested that there is not a positive correlation between avidity and 
immunodominance in this system. Analysis of the SV5-specific CTL response 
identified an immunodominant response to be directed against an epitope 
within the M protein and subdominant responses to be directed against 
epitopes in the P, F and HN proteins of the virus (Gray et al., 2001a). The 
avidities of these responses were subsequently assessed using a modified 
ELISPOT assay to measure the contribution made by low avidity CTL to each 
protein-specific response. The determination of the relative proportion of high
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and low avidity CTL 6 days after immunisation revealed that while the 
immunodominant M protein-specific response and subdominant F- and HN- 
protein specific responses were comprised of both high and low avidity CTL, 
the subdominant response directed against the epitope present in the P 
protein was exclusively high avidity. From these results, it was hypothesised 
that the size of an immunodominant response could be due in part to 
activation of lower-avidity precursors in addition to higher avidity precursors. 
By contrast, the size of a subdominant response could be the result of 
elicitation of only a subset of CTL which possess a restricted avidity. The 
method used for analysis of the avidity of HIV-specific responses studied here 
did not allow for the differentiation of high and low avidity T cells within 
individual immunodominant and subdominant responses.
By contrast, investigation of T cell responses made to a panel of minor 
histocompatibility antigens in a murine model showed functional avidity to 
partially reflect the hierarchy of the response (Yoshimura et al., 2004), and 
assessment of LCMV-specific responses also provide some support for a 
relationship between the avidity of a response and its relative dominance. As 
can be seen form the data summarised in Table 4.1, the NP396-specific 
epitope elicits the highest magnitude response in LCMV-infected C57BL/6 
mice, and this is also the highest avidity response too, being able to sensitise 
target cells for CTL lysis at very low peptide concentrations.
In summary, this part of the study provided some support for there being 
preferential expansion of responses of high functional avidity during the 
primary HIV-specific CD8+ T  cell response, but did not provide definitive 
evidence to indicate that this was particularly favoured in the context of limited 
help/APC activation. This was addressed more directly in mouse models.
The CD8+ T cell response made to LCMV in H-2b mice was studied initially as 
viral epitopes recognised in this mouse strain are well characterised (Gairin et 
al., 1995; Klavinskis et al., 1990; Oldstone et al., 1988; Schulz et al., 1989; 
van der Most et al., 1998) and the immunodominance hierarchy of the 
response has been addressed in previous studies (Murali-Krishna et al., 1998; 
van der Most et al., 2003; van der Most et al., 1998). Help for the priming of 
the LCMV-specific CD8 response was removed by administration of a CD4+ 
cell depleting antibody (or in later experiments using IA k/o mice) and the 
response made to LCMV in CD4 cell deficient mice vs. control mice was 
assessed by looking at the relative hierarchy of responses made to epitope
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peptides in an IFN-y ELISPOT assay. Results from this experiment showed 
that the LCMV-specific CD8+ T cell response induced in CD4-depleted mice 
was of slightly lower magnitude than that induced in control mice, but the 
hierarchy of immunodominance of responses to individual viral epitopes was 
not markedly altered.
Interestingly, the hierarchy of responses observed in control mice was not in 
agreement with other published studies. First I found that the response to the 
GP33 epitope was of higher magnitude than that to the NP396 epitope. The 
data in the literature regarding the relative immunodominance of responses to 
the NP396 and GP33 epitopes is controversial, with some studies reporting 
that NP396 is more dominant than GP33 (Murali-Krishna et al., 1998; Wherry 
et al., 2003a), and others finding that the opposite is true (Gallimore et al., 
1998). In the IFN-y ELISPOT assays I carried out, it was always seen that 
GP33 elicited a higher magnitude response than NP396. However, when 
tetramers were used to read out the response to both Derestricted epitopes, 
the NP396 response was more dominant (data not shown). This discrepancy 
may be due to some of the cells responding to the high affinity NP396 epitope 
being ‘exhausted’ and being unable to make IFN-y in the ELISPOT assay -  
the response to this epitope (but not the GP33 epitope) exhausts readily 
following high dose LCMV infection (Zajac et al., 1998). Alternatively it could 
be explained by the fact that the sequence of the Db restricted GP33-41 
epitope partially overlaps with another epitope, GP34-41, which is presented 
in the context of Kb. Therefore functional analysis of GP33-41 specific cells is 
complicated by the simultaneous presentation of the GP34-41 peptide 
accounting for a proportion of the IFN-y response seen to be elicited by the 
GP33-41 peptide. Tetramer staining only detects cells in a MHC-restricted 
manner, so a Db tetramer would only specifically detect the Db-restricted 
GP33-specific cells. I also observed a larger response to the NP205 epitope 
than would be expected on the basis of published data. In early experiments I 
carried out (data from which is not shown) the response to NP205 was in 
agreement with the published hierarchy, with it being a minor epitope inducing 
a response somewhere between the level induced by GP276 and GP92. 
However, in later assays using the same peptides, the NP205 response 
emerged as a more dominant response. Whether this had something to do 
with the peptide being chemically unstable, giving rise to an atypical response, 
is not clear.
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Another aspect of the CD8 response primed in the absence of CD4 help which 
was explored was the clonality of the epitope-specific response. No major 
differences, such as a more restricted TCR V/? family usage, were observed in 
the utilisation of various TCR V£ families by LCMV-specific cells in CD4- 
depleted and control mice.
One drawback of using the LCMV infection model to explore the effect of lack 
of CD4+ T cell help at the time of priming on the hierarchy of the CD8 
response induced is that a robust primary CD8+ T cell response can still be 
induced to this virus in the absence of help, as observed here and in previous 
studies (Christensen eta l., 1994; Leist et a/., 1987; Moskophidis etal., 1987b; 
Rahemtulla et al., 1991). There is controversy in the literature over the 
requirement for CD4 help for priming of CD8+ T cell responses. Some studies 
suggest that it is not needed (Aichele et al., 1990; Buller et al., 1987; Janssen 
et al., 2003), whilst other suggest that it is required. The requirement for CD4+ 
T cell help for primary CD8 expansion can be demonstrated most clearly in 
situations where there is no ‘adjuvant’ effect present, for example in the 
response to the H-Y antigen (Millrain et al., 2001) or cross-priming of 
responses to protein antigens (Bennett et al., 1997). In the ’help-independent’ 
systems, a weight of evidence suggests that the APC activation necessary to 
see expansion of naive CD8+ T cells is substituted for by signalling through 
pattern recognition receptors responsive to pathogen components (e.g. TLRs), 
and innate/inflammatory cytokines (Hertz et al., 2001; Janeway & Medzhitov, 
2002; Le Bon et al., 2003). Hence in an infection such as LCMV where there is 
a high level of virus replication in lymphoid tissues and a strong innate 
cytokine response, the primary CD8+ T cell response is expanded almost as 
well in the absence of help as in its presence. Weaker responses are seen 
when there is less APC activation by viruses. In studies using two subtypes of 
influenza virus that differed in their requirement for CD4 help for the CD8 
responses they elicited, it was found that the H2N2 subtype (help- 
independent) induced co-stimulatory activity on APCs, but that the H1N1 
subtype (help-dependent) did not (Wu & Liu, 1994). Co-stimulation provided 
by APCs infected with H2N2, but not H1N1, were able to induce the efficient 
clonal expansion and functional maturation of CD8+ T cells.
In order to overcome the problem of the CD4-independence of the LCMV- 
specific CD8 response, I also carried out experiments to look at the effects of 
CD4 help on the hierarchy of the LCMV-specific CD8 response induced using 
recombinant vaccinia viruses expressing LCMV epitopes, as it was thought
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this infection may induce less co-stimulation. Results obtained using this 
system did provide some evidence to support the hypothesis that the CD8+ T 
cell response to the high affinity NP396 epitope was slightly favoured in the 
absence of CD4 T  cell help, although this was not statistically significant. 
However it was notable that here, as in LCMV infection, lack of CD4+ T cell 
help caused only a small reduction in the overall magnitude of the virus- 
specific CD8+ T cell response, suggesting that here too, sufficient APC 
activation was occurring to support near-optimal CD8+ T cell expansion. 
Another system used was influenza virus infection of mice, as it was predicted 
the CD8+ T cell response to influenza virus inoculated i.p. would possibly be 
more help-dependent. This was also another model for which a number of H- 
2b-restricted epitopes have been well characterised. However, the information 
regarding the MHC binding affinities of the influenza peptides in the literature 
was incomplete, so this was determined experimentally. There were 
discrepancies between the results of all studies addressing this, both those in 
the literature and the results obtained here. This could be due in part to 
differences in the assays used to measure peptide binding affinities. Two 
types of assay are traditionally used: stabilisation assays (described in section 
4.3) and competition assays. In competition assays, increasing concentrations 
of a competitor test peptide are added to cells which have been radiolabelled 
with a probe and the concentration of the competitor required to yield 50% 
inhibition of the binding of the radiolabelled probe is used as a measure of its 
affinity. Although the two assays give different measures of affinity, a series of 
peptides tested using both methods should give similar results in terms of the 
hierarchy the peptides are placed in. However, differences are also apparent 
between results obtained using the same assay (as can be seen from 
comparison of the measurements of LCMV peptide MHC binding affinities 
made by different groups shown in Table 4.1). The reasons for this variation 
are unclear; discrepancies may potentially relate to differences in the quality of 
the peptides used in different studies.
Other, more novel methods which provide a more direct measurement of 
peptide binding to MHC, such as an ELISA method, could potentially have 
been used to try and obtain a more reliable picture of the MHC binding 
affinities of the influenza (and LCMV) peptides. In this type of assay, 
recombinant MHC class I heavy chain molecules are diluted in a buffer 
containing /?2m end the appropriate peptide, and peptide-MHC complexes fold 
in a peptide-dependent manner. The complexes can be captured on a plate
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coated with a conformation-dependent antibody and subsequently detected by 
a quantitative ELISA assay. How many complexes are generated can be 
plotted as a function of how much peptide is offered from the results of the 
ELISA, and the affinity of the peptide-MHC interaction thereby determined 
(Sylvester-Hvid et al., 2002).
When the response to influenza was measured in IA k/o mice, there was 
evidence to suggest that the response to this virus was slightly more help- 
dependent compared to that to LCMV or W -LC M V . When the total 
magnitudes of responses to all epitopes were compared for the control and 
CD4-deficient mice, that to LCMV was reduced by 19% in the CD4-deficient 
mice, that to W -L C M V  by 18%, and that to influenza by 34%. However 
despite this, no evidence was obtained to suggest that there was marked 
expansion of responses to the highest affinity epitopes when help was limited 
at the time of induction of the CD8+ T cell response. These findings are in 
agreement with the results of a study by Chen et al (Chen et al., 2002) who 
examined the influence of CD4 help on the immunodominance hierarchy in 
C57BL/6 mice infected i.p. with influenza PR8 virus by using mice with 
targeted deletions of CD4 or the l-Ab 0  chain. It was found that absence of 
CD4 help resulted in a decrease in the number of responding splenic CD8+ T 
cells but had little effect on the immunodominance hierarchy of the response.
In summary, in none of the viral infections used was any strong evidence seen 
for there being a preferential expansion of responses to high affinity epitopes 
or of high avidity responses when CD4 cells were absent. A trend was 
observed towards lower magnitude responses being made in the absence of 
CD4 help, but the overall immunodominance hierarchies of epitope-specific 
CD8 responses were not greatly affected by absence of CD4 cells. It would 
have been interesting, had time permitted, to repeat the epitope hierarchy 
experiments using mice that may better mimic the defects in APC 
numbers/function thought to be present in acute/early HIV-1 infection.
One study has suggested that during primary HIV-1 infection, DCs expressing 
low levels of co-stimulatory molecules accumulate in lymph nodes (Lore et al., 
2002). Reports in the literature suggest that absence of CD28-mediated co­
stimulation does not affect the hierarchy of epitope immunodominance of 
virus-specific CD8+ T  cell responses in mice. For example, Christensen et al 
found that when the LCMV-specific response to the two immunodominant 
epitopes was compared in experiments using CD28 mice, there was no 
evidence for enhanced biasing of the response to the high affinity NP396
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epitope in the absence of CD28 signalling (Christensen et al., 2002). Likewise, 
Chen et al who addressed the role co-stimulation plays in establishing epitope 
immunodominance hierarchies in mice infected with influenza virus found that 
when B7-mediated signalling was interrupted, epitope-specific CD8+ T cells 
retained their relative positions in the hierarchy (although it positively 
influenced the activation of naive virus-specific CD8 cells of all epitope 
specificities) (Chen et al., 2002). Interestingly however, other studies have 
indicated that in the absence of CD28 co-stimulation, CD8 responses were 
exclusively directed at immunodominant tumour peptides, whereas CD8 
responses against subdominant epitopes only occurred when CD28 co­
stimulation was present (Johnston et al., 1996). Hence in the virus infection 
models, infection-associated innate activation may be able to substitute for 
engineered defects in co-stimulation. Importantly however, during primary 
HIV-1 infection there are likely to be multiple concurrent immunological 
abnormalities, in both APC numbers and functional capacity and the 
availability of CD4 T  cell help. Under these conditions, infection-associated 
APC activation may be insufficient to ‘rescue’ adequate APC functions. 
Experiments could potentially be done in murine models to limit APC number 
and/or function more dramatically (using for example combinations of 
antibodies to block multiple pathways of help/co-stimulation, chimeric mice 
deficient in APC subsets, or chronic LCMV infection which reduces APC 
function) and the effects on the nature of the CD8 response induced following 
virus infection under these conditions addressed.
Not only can CD4+ T cells play a role in the primary expansion of CD8+ T cells 
and their differentiation into cytotoxic effector cells, but it has also been shown 
that secondary CTL expansion is completely dependent on the presence of 
helper T cells during, but not after, priming (Janssen et al., 2003; Shedlock & 
Shen, 2003; Sun & Bevan, 2003). In a virus infection, CD4 cells may thus be 
more important for secondary rather than primary CTL expansion, or in the 
context of a chronic viral infection such as HIV, for maintaining CD8 T cell 
responses. This has been demonstrated in LCMV (Matloubian et al., 1994) 
and MHV-68 infection (Cardin et al., 1996) in mice. In chronic LCMV infection 
of CD4-depleted mice, the response does not get biased towards NP396 
because these cells are deleted by exhaustion (Zajac et al., 1998). A changing 
pattern of epitope dominance has been observed during acute and persistent 
murine herpes virus (MHV)-68 infection in intact mice, which is thought to
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relate to differential expression of lytic/latent viral proteins during different 
phases of the infection (Stevenson et al., 1999); but MHV-68 infection (which 
unlike LCMV, is a lytic virus) of l-Ab-/- mice eventually results in death as a 
consequence of continuing, low-level infection (Cardin et al., 1996) (thought to 
be due to the absence of IFN-y producing CD4+ effector cells which mediate 
direct control of the infection (Christensen et al., 1999)). These models thus do 
not provide full insight into how the CD8 T  cell repertoire may evolve over time 
in the absence of CD4 T cell help. During chronic HIV infection limited 
availability of CD4 help may perhaps lead to biasing of responses to high 
avidity responses over time. This is addressed in chapter 5. Here, the focus 
was on what may be happening in primary HIV infection, when CD8+ T cell 
responses were expanded initially.
Another possibility as to why certain responses might be preferentially able to 
expand under conditions where APC functions and/or CD4 help are 
suboptimal (in addition to the idea that they may be specific for epitopes with 
high affinity for MHC restriction elements or particularly high avidity 
responses) is if they are mediated by memory cells. Memory T cells possess a 
number of properties which enable them to respond early upon secondary 
encounter with a pathogen and be protective. They persist at relatively high 
frequencies, express high levels of adhesion molecules and, being 
constitutively at a higher state of activation, are easier to stimulate than naive 
cells and can also be triggered by relatively low affinity interactions through 
their TCRs (Lau et al., 1994; Pihlgren et al., 1996; Razvi et al., 1995; Selin & 
Welsh, 1997; Selin et al., 1996; Sprent & Tough, 1996; Tabi et al., 1988; 
Tough & Sprent, 1994; Tough et al., 1996). When a CD8 response is induced 
to HIV, pre-existing memory cells may be present that were raised to some 
previous infection, and are able to cross recognise an HIV epitope. These 
memory cells may have the capacity to expand more rapidly than naive cells, 
and this may be accentuated when there is a lack of CD4 help.
One question I addressed, using murine models, was whether as predicted, 
memory CD8+ T cells are less dependent on CD4 help for their expansion than 
naive CD8+ T cells. An experiment was carried out to look at the help- 
dependency of the secondary response of female mice to the male H-Y 
antigen, the primary OD8 response to which is known to be dependent on 
CD4 help (Simpson & Gordon, 1977). The response made to male
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splenocytes was assessed in appropriate groups of CD4-depleted mice which 
had or had not been previously primed (the initial prime occurring in the 
presence of CD4 help). Tetramer staining of cells revealed that an average of 
5.7% of CD8+ cells were H-Y-specific in the pre-primed mice boosted in the 
absence of CD4 help, whereas the memory level of H-Y-specific cells in 
unboosted mice was only 2.1%. Expansion of H-Y-specific cells memory cells 
thus did occur, supporting the idea that expansion of a memory H-Y response 
can occur independently of help, unlike priming of naive cells to make a H-Y 
response.
However, this experiment was not ideal in that the antibody-mediated removal 
of CD4+ cells was not as efficient as was hoped for, and some help was likely 
present for the expansion of the secondary response. To ensure the total 
absence of help, an experiment involving the adoptive transfer of pre-sorted 
tetramer positive memory cells into IA k/o mice and following their expansion 
upon secondary activation would have been required. Use of IA k/o mice 
would have also addressed the potential problem that the primed H-Y-specific 
CD4 cells may have be harder to deplete than the general CD4+ T cell pool 
due to an altered activation state or in vivo location.
As briefly reviewed earlier in the discussion, previous studies in murine 
models have demonstrated that there can be cross-reactivity in CD8 
responses between distantly related viruses (e.g. LCMV and Pichinde virus) or 
even unrelated viruses (e.g. LCMV and vaccinia virus) (Yang & Welsh, 1986; 
Yang et al., 1989). It has also been shown that if there are cross-reactive 
CD8+ T cells in the memory pool, these are preferentially expanded in the 
immune response to the second virus (Selin et al., 1994), and this can confer 
cross protection too (Chen et al., 2001; Selin et al., 1998). For example, a 
study by Brehm et al (Brehm et al., 2002) using PV and LCMV infection of 
C57BL/6 mice showed that previous infection with either virus provided partial 
protection against infection with the other virus, and that this protection was 
mediated by the presence of cross-reactive CD8+ T cells in the memory pool. 
Furthermore, it was also shown that in the CD8 T cell response elicited by 
LCMV infection in PV-immune mice, there was a reduced frequency of cells 
responding to normally immunodominant epitopes and expansion of cross- 
reactive NP205-specific T cells (which are normally subdominant), i.e. the 
hierarchy of the LCMV-specific response differed from that normally seen in 
C57BL/6 mice. Selective expansion of cross-reactive memory cells thus can
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occur during an antiviral immune response, and impact on the hierarchy of 
epitope immunodominance.
In this study, I addressed the question, if help was limiting during the induction 
of a CD8 response, do cross-reactive memory responses expand to become 
even more immunodominant than when help is present? To study the effects 
of the presence of a pre-existing pool of memory cells on an antiviral response 
induced under conditions where CD4 help was limited, PV immune mice were 
CD4 depleted and then infected with LCMV. I found that the response to the 
NP205 epitope was enhanced in LCMV-infected mice with prior immunity to 
PV compared to naive LCMV-infected mice, confirming that this was a cross­
reactive epitope; but did not observe this effect to be accentuated even more 
when the response to the second virus was induced in the absence of CD4 
help. However given the lack of help-dependency of the LCMV-specific 
response, as discussed earlier, this result is perhaps not surprising. A similar 
experiment using recombinant vaccinia viruses encoding LCMV structural 
genes may experience the same problem, and so future experiments to re­
address this question in a situation where the number of activated APCs is 
limited (approaches to achieving which were discussed above) may be of 
more value.
Cross-recognition of epitopes from different viruses by human CD8+ T cells 
has also been reported. For example, an immunodominant HLA-A2 restricted 
epitope in HCV shares 7 out of 9 amino acids with an immunodominant 
influenza epitope (Wedemeyer et al., 2001), and T cells have shown to cross- 
react with the two epitopes. Another example of this is the cross-reactivity 
found between EBV and influenza (Welsh et al., 2004). Cross-reactive T cells 
specific for the main HLA-A2 restricted immunodominant peptide of EBV and 
main HLA-A2 restricted immunodominant peptide of influenza have been 
described, even though the peptides have only three amino acids in common. 
How a host responds to an infectious agent could therefore be influenced by 
its history of previous infections and their influence on the memory T cell pool. 
Is it possible that a history of influenza infection might confer a level of 
resistance to HCV? Does a strong presence of influenza-induced M1-specific 
cells in the memory T  cell pool influence the outcome of EBV infection?
I looked for evidence for responses that were preferentially expanded in a 
primary HIV-specific immune response representing cross-recognition of HIV 
epitopes by pre-existing memory cells induced to another pathogen. In patient
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WEAU, a potential epitope which may have primed the immunodominant HLA- 
B44-restricted HIV-specific AENLWVTVY(Y) response observed in primary 
infection in this individual (Borrow et al., 1997) was identified in EBV. This 
epitope (EENLLDFVRF) was also HLA-B44*03-restricted and shared several 
amino acids with the HIV epitope, with chemically similar residues at other 
positions. However when tested, this epitope was found not to be recognised 
by PBMCs from WEAU. As this approach to studying a potentially cross­
reactive response was not optimal (had they been available, cells 
cryopreserved from the subject prior to HIV infection should have been tested 
for reactivity to the EBV and HIV epitopes), a HIV seronegative donor known 
to respond to the EBV epitope was also studied, to see if this response could 
cross-recognise the HIV epitope. However, no recognition of the HIV epitope 
was detected in this subject.
As I did not find evidence for cross-reactivity between the EBV EENLLDFVRF 
response and the HIV AENLW VTVY(Y) response, a search was made for 
other epitope-specific responses that could have initially primed the response. 
Viral sequences from viruses which people are commonly infected with, that 
bore resemblance to the immunodominant HIV epitope AENLWVTVY(Y) were 
tested for recognition by PBMCs from WEAU in an IFN-y ELISPOT assay. 
However, none of the candidate cross-reactive peptides were recognised by 
patient PBMCs.
A similar approach was adopted to find a viral sequence which might have 
primed the immunodominant HIV-specific response in patient BORI. Despite 
the initial finding of two sequences in HSV-2 that were recognised by BORI, 
follow-up studies revealed that it was likely that the cross-recognition was 
happening the other way around, with the HIV-specific cells weakly 
recognising the HSV-2 sequences at high peptide concentrations, suggesting 
that the HSV-2-specific response did not prime the HIV-specific response. 
Another possibility of an example of a cross-recognised peptide came from 
HIV- and EBV-specific responses studied in patient SC1. This patient was 
found to have a CD8 response to several known EBV epitopes, including the 
HLA-B8 EBV epitope RAKFKQLL. It was noticeable that when the relative 
magnitude of the response to this epitope peptide was measured at two 
timepoints in acute and then in later infection using IFN-y ELISPOT assays, 
the magnitude of the response to the EBV peptide was higher at the later 
timepoint (data not shown), indicative of expansion of epitope-specific cells as
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the HIV-specific CD8 T  cell response was induced. There are a number of 
potential explanations for this finding, but one possibility is that this response 
was expanded due to cross-recognition of a HIV peptide. Notably, patient SC1 
made an immunodominant response to the HLA-B8-restricted HIV epitope 
FLKEKGGL in primary infection, which shares significant sequence homology 
with the EBV RAKFKQLL peptide (although when a model was generated to 
show how they would both look when bound to the HLA-B8 molecule, they did 
not look very similar). Unfortunately time did not permit cross-reactivity 
between these epitopes to be explored.
In summary, I was not able to find evidence for CD8+ T cell responses that are 
expanded rapidly to high levels in acute HIV infection representing expansion 
of pre-existing memory responses to other pathogens. However, given the 
vast number of pathogens an individual may encounter during their lifetime, is 
perhaps not surprising how difficult it is to identify cross-recognised epitopes.
I also tried to look for cross-recognition of HIV epitopes in HIV seronegative 
individuals. In an attempt to examine this, cells from ten HIV-seronegative 
subjects were screened for reactivity to overlapping peptides corresponding to 
the HIV-1 clade B Gag consensus sequence, but no evidence of cross­
recognition of HIV Gag peptides was found. This study would need to be 
extended to a greater number of subjects, looking at a greater proportion of 
the proteome to give a better idea of the frequency of occurrence of HIV 
cross-reactivity in HIV seronegative subjects.
There are however, reports in the literature which do support that cross­
recognition of HIV in HIV seronegative donors can occur. CD4+ T cell 
responses to peptides corresponding to the HIV Gag p24 region have been 
demonstrated in HIV seronegative individuals, suggesting that the responses 
were due to the priming of such subjects with cross-reactive antigens 
(Vyakarnam et al., 1991). In addition, the existence of cross-reactivity between 
HLA-A2 restricted influenza M1:58-66 and HIV-1 p17 Gag:77-85 epitopes was 
demonstrated following in vitro stimulation of PBMC from HIV seropositive or 
seronegative HLA-A2 donors (Acierno et al., 2003). Together with the finding 
that in vitro stimulation of PBMC from a seronegative donor with the influenza 
and Gag peptides resulted in expansion of identical T cell clonotypes, this 
suggested that immunity to the matrix protein of influenza virus may drive a 
specific immune response to an HLA-A2 restricted HIV Gag epitope in HIV- 
infected and influenza-immune individuals.
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It would be thought that having pre-existing memory cells present would be of 
value in defence against a pathogen (after all, protection can be conferred by 
vaccination strategies that elicit virus-specific CD8 T cell responses (Amara et 
al., 2001; Barouch et al., 2000; Rose et al., 2001; Shiver et al., 2002)). 
However if, in a situation where APC activation and/or help is deficient, it 
results in the expansion of a response of extremely limited specificity, it may in 
fact perhaps be disadvantageous. A highly focused response may be rapidly 
escaped (Borrow et al., 1997; Jones et al., 2004). It may also be more likely to 
be exhausted (Pantaleo et al., 1997a). Substantial distortion of the T cell 
repertoire by monoclonal/oligoclonal T cell expansions during primary HIV 
infection was observed in patients who went on to establish high but not low 
persisting viral loads (Pantaleo et al., 1997b). However it is not clear whether 
these distortions occurred as a consequence of events in acute infection (e.g. 
high level initial viral replication and associated defects in APC function) 
and/or played a causative role in determining the persisting viral load 
established in these individuals.
In summary, in this chapter, mechanisms to account for the rapid initial 
expansion of small numbers of highly immunodominant responses during 
primary HIV infection were explored. It was hypothesised that when CD4 help 
and numbers of fully activated APCs are limiting, there may be an initial 
expansion of T cell responses that are less dependent on help/co-stimulation, 
followed by a slower expansion of additional responses. I addressed the ideas 
that these responses may include high avidity responses and/or responses 
mediated by HIV-cross-reactive T cells in the memory pool. While further work 
remains to be done to provide clear-cut answers as to the validity of these two 
hypotheses, it is possible that both events are occurring.
Expansion of limited numbers of high avidity T cell responses may give rise to 
the oligoclonal expansions of the T cell V£ repertoire observed in many HIV- 
infected patients by Pantaleo et al (Pantaleo et al., 1997b). In those patients 
who have memory T  cells that can cross-recognise HIV epitopes, there may 
be a strong mono-specific response superimposed on this, giving rise to the 
huge expansion of T  cells in a single V0 family observed by Pantaleo et al in 
-10%  of patients during acute infection.
As emphasised in the introduction to this chapter, the current picture of 
expansion of the HIV-specific CD8+ T cell responses in primary infection is 
very incomplete. Studies described in the following chapter aimed to give
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more insight into the magnitude/kinetics of expansion of different epitope- 
specific components of the primary HIV-specific CD8+T cell response, and the 
phenotype of the responding cells.
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Chapter 5
Characterisation of epitope-specific CD8+ T cell responses 
in primary HIV-1 infection
5.1 Introduction
During acute viral infections, high levels of viraemia are generally associated 
with the expansion of virus-specific CD8+ T cells. Precise quantitation of the 
dynamics of CTL responses in viral infections has been largely restricted to 
studies in mouse models such as infection with LCMV. During LCMV infection, 
the virus-specific CD8+ T  cell response peaks just after the peak of viral 
replication, at around day 8 post-infection, with virus-specific CD8+ T cells 
comprising >50%  of all splenic CD8+ T cells at this time (Murali-Krishna et a/., 
1998), then declines as the viral load falls. Studies of the dynamics of the 
virus-specific CD8+ T cell response during primary HIV infection have been 
much more limited. These have indicated that HIV-specific CD8+ T cell 
responses are expanded as the acute burst of viral replication occurs (Borrow 
et al., 1994; Koup et a/., 1994), and can potentially reach very high 
magnitudes (Borrow et al., 1997; Pantaleo et al., 1994); however the dynamics 
of expansion of epitope-specific components of the response have not been 
well characterised. Limited analysis of the dynamics of responses to just one 
or two viral epitopes in one-three patients has been reported (Appay, 2002; 
Wilson et al., 2000), but in some cases, the T cell response was quantified at 
timepoints when the subject was receiving antiretroviral therapy, which likely 
influenced the picture obtained. Furthermore, multiple epitope-specific 
responses were not studied, and it was not known whether the responses 
which were tracked were the initial and/or most dominant responses within the 
patient’s entire primary HIV-specific response. Therefore many questions 
remain unanswered about the primary HIV-specific CD8+ T cell response. For 
example, it is unclear how large the total HIV-specific CD8+ T cell response 
expanded is; and what the kinetics are with which initial epitope-specific 
response(s) expand and decline, or how they relate to the kinetics of the acute 
burst of viral replication.
In chapter 3, I used IFN-y ELISPOT assays to assess the ‘entire’ HIV-specific 
CD8+ T cell response during early infection in a number of individuals. 
Although ELISPOT assays allow for easy and rapid identification of 
responses, they have limitations, for example they are not very quantitative. 
However the identification of optimal HIV CD8+ epitopes and their restricting
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HLA alleles in chapter 3 allowed for the use of peptide-MHC tetramers for 
more in-depth analysis of individual epitope-specific responses. Tetramers 
have the advantage of being able to detect all T cells specific for an epitope, 
regardless of function, and therefore magnitudes of responses can be 
determined more accurately using this technique. In this chapter, I used 
tetramers specific for different epitopes within a patient’s response to address 
the kinetics of expansion of T cells of different specificities, by staining cells 
cryopreserved over a series of timepoints during acute and early infection and 
determining the size of the tetramer-positive population at each timepoint. 
Another aspect of the HIV-specific CD8+ T cell response which was explored 
in chapter 3 was the repertoire of T cells used within an individual response. In 
chapter 3, this was determined using cells from a single timepoint. How the 
repertoire of T cells used in an epitope-specific response might alter 
throughout the course of infection (for example, do changes in the T cell 
repertoire reflect affinity maturation of the epitope-specific T cell response?) is 
another question of interest. Therefore, in this chapter, as an extension to the 
kinetic analysis of individual epitope-specific responses, the Vp family usage 
by T cells responding to an individual epitope at different timepoints was also 
determined.
By co-staining tetramer-positive cells with antibodies to other surface and 
intracellular molecules, phenotypic characterisation of HIV-specific cells can 
be performed. There have been many phenotypic studies of HIV-specific CD8+ 
T cells, which have been carried out to address qualitative aspects of the 
response and whether these may be related to its ability to control viral 
replication. It has been suggested that a high proportion of the HIV-specific 
CD8+ T cells present in chronically-infected patients may not be fully 
functional. Many of these cells are reported to have an ‘immature’ phenotype 
(CCR7' CD27+ CD45RA ) suggestive of incomplete maturation (Appay et al., 
2000; Champagne et al., 2001), to contain low levels of perforin, and to exhibit 
low ex vivo IL-2 production and proliferative capacity (Appay et al., 2000; 
Appay et al., 2002; Champagne et al., 2001; Migueles et al., 2002; van Baarle 
et al., 2002a). Furthermore, some (Goepfert et al., 2000; Kostense et al., 
2001; Shankar et al., 2000) but not other studies (Goulder et al., 2000) have 
found deficits in the ability of HIV-specific CD8+ T cells to produce antiviral 
cytokines. These studies have been largely limited to chronically-infected 
patients, so it is not clear whether dysfunctional HIV-specific cells are also 
present in acute infection (although the expression of CD27 on a large
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proportion of HIV-specific CD8+ T cells has also been found to be a feature of 
primary infection (Appay, 2002; Papagno et al., 2004)).
In this chapter the maturation state of the T cells responding to different viral 
epitopes during acute and early HIV infection was examined, by analysing the 
phenotype (expression of CCR7, CD27, CD28 and CD45RA) of tetramer- 
positive cells, to reveal whether defects in the maturation state of HIV-specific 
cells are present from primary infection, and/or whether these defects are 
acquired over time. Other markers of interest were also examined to obtain 
information about the replicative capacity of the cells and their ability to 
respond to stimulatory cytokines. T cells responding to different 
(immunodominant and subdominant) viral epitopes were studied, to determine 
whether they had similar phenotypic characteristics; further, this type of 
analysis was carried out on cells from patients who established different 
persisting viral loads to determine whether there were any qualitative 
differences in the CD8+ T cell response in patients who control viral replication 
with differing efficiency.
The overall aim of the work in this chapter thus was to further characterise the 
HIV-specific CD 8+ T cell response during primary infection with the use of 
tetramers, to build upon the initial observations about the response made in 
the previous chapters.
5.2 Analysis o f  the m agnitude and kinetics o f expansion o f CD8* T cells 
responding to different H IV  epitopes during prim ary infection.
Early reports revealed that HIV-specific CD8+ T cell responses can be induced 
very early on in infection (Borrow et al., 1994; Koup et al., 1994; Pantaleo et 
al., 1994). However the techniques used in these studies did not allow for 
accurate quantitation of the expansion and contraction of epitope-specific 
responses. The later availability of tetramers has allowed for more accurate 
assessment of the kinetics of HIV epitope-specific responses, but only limited 
studies have been carried out using this technology (Appay, 2002; Wilson et 
al., 2000), and thus many questions remain unanswered. For example, it has 
yet to be established whether the T cells responding to different epitopes 
expand with similar kinetics, or whether some responses evolve more slowly 
than others. To address this question, PBMCs from different HIV-infected 
individuals cryopreserved at sequential timepoints during acute and early 
infection were stained using MHC-peptide tetrameric (or pentameric) 
complexes to determine the magnitude of epitope-specific CD8 T cell
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responses at each timepoint and reveal the dynamics of expansion and 
decline of responses to different viral epitopes.
The epitope-specific responses to be studied in this way were chosen on the 
basis of results obtained in chapter 3. Patients were selected in whom two or 
three dominant and subdominant responses had been identified to epitopes 
that it was possible to obtain tetramers/pentamers for. I also tried to include 
patients who established different persisting viral loads, so that it would be 
possible to determine whether there were any differences in the rate of 
expansion of responses in patients who controlled early viral replication with 
differing efficiency.
Altogether, responses were studied in one patient who established a high 
persisting viral load (MM25), three who established intermediate-high 
persisting viral loads (MM12, MM27 and MM14) and two patients who 
established low-intermediate persisting viral loads (MM13 and MM28). It 
should be noted that the epitope-specific responses studied in each patient did 
not represent the total HIV-specific response of that patient, only selected 
epitope-specific responses for which tetramers could be obtained.
PBMC cryopreserved at sequential timepoints during acute and early infection 
were co-stained with the appropriate tetramer or pentamer, an anti-CD3 
antibody and an anti-CD8 antibody, and the frequency of CD8+ T cells specific 
for the epitope determined by flow cytometry by calculating the percentage of 
CD8+ tetramer+ cells when acquired events were gated on the CD3+ CD8+ 
lymphocyte population. Representative dot plots from one such timecourse of 
staining are shown in Figure 5.1, where the frequency of CD8+ T cells specific 
for the A3 RLRPGGKKK epitope was determined in samples cryopreserved 
from patient MM25 at sequential timepoints from acute/subacute infection until 
the time when the viral setpoint was established. The proportion of CD8+ cells 
that were tetramer+ was high (3.3%) at the first timepoint investigated (17 
DFOSx) and increased to a peak of 6.2% at 31 DFOSx. Thereafter, the 
response declined in magnitude, but there was still a sizeable proportion of 
cells stained by this tetramer at the latest timepoint studied (2.1% at 185 
DFOSx). This example illustrates that the magnitude of an individual HIV- 
specific response can be quite large at its peak — over 6% of CD8 cells in the 
case of this response. Given that this is not the only epitope that was 
recognised in patient M M 25’s early HIV-specific response (it can be seen in 
Figure 5.2a that during early infection there were strong responses to three 
additional epitopes, plus a number of more minor responses), the total
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of infection in patient MM25. PBMC cryopreserved from patient MM25 at sequential timepoints during the course of 
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Figure 5.2. Analysis of the magnitude and kinetics of expansion of HIV-specific CD8+ T cell 
responses within HIV-infected individuals who established different persisting viral loads.
Long peptides corresponding to HIV epitopic regions shown to be recognised by the early HIV- 
specific CD8+ T cell response of selected patients, and the magnitude of the response they elicited 
in an IFN-y ELISPOT assay (determined as described in Figures 3.11-3.13) are shown in the upper 
half of part of the figure. HIV epitopes were predicted within the selected long peptides circled in the 
bar chart and CD8+ T cell responses targeting predicted epitopes were further characterised. 
PBMCs cryopreserved from seven HIV seroconvertors at sequential timepoints over the course of 
primary HIV infection were co-stained with antibodies to CD3, CD8 and MHC class I tetramers or 
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tetramer/pentamer at each timepoint is plotted alongside viral load data to illustrate the expansion 
of each response relative to the viral load for (a) MM25, a patient who established a high persisting 
viral load, (b) MM12, MM27 and MM14, patients who established intermediate-high persisting viral 
loads, (c) MM13 and MM28, patients who established low-intermediate persisting viral loads, and 
(d) SUMA, a patient who established a low persisting viral load. N.B. HIV epitopes were identified 
using a different approach for patient SUMA compared to that used for other patients, and so 
comparable data about the entire early response is not available. The data in part (d) of this figure 
were generated by Dr N. A. Jones.
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magnitude of the primary HIV-specific CD8+ T cell response is potentially very 
high.
Other tetramers were used in a similar manner to analyse the magnitude of 
epitope-specific responses over time in this and other patients. The results 
obtained are shown in Figure 5.2.
In addition to the RLRPGGKKK-specific response mounted by MM25 in early 
infection, the B7-restricted epitope RPQVPLRPMTY was also targeted. The 
responses to the long peptides containing these epitopes as measured by 
IFN-y ELISPOT assay were both relatively strong within this patient’s early 
response. In Figure 5.2a, the magnitude of the response made to these two 
epitopes over a series of timepoints, as revealed by tetramer staining, has 
been plotted. It can be seen that the T cells specific for the two epitopes 
expanded simultaneously, rising up to a peak of around 6-8% of CD8+ cells at 
31 DFOSx and then declining to an almost steady level by 66 DFOSx. As the 
viral load was >107 RNA copies/ml at 7 DFOSx, it is likely that this was (or was 
close to) the timepoint at which the acute burst of viral replication reached its 
peak. If the peak of viraemia is taken as being at 7 DFOSx (the timepoint at 
which the highest viral load was recorded) the two responses studied reached 
their peak magnitude between one and three weeks following the peak in viral 
load (the possibility that the responses peaked between 17 and 31 DFOSx 
cannot be excluded as there were no samples available for testing between 
these two timepoints).
The evolution of four responses was followed in patient MM12 (Figure 5.2bi); 
these exhibited a somewhat different pattern of expansion than that of the 
responses studied in patient MM25 (although this may be simply be due to a 
more limited number of responses being studied in patient MM25). The 
epitopes to which responses were studied were located within three long 
peptides used for mapping the early response, as one of the long peptides 
was found to contain two epitopes restricted by different HLA alleles. It can be 
seen that the most dominant response in early infection was made to the A3- 
restricted epitope QIYAGIKVK, with a relatively strong response also being 
made to the long peptide containing the A3 QVPLRPMTYK and B7 
RPQVPLRLMTY epitopes (although the relative dominance of responses 
made to the two individual epitopes is unknown). B7 IPRRIRQGL represents a 
subdominant epitope within this patient’s early HIV-specific response. Unlike 
the two responses studied in patient MM25, the four responses studied in 
MM12 did not expand in parallel, but rather at different rates, with two faster
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and two slower evolving responses. This patient’s peak viral load probably 
occurred at around 7 DFOSx. The first of the four responses studied to 
expand was the A3 QIYAGIKVK-specific response, which was in fact the most 
dominant of the responses detected in this patient in early infection. T cells 
targeting this epitope were detected at 16 DFOSx, just over a week after the 
highest recorded viral load, and the response peaked at around 40 DFOSx, at 
around 3% of CD8+ cells. A lower magnitude response was raised against the 
A3 QVPLRPMTYK epitope. This response expanded with similar kinetics to 
the A3 QIYAGIKVK epitope. The two other responses studied were slower to 
emerge, and were only detected as the other two faster evolving responses 
were declining, after 75 DFOSx. The B7 IPRRIRQGL-specific response 
peaked at 104 DFOSx, while at 139 DFOSx, the B7 RPQVPLRLMTY-specific 
response was the slowest of the four responses studied to peak.
Responses were detected to only three long peptides in patient MM27 in early 
infection (Figure 5.2bii), and tetramers corresponding to epitopes in all three 
long peptides were obtained. It was not possible to precisely relate the kinetics 
of T cell expansion in this patient to the kinetics of acute viral replication, as 
the first timepoint at which the viral load was measured in this patient was 
likely well after the peak in viraemia. Nonetheless, the three responses all 
expanded with delayed kinetics, not reaching their peak levels until 81 DFOSx. 
However, it was feasible that there could have been response(s) that emerged 
earlier that were not identified in the mapping of this patient’s early response. 
It is interesting that the relative magnitude of the responses to the three 
epitopes as measured by tetramer staining does not reflect the relative 
magnitude of the responses to the long epitope-containing peptides measured 
by IFN-y ELISPOT assay at 53 DFOSx. Notably, the response to the long 
peptide containing the A2 YTAFTIPSI epitope appeared most dominant in the 
ELISPOT assay, whereas the tetramer recognising T cells responsive to this 
epitope bound a lower number of CD8+ T cells than the A3 RLRPGGKKK 
tetramer. This might be explained by the tetramer not corresponding to the 
optimal epitope within the most dominant long peptide. Two variants of the 
same epitope were possible, one a 10 amino acid seguence, and the other a 9 
amino acid sequence. When peptides corresponding to the two possible 
epitopes were tested by IFN-y ELISPOT, the response detected to the 10mer 
was of slightly higher magnitude than that to the 9mer. However, due to 
technical reasons, it was only possible to have the tetramer synthesised using 
the 9mer sequence, which might have influenced the relative magnitude of
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response detected using this tetramer. Another possible explanation for why 
the dominance of the long peptide containing the A2 YTAFTIPSI epitope in the 
ELISPOT assay was not reflected by observations made by use of an A2 
YTAFTIPSI tetramer, was that the dominant long peptide may have contained 
an additional epitope that was not identified.
The B8 FLKEKGGL-specific response represented one subdominant 
component within patient MM14’s early HIV-specific CD8+ response (Figure 
5.2biii). It was not possible to obtain tetramers suitable for following the other 
epitope-specific responses mapped in this patient. It was not quite so clear in 
this case as to when the epitope-specific T cell response peaked relative to 
the peak in viral load as it was hard to establish when the peak in viral 
replication occurred. The highest recorded viral load was at 40 DFOSx; but it 
seems likely (based on observations made in other patients) that the peak in 
viral load was reached considerably before this, with the fall and then apparent 
rise in viral load between 11 and 40 DFOSx representing fluctuations in 
viraemia as viral replication was being contained. Figure 5.2biii shows that T 
cells specific for FLKEKGGL were detected from the earliest timepoint tested 
(32 DFOSx), and reached an initial maximum frequency by 47 DFOSx. This 
frequency was maintained (or slightly increased) at the last timepoint tested 
(111 DFOSx).
Tetramers were obtained to enable one dominant (B8 FLKEKGGL) and two 
subdominant (A1 GSEELRSLY and B57 KAFSPEVIPMF) epitope-specific 
responses to be tracked in patient MM13. It can be seen from the viral load 
data plotted in Figure 5.2ci that this patient was likely enrolled onto the study 
after the peak in primary viraemia had already occurred, as the highest 
recorded viral load was only 131 800 RNA copies/ml, whereas peak viraemia 
is typically 106-108 RNA copies/ml. T cells specific for all four epitopes were 
detected from the first timepoint where cells were available for study (16 
DFOSx), but the responses subsequently evolved in different ways. The 
dominant FLKEKGGL-specific response was already at its highest recorded 
magnitude at the first timepoint tested, suggesting that this response emerged 
very rapidly. The response quickly declined, and the magnitude of the 
response at the next timepoint (24 DFOSx) was only half of what it was at 16 
DFOSx. Although the general trend was that of a decline from 16 DFOSx 
onwards, there was an increase in the magnitude of the response between 31 
and 98 DFOSx, which interestingly paralleled the fluctuation of the viral load at 
this time, suggesting that viral rebound might have led to the expansion of this
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immunodominant response once more. By contrast to the dominant response, 
responses to the subdominant epitopes were much slower to reach their peak. 
The response to the GSEELRSLY epitope peaked at 98 DFOSx, whilst that to 
KAFSPEVIPMF was still rising at the last timepoint studied (unrelated studies 
done using cells from later timepoints revealed that the response may have 
peaked as late as 1125 DFOSx).
A 11 tetramers were obtained containing two different sequences 
(VPLRPMTYK and AAVDLSHFLK) which could both represent epitopes within 
the same long peptide (RPQVPLPMTYKAAVDLSHF), to which a dominant 
response was observed in patient MM28 in early infection (Figure 5.2cii). This 
patient’s peak viral load probably occurred at (or prior to) 6 DFOSx; responses 
to the two tetramers emerged soon after this, although they expanded at 
slightly different rates. The smaller of the two responses (AAVDLSHFLK) 
peaked at 20 DFOSx, approximately two weeks following the peak in viral load 
(although the low magnitude of the response to this epitope at all timepoints 
perhaps makes it difficult to be certain about this). The peak of the larger of 
the two responses (VPLRPMTYK) (around 3% of CD8+ cells) was recorded at 
34 DFOSx, approximately four weeks after the viral load likely peaked.
One limitation of the London cohort was that there were no patients available 
who established low persisting viral loads. However there was one such 
patient (patient SUMA) from another patient cohort. Epitope-specific 
responses in patient SUMA had been followed by tetramer staining throughout 
the course of acute and early infection by Dr N. A. Jones (unpublished data) -  
the results of this analysis are shown in Figure 5.2d, and are included in all 
subsequent analyses (where data from multiple patients are combined) so that 
the analysis includes patients who established persisting viral loads falling into 
all four viral load quartiles.
The primary HIV-specific CD8+ T cell response mounted by patient SUMA was 
directed against >40 epitopes, with the most dominant response being that to 
the B15-restricted M TYKGLGISY epitope, and other responses bring of lower 
magnitude and more co-dominant. Four epitope-specific responses were 
followed in patient SUMA: the dominant B15 MTYKGLGISY-specific response, 
and three less dominant responses, B14 ERYLKDQQL, A11 AFDLSHFLKand 
A24 FYCNTTQLF. In Figure 5.2d it can be seen that the response detected to 
B15 M TYKGLGISY by tetramer staining was of considerable magnitude, with 
>20% of CD8 cells being specific for this epitope at the peak of the response. 
Furthermore, the MTYKGLGISY-specific response expanded with extremely
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rapid kinetics, the highest recorded magnitude response occurred very early 
(between 0 and 7 days) after the highest recorded viral load (recorded at 8 
DFSOx). A sizeable response was also detected towards B14 ERYLKDQQL, 
and this response was also one which was quick to expand, reaching > 5% of 
CD8 T cells at 15 DFOSx. The two other epitope-specific responses followed 
(A11 AFDLSHFLK and A24 FYCNTTQLF) were of lower magnitude (<1 % of 
the CD8 T cells at all timepoints studied) and expanded with slower kinetics 
relative to the two more dominant epitope-specific responses. The highest 
magnitude responses to these epitopes were recorded at 69 and 41 DFOSx 
respectively, but it is possible that these responses may have continued to 
rise, as timepoints beyond 69 DFOSx were not tested using these particular 
tetramers.
Considering all epitope-specific responses studied in all patients, the highest 
peak response observed to a single viral epitope was almost 22% of CD8+ 
cells (the MTYKGLGISY-specific response in patient SUMA); other responses 
generally peaked at 7% or less of CD8+ T cells. The minimal size of individual 
responses was around the level of detection of this technique, at 0.01% of 
CD8+ cells. When the magnitude of the individual responses studied within 
each patient were combined, the highest total HIV-specific CD8 response was 
that seen in patient SUMA, with 26.7% of CD8 cells being directed towards 
just two epitopes. The next largest combined response was that observed in 
patient MM25 in whom 13.5% of CD8 cells were directed towards two 
epitopes. These values provide an underestimate of the magnitude of the 
entire HIV-specific CD8+ T cell response in the individuals concerned, as each 
also mounted responses to additional epitopes that were not included in the 
analysis. It would be unfair to comment on minimal size total responses as in 
some patients, responses to only a limited number of epitopes were studied, 
and these did not constitute the most dominant components of the patient’s 
primary HIV-specific response.
The kinetics of expansion of different epitope-specific responses was quite 
variable, as can be seen when all responses are plotted together on a graph 
of the magnitude of the response against the time from the estimated peak 
viral load (defined as the day at which the highest viral load was recorded, or 
was estimated to have occurred in those patients where it was likely that the 
peak in viraemia had been missed) (Figure 5.3). The time at which the peak in 
the epitope-specific response occurred relative to the estimated peak in viral 
load varied between 0 and 189 days. However, of the 19 responses studied,
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Figure 5.3. Variation in the kinetics of expansion of epitope-specific CD8+ T cell responses in HIV-infected patients. PBMC 
cryopreserved over the course of acute, early (and later) infection from patients SUMA, MM28, MM13, MM14, MM27, MM12 and MM25 
were stained with tetramers/pentamers corresponding to HIV epitopes identified to be recognised by the early HIV-specific CD8+ T cell 
response of the patient (as indicated in the key), and antibodies specific for CD3 and CD8. The percentage of CD8+ tetramer+ cells at 
each timepoint was determined by flow cytometry and is plotted above against the time from the estimated peak viral load that the cells 
were cryopreserved. Different responses are color-coded in the graph to indicate the persisting viral load established by the patient in 
which the response was followed (as indicated in the key).
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only 2 (both in patient SUMA) peaked within a week of the estimated peak in 
viral load, the remainder took a minimum of 14 days to reach their peak. 
Almost half of the responses studied reached their maximum recorded level 
within 33 days after the estimated peak in viral load.
Considering the expansion of responses to different epitopes within individual 
patients, responses generally expanded asynchronously, with some faster and 
some slower evolving responses within each patient. This was the case for 4 
of the 6 patients in which more than one epitope-specific response was 
studied. However in two cases, responses expanded in parallel (in patient 
MM25 the maximum recorded magnitude of the two epitope-specific 
responses studied occurred 24 days after the estimated peak in viral load; in 
patient MM27, three responses peaked after 72 days). However, this analysis 
is complicated by the fact that it is not certain that all responses in early 
infection were followed for all patients, so there may have been other 
responses not studied in these two patients that expanded asynchronously 
relative to the others.
One question of interest is whether a relationship exists between the kinetics 
of expansion of a response and its magnitude, for example, do larger 
responses peak earlier? To address this question, for all epitope-specific 
responses followed in all patients studied, the DFOSx at which the highest 
magnitude response was recorded was plotted against the highest recorded 
magnitude of the response (Figure 5.4). Combining the data from all epitopic 
responses revealed that there was an inverse correlation between the 
magnitude and kinetics of responses; this relationship was found to be 
statistically significant using Pearson’s correlation test (p=0.04).
A further question of interest is whether responses in patients who control viral 
replication with differing efficiency differ in terms of magnitude and kinetics of 
expansion. With respect to the magnitude of responses, similar to results 
obtained in chapter 3 using IFN-y ELISPOT assays to assess responses, it 
was found that the magnitude of HIV-specific CD8 responses can be large in 
patients who control early viral replication with efficiencies at both ends of the 
spectrum; high magnitude responses were observed in both patient SUMA 
and patient MM25, who controlled early viral replication well and poorly 
respectively. W hat is interesting is the kinetics with which responses were 
expanded in patient SUMA compared to the other patients studied: the most 
dominant response in patient SUMA reached its highest recorded value 
rapidly relative to the estimated peak in viral load (between 0 and 7 days); and
317
25
0(/>co
Q .(/)
20
15-o t^ a)
■E |cn co ro
E 2  
■a +
^  §  10
o O
0  <5
w0
_CO)
p=0.04
40 80 12020 60 100 160
DFOSx when the highest magnitude response was recorded
Figure 5.4. Relationship between the kinetics and magnitude of HIV epitope-specific CD8* T cell responses. The
kinetics of expansion and magnitudes of epitope-specific responses in seven HIV-infected subjects were determined using 
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line has been fitted through the data points and the p value shown (as calculated by Pearson’s correlation test) indicates that 
there is a significant correlation between the two variables.
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another sizeable response reached its highest level between 0 and 14 days 
after the highest recorded viral load. In all other patients, responses were 
slower to evolve, and at least a 14 day period was observed between the 
estimated peak viral load and highest recorded magnitude of the epitope- 
specific response. It would have been of great interest to have extended this 
analysis to further patients who controlled viral replication efficiently, to 
determine whether rapid expansion kinetics are a common feature of the 
primary HIV-specific CD8+ T cell response in such individuals.
In summary, tetramer analysis of epitope-specific responses in seven infected 
individuals revealed that very high magnitude responses can be induced in 
primary infection, and that there are heterogeneous patterns in the dynamics 
of expansion of different responses both within and between different patients. 
A negative correlation was found between the magnitude and kinetics of 
expansion of the responses that were able to be studied, with faster evolving 
responses being of greater magnitude. A patient who controlled viral 
replication very efficiently was found to mount a high magnitude HIV-specific 
CD8 response extremely quickly.
5.3 Analysis o f changes in the clonal composition o f H IV  epitope-specific 
responses over the course o f infection
In section 3.7, the clonal composition of different HIV epitope-specific 
responses was explored. V/? family usage by epitope-specific cells was 
assessed at a timepoint corresponding to the peak of each response, to 
compare the breadth of clonal usage in patients who established different 
persisting viral loads. However it was also of interest to investigate whether 
changes in the clonal composition of cells involved in the response to a given 
epitope occurred over time. To explore this, V/? family usage by epitope- 
specific T cells in four patients was assessed at sequential timepoints. The 
four patients chosen for study established persisting viral loads in the four 
different viral load quartiles. PBMC cryopreserved at sequential timepoints 
during evolution of the response were co-stained with the relevant MHC 
peptide tetramer and antibodies specific for CD3, CD8 and one of a panel of 
antibodies specific for different TCR V0 families, and the percentages of 
tetramer-stained cells using each V£ family was determined by flow cytometry. 
(Figures 5.5-5.8). The timepoints analysed were selected on the basis of 
results from section 5.2 and were chosen so that the tetramer-positive 
population of cells was large enough for study (preferably >1% of CD8+ T
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Figure 5.5. Analysis of changes in the clonal breadth of a HIV epitope-specific response over time in a patient who 
established a high persisting viral load. The Vp families used by the T cell receptors of cells responding to the HIV 
epitope RLRPGGKKK were determined at several timepoints during infection in patient MM25. The magnitude and kinetics 
of expansion of the RLRPGGKKK-specific response is shown in the line graph accompanying the bar chart, with the 
timepoints when analysis of Vy? usage was carried out being indicated by circles. Cryopreserved PBMC were co-stained with 
a RLRPGGKKK tetramer, antibodies against CD3 and CD8 and an antibody specific to one of 22 different TCR V/? families 
(or an isotype control antibody). The percentage of tetramer-positive cells using each V/? family at each timepoint was 
determined by flow cytometry and is shown in the bar charts. V/? antibody staining of <1% of tetramer-positive cells was 
regarded as background and is therefore not shown. The percentage of the entire tetramer-positive population detected by 
staining using the V/? family antibodies that were available at each timepoint is indicated in brackets in the key.
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Figure 5.6. Analysis of changes in the clonal breadth of HIV epitope-specific responses over time in a patient who 
established an intermediate to high persisting viral load. The V/? families used by the T cell receptors of cells responding to 
the HIV epitopes QIYAGIKVK and IPRRIRQGL were determined at several timepoints during infection in patient MM12. The 
magnitude and kinetics of expansion of each epitope-specific response is shown in the line graph accompanying each bar chart, 
with the timepoints when analysis of \l/3 usage was carried out being indicated by circles. Cryopreserved PBMC were co-stained 
with an appropriate MHC class I tetramer, antibodies against CD3 and CD8 and an antibody specific to one of 22 different TCR 
V/? families (or an isotype control antibody). The percentage of tetramer-positive cells using each V/? family at each timepoint was 
determined by flow cytometry and is shown in the bar charts. V/? antibody staining of <1% of tetramer-positive cells was regarded 
as background and is therefore not shown. The percentage of the entire tetramer-positive population detected by staining using 
the V/? family antibodies that were available at each timepoint is indicated in brackets in the key.
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Figure 5.7. Analysis of changes in the clonal breadth of HIV epitope-specific responses over time in a patient who 
established an intermediate to low persisting viral load. The V/? families used by the T cell receptors of cells responding to the 
HIV epitopes FLKEKGGL and KAFSPEVIPMF were determined at several timepoints during infection in patient MM13. The 
magnitude and kinetics of expansion of each epitope-specific response is shown in the line graph accompanying each bar chart, with 
the timepoints when analysis of V/? usage was carried out being indicated by circles. Cryopreserved PBMC were co-stained with an 
appropriate MHC class I tetramer, antibodies against CD3 and CD8 and an antibody specific to one of 22 different TCR V/? families 
(or an isotype control antibody). The percentage of tetramer-positive cells using each V/? family at each timepoint was determined by 
flow cytometry and is shown in the bar charts. V/? antibody staining of <1% of tetramer-positive cells was regarded as background 
and is therefore not shown. The percentage of the entire tetramer-positive population detected by staining using the V/? family 
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Figure 5.8. Analysis of changes in the clonal breadth of HIV epitope-specific responses over time in a patient who 
established a low persisting viral load. The V/? families used by the T cell receptors of cells responding to the HIV epitopes 
MTYKGLGISY and ERYLKDQQL were determined at several timepoints during infection in patient SUMA. The magnitude and 
kinetics of expansion of each epitope-specific response is shown in the line graph accompanying each bar chart, with the 
timepoints when analysis of V/? usage was carried out being indicated by circles. Cryopreserved PBMC were co-stained with an 
appropriate MHC class I tetramer, antibodies against CD3 and CD8 and an antibody specific to one of 22 different TCR V/? 
families (or an isotype control antibody). The percentage of tetramer-positive cells using each V/? family at each timepoint was 
determined by flow cytometry and is shown in the bar charts. V/? antibody staining of <1% of tetramer-positive cells was regarded 
as background and is therefore not shown. The percentage of the entire tetramer-positive population detected by staining using 
the V/? family antibodies that were available at each timepoint is indicated in brackets in the key.
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cells), and where possible, corresponded to when the response was 
expanding, at the peak, in decline plus late into infection.
The A3 RLRPGGKKK-specific response was studied in patient MM25 (Figure 
5.5). This was one of this patient’s dominant responses during early infection, 
and expanded relatively rapidly following the peak in viral load. The clonal 
composition of T cells targeting this epitope was analysed at four timepoints: 
17 DFOSx as the response was expanding, 31 DFOSx at the peak of the 
response, 66 DFOSx as the response was coming down, and at 185 DFSOx 
(a later timepoint). At 17 DFOSx, only a quarter of the response was detected 
using the available V/? family antibodies. The epitope-specific cells detected 
used V/?s 1, 2 and 23 -  it is likely that remaining cells also used a limited 
repertoire of V/?s, with the bulk of the epitope-specific T cells potentially using 
TCRs from just one or two unidentified families. By as early as 31 DFOSx, a 
marked change was observed in V/? family use by epitope-specific T cells, with 
almost 50% of cells now using TCRs in the V/?2 family. At later timepoints, 
there was an even greater bias towards V/?2 usage, with over 80% of cells 
using this family at 66 DFOSx. At 185 DFOSx, there was more involvement of 
other V/? families, but still a large proportion of the responding T cells utilised 
V£2.
The V/? family usage by T cells involved in the response to two epitopes was 
followed in patient MM12 (Figure 5.6): the dominant A3 QIYAGIKVK-specific 
response, which expanded rapidly, peaking at 40 DFOSx; and the 
subdominant B7 IPRRIRQGL-specific response, which was more delayed in 
its expansion, peaking at 104 DFOSx. The pattern of V/? family use by T cells 
responding to the two epitopes was revealed to be very different. A3 
QIYAGIKVK-specific cells used a broad spectrum of V/? families, with all 
except 2 of the 22 families being represented at one timepoint or another. This 
was quite unusual, as a broad usage of V/? families was not found to be 
common during primary infection. As with the RLRPGGKKK-specific response 
in MM25, there was increasing usage of V/?2 over time, although MM13’s 
QIYAGIKVK-specific response remained heterogeneous at all timepoints 
studied. However, once again, due to detection of only a proportion of epitope- 
specific T cells by the available TCR V/? family antibodies (particularly at 
earlier timepoints), it cannot be ruled out that there may have been a large 
expansion of cells using one particular family. By contrast, the response to the 
IPRRIRQGL epitope showed more restricted V/? family usage, with the 
majority of epitope-specific cells using TCRs in V/? families 6.7 and 13.6.
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Again here, TCR V/? family use was found to evolve over time, with the 
frequency of V/?6.7-utilising cells increasing between 139 and 230 DFOSx, 
and very different V/? families contributing to the response by 567 DFOSx.
An early (FLKEKGGEL) and a late response (KAFSPEVIPMF) were also 
studied in patient MM13 (Figure 5.7). The V/? usage of FLKEKGGL-specific 
cells was biased towards one family, V/?22. This was observed at each 
timepoint studied, from the peak of the response to late on during infection. 
Although the KAFSPEVIPMF-specific response was initially skewed towards 
the usage of one particular family (V/? 17), there was substantial involvement of 
other families at the earlier timepoints. However, as the total epitope-specific 
response increased in magnitude, there was increasing usage of V/?17, with 
over 90% of tetramer positive cells using this family by 1125 DFOSx. For this 
particular response, the patient therefore started off with a broader repertoire, 
which was narrowed down over time.
In patient SUMA, the dominant MTKGLGISY-specific response peaked a 
week prior to the less dominant ERYLKDQQL-specific response. Both 
responses were only studied at two timepoints due to sample shortage, one 
earlier and one later timepoint during the course of infection (Figure 5.8). Cells 
targeting the MTKGLGISY epitope utilised a number of V/? families, each 
family accounting for only a small proportion of cells at both timepoints, and no 
major changes were seen from one timepoint to the next. However, since 
under half of the total epitope-specific response was detected using the 
available V/? family antibodies at both timepoints, it cannot be ruled out the 
remainder of the undetected response may have been quite biased towards 
one particular V/? family. ERYLKDQQL-specific cells also used a substantial 
number of V/? families (9 out of 22) at an subacute/early timepoint (22 
DFOSx), with almost 30% using V/?2. However by 483 DFOSx, the relatively 
broad repertoire at an early timepoint (22 DFOSx) had now narrowed down to 
usage of only three families, with V/?2 remaining prominent. Again, however, 
the available panel of V/? family-specific antibodies did not stain all epitope- 
specific T cells, hence a substantial proportion of epitope-specific T cells may 
have utilised one or more unidentified V/? families.
In summary, the patterns of V/? family utilisation by TCRs of different epitope- 
specific cells were quite variable both within patients and between different 
patients. In some cases the initial responses were restricted, with bias towards 
utilisation of one particular V/? family, the degree of which may or may not 
have increased over time. In other cases heterogeneous responses initially
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observed, which either remained so at all timepoints studied, or became more 
restricted over time. However, as mentioned several times, these results 
should be interpreted with caution since, due to the failure to detect all cells 
specific for certain epitopes using the available panel of V/? family antibodies, 
important features of certain responses may have been missed.
5.4 Comparison of the relative avidity of HIV epitope-specific T cells at 
different stages of infection
Results from section 5.3 suggested that the repertoire of T cells involved in the 
response to certain epitopes evolved over time. In some cases there was 
evidence of selection for T cells using TCR(s) from a particular V/? family 
within the epitope-specific T cell population over time. This leads to the 
question of why such selective changes took place. One possibility is that as 
TCR use may affect the avidity of interaction between CD8+ T cells and the 
APC or target cell, and so T cells using particular TCRs may have come to 
dominate the epitope-specific T cell population over time because they 
interacted with epitope-bearing cells with high avidity. Other possible reasons 
as to why selection for certain T cells may have occurred over time are 
considered in the discussion. Here the temporal relationship between TCR V/? 
family usage and the avidity of the response was studied.
To address this, the relative avidities of the epitope-specific T cell populations 
present at early and late timepoints were compared to see if, coincident with 
the selection for epitope-specific cells bearing TCR(s) in a certain V/? family, 
there were changes in the avidity of the response and the T cells from the later 
timepoint were of higher avidity. Possible changes in the avidity of the T cell 
response were studied for two epitopes, one where epitope-specific cells 
exhibited stable V/? family use (FLKEKGGL-specific cells in MM13) (Figure 
5.9) and one where there was selection for preferential usage of one particular 
V/? family over time (RLRPGGKKK in MM25) (Figure 5.10). As described in 
section 4.2, the relative avidities of T cell responses were measured by 
determining the concentration of the epitope peptide required to stimulate half 
of the maximum response in an IFN-y ELISPOT assay.
The avidity of the T cell response to the FLKEKGGL epitope in patient MM13 
had already been determined using cells cryopreserved at a late timepoint 
(cells combined from 275 DFOSx and 353 DFOSx). T cells from this stage of 
infection required a peptide concentration of 10'7M to stimulate half of the 
maximum specific IFN-y response (Figure 4.3a). Here, the avidity of T cells
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Figure 5.9. Comparison of the relative avidity of the T cell response made to the B8 
FLKEKGGL epitope by patient MM13 at an early and a late timepoint during infection.
The response of PBMCs cryopreserved from patient MM13 at an early (cells combined from 
24 DFOSx and 45 DFOSx) and a late (cells combined from 275 DFOSx and 353 DFOSx) 
timepoint to a peptide corresponding to the FLKEKGGL epitope at a range of dilutions from 
10'5M to 10'12M, was determined by IFN-y ELISPOT assay. Results are expressed as 
specific SFC per 106 PBMC (i.e. after deduction of the background level of IFN-y 
production). The concentration of peptide required to stimulate half the maximum response 
(defined as that observed when cells were stimulated with peptide at 10'5M) was calculated 
as a measure of the relative avidity of the T cell response made to the epitope at each 
timepoint.
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Figure 5.10. Comparison of the relative avidity of the T cell response made to the A3 
RLRPGGKKK epitope by patient MM25 at an early and a late timepoint. The response 
of PBMCs cryopreserved from patient MM25 at an early (17 DFOSx) and a late (185 
DFOSx) timepoint to a peptide corresponding to the RLRPGGKKK epitope at a range of 
dilutions from 10'5M to 10'12M, was determined by IFN-k ELISPOT assay. Results are 
expressed as specific SFC per 106 PBMC (i.e. after deduction of the background level of 
IFN-y production). The concentration of peptide required to stimulate half the maximum 
response (defined as that observed when cells were stimulated with peptide at 10'5M) was 
calculated as a measure of the relative avidity of the T cell response made to the epitope at 
each timepoint.
2500
2000 i 
o *
2 m
1500 -
(O  .
<  >(■oT”
5a.
o
Li­en
1000 -
500 -
Peptide concentration (M)
331
targeting this epitope was also determined at an early timepoint (using cells 
combined from 24 DFOSx and 45 DFOSx). The peptide dose-response curves 
of cells at both stages of infection are shown in Figure 5.9. This illustrates that 
although the magnitude of the response at the earlier timepoint was more than 
twice that at the later timepoint, the peptide concentration required to stimulate 
half the maximum response was still 10'7M. Therefore for this epitope-specific 
response, there was no change in the avidity of the response with time.
The avidities of T cells responding to the RLRPGGKKK epitope in patient 
MM25 were also measured at earlier (17 DFOSx) and later (185 DFOSx) 
stages of infection. In Figure 5.10 it can be seen that a lower concentration of 
peptide was required to stimulate half of the maximum level of response when 
cells from the later timepoint were used in the assay compared to cells from 
the earlier timepoint. The relative avidity of the response was 10'7M at the 
earlier timepoint, and 10'9M at the later timepoint. This may have been due to 
selection of T cells with higher affinity TCR(s), which could in turn be related to 
the skewing of the T cell repertoire towards utilisation of one dominant V/? 
family (V/?2), as seen in Figure 5.5. Experiments that could have been carried 
out to address the relationship between TCR V/? family usage and the avidity 
of responses in more depth are considered in the discussion.
5.5 Phenotypic characterisation of HIV-specific CD8+ T cells
In addition to repertoire-related aspects of an epitope-specific CD8+ T cell 
response, the phenotype of the cells can also be studied using tetramers to 
find out more about the qualitative aspects of the response. It has been 
suggested that there may be defects in the maturation and/or functional 
properties of HIV-specific T cells (Appay et al., 2000; Appay et al., 2002; 
Champagne et al., 2001; Goepfert et al., 2000; Kostense et al., 2001; 
Petrovas et al., 2004; Shankar et al., 2000; van Baarle et al., 2002a), for 
despite the induction of high magnitude virus-specific CD8+ T cell responses 
during early HIV-1 infection, the virus is still able to replicate at high levels. In 
this section, the phenotype of epitope-specific T cells was studied over the 
course of infection to see if any defects in T cell maturation could be detected, 
and if so how early in infection they were acquired (other studies have 
predominantly focused upon chronic infection (Appay et al., 2000; Champagne 
et al., 2001; Goepfert et al., 2000; Kostense et al., 2001; Shankar et al., 
2000)). Patients representative of the four viral load quartiles were studied 
(MM25, MM12, MM13 and SUMA, representing patients who established high
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down to low persisting viral loads) to see if there were any differences in the 
phenotype of the HIV-specific T cells in these individuals (which could be 
either a consequence or a cause of the differing efficiency with which early 
viral replication was controlled). Where possible, the phenotypic analysis was 
carried out for T cells specific for both an immunodominant and a subdominant 
epitope within each patient’s early response to see if there were any 
qualitative differences in these quantitatively different responses. In patient 
MM25 the dominant RLRPGGKKK-specific response was monitored over 
time; in patient MM12, both early expanding dominant QIYAGIKVK-specific T 
cells and later emerging subdominant IPRRIRQGL-specific T cells were 
studied; in patient MM13, the early dominant response towards FLKEKGGL 
and the later response to KAFSPEVIPMF were both phenotypically 
characterised, and in patient SUMA, the dominant MTKGLGISY-specific 
response, and the somewhat less dominant ERYLKDQQL-specific response 
were followed.
5.5.1 Changes in differentiation status undergone by HIV-specific CD8+T cells 
over the course of infection
The expression of the markers CCR7, CD27, CD28 and CD45RA can be used 
to determine the differentiation/maturation status of CD8+ T cells (Beverley, 
1987; Hamann et al., 1997; Sallusto et al., 1999). Naive CD8+ T cells are 
characterised by a CCR7+ CD27+ CD28+ CD45RA* phenotype. Following 
antigenic stimulation, antigen-experienced cells mature into memory and 
effector T cells: the cells start to express the RO rather than the RA isoform of 
the CD45 molecule and sequentially down regulate CCR7, CD28 and CD27. 
Memory cells are often defined by the expression of the RO isoform of CD45, 
with the central memory subset expressing CCR7 and effector memory subset 
lacking CCR7 expression (Sallusto et al., 1999). Fully differentiated effector T 
cells are thought to have a CCR7' CD27" CD28' phenotype and may also re­
express CD45RA (Appay et al., 2002; Champagne et al., 2001; Dunne, 2002; 
Hamann, 1999; Wills, 2002). Studies of chronically-infected patients have 
suggested that HIV-specific CD8+ T cells may be unable to differentiate into 
fully mature effector cells, and are arrested at a pre-terminally differentiated 
stage of maturation where they are predominantly of the phenotype CCR7' 
CD27+ CD28' CD45RO+ (Appay et al., 2000; Champagne et al., 2001). To 
determine whether cells present in the acute phase of infection also possess 
this ‘immature’ phenotype, and if not, to assess the kinetics with which this
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phenotype may be acquired, the expression of CCR7, CD28, CD27 and 
CD45RA was characterised on tetramer-positive cells of different specificities 
during different phases of the expansion and decline of epitope-specific 
responses. PBMC cryopreserved at various timepoints throughout the course 
of infection were thawed and stained with a HIV tetramer (or pentamer), an 
anti-CD8 antibody and antibodies specific for CCR7, CD27, CD28 and 
CD45RA. The expression of these fluorescent markers on tetramer-labelled 
cells was then determined by four-colour flow cytometry. Since the use of four- 
colour flow cytometry enabled CD8+ tetramer-positive cells to be 
simultaneously stained with antibodies specific for two other markers, co- 
staining with combinations of antibodies of potential interest was carried out. 
Figure 5.11 shows the expression of CD45RA, CCR7, CD27 and CD28 on the 
total CD8 lymphocyte population and on the HIV QIYAGIKVK-specific CD8+ 
cells in patient MM13 at 40 DFOSx (the QIYAGIKVK-specific population 
representing 3-4% of the total CD8 population). CD45RA+ and CD45RA' 
populations of T cells are evident within the total CD8 pool, with the balance 
between the populations being heavily skewed towards CD45RA' cells. 
Notably, the majority of HIV tetramer+ cells are also CD45RA': the high 
percentage of HIV-specific CD8+ T cells present in the blood at this timepoint 
is thus likely responsible for biasing the composition of the total CD8 pool 
towards CD45RA' cells. Likewise there are also more CCR7' than CCR7+ cells 
in the total CD8 T cell pool, and the majority of HIV tetramer+ cells have a 
CCR7‘ phenotype. Both CD28+ and CD28' populations are evident within the 
total CD8 pool. The HIV tetramer+ cells also include both CD28+ and CD28' 
subsets, although a higher proportion of cells in the overall CD8+ T cell pool 
express CD28 than is observed in the HIV tetramer+ population. Only a low 
percentage of all CD8 T cells are CD27"; and the majority of HIV tetramer+ 
CD8+ T cells are also CD27+. The HIV-specific population contains fewer 
CD27‘ CD28' cells than the total CD8 population, which suggests that although 
this subject has a reasonable proportion of CD8+ cells with characteristics of 
more advanced stages of differentiation, their HIV-specific cells are not part of 
this subset of cells and do not have the phenotypic characteristics of fully 
differentiated effector cells. Of the CD45RA+ cells, similar proportions in the 
HIV-specific population and total CD8 population are also CD28', the 
phenotype associated with the CD45RA revertant population. Compared to 
the total CD8 population, the vast majority of HIV-specific cells are CCR7' 
C D 27\ consistent with them having seen antigen but being at a relatively early
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Figure 5.11. CD45RA, CCR7, CD28 and CD27 and expression on total 
CD8+ cells and HIV-specific CD8+ cells in patient MM12. Cells 
cryopreserved from patient MM 12 at 40 DFOSx were co-stained with an A3 
QIYAGIKVK tetramer and antibodies specific for CD8 and either CD45RA, 
CCR7, CD28 or CD27. Plots on the left are gated on the CD8+ lymphocyte 
population, and those on the right on the CD8+ tetramer+ population. In (A) 
the proportion of cells in the total CD8+ lymphocyte population or the CD8+ 
tetramer+ population expressing each of the markers (blue histograms) at 
levels above the background staining of cells incubated with appropriate 
isotype control antibodies (green histograms) is indicated in the M1 region of 
each plot. In (B) co-expression of CD27 and CD28, CD28 and CD45RA, and 
CCR7 and CD27 on the total CD8+ and HIV-specific CD8+ populations are 
shown, and the percentage of cells in each quadrant expressing the 
indicated combination of markers is given.
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stage of differentiation, whereas the total CD8 population is more 
heterogeneous in the expression of the two markers.
The expression of CD45RA, CCR7, CD27 and CD28 on CD8 cells specific for 
the A3 QIYAGIKVK epitope in patient MM12 at different stages of the 
evolution of the response (16 DFOSx and 23 DFOSx, two timepoints when the 
response was expanding; 40 DFOSx at the peak of the response; then 75 
DFOSx, 321 DFOSx and 742 DFOSx, as the response was declining) is 
shown in Figure 5.12. All histogram plots were gated on the CD8+ tetramer+ 
population of cells indicated and the percentage of CD8+ tetramer+ cells 
expressing each marker is given. The majority of tetramer-positive cells were 
CD45RA' during early infection, but at later timepoints (321 and 742 DFOSx), 
there was a proportion of cells which re-expressed this marker. CCR7 was not 
found to be expressed on tetramer-positive cells at any timepoint (not shown). 
CD27 was expressed by over 90% of tetramer-positive cells at the timepoints 
when the response expanded and peaked; thereafter, the percentage of 
CD27+ tetramer positive cells was slightly lower, although CD27 expression 
was still found to be expressed on greater than 80% of tetramer-positive cells 
even at late timepoints. CD28 was expressed by a moderate percentage of 
the tetramer-positive population at the first timepoint analysed (26.7% at 16 
DFOSx), but this percentage became gradually smaller over time, with 15% of 
tetramer-positive cells expressing CD28 by 742 DFOSx. Overall, from the 
earliest timepoint, the cells showed characteristics of having seen antigen 
(CCR7' CD45RA') and pre-terminal differentiation (retaining CD27 and to a 
lesser extent, CD28 expression). A proportion of cells at the later timepoints 
had some characteristics of late differentiated cells (re-expression of 
CD45RA).
The expression of these markers of cellular differentiation was determined in a 
similar manner over time for HIV-specific cells targeting other epitopes in other 
patients. The results of this analysis are summarised in Table 5.1, where the 
relative levels of expression of the different markers are represented by 
symbols, as explained in the figure legend.
The overall trend was for all tetramer-positive cells to be CD45RA negative at 
early timepoints for all epitope-specific responses studied, consistent with 
them having been antigen-primed; but at later stages of infection, there was 
evidence of some cells re-expressing CD45RA again. There was a universal 
lack of CCR7 expression on HIV tetramer-positive cells. CD27 was typically 
expressed on a high percentage of tetramer-positive cells. A slight decrease in
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Figure 5.12. Expression of CD45RA, CD27 and CD28 on A3 QIYAGIKVK-specific CD8+ 
cells over the course of HIV infection. Cells cryopreserved from patient MM12 at 16, 23, 40, 
75, 321 and 742 DFOSx were co-stained with an A3 QIYAGIKVK-PE tetramer and anti-CD8 
antibody and (a) CD45RA-APC antibody, (b) CD27-FITC antibody or (c) CD28-APC antibody. 
Each histogram plot is gated on the CD8+ tetramer+ population shown in the R3 region in the 
corresponding dot plot on the left. The blue histogram plot at each timepoint shows the levels of 
expression of the marker on the tetramer positive population above background staining of the 
cells with an appropriate isotype control antibody (green line). The percentages of CD8+ 
tetramer" cells (in the R3 region) at each timepoint are given, as are the percentages of CD8+ 
tetramer" cells expressing CD45RA, CD27 or CD28 (in the M1 region).
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Patient Specificity of CD8+ T 
cells
Timepoint at 
which cells 
were taken for 
phenotyping 
(DFOSx)
Phenotype of HIV epitope-specific 
cells at indicated timepoint
CD45RA CCR7 CD27 CD28
MM25 A3 RLRPGGKKK 17 - - +++++ +
31 - - +++++ -
66 - - +++++ ±
185 - - +++++ +
MM12 A3 QIYAGIKVK 16 - - +++++ +
23 - - +++++ +
40 - - +++++ +
75 ± - ++++ ±
321 + ++++ ±
742 + - ++++ ±
B7 IPRRIRQGL 139 + - ++++ +
230 + - +++ -
567 + - +++ -
MM13 B8 FLKEKGGL 16 - - +++++ +
31 + - +++++ ±
196 + - ++++ ±
544 + - ++++ +
B57 KAFSPEVIPMF 98 + - +++ ±
196 + - ++++ +
544 - - ++++ ±
SUMA B15 MTKGLGISY 8/15 - - +++++ ±
29/41 - - +++++ ±
B14 ERYLKDQQL 22 - - +++++ +
483 ± - ++ -
Symbols represent percentage of CD8+ tetramer+ cells expressing a given 
marker at the indicated timepoint:
- 0% - 9% ± 10% - 19% + 20% - 39%
++ 40% - 59% +++ 60% - 79%
++++ 80% - 89% +++++ 90% - 100%
Table 5.1. Expression of CD45RA, CCR7, CD27 and CD28 on HIV-specific CD8+T cells 
over the course of infection. PBMC cryopreserved from patients MM25, MM12, MM13 and 
SUMA at different stages of infection were stained with the indicated tetramers (or 
pentamers) to identify HIV-specific CD8+ T cells responding to one or two different viral 
epitopes, and were co-stained with fluorescently labelled antibodies specific for CD8 and 
CD45RA, CCR7, CD27 or CD28 to allow assessment of the phenotype of epitope-specific T 
cells. The percentage of CD8+ tetramer+ cells expressing each marker was assessed by flow 
cytometry, and is represented in the table by + and -  signs as explained in the key.
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the percentage of CD27+ tetramer+ cells was often observed after the peak of 
the response, but this marker was still expressed on the majority of cells at all 
timepoints studied. By comparison, CD28 was found to be expressed on a 
much lower percentage of cells across all timepoints. In some cases, little 
change was observed in the expression of this marker during different phases 
of the response (for example, for FLKEKGGL-specific cells in MM13), but in 
other cases, a decrease in the percentage of CD28+ cells was observed at 
timepoints when the response was in decline (for example the IPRRIRQGL- 
specific response in MM12).
Looking at all the markers together, HIV-specific T cells did not exhibit what 
has been defined as a fully differentiated effector cell phenotype, i.e. CCR7' 
CD28" CD27' CD45RA+ at any of the timepoints studied, suggesting that HIV- 
specific cells fail to acquire the phenotype which is associated with full effector 
function at any stage in infection. HIV-specific cells instead had a phenotype 
that was more consistent with a pre-terminally differentiated stage, retaining 
CD27 expression throughout infection, although at later, chronic timepoints, 
they did show some features of late differentiated cells (such as re-expressing 
CD45RA and having downregulated CD28 expression). These results indicate 
that defects in the maturation/differentiation of HIV-specific cells are present 
from acute/early infection onwards. This was the case for all patients studied, 
even a patient who contained viral replication well (patient SUMA). This is 
discussed in more depth at the end of the chapter.
5.5.2. Expression of cytokine receptors on HIV-specific CD8+ T cells 
IL-2 (Mier & Gallo, 1980) and IL-7 (Chatterjee et al., 1994; Chazen et al., 
1989; Welch et al., 1989) are cytokines which both have roles in stimulating T 
cell proliferation and maintenance. It has been suggested that altered 
responses to such cytokines may be among the factors that contribute to 
abnormalities in the HIV-specific CD8+ T cell response, and that this may be 
associated with altered expression of the receptors for these cytokines (Mier & 
Gallo, 1980; Vingerhoets et al., 1998). To investigate this possibility, HIV- 
specific cells were stained with antibodies specific for the IL-7R and CD25. 
CD25 is the high affinity IL-2R o chain, expression of which can also be used 
as a marker for T cell activation.
The expression of IL7-R and CD25 were initially compared on total CD8 cells 
and HIV QIYAGIKVK-specific cells at 40 DFOSx in patient MM12 (Figure 
5.13). By contrast with the total CD8 cell population (29.7% of which were IL-
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Figure 5.13. IL-7R and CD25 expression on total CD8+ cells and 
HIV-specific CD8+ cells from patient MM12. Cells cryopreserved from 
patient MM12 at 40 DFOSx were co-stained with an A3 QIYAGIKVK 
tetramer and antibodies specific for CD8 and either the IL-7R or CD25. 
The proportion of cells in the total CD8+ lymphocyte population or the 
CD8+ tetramer+ population expressing each of the markers (blue 
histograms) at levels above the background staining of cells incubated 
with appropriate isotype control antibodies (green histograms) is 
indicated in the M1 region of each plot.
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7R+), IL-7R was not expressed on a significant proportion of HIV-specific CD8 
cells, suggesting that lack of IL7-R expression was specific to the HIV-specific 
cells and was not a universal feature of all CD8 cells. CD25 expression was 
absent from both the total CD8 population and the HIV-specific CD8 cell 
population.
Figure 5.14 shows the results obtained when QIYAGIKVK-specific cells 
cryopreserved from patient MM12 at series of timepoints were stained to 
reveal the expression of IL-7R and CD25 on tetramer positive cells. It can be 
seen that staining for these two markers was absent at all timepoints. An 
absence of CD25 and IL-7R expression on HIV-specific T cells was a common 
feature of all responses studied (Table 5.2), except for the KAFSPEVIPMF- 
specific response in patient MM13 at very late timepoints where there was a 
low proportion of cells that expressed CD25.
5.5.3 Expression of markers indicative of the proliferative status and terminal 
differentiation of HIV-specific CD8+ T cells
A desirable feature of a virus-specific CD8+ T cell response, particularly in the 
context of chronic infection, may be the presence of cells which possess a 
strong proliferative capacity. In order to look features of HIV-specific CD8+ T 
cells associated with their division and replicative history, the levels of Ki67 
and CD57 expression on the cells were assessed. Ki67 is an intracellular 
marker of proliferation and so the proportion of Ki67+ cells can be used as a 
measure of T cell division. On the other hand, CD57 is reported to be a marker 
on cells that have undergone multiple rounds of cell division and are unable to 
proliferate after antigen-specific stimulation in vitro, and undergo activation- 
induced apoptosis (Brenchly et al., 2003).
When the expression of Ki67 and CD57 on HIV-specific cells and the total 
CD8 population in patient MM12 at 40 DFOSx were compared (Figure 5.15), it 
was apparent that a higher percentage of HIV-specific cells expressed the two 
markers than did CD8 cells in the total CD8 pool, which is consistent with the 
HIV-specific cells having undergone more rounds of division and being less 
capable of further proliferation than most CD8+ T cells of other specificities, a 
probable consequence of chronic antigenic stimulation.
Changes in expression of Ki67 and CD57 on A3 QIYAGIKVK-specific cells as 
the response evolved in MM12 are shown in Figure 5.16. During the 
expansion phase of the response, the majority of tetramer positive cells were 
CD57' and a considerable proportion (-30%  of tetramer positive cells) showed
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Figure 5.14. Expression of CD25 and IL-7R on A3 QIYAGIKVK-specific 
CD8+ T cells during the course of HIV infection. Cells cryopreserved from 
patient MM 12 at 16, 23, 40, 75, 321 and 742 DFOSx were co-stained with an 
A3 QIYAGIKVK-PE tetramer and an IL7R biotin-SA FITC or CD25 APC 
antibody. Each dot plot is gated on the CD8+ tetramer+ population shown on the 
corresponding dot plot shown on the left. The histogram plot at each timepoint 
shows the levels of expression of the marker on the tetramer positive 
population (blue histogram) above background staining of the cells with an 
appropriate isotype control antibody (green line). The percentages of CD8+ 
tetramer* cells (in the R3 region) at each timepoint are given.
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Patient Specificity of CD8+ T 
cells
Timepoint 
at which 
cells were 
taken for 
phenotyping 
(DFOSx)
Phenotype of HIV 
epitope-specific 
cells at indicated 
timepoint
IL-7R CD25
MM25 A3 RLRPGGKKK 17 - -
31 - -
66 - -
185 - -
MM12 A3 QIYAGIKVK 16 - -
23 - -
40 - -
75 - -
321 - -
742 - -
B7 IPRRIRQGL 139 - -
230 - -
567 - -
MM13 B8 FLKEKGGL 16 - -
31 - -
196 - -
544 - -
B57 KAFSPEVIPMF 98 - -
196 - ±
544 - +
SUMA B15 MTKGLGISY 8/15 - -
29/41 - -
B14 ERYLKDQQL 22 - -
483 - -
Symbols represent percentage of CD8+ tetramer+ cells expressing a given marker:
- 0% - 9%
±10%-19%
+ 20% - 39%
++ 40% - 59%
+++ 60% - 79%
++++ 80% - 89%
+++++ 90% - 100%
Table 5.2. Expression of cytokine receptors on HIV-specific CD8+ T cells over the course 
of infection. PBMC cryopreserved from patients MM25, MM12, MM13 and SUMA at different 
stages of infection were stained with the indicated tetramers (or pentamers) to identify HIV- 
specific CD8+ T cells responding to one or two different viral epitopes, and were co-stained with 
fluorescently labelled antibodies specific for CD8 and IL-7R or CD25 to allow assessment of the 
phenotype of epitope-specific T cells. The percentage of CD8+ tetramer+ cells expressing each 
marker was assessed by flow cytometry, and is represented in the table by + and -  signs as 
explained in the key.
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Figure 5.15. Ki67 and CD57 expression on total CD8+ cells and 
HIV-specific CD8+ cells from patient MM12. Cells cryopreserved 
from patient MM12 at 40 DFOSx were co-stained with an A3 
QIYAGIKVK tetramer and antibodies specific for CD8 and either 
Ki67 or CD57. Plots on the left are gated on the CD8+ lymphocyte 
population, and those on the right on the CD8+ tetramer+ 
population. The proportion of cells in the total CD8+ lymphocyte 
population or the CD8+ tetramer* population expressing each of the 
markers (blue histograms) at levels above the background staining 
of cells incubated with appropriate isotype control antibodies (green 
histograms) is indicated in the M1 region of each plot.
345
(a) Ki67 (b) CD57
16 DFOSx
1C? 101 1C? 1C? id 4 
A3 QIYAGIKVK PE
o<M 31.1%
o M1
o
KI67 FITC
7.9%
IT'
O M1
IT*
CD57 FITC
23 DFOSx
40 DFOSx
75 DFOSx
321 DFOSx
n n«| ...... ..
1cP 101 1C? 1C? id 4
A3 QIYAGIKVK PE
ic P  io 1 ic ?  ic ?  i d 4
A3 QIYAGIKVK PE
1 (P 101 1C? 1C? id 4 
A3 QIYAGIKVK PE
1(9 101 1 (? 1(? 1 (f  
Ki67 F ITC
1(P 101 1C? 1C?
Ki67 FITC
1C? 101 1C? 1C? id 4 
Ki67 FITC
2 .0%
M1
KI67 FITC
1(? 101 1(? 1(? id 4 
C D 57 FITC
icP  io 1 ic ?  ic ?  i d 4
CD57 FITC
o<m
32.1
o
o
C D 5 7  F ITC
o
1.4%co
M1
CSI
O
C D 57 FITC
ic ?  ic ?  i d 4
A3 QIYAGIKVK PE
Figure 5.16. Expression of Ki67 and CD57 on A3 QIYAGIKVK-specific CD8+ cells 
during the course of HIV infection. Cells cryopreserved from patient MM12 at 16, 23, 40, 
75 and 321 DFOSx were co-stained with an A3 QIYAGIKVK-PE tetramer and anti-CD8 
antibody and (a) Ki67-FITC antibody or (b) CD57-FITC antibody. Each histogram plot is 
gated on the CD8+ tetramer+ population shown in the R3 region in the corresponding dot plot 
shown on the left. The histogram plot at each timepoint shows the levels of expression of the 
marker on the tetramer positive population (blue histogram) above background staining of 
the cells with an appropriate isotype control antibody (green line). The percentages of CD8+ 
tetramer+ cells (in the R3 region) at each timepoint are given, as are the percentages of 
CD8+ tetramer+ cells expressing Ki67 or CD57 (in the M1 region).
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Ki67 expression. Later on, after the response had peaked, the cells lost Ki67 
expression, and over time, an increased frequency of epitope-specific cells 
were found to express CD57 (48% of tetramer positive cells were CD57+ by 
321 DFOSx). This pattern of expression of the two markers is typical of what 
was also seen for the majority of the responses studied (Table 5.3). 
Expression of Ki67 during the expansion phase of the response is likely a 
reflection of intense proliferation of antigen-specific cells during acute 
infection; the proportion of Ki67+ cells subsequently decreases as the 
response stabilises and/or contracts. Increases in the proportion of cells 
expressing CD57 with time may reflect chronic antigenic stimulation of cells 
promoting continuous rounds of cell division and eventual terminal 
differentiation of antigen-specific cells. IPRRIRQGL-specific cells were CD57+ 
at all timepoints studied, as the response was only examined at timepoints 
when the response was in decline. The interesting exception to this was in 
patient MM13 in whom very few KAFSPEVIPMF-specific cells exhibited Ki67 
expression and a moderate level displayed CD57, yet cells were phenotyped 
at timepoints when this response was in the earlier stages of expansion. This 
may be explained by the observation that this response showed an unusually 
slow expansion, over a very long period of time (it was still increasing at the 
latest timepoint studied, which was two years into infection), so the proportion 
of cells that were proliferating was low (hence the very low levels of Ki67 
expression), and some cells had probably already undergone many rounds of 
division over this time, and their replicative lifespan was coming to an end 
(hence the moderate levels of CD57+ cells).
5.6 Discussion
During primary HIV infection, there is an acute burst of viral replication, 
associated with which, a virus-specific CD8+ T cell response is induced 
(Borrow et al., 1994; Koup et al., 1994). However relatively few studies have 
examined the virus-specific T cell response in primary HIV infection, and many 
questions remain unanswered. Notably, our understanding of the magnitude 
and kinetics of the initial expansion of response(s) in acute infection is very 
limited; and whether or not multiple epitope-specific responses all expand 
together in primary infection, or whether different epitope-specific responses 
expand asynchronously (and if so, whether the later-expanding responses are 
subdominant responses), is also unclear. Also, how do these parameters differ
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Patient Specificity of CD8+ T 
cells
Timepoint 
at which 
cells were 
taken for 
phenotyping 
(DFOSx)
Phenotype of HIV 
epitope-specific 
cells at indicated 
timepoint
Ki67 CD57
MM25 A3 RLRPGGKKK 17 ++ -
31 + -
66 ± ±
185 - +
MM12 A3 QIYAGIKVK 16 + -
23 + -
40 + ±
75 - +
321 ++
742 N.D. N.D.
B7 IPRRIRQGL 139 N.D. +
230 N.D. +
567 N.D. +
MM13 B8 FLKEKGGL 16 ++ -
31 + ++
196 - +
544 N.D. +
B57 KAFSPEVIPMF 98 - +
196 - +
544 - +
SUMA B15 MTKGLGISY 8/15 + -
29/41 - ±
B14 ERYLKDQQL 22 + -
483 - +
Symbols represent percentage of CD8+ tetramer+ cells expressing a given marker:
- 0%-9% ±10% -19% +20%-39%
++ 40% - 59% +++ 60% - 79%
++++ 80% - 89% +++++ 90% - 100%
N.D. not determined
Table 5.3. Changes in expression of markers of cell turnover on HIV-specific CD8+T cells 
over the course of infection. PBMC cryopreserved from patients MM25, MM12, MM13 and 
SUMA at different stages of infection were stained with the indicated tetramers (or pentamers) to 
identify HIV-specific CD8+ T cells responding to one or two different viral epitopes, and were co­
stained with fluorescently labelled antibodies specific for CD8 and Ki67 or CD57 to allow 
assessment of the phenotype of epitope-specific T cells. The percentage of CD8+ tetramer+ cells 
expressing each marker was assessed by flow cytometry, and is represented in the table by + 
and -  signs as explained in the key.
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between patients, and importantly, if there are differences, how do these relate 
to the persisting viral load established?
To address these questions, tetramers were used to stain PBMC samples 
cryopreserved at a series of timepoints throughout the course of acute and/or 
early infection from different infected individuals to reveal the magnitude and 
kinetics of expansion of different epitope-specific responses. A number of 
different tetramers were used, to allow comparison of several responses within 
the same patient, and comparison of responses in patients who went on to 
establish different persisting viral loads. The use of tetramer staining allows 
accurate assessment of the total magnitude of individual responses, as 
tetramers detect epitope-specific cells regardless of their functional capacity. 
This may be especially important in primary infection where many cells are 
highly activated and likely to die on in vitro restimulation. Such cells may not 
be detected by other methods which rely on cells to be able to perform a 
specific function, such as in IFN-y based ELISPOT assays.
One of the issues I addressed was the magnitude of responses to individual 
viral epitopes during primary HIV infection. When tetramer staining was used 
to follow a number of HIV epitope-specific responses in seven patients the 
highest recorded magnitudes of the responses studied ranged from 22% to 
0.2% of CD8+ cells. Whether the highest recorded magnitude of a response 
represents the actual peak of the response is uncertain, since tetramer 
staining could only be carried out at timepoints from which PBMC samples 
were available (typically spaced -one week apart), so it is possible that 
responses may have actually peaked at a timepoint when a sample was not 
available for testing. Nonetheless, these results indicate that responses to 
immunodominant HIV epitopes can reach very high magnitudes during 
primary infection.
In line with this, when Pantaleo et al used a semi-quantitative PCR approach 
to look at changes in patterns of TCR V/3 family usage by PBMCs of HIV- 
infected individuals during acute/early infection, in one patient a major 
expansion in V£19+ cells was observed, comprising 40% of PBMC (Pantaleo 
et al., 1994). It was likely that the 40% of PBMCs expressing this single V£ 
family (V£19) corresponded to cells responding to a single highly 
immunodominant epitope found to be recognised in the same patient by 
Borrow et al (Borrow et al., 1997). The total frequency of epitope-specific cells 
may thus have been greater than 40% of all CD8 cells in this patient at/near
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the peak of the response. The limited studies which have previously been 
done using tetramers to enumerate the primary HIV-specific CD8 response 
have indicated that epitope-specific T cell frequencies reach up to between 
2% and 5% of CD8 cells (Appay, 2002; Wilson et al., 2000), which is within the 
range observed in the patients I studied. As the patients progress to the 
chronic stage of infection, responses are typically reported to be of lower 
magnitude, but responses against individual epitopes which comprise 1-2% of 
CD8 cells are still common (Altman eta/., 1996; Ogg et al., 1998).
The total magnitude of the primary HIV-specific CD8 T cell response was 
more difficult to estimate from the analysis I carried out, since responses to 
only a few epitopes were studied using tetramers in each patient. Although 
results in chapter 3 indicate what the most dominant responses were in early 
infection in each patient, it is unclear which of these was the most dominant 
during acute/subacute infection; plus it is also possible that there may have 
been responses to other epitopes that were not detected due to differences 
between the patient’s autologous virus sequence and the sequence of the 
consensus peptides used for epitope identification. However minimum 
estimates of the total magnitude of the HIV-specific CD8 response can still be 
made from results here. In patient SUMA, at least 25% of CD8 cells were 
likely HIV-specific at/near the peak of the response (considering the combined 
magnitude of the responses to the B15 MTYKGLGISY and B14 ERYLKDQQL 
epitopes). In patient MM25 the total HIV-specific response reached a 
maximum magnitude of at least 14% of all CD8 cells (again, this was 
calculated by combining the percentages of cells specific for two epitopes). 
However, in the latter patient it is notable that the two epitopes which were 
studied using tetramers corresponded to only two of four dominant responses 
identified in this patient (Figure 3.11c). Although a possible optimal epitope 
was identified within a third of the four long peptides to which a strong 
response was seen in early infection in this patient, a tetramer corresponding 
to this epitope could not be obtained. The optimal epitope was not able to be 
predicted for the fourth dominant response. In addition, it was possible that 
another epitope was contained within the long peptide which corresponded to 
the RPQVPLRPMTY epitope. Consequently, it is likely that the overall primary 
HIV-specific response in MM25 was much larger than the minimal estimate 
obtained by using two tetramers to study the response.
One of the questions it was hoped these results may answer was whether the 
total magnitude of the primary HIV-specific CD8+ T cell response differs in
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patients who subsequently establish different persisting viral loads. Due to 
reasons already mentioned, this cannot be answered with confidence; but 
from the minimum total responses that were detected, it appears that a high 
magnitude response alone doesn’t predict good clinical outcome. Both 
patients SUMA and MM25 made large magnitude responses, but they 
controlled early viral replication with quite different efficiencies. Further 
evidence suggesting that high magnitude primary HIV-specific T cell 
responses may be mounted in patients who establish high persisting viral 
loads is provided by the studies of Pantaleo et al mentioned above (Pantaleo 
et al., 1994; Pantaleo et al., 1997b), where large distortions of the T cell 
repertoire indicative of expansion of HIV-specific T cell responses were 
observed during primary infection in multiple patients who subsequently 
contained viral replication poorly.
High magnitude primary virus-specific CD8+ T cell responses have been 
described in other viral infections too, such as in LCMV infection in mice 
where 50% of CD8+ cells in H-2d mice can be directed against one dominant 
epitope at the peak of the acute response, and the total LCMV-specific 
response can comprise almost 63% of all CD8 cells (Murali-Krishna et al., 
1998); likewise in primary EBV infection, a massive expansion of cells specific 
for a single epitope has been observed, comprising 44% of CD8+ T cells 
(Callan etal., 1998).
By contrast, in the acute phase of some other viral infections, while significant 
populations of virus-specific CD8+ cells have been observed at/near the peak 
of the primary response, these have not been found to be as large as those 
described above for LCMV, HIV and EBV. Studies of epitope-specific 
responses in primary hepatitis C infection have commonly reported 
frequencies of tetramer-positive cells of up to ~ 3% of CD8 cells (Gruener et 
al., 2001; Kantzanou et al., 2003; Lechner et al., 2000b; Urbani et al., 2002), 
although two studies were able to detect HCV-specific responses of around 
7% (Lechner et al., 2000a) and 20% of CD8 cells (Timm et al., 2004).
The magnitude of the virus-specific response detected during primary HBV 
infection has only been reported to reach levels of -1%  of CD8+ T cells (Maini 
etal., 1999; Urbani etal., 2002).
These differences in the magnitude of the virus-specific CD8 responses in 
different viral infections may potentially reflect differences in the tissue sites of 
replication of the virus, which may affect the size of response induced and/or 
the distribution of virus-specific T cells. For example LCMV and HIV are both
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viruses which replicate systemically in lymphoid tissues so it is perhaps not 
surprising that they are able to elicit such high magnitude CD8+ T cell 
responses. Replication within the immune system, in B cells, may also 
contribute to the antigenicity of EBV. By contrast HBV and HCV infections 
preferentially replicate in the liver. However a high magnitude virus-specific 
CD8+ T cell response is induced in influenza virus infected mice, despite the 
fact that the replication of this virus is confined to the respiratory tract (Belz et 
al., 2001; Marshall et al., 2001). In addition, virus-specific T cell frequencies 
are commonly measured in peripheral blood (or lymphoid tissues in mice). 
Virus-specific CD8+ T cells sequestered at tissue sites of viral replication may 
thus go undetected, resulting in an underestimation of the magnitude of the 
total virus-specific response, particularly in those infections where virus 
replication is confined to, for example, the liver.
Another factor which may influence the activation of a virus-specific CD8+ T 
cell response is the kinetics of viral replication. Hepatitis viruses replicate very 
slowly by comparison to viruses such as LCMV. Measurements of LCMV 
epitope-specific T cell responses induced by different strains of LCMV showed 
that slowly replicating strains induced weaker responses than more rapidly 
replicating strains (Bocharov et al., 2004). It was thus proposed that the speed 
of viral replication may influence the initial strength of the CD8 response. This 
may explain the weaker responses observed in infection with slowly replicating 
viruses such as HBV and HCV.
Another issue I addressed was the kinetics of expansion of epitope-specific 
CD8+ T cell responses in primary infection. The kinetics of expansion of one to 
four different epitope-specific responses were followed in relation to the 
kinetics of viral replication in patients who established different persisting viral 
loads. There were some limitations to this analysis - without daily samples, the 
precise kinetics of viral replication and expansion of CD8 responses could not 
be determined (i.e. the timepoints at which viral replication and the frequency 
of epitope-specific cells peaked could only be estimated from available data, 
as values at intermediate timepoints were unknown). Also, due to not having 
tetramers corresponding to all viral epitopes recognised during the primary 
HIV-specific CD8+T cell response in each individual, it was not certain that the 
first epitope-specific response to expand in a given patient was studied here. 
Nonetheless, some interesting observations emerged from this analysis.
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The time between the estimated peak viral load and the highest recorded CD8 
expansion was determined for each epitope-specific response followed. The 
day at which the peak in viraemia occurred was taken to be either that when 
the highest viral load was recorded (at 7 DFOSx for MM25, 6 DFOSx for 
MM28 and 7 DFOSx for MM12 and 8 DFOSx for SUMA) or if it was clear that 
the highest viral load recorded was not the peak viral load, 9 DFOSx was 
taken to be a reasonable estimate (for MM27, MM 14), except in the case of 
MM13 in whom it was apparent that the peak in acute viral replication must 
have occurred prior to 9 DFOSx. It may have been possible that the virus 
replicated with slightly faster kinetics in MM13 compared to the average 
patient; alternatively, the recorded day of onset of symptoms may not have 
been accurate. In this patient, 7 DFOSx was taken as an estimate of the day 
at which the viral load may have peaked.
The shortest time between the peak viral load and peak CD8 expansion was 
that observed in patient SUMA where the highest value for the MTKGLGISY- 
specific response was recorded at the same timepoint as for when the highest 
viral load was recorded (8 DFOSx). Due to the timepoints at which epitope- 
specific T cell frequencies were evaluated, it was possible that the response 
may have peaked anywhere between -4 days and +7 days relative to the 
highest recorded viral load -  but even using the latter estimate, this was a 
rapidly-expanded response. The slowest response to evolve was seen in 
MM19 in whom the response to KAFSPEVIPMF expanded with very slow 
kinetics and was still rising at the last timepoint studied (189 days after the 
estimated time at which the peak viral load occurred). Taking into 
consideration all epitope-specific responses studied, the average time 
between the peak viral load and maximum epitope-specific response was 62 
days. Perhaps more importantly, the average time between the peak viral load 
and the point when the most rapidly-expanding of the responses studied in a 
given individual reached its maximum recorded value was 39 days.
Compared with some other viral infections, the HIV-specific response thus 
appears to expand with relatively delayed kinetics. In the LCMV model, the 
precise kinetics of viral replication and expansion of CD8 responses have 
been studied, and LCMV-specific responses have found to be mounted very 
rapidly following infection, and typically peak within a few days following the 
peak in acute viral replication (Lau et al., 1994). Similarly, during primary 
SIVmac infection of rhesus monkeys, a rapid expansion of an epitope-specific
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response was observed to occur, which peaked approximately four days after 
the peak of viraemia (Kuroda et al., 1999).
Data about the kinetics of virus-specific CD8+ T cell expansion relative to 
primary viral replication in human viral infections other than HIV-1 is relatively 
incomplete. This is due in part to insufficient monitoring of responses over the 
acute/early stages of infections; the lack of acute/early viral load data; and the 
fact that often T cell responses of only chosen specificities are studied, and it 
is possible that subjects develop more significant early responses against 
antigenic specificities not tested.
However there are some studies which suggest that HBV and HCV infection 
may be similar to HIV in that virus-specific CD8+T cell responses are relatively 
slow to develop after infection. The few studies where longitudinal analyses of 
viral load and epitope-specific responses were carried out show that there 
may be a delay of possibly several weeks between the peak in viraemia and 
peak CD8 response in HBV and HCV infections (Thimme et al., 2001; 
Webster & Bertoletti, 2002).
HIV, HBV and HCV are all viruses which persist in their hosts, so it possible 
that the delay in expansion of the virus-specific CD8+ T cell response may one 
factor which may contribute to the failure of the host to successfully clear 
these infections. Studies in murine models have shown that small changes in 
the speed and efficiency of CTL inhibition of viral replication can have 
profound effects on viral control (Ehl et al., 1997). Consistent with this idea is 
the finding that there is a delay in activation of antigen-specific CD8+ T cells 
following SHIV challenge of vaccinated monkeys, which is thought to allow for 
unimpeded early viral replication and contribute to the inability of vaccine- 
elicited T cell responses to prevent establishment of persistent infection 
(Davenport et al., 2004).
Notably, although the number of patients I studied was small, and the 
possibility that potentially significant epitope-specific responses were not 
followed in some subjects means that definitive statements cannot be made 
as to which patients had the fastest/slowest evolving responses, it is 
interesting that the response which expanded with the most rapid kinetics was 
observed in the patient who controlled early viral replication the most 
efficiently (the MTKGLGISY-specific response in SUMA). The rapid 
mobilisation of a high magnitude virus-specific CD8+ T cell response in patient 
SUMA may have been one of the factors contributing to the ability of this
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patient to control early viral replication very efficiently (although cause and 
effect are hard to distinguish).
To explore this idea further, more comprehensive studies of the kinetics of 
expansion of epitope-specific CD8+ T cell responses in larger numbers of 
infected individuals would need to be carried out. It would also be interesting 
to compare the kinetics of the virus-specific response in the minority of HCV- 
infected patients who are able to spontaneously clear acute infection to that in 
patients who are unable to clear the virus and establish a chronic infection. Is 
the more favourable outcome in those who clear the virus related to the ability 
to mount a faster HCV-specific response? One study did look at the primary 
virus-specific CD8+ T cell response in patients representing the two different 
outcomes of infection (Thimme et al., 2001), but the results did not enable a 
fair comparison of the kinetics of expansion of CD8+ T cell responses, for the 
chronically infected patient failed to induce a significant T cell response that 
was amenable to detection using the tetramers used for following HCV- 
specific responses (although if this patient in fact failed to induce a significant 
response at all, this could itself have been responsible for viral persistence).
The availability of tetramers to follow more than one epitope-specific response 
within a particular patient allowed for the study of the synchronicity with which 
different epitope-specific responses expanded in six patients. In four of these 
individuals (SUMA, MM28, MM13 and MM12), the responses expanded 
asynchronously, with some responses expanding at earlier timepoints, and 
others later. In the other two patients (MM27 and MM25), the epitope-specific 
responses studied both expanded and contracted simultaneously; however 
there may have been other responses not studied in these individuals which 
exhibited a different pattern of expansion. It may thus potentially be the case 
that responses expand asynchronously in all patients.
The asynchronous expansion of epitope-specific T cell responses observed 
during the first -six months of HIV-1 infection likely reflects a combination of 
differing rates of initial activation/proliferation of epitope-specific T cells and 
subsequent shifts in the hierarchy of responses to different viral epitopes as a 
result of antigenic changes in the persisting viral quasispecies.
The asynchronous initial expansion of different epitope-specific responses in 
HIV infection is in contrast to what is seen in LCMV infection. Here the initial 
pattern of expansion of responses is one in which dominant and subdominant
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responses all expand and decline in parallel (Murali-Krishna et aI., 1998) 
(although if the virus persists, the immunodominance hierarchy can change 
over time (Wherry et al., 2003a)). Further, in a (less comprehensive) study of 
the expansion of T cell responses of more than one specificity in two patients 
with self-limited primary HBV infection, a synchronous pattern in the evolution 
of responses was observed during primary infection (Maini et al., 1999). By 
contrast the data available from HCV infection suggest that epitope-specific 
responses do not expand in parallel in this infection (Lechner et al., 2000a). 
Factors that may underlie the preferential expansion of certain T cell 
populations in primary HIV infection were discussed in chapter 4. It was 
hypothesised there that limited availability of activated APCs and/or CD4+ T 
cell help (which may also be features of primary HCV infection) may result in 
fierce competition between HIV-specific T cells, and initial expansion of T cells 
with the least stringent activation requirements (e.g. cells responding to high 
affinity epitopes and/or previously primed T cells). It was notable that the 
responses which evolved with the most rapid kinetics in primary HIV infection 
were typically dominant responses. In agreement with this are observations 
made in other studies, which likewise found that subdominant responses had 
a slower rate of expansion (Davenport et al., 2004; De Boer et al., 2001). 
Studies in which control and IFN-y deficient mice were immunised with DNA 
vaccines encoding dominant and subdominant LCMV epitopes demonstrated 
that subdominant T cell responses can be suppressed by dominant CD8 T cell 
responses in an IFN-y-dependent manner (Rodriguez et al., 2002). This 
mechanism could also contribute to the immunodominance of those HIV- 
specific T cell populations that initially start to expand first in primary HIV 
infection.
Delayed expansion of responses of certain epitope specificities may reflect 
changes in the epitopes presented to virus-specific T cells at different stages 
of infection. For example in EBV infection, the kinetics of expansion of 
responses to lytic and latent antigens are different, with responses to lytic 
epitopes dominating during the primary EBV-specific response (when a lot of 
productive viral replication is occurring) but these responses subsequently 
declining, and responses to latent epitopes being proportionately increased 
after the transition to persistent infection occurs (Hislop et al., 2002). In HIV 
infection, marked changes in the pattern of viral protein production do not 
occur at different stages of infection; however the composition of the viral
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quasispecies does change over time. Amino acid changes can be selected for 
in/around CD8+ T cell epitopes that confer escape from the epitope-specific T 
cell response -  presentation of certain viral epitopes may thus be markedly 
diminished within as little as one-two months following the acute viral burst 
(Borrow et al., 1997; Jones et al., 2004). The magnitude of the CD8+ T cell 
response to these epitopes may then decline, enabling expansion of 
responses to previously subdominant epitopes -  i.e. viral escape may drive 
shifts in the specificity of the HIV-specific CD8+ T cell response (Nowak et al., 
1995). This may explain the differences in the specificity of the HIV-specific 
CD8+ T cell response observed in the primary and chronic phases of infection 
(Altfeld et al., 2001a; Dalod et al., 1999b; Goulder et al., 2001a), for example 
the delayed appearance of the A2-restricted response directed towards the 
SLYNTVATL epitope despite the presence of this epitope in the infecting viral 
strain (Goulder et al., 2001a).
The clonal composition of different HIV-specific CD8+ T cell responses as they 
evolved was also studied in this chapter. Results from analysis of the clonal 
composition of HIV epitope-specific CD8+ T cell responses at one timepoint (at 
or near the peak of their expansion) in chapter 3 suggested that responses 
tended to involve cells expressing a limited range of Vyff families. This led to 
the question of whether the response was initially broad and certain TCRs 
were selected for as the response expanded to its peak magnitude, or whether 
a limited response was initially raised? A further question of interest was 
whether the same V/? families were used in a given response over time, or 
whether the response evolved to involve new populations of T cells? TCR V/? 
family usage by epitope-specific cells was assessed at different timepoints 
during the course of infection in different patients to address such questions. 
Whether there were any differences in the pattern of V/? family usage in 
responses that expanded early and later, and between responses in patients 
who controlled viral replication with differing efficiency was also addressed. As 
discussed in chapter 3, limitations of using this approach to assess the TCR 
usage by epitope-specific T cells include the fact that it does not provide 
information about the range/identity of T cell clones within a given V/? family 
involved in the response; also there were certain V/? families for which no 
antibodies were available, which meant that if a large proportion of the 
response remained unaccounted for using the antibodies available, it could
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not be determined whether the remainder of the response was broad or highly 
focused in terms of V/? family usage.
Results from studying responses to seven epitopes in four patients suggested 
that great heterogeneity of TCR use in HIV-specific responses was 
uncommon: for only one response was there a heterogeneous TCR usage 
observed which remained heterogeneous over time (QIYAGIKVK-specific T 
cells in MM12 (Figure 5.6)). There were three examples of responses which 
were of moderate heterogeneity at the first timepoint studied (although with a 
more prominent component to the response in each case), and which then 
exhibited greater focusing towards one particular V£ family over time 
(KAFSPEVIPMF-specific T cells in MM13 and MTYKGLGISY-specific and 
ERYLKDQQL-specific response in patient SUMA, although a large proportion 
of the two latter responses were undetected using the available V0 family 
antibodies). There were two examples of responses (Figures 5.5 and 5.6) 
which were more narrowly focused from the start and in which the dominant 
TCR V/? family used changed over time, the RLRPGGKKK-specific response 
in MM25 showing the more rapid and dramatic change. Another response 
(FLKEKGGL-specific response in MM13 (Figure 5.7)), was also focused on a 
limited number of Vp families, but a stable response to the dominant V/? family 
used was seen at all timepoints.
This leads to the question of why, in five out of seven epitope-specific 
responses studied, does TCR usage change over time? An important 
consideration in this respect is that the composition of the viral quasispecies 
may be changing, and so the observed change in TCR usage could be a 
reflection of alterations in the stimulation of different populations of epitope- 
specific T cells by variant epitope sequences. However, the changing TCR 
usage may be a consequence of clonal exhaustion or selection for certain 
clones of cells. Clones of T cells which disappear by exhaustion would be 
replaced by other clones of cells within the epitope-specific population, and 
this may lead to changes in the TCR usage of epitope-specific cells observed 
(Pantaleo et al., 1997a). If selection for T cell clones utilising a specific Vp 
family is occurring, this leads to the question of why, and whether there are 
immunological benefits to be gained?
Greater heterogeneity of TCR usage in an epitope-specific CD8 response may 
be beneficial by allowing recognition of variant versions of the epitope peptide, 
and reducing the capacity for immunological escape by the virus via the 
acquisition of mutations that may reduce T cell recognition (Lopes et al.,
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2003). However, biasing of TCR usage towards a single receptor, the use of 
which is associated with a beneficial outcome, might also be advantageous. 
For example, the selected TCR may have a high capacity to recognise 
potential epitope variants (Dong et al., 2004), or perhaps have a higher affinity 
for its ligand and contribute to a higher avidity response (Busch & Pamer, 
1999; Savage etal., 1999).
To investigate whether T cells expressing high avidity TCRs were selected for 
during the course of infection (resulting in the changes in V/? usage by 
epitope-specific T cells observed to take place in some cases), the functional 
avidity of epitope-specific T cells at an earlier and a later timepoint during 
evolution of a response were determined. One limitation to this approach is 
that it was assumed that the peptide(s) used in experiments to determine 
functional avidity corresponded to the autologous viral peptide sequence, but 
this was not known for certain. Therefore alterations in the avidity of the 
response as measured in vitro using non-autologous viral sequence may not 
necessarily be representative of the avidity of the response in vivo.
For the FLKEKGGL-specific response in MM13, where V/? usage was 
relatively stable, there was no change in the avidity of the T cell response with 
time. However, for the RLRPGGKKK-specific response in MM25, for which 
there was gradually more selection for V£2 usage with time, there was an 
increase in avidity of the response by an order of two logs, such that the cells 
at the later timepoint were now sensitive to a much lower level of peptide. That 
the higher avidity cells had a greater percentage of V£2+ T cells suggests that 
for this response, there was correlation of V/?2 usage with higher avidity, and 
that TCRs utilising this particular V/? family may have been associated with 
improved interaction with the peptide-MHC complex, contributing to a higher 
avidity response. This could have been confirmed by making T cell 
lines/clones of V£2+ and V/?2‘ epitope-specific T cells and comparing their 
avidities. However, there are also other factors which could influence the 
avidity of a T cell response. For example, in addition to changes in TCR  
usage, an increase in the expression of adhesion or co-stimulatory molecules 
on T cells may contribute to an increase in the avidity of the response.
A possible advantage to the host of using cells with a higher functional avidity 
is that higher avidity CTL may be more effective than lower avidity CTL at 
combating viral infection, as several studies have shown (Alexander-Miller et 
al., 1996; Gallimore et al., 1998; Sedlik et al., 2000). Higher avidity CTL were 
shown to be more efficacious at preventing spread of virus as they were able
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to recognise infected cells earlier, at a time when little viral protein had been 
made and few new virions produced (Derby et al., 2001).
Why should a low avidity response be induced to some viral epitopes initially, 
if the host has the capacity to mount a higher avidity response? Changes in 
the avidity of a HIV-specific response may be a reflection of improved APC 
function later during the course of infection, enabling higher avidity T cells to 
expand. Studies have shown that CD4 help and high levels of co-stimulation 
have a role in the induction of high avidity CTL (Oh et al., 2003). Clinical data 
for patient MM25 show that there was not a substantial difference in the CD4 
count at the two timepoints when the avidity of the RLRPGGKKK-specific 
response was measured, but it is feasible that improved APC function and/or 
late induction or recovery of function of HIV-specific CD4+ T cells might have 
contributed to the increased avidity of the CD8+ T cell response to this epitope.
A further series of experiments explored the phenotypic characteristics of 
tetramer binding cells, using four-color flow cytometry. The majority of HIV- 
infected individuals are unable to control viral replication despite the presence 
of large numbers of HIV-specific CD8+ T cells. It is suggested that this may be 
due in part to failure of these cells to mature into fully differentiated effector 
cells.
The differentiation of CD8+ T cells has been the subject of many studies, but is 
still not fully understood, and it is debated as to what the lineage relationship 
between phenotypically distinct subsets of CD8+ T cells may be.
Naive cells are defined by the phenotype CD45RA+ CD27+ CD28+ CCR7+. 
After activation cells become CD45RA' RO+. Whilst expression of 
CD45RA/RO used to be used to define naive and antigen experienced cells, it 
is now clear that cells can revert from being CD45RO+ to CD45RA+ (with late 
differentiated cells expressing CD45RA (Champagne et al., 2001; Hamann et 
al., 1997)), although it is not clear what this switch signifies.
CD27 and CD28 are co-stimulatory molecules which provide signals needed 
for activation of T cells (Hendriks et al., 2000; June et al., 1994; Lenschow et 
al., 1996). After interaction of CD27 and CD28 with their ligands, T cells no 
longer require a signal through these molecules and CD27 and CD28 are 
downregulated (Azuma, 1993; Hintzen, 1993). A gradual loss of CD28 
followed by CD27 is thought to occur as cells mature to fully differentiated 
cells which are CD28' CD27'(Hamann etal., 1997).
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Two subsets of memory cells can be distinguished on the basis of differential 
expression of CCR7. CCR7 is a chemokine receptor which is necessary for 
lymphocytes to cross the high endothelial venule barrier to enter lymph nodes, 
and therefore has a role in mediating homing of cells to lymphoid sites of 
infection (Campbell etal., 1998; Forster et al., 1999; Gunn etal., 1998). Naive 
cells are C C R 7\ whereas antigen-experienced cells can either be CCR7+ or 
CCR7' (Sallusto et al., 1999). Memory cells which lack expression of CCR7 
are termed effector memory cells; they migrate to peripheral tissues where 
they have immediate effector function. Memory cells which do express CCR7 
are termed central memory cells; they have the potential to home to 
secondary lymphoid organs where they have little effector function, but 
possess greater proliferative potential (Sallusto et al., 2004; Sallusto et al., 
1999). It is unclear what the lineage relationship between these may be (if 
any). Two models of linear differentiation of CD8+ T cells have been proposed: 
Naive -*■ central memory -+ effector memory effector (Champagne et al., 
2001; Sallusto et al., 1999) and naive -> effector -* effector memory -* 
central memory (Wherry etal., 2003b).
There have been numerous studies that have addressed the phenotype of 
CD8+ T cells in persistent viral infections. These have indicated that during the 
primary stage of infection virus-specific CD8+ T cells are predominantly 
CD45RA'/RO+; are generally CCR7', and may have down-regulated 
expression of CD28 and/or CD27, i.e. are activated, and contain a high 
proportion of effector or effector/memory cells, which in some cases may be at 
early stages of differentiation (Appay et al., 2002).
As infections progress into chronicity, greater heterogeneity becomes 
apparent, with virus-specific T cells retaining an ‘immature’ phenotype in some 
cases, but a proportion of cells acquiring a ‘later differentiation’ phenotype in 
other infections. For example in primary HCV infection, HCV-specific T cells 
have a CD45RA" CD27+ CCR7' phenotype (Urbani et al., 2002), and remain 
CD27+ (and CD28+) during chronic infection (Appay et al., 2002).
While the majority of EBV-specific cells in primary infection have been 
reported to have an activated phenotype (CD45RO+) (Callan et al., 1998a), 
primary EBV infection has also been reported to also induce the differentiation 
of CD27* CD28‘ cells (Roos, 2000). Later on, during the persistent phase of 
infection, the frequency of CD45RA+ cells has been found to increase, with a 
corresponding decrease in CD45RO+ cells (Callan et al., 1998a). A difference
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in the differentiation of T cells (depending on the source of the epitope) was 
later discovered, with T cells specific for both lytic and latent epitopes during 
primary EBV infection being CCR7‘ CD45RO+, but during persistent infection, 
those T cells specific for lytic epitopes acquired CCR7 expression, and were 
CCR7+ CD45RO+, whereas T cells specific for latent epitopes had 
differentiated into CCR7' CD45RA+ cells (Hislop etal., 2002).
In primary CMV infection (which is often difficult to study given its 
asymptomatic nature), cells were found to be predominantly CD45RO+ CD28* 
CCR7". During convalescence, an expansion of CD45RA+ cells was observed, 
and in the memory pool, virus-specific CD8+ T cells were abundant in both the 
CD45RO+ and CD45RA+ subsets, and both CD27+ CD28' and CD27‘ CD28' 
populations (Wills, 2002).
In studies of chronic EBV and CMV infection, the general consensus is that in 
healthy (HIV seronegative) subjects the majority of EBV and CMV-specific 
cells have a memory phenotype (CD45RO+ CD27+) (Appay et al., 2002; 
Gamadia et al., 2001; Gillespie et al., 2000; Hislop et al., 2001) with low levels 
of effector phenotype cells (van Baarle et al., 2002b) (although others have 
found that EBV-specific (Roos, 2000) and CMV specific (Appay et al., 2002) 
CD8+ T cell populations can include significant numbers of CD27‘ cells, and 
may exhibit other features characteristic of more differentiated cells, e.g. there 
are reports of CD45RA+ CD27' CD28' CCR7‘ CMV-specific cells (Sacre et al., 
2005; Tussey et al., 2003)).
Analysis of EBV- and CMV-specific T cells in HIV-infected individuals has 
suggested that a higher proportion of CMV-specific cells in HIV-infected 
patients have a late differentiation pattern (CCR7' CD45RA+ CD27‘ CD28 ) 
(Appay etal., 2000; Champagne etal., 2001; Chen, 2001; Doisne etal., 2004; 
Ellefsen et al., 2002; Sacre et al., 2005), with mixed phenotypes reported for 
EBV-specific cells: CD45RA+/'CD27+ CCR7‘ (Chen, 2001; Doisne et al., 2004; 
van Baarle et al., 2002b) (although some reports suggest that a substantial 
proportion of EBV-specific cells can be CD27‘ (van Baarle et al., 2002b)). The 
differences in reported phenotype of CMV and EBV-specific cells in healthy 
donors compared to those co-infected with HIV may reflect differences in 
recent antigen encounter. The memory phenotype of EBV and CMV-specific 
cells in healthy donors suggests that they have not recently encountered 
antigen. In HIV-infected donors, a higher proportion of EBV and CMV cells 
have downmodulated CD27 and there is a trend towards more expression of 
CD45RA suggesting that the cells may have been more recently activated in
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HIV-infected individuals compared to in healthy donors. This may reflect 
bystander activation or reactivation of EBV and CMV in the context of HIV- 
associated immununosuppression.
Multiple studies have indicted that HIV-specific cells in chronically-infected 
individuals show signs of incomplete differentiation when compared to CMV 
and EBV-specific cells, with HIV-specific cells having a CD45RA' CCR7' 
CD27+ CD28+/* phenotype (Appay etal., 2000; Appay et al., 2002; Champagne 
etal., 2001; Chen, 2001; Ellefsen etal., 2002; Ogg, 1999; Scott-Algara etal., 
2001; Shankar et al., 2000; van Baarle et al., 2002b). Limited studies of HIV- 
specific CD8 cells in primary infection have found that a CD45RA' CCR7' 
CD27+ CD28* phenotype is also apparent at this time (Appay, 2002; Doisne et 
al., 2004; Papagno etal., 2004).
It has also been suggested that HIV-specific T cells may be functionally 
immature, in addition to phenotypically immature (Appay et al., 2000; Appay et 
al., 2002; Champagne etal., 2001). Many studies have reported defects in the 
cytolytic ability of HIV-specific CD8+ T cells (Appay et al., 2000; Shankar et al., 
2000; Trimble & Lieberman, 1998). Furthermore, HIV-specific CD8+ T cells 
were reported to contain less perforin compared to that of the CMV-specific T 
cells from the same subject in both primary (Doisne et al., 2004) and chronic 
HIV infection (Appay et al., 2000) (and this was associated with poor ex vivo 
killing ability compared to that of the CMV-specific cells which did express 
perforin (Appay et al., 2000)). Other studies are in agreement that HIV-specific 
cells in the periphery have a low level of or lack perforin expression (Appay, 
2002; Appay et al., 2002; Shankar et al., 2000). Furthermore, perforin was 
found not to be expressed in T cells in lymph nodes during primary and 
chronic HIV infection (Andersson etal., 1999; Andersson etal., 2002).
It is unclear whether the perforin' phenotype is a result of accumulation of T 
cells at a specific stage of differentiation (Champagne et al., 2001), or is 
reflective of an impairment in T cell responsiveness or functional capacity 
(anergy) (Lieberman et al., 2002; Zhang et al., 2003a). Another suggestion 
has been that the absence of perforin is due to the presence of persistent viral 
antigen triggering degranulation of cytotoxic granules of HIV-specific CTL. 
However, degranulation would deplete granzymes too, but an abundance of 
cells that are granzyme+ in the lymph nodes argues against recent 
degranulation as being an explanation for the observed lack of perforin 
expression (Andersson et al., 1999). Also, in those patients on therapy, low
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levels of perforin are still found despite suppression of the viral load to 
undetectable levels.
Although, as described above, some studies have addressed the phenotype of 
HIV-specific T cells in primary infection, only a limited number of patients and 
epitope-specific responses were studied, and therefore it remains unclear 
whether the observations made are representative of most patients and 
epitope-specific responses, and whether there are any differences in patients 
who subsequently control viral replication with differing efficiency. Here, I used 
HIV-specific tetramers and antibodies against relevant markers to follow the 
phenotype of expanded populations of HIV-specific cells from primary infection 
onwards. This allowed me to see if the pre-terminally differentiated phenotype 
of cells in chronic infection was also characteristic of most cells present during 
primary infection (as others previously observed for the limited responses 
studied (Appay, 2002; Papagno et al., 2004)), or to follow the kinetics with 
which cells of this phenotype are acquired during infection. Different epitope- 
specific responses in different patients were studied to address whether cells 
responding to different epitopes may differ in phenotype and how the 
phenotype of HIV-specific T cells may relate to the persisting viral load 
established in different individuals.
In primary infection, most HIV-specific CD8+ T cells were found to be CD45RA' 
which is consistent with them having recently been activated. A low 
percentage of CD45RA+ cells was detected (possibly CD45RA revertants). 
The tendency (for most epitope-specific responses) was for all cells to be 
CD45RA' to start with, and then a low percentage of CD45RA+ cells to appear 
over time. Interestingly, some of the responses which expanded later seemed 
to have a proportion of CD45RA+ cells present from early within the response 
onwards. The reasons for this are unclear. There was no difference in 
CD45RA expression between different patients/epitopes. The implications of 
these observations in terms of functional efficacy are not clear.
Results from looking at the expression of CD27 on HIV-specific cells were 
consistent with studies in chronic infection (Appay et al., 2000; Ogg, 1999; 
Shankar et al., 2000; van Baarle et al., 2002b): it was found that CD27 was 
retained on a high proportion of HIV-specific cells of all antigenic specificities 
in all patients. Absence of CD27' terminally differentiated cells within the 
tetramer-stained populations may imply that, despite continuous activation of 
cells by persistent antigen, there is a defect in the maturation of cells and the
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generation of effector cells. Persistent CD27 expression on HIV-specific cells 
was seen from the earliest timepoint studied onwards, implying that 
incomplete maturation of cells is a feature of primary infection onwards. In 
contrast to some reports (Appay et al., 2000; Shankar et al., 2000; van Baarle 
et al., 2002b), CD28 was found on a proportion of HIV-specific cells. However, 
there was evidence of cells losing expression of CD28 by the later timepoints 
during the responses to IPRRIRQGL in MM12 and ERYLKDQQL in SUMA, 
suggesting that for these two responses the cells may be able to progress to a 
later stage of maturation at later timepoints. That this was true of two 
responses which were not initially immunodominant in the two subjects with 
the lowest persisting viral loads may lead to speculation about an association 
between the ability of the cells to mature to the CD28' stage of differentiation, 
and the persisting viral load of the subject (or the relative dominance of 
responses). Additional responses would need to be analysed in order to 
explore this further. A previous report also suggested that T cells responding 
to different epitopes within the same patients may have differing phenotypes 
(in this case, differing in terms of the proportion of CD27' cells) implying that 
cells specific for one epitope may have differentiated more efficiently into T 
cells with an effector phenotype with corresponding functional capacity than 
cells specific for another epitope restricted by the same HLA allele (Kostense 
et al., 2001). However, the relative dominance of these two responses in the 
patients studied was not indicated.
In one study which followed the phenotype of HIV-specific cells throughout the 
course of infection from the primary stage to the chronic stage (Appay, 2002), 
during primary infection, high numbers of CD28+ CD27+ cells were observed 
(likely to be generated from a population of naive cells) which differentiated 
rapidly (within 2-4 weeks) into an intermediate stage of differentiation, where 
cells were CD28+ CD27'. The chronic/memory phase showed an enrichment 
of CD28+ CD27' cells mixed with smaller numbers of CD28+ CD27+ cells and 
CD28' CD27‘ cells. The observations made here were similar, although the 
kinetics of CD28 loss were typically slower than observed by Appay et al. 
HIV-specific CD8+ T cells in the circulation were found to be universally CCR7' 
irrespective of time, specificity or persisting viral load. This could imply that 
CCR7+ cells are all localised within the lymph nodes (and so cannot be 
detected when analysing HIV-specific cells using peripheral blood samples), 
or that there is a lack of the CCR7+ central memory cell subset. In support of 
the latter explanation is one study in which, looking at the simultaneous
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expression of CCR7 and CD45RA on total peripheral blood CD8+ T cells, HIV- 
infected donors were found to have a marked reduction in CCR7+ naive and 
central memory cells within their CD8 lymphocyte population (Chen, 2001). In 
the same study, a lack of lymph node homing receptors on HIV-specific cells 
(and also EBV- and CMV- specific cells within the same donor) during chronic 
infection was also observed, and was found to be associated with a reduction 
in the frequency of antigen-specific cells in the lymph nodes. Therefore the 
lack of expression of CCR7 on HIV-specific cells may affect their ability to 
traffic efficiently and localise at principal sites of HIV replication, and thus 
interfere with their ability to provide protection. A study of primary SIV infection 
also suggested that SIV-specific CD8+ T cells were excluded from lymph 
nodes (Kuroda et al., 1999). That CMV and EBV-specific cells were also 
deficient in CCR7 expression in HIV-infected patients and healthy donors 
(Chen, 2001) suggests that in the setting of chronic infection and persisting 
antigenic stimulation, antigen-experienced CD8 cells may be selectively 
excluded from lymph nodes. This may serve as a protective mechanism 
against immunopathological damage caused by inflammatory cytokines and 
cytolytic enzymes.
That there are cells of an early differentiated phenotype present during HIV 
infection may not be an adverse characteristic of the response, for such cells 
may have better proliferative ability and be associated with protective 
immunity, as described in LCMV infection (Wherry et al., 2003b). Also, in HIV 
infection it was shown that the presence of HIV-specific cells which maintained 
a strong proliferative capacity following in vitro stimulation (cells defined 
mainly as CD45RO+ CD28+ CD27+ early differentiated cells) and were able to 
express high levels of perforin under certain conditions of stimulation was 
observed in non-progressor subjects (Migueles et al., 2002). This raises 
questions regarding the ideal phenotypic profile of ‘protective effector cells’. 
Should vaccination strategies be designed to favour expansion of perforin- 
high, late differentiated cells when these cells could have characteristics of 
replicative senescence? In line with this, in contrast to thinking of loss of CD28 
expression as being associated with a ‘good’ effector phenotype, it has been 
suggested that that the accumulation of CD28' HIV-specific cells during 
disease progression is not a favourable thing (Gamberg et al., 2004). A 
predominance (and accumulation) of CD28' cells reflects continuous 
differentiation of CD28+ cells in response to chronic viral stimulation, depleting
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reserves of potential effector cells within the CD28+ population. This could 
have a negative impact on the ability to recruit new effector cells from the 
CD28+ population.
Contrastingly, in support of late differentiated cells being more beneficial, in 
patients with recent acute infection, the expansion of activated CD8 cells that 
were CD57+ or CD45RA+ was found to be inversely correlated with a reduced 
viral setpoint after primary infection (Lieberman et al., 1999), suggesting that 
the cells displaying properties of later stages of differentiation may be 
associated with an ability to control the virus. Furthermore, consistent with 
virus-specific CD27' cells having stronger effector function compared to CD27+ 
cells, higher numbers of HIV-specific CD27' cells have been associated with 
delayed progression to AIDS (van Baarle et al., 2002b). However, it was 
suggested that a large number of highly differentiated cells may simply 
accumulate over time in chronic infection, whilst playing no part in delaying 
disease progression (Papagno et al., 2004).
In order to find out more about the turnover of HIV-specific cells, the 
expression of Ki67 and CD57 on tetramer-labelled cells were also followed. 
Ki67 is an intracellular marker of proliferation, expression of which is restricted 
to cells in cycle (Gerdes, 1984) and so the proportion of Ki67+ cells can be 
used as a measure of T cell production and turnover. Ki67 has been found to 
be expressed on a high proportion of cells in primary HIV infection (Appay, 
2002; Doisne et al., 2004; Papagno et al., 2004), and on a lower proportion of 
cells in chronic HIV infection (Appay et al., 2000; Champagne et al., 2001). As 
expected, I observed that Ki67 expression in HIV-specific CD8+ T cells was 
mainly detected during the expansion phase of each response when cells 
were proliferating, and subsequently decreased.
CD8+ CD57+ cells are thought to represent a terminal differentiation state of 
activated effector CTL which are enriched in antigen-specific populations and 
have down-modulated their cytotoxic potential (Mollet et al., 1998). As CD8 
cells differentiate further, they express increasing levels of CD57, and so this 
molecule has been used as a marker of proliferative inability or replicative 
senescence (Bandres et al., 2000; Weekes et al., 1999). Here, it was found 
that cells did not express CD57 as the HIV epitope-specific response 
expanded, but as each response progressed, there was expression on an 
increased proportion of cells. The increasing proportion of cells expressing 
CD57 is likely a consequence of continual stimulation by antigen/cytokines,
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with CD57+ cells having a long proliferative history and a reduced ability to 
proliferate further. In line with my observations, a study of HIV-specific cells 
found them to be CD57' during primary infection, but showed that CD57 
expression increased following primary infection as disease progressed 
(Papagno et al., 2004), suggesting that T cells exhibit characteristics of 
replicative senescence as they differentiate further with increasing stage of 
infection.
Cytokines such as IL-2 and IL-7 are stimulatory cytokines which can affect T 
cell maturation and differentiation, enhance CD8+ T cell proliferation and 
cytolytic activity (Carini & Essex, 1994; Carini etal., 1994), and also have anti- 
apoptotic effects (Estaquier et al., 1996). It has also been shown, using an 
LCMV infection model, that the expression of the IL-7R a  chain distinguishes 
the subset of cells in the acute CD8+ T cell response that will differentiate into 
memory cells (Kaech, 2003; Huster 2004).
It could be hypothesised that the interruption of essential cytokine signalling 
pathways may underlie the impairment of CTL activity in HIV disease. As 
suggested by other studies (Vingerhoets et al., 1998), the mechanism involved 
could involve the expression of cytokine receptors since down regulation of 
receptor expression may result in signalling defects. Indeed, IL-7R expression 
was found to be reduced in HIV-infected individuals compared to in healthy 
controls, and improved immune function with effective antiretroviral therapy 
was associated with recovery of expression of this molecule (MacPherson et 
al., 2001).
CD25 is the high affinity IL-2Ra chain which is important in regulating the T 
cell response to antigen (Nelson & Willerford, 1998). It was also found that 
cells from HIV-infected individuals were unable to upregulate expression of 
CD25 upon antigenic stimulation (Vingerhoets etal., 1998), so this defective 
CD25 expression may be involved in T cell unresponsiveness. It has been 
suggested that absence of a co-stimulatory signal induced by IL-2R 
engagement may be linked to the deficiencies in perforin expression in HIV- 
specific CD8+ T cells in infected individuals (Zhang et al., 2003a). The defect 
in expression of CD25 upon activation may be secondary to defects in key 
signalling molecules in HIV-specific CD8+ T cells. CD 3f and CD28 have been 
found to be down-regulated on HIV-specific CD8+ T cells (Trimble et al., 2000). 
This may raise the threshold for induction of functions induced by TCR 
engagement, such as cytotoxicity (the reduced cytotoxicity of freshly isolated
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CD8+ T cells from HIV-infected subjects has been shown to be linked to the 
downmodulation of C D 3f (Trimble & Lieberman, 1998)). Indeed, upon 
activation, cells with decreased CD 3f and CD28 did not express CD25 
(Trimble et al., 2000).
In the studies here of different epitope-specific responses in different patients, 
neither IL-7R nor CD25 expression were detected on a large part of any 
epitope-specific population. The absent expression of cytokine receptors 
implies that HIV infection may cause down-modulation of their expression, 
leading to signalling defects in CD8+ T cells and altered responses to 
stimulatory cytokines. However, the failure to detect CD25 expression on any 
CD8 population raises suspicion as to whether the antibody was working 
properly (although this antibody was found to stain a proportion of HIV-specific 
cells in earlier experiments (data not shown)). To determine whether the 
antibody was no longer working or whether CD25 was universally not 
expressed, the antibody could have been used to stain cells activated in vitro 
by stimulation with PHA.
Functionally defective and phenotypically immature HIV-specific responses 
could result from problems with the initial priming of the response and/or with 
maintenance of the response over time once naive cells have been activated. 
The fact that an ‘immature’ phenotype was detected from the initial expansion 
of the response in primary infection suggests that the problems arise from the 
priming stage onwards (although there may be problems with maintenance 
too). Using CD27 and perforin expression to examine the maturation status of 
HIV-specific cells, Janssen et al also concluded that the impaired maturation 
of HIV-specific cells was established ‘early’ on in infection (Jansen et al., 
2004) (although this study only compared cells at two timepoints: ‘early’ and 
‘late’, early here being defined as 1-2 years following seroconversion and late 
around the time of AIDS diagnosis, or in the case of slow progressors, 10 
years after seroconversion). Partial differentiation (as reflected by a slight 
increase in perforin expression in HIV-specific cells over time) was however 
found to be possible in those individuals with slowly progressing infection. 
What factors could be important in influencing the failure of HIV-specific cells 
to differentiate fully? T cell activation/differentiation are known to be influenced 
by antigen exposure, by signals received from APCs and CD4+ T cells, and by 
soluble factors including type I IFNs, IL-15 and IL-2. The failure of CD8+ T cells
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to mature and function properly may be a consequence of perturbation of any 
of these factors.
Antigenic stimulation is a major driving force for T cell activation. During 
chronic viral infections, the antigen burden is thought to be a key determinant 
of the activation state of virus-specific CD8+T cells. Tussey et al observed that 
memory phenotype cells tended to predominate in chronic viral infections 
where antigen loads were absent or low (such as in EBV infection), and 
significant numbers of terminally differentiated cells were present when the 
antigen burden was higher (such as in CMV infection) (Tussey et al., 2003). 
This led to the construction of a dynamic model of T cell differentiation with 
virus-specific T cells switching between subsets in response to changes in 
plasma viral load. It was suggested that when the antigen burden is low, cells 
mature to memory, but during recrudescence, some of these memory cells are 
recruited back to the more activated subset of CD45RO+ CD27+ CD28' cells 
(i.e. a phenotype associated with acute phase expansions). This was 
supported by longitudinal analysis of HIV-infected patients, in which a shift 
towards memory was observed as viral load decreased and reversion back to 
an acute expansion phenotype as viral load increased (Tussey et al., 2003); 
although another study found no relationship between levels of HIV plasma 
viral load and the differentiation phenotype of HIV-specific CD8+ T cells 
(Appay et al., 2002). This may also explain the differences in the phenotype of 
EBV-specific cells in healthy carriers and HIV-infected subjects, with EBV- 
specific cells in the context of HIV infection being triggered to undergo 
differentiation into a more mature phenotype (van Baarle et al., 2002b).
During acute/early HIV infection, very high antigen loads are present, yet HIV- 
specific CD8+ T cells do not acquire a ‘fully mature’ CD45RO+ CD27' CD28' 
phenotype. One explanation for this is that high persistent antigenaemia may 
result in impairment of CD8 function (Lieberman et al., 2002).
However antigenic stimulation is not the only factor that drives T cell 
differentiation/maturation. In addition to antigen, APCs and CD4+ T cells have 
an important role in influencing CD8+ T cell differentiation.
As reviewed earlier, numbers of both conventional and plasmacytoid DCs in 
the blood are reduced in primary HIV infection (Kamga et al., 2005; 
Pacanowski et al., 2001; Soumelis et al., 2002), and there is evidence that 
there may also be impairments in the function of PDCs and conventional DCs
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(Donaghy et al., 2003; Feldman et al., 2001; Kamga et al., 2005; Lore et al., 
2002). In addition, monocytes/macrophages may have reduced expression of 
molecules required for effective stimulation of T cells (e.g. MHC class II and 
CD80/CD86 (Clerici etal., 1991)), and increased expression of molecules that 
can trigger apoptosis such as Fas and FasL (Badley et al., 1996). Defects in 
innate cytokine production by DCs and abnormalities in contact-dependent 
interactions between T cells and DCs could result in incomplete or aberrant T 
cell stimulation, leading to the observed failure of HIV-specific CD8+ T cells to 
acquire a fully mature phenotype in primary HIV-1 infection.
CD4+ T helper cells also provide help for expansion and maintenance of fully 
functional CD8+ T cell responses through their ability to provide co-stimulatory 
and cytokine support. In support of this, cells responding to LCMV infection in 
mice which lacked helper T cells, were found to be deficient in function (Zajac 
et al., 1998). In HIV-infection the enhancement of HIV-specific CD8+ T cell 
function in vitro after short term incubation with IL-2 (Shankar et al., 2000; 
Trimble & Lieberman, 1998; Trimble et al., 2000) also supports that a lack of 
CD4 help may contribute to the functional impairment of HIV-specific CD8+ T 
cells. Associations between the degree of functional defect and disease 
stage/CD4 count (Shankar et al., 2000), and the presence of preserved virus- 
specific CD4 function in those with CD8+ T cells with fully effector/a more 
differentiated phenotype (Hess et al., 2004; van Baarle et al., 2002b), 
suggests that maturation of virus-specific CD8+ T cells may be linked to 
preservation of HIV-specific CD4+ T cell function.
Since HIV-specific CD4+ T cells are preferentially infected by HIV (Douek et 
al., 2002) and the initial loss of help is specific for HIV antigens during primary 
HIV infection (Musey et al., 1999), this may explain why HIV-specific cells fail 
to acquire a fully differentiated phenotype from primary infection. By contrast, 
when the response to e.g. CMV is primed, adequate CD4+ T cell help is likely 
present. The eventual loss of functional CMV-specific CD8 cells associated 
with end stage AIDS disease when CD4 counts are severely diminished 
reflects a universal loss of CD4 helper function. This, together with the 
observation that in patients with very low CD4 T cell counts, even CMV- 
specific cells had no direct virus-specific effector activity (Spiegel et al., 2000), 
further support that CD4 help is an important contributing factor to CD8+ T cell 
maintenance.
However, the observations that even in those exhibiting high HIV-specific CD4 
responses in primary infection, HIV-specific CD8+ T cells did not differentiate
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further (Appay, 2002), and that CD27+ CD28' cells were found even in LTNPs 
or those with therapy-induced viral suppression (both situations where help 
may be preserved) (Appay et al., 2002), do not support the idea that CD4 help 
is the major determinant of CD8 cell differentiation.
Another proposed explanation for the apparent defect in maturation or 
functionality of HIV-specific cells is that chronic antigen exposure may cause 
the immune system to go into a protective mode to protect against potential 
damage caused by such chronic activation. In accordance with this, some of 
the reported defects have been found to be apply to T cells in other chronic 
virus infections, and not just for HIV. Perforin expression was found to be 
low/absent in the same HIV-infected donor in most cells specific for HIV, CMV 
or EBV stained ex vivo without restimulation (Appay et al., 2002; Sandberg et 
al., 2001; Zhang et al., 2003a). The associated impaired cytotoxicity of cells 
that had repeatedly seen antigen (Zhang et al., 2003a) was thought to protect 
against damage that could arise by T cell recognition and destruction of 
uninfected cells displaying weakly reactive self peptides. The universal lack of 
CCR7 expression on HIV, CMV and EBV-specific cells (Chen, 2001) also 
supports for a mechanism for protecting against immunopathology.
The phenotype of virus-specific CD8 cells thus varies in different virus 
infections, and it is not clear what exactly is optimal. Although it may be that 
viruses block/divert T cell differentiation as part of their evasion of the host 
immune response, it has also been proposed that distinct patterns of 
differentiation may result from different routes of antigen exposure or particular 
homeostatic environments occurring in different virus infections, and that the 
phenotype of the cells primed may represent an appropriate response to the 
virus. In primary HIV infection, I found that the majority of virus-specific CD8+ T 
cells had a CD45RA', CCR7', CD27+, CD28+/‘ phenotype similar to that 
described in chronic HIV infection, which has been proposed to constitute an 
incompletely differentiated phenotype. However even in the case of EBV and 
influenza virus infection, viral infections which are controlled, virus-specific 
CD8+ T cells can be found at an early stage of differentiation (Appay et al., 
2002). The precise phenotype of an ideal protective virus-specific response, 
and whether the phenotype of HIV-specific CD8+ T cells is indeed reflective of 
a suboptimal protective capacity therefore remain unclear.
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In summary, in this chapter, epitope-specific components of the HIV-specific 
CD8+ T cell response were studied using fluorescently labelled multimeric 
peptide-MHC complexes to build upon initial observations made in chapter 3 
about the nature of the response expanded in different patients. This revealed 
that CD8+ T cell responses of very high magnitude can be expanded in 
primary HIV infection in patients who establish both high and low persisting 
viral loads. Analysis of the kinetics of expansion of epitope-specific CD8+ T cell 
responses in primary HIV infection showed that in many patients there is a 
period of -  5-6 weeks from the peak in acute HIV replication until the time 
when the earliest HIV-specific CD8+ T cell response (that was studied here) 
was found to reach its peak. Furthermore, in the majority of patients studied, 
different epitope-specific components of the response expanded with differing 
kinetics, such that an overall picture of asynchronous expansion of different 
responses emerged. Interestingly, the pattern of expansion of responses was 
somewhat different in the one patient studied who established a low persisting 
viral load, in whom a rapid, more synchronous expansion of responses was 
observed. Other similar patients would need to be studied to determine 
whether this is a feature of the response which differentiates all patients who 
are able to control primary viral replication efficiently.
Analysis of the changes in the clonal composition of epitope-specific T cell 
responses by TCR V£ family analysis revealed there to be a heterogeneous 
pattern of evolution of V/? family usage over time. When increasingly 
preferential usage of one particular family was observed over time, this was 
found to be coincident with an increase in the avidity of the response. 
Phenotypic analysis of tetramer/pentamer-labelled cells revealed, in all 
patients and for both dominant and subdominant responses, there to be a lack 
of CD8+ T cells possessing what is thought to constitute a fully differentiated 
phenotype. HIV-specific cells were found to retain expression of CD27 (and 
CD28) from timepoints corresponding to acute infection onwards, although the 
functional significance of this observation remains to be determined. Overall, 
these results suggest that factors other than just the magnitude of the primary 
HIV-specific CD8+ T cell response, potentially including kinetic and/or 
qualitative aspects of the response, may have a key impact on the efficiency 
of control of acute/early virus replication.
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Chapter 6 
General discussion
The events which take place in the early stages of HIV-1 infection are critical 
determinants of the subsequent disease course: a setpoint level of persisting 
virus is established at this time that is predictive of the rate of progression to 
AIDS (Mellors et al., 1996). Although the immune response mounted following 
infection fails to mediate virus clearance, there is good evidence to suggest 
that antiviral immunity, in particular the HIV-specific CD8+ T cell response, 
does play an important role in containment of early viral replication.
This includes the loss of control of virus replication following CD8+ T cell 
depletion of SIV-infected macaques (Jin et al., 1999; Schmitz et al., 1999); the 
selection of viral variants able to escape CD8+ T cell recognition in both HIV- 
infected individuals (Borrow et al., 1997; Goulder et al., 1997a; Jones et al., 
2004; Price et al., 1997) and SIV-infected macaques (Allen et al., 2000b; 
Evans et al., 1999); and the association of certain HLA class I alleles with the 
rate of disease progression (Carrington eta!., 1999; Kaslow etal., 1996). 
Consequently, the enhancement/induction of HIV-specific CD8+ T cell 
responses is the goal of many prophylactic and therapeutic strategies 
currently in development (review in (Garber et al., 2004)). However, our 
current picture of the early HIV-specific CD8 response is very incomplete, and 
it is still unknown what kind of response is able to provide the best long term 
control of viral replication. Such knowledge would help inform the design of 
more effective T cell-based vaccines. In consideration of this, the aim of this 
project was to characterise the HIV-specific CD8+ T cell response in primary 
infection in a number of HIV-infected individuals to increase our understanding 
of the response with respect to its magnitude, kinetics, breadth, epitope 
specificity, and the avidity and phenotype of different epitope-specific T cells. 
Furthermore, efforts were made to compare these features of the response in 
patients who naturally controlled early viral replication with differing efficiency 
in order to identify features of the response associated with poor and good 
viral control.
More prior studies of the HIV-specific CD8+ T cell response have focused on 
responses during chronic infection, and not during primary infection. At the 
time this project was started, there were thus many gaps in our knowledge 
about the primary HIV-specific CD8+ T cell response. It was known that HIV- 
specific CD8+ T cell responses can be detected very early in infection, prior to
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the peak in acute viral replication (Borrow et al., 1994; Koup et al., 1994); and 
that individual epitope-specific responses can potentially reach very high 
magnitudes in primary infection (Borrow et al., 1997; Pantaleo et al., 1994). 
However the total magnitude of the HIV-specific CD8+ T cell response 
expanded in primary infection and the extent to which this may vary between 
patients were not clear. Further, the kinetics of expansion/contraction of the 
overall response and of epitope-specific components of the response were not 
well defined. Limited studies had addressed the dynamics of responses to 
individual viral epitopes in a small number of patients (some of whom were 
treated with antiretroviral therapy during primary infection) using tetramer 
staining (Appay, 2002; Wilson et al., 2000), but the immunodominance of the 
responses followed in these patients was not known, leaving it uncertain as to 
how representative their magnitude/kinetics were of the dynamics of all 
epitope-specific components of the primary CD8+ T cell response. Likewise, 
although some phenotypic analysis of CD8+ T cells involved in the primary 
response had been carried out (Appay, 2002; Appay et al., 2002; Doisne et 
al., 2004; Papagno et al., 2004), it was again unclear how representative the 
findings were of all cells participating in the response. Lieberman et al 
(Lierberman et al., 2001) highlighted the fact that the epitopes used in 
tetramers are rarely immunodominant (Altfeld et al., 2001b; Betts et al., 2000; 
Lieberman et al., 1997; Lieberman et al., 1992), and that CD8 cells targeting 
subdominant epitopes may have lower avidity interactions with target cells 
than T cells targeting immunodominant responses (Sercarz et al., 1993). 
Since low avidity interactions may alter T cell activation and differentiation 
(Leitenberg & Bottomly, 1999), the nature of the epitope studied may influence 
the conclusions drawn, and so observations should ideally be confirmed using 
a broad array of tetramers to follow responses to different viral epitopes. 
Another aspect of the primary HIV-specific CD8+ T cell response about which 
limited information was available was its breadth and whether/how this may 
vary in patients who controlled viral replication with differing efficiencies. 
Pantaleo et al (Pantaleo et al., 1994; Pantaleo et al., 1997b) reported an 
association between expansion of T cells using TCRs in one or a small 
number of V/? families during primary HIV-1 infection and poor control of virus 
replication. This could reflect differences in the clonality and/or breadth of the 
primary HIV-specific CD8+ T cell responses in patients who control viral 
replication with differing efficiency; and/or may reflect differences in the timing 
with which expansion of epitope-specific responses and/or different clones of
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T cells involved in a given response occurs. A small number of studies had 
addressed the epitope breadth of the primary HIV-specific CD8+ T cell 
response, although these were typically performed in very early (rather than 
acute) infection (Addo et al., 2003; Cao et al., 2003; Dalod et al., 1999b). 
These studies indicated that the epitope breadth of the HIV-specific CD8+ T 
cell response tends to be narrower in primary infection than in chronic 
infection, but did not observe a relationship between the breadth of the 
response and concurrent viral load. However they did not address the 
relationship between the epitope breadth of the CD8+ T cell response in 
acute/subacute infection and the persisting viral load established by -six 
months post-infection.
The approach taken to this study was to initially map the epitope-specificity of 
the entire HIV-specific CD8+ T cell response in early infection in a panel of 
infected individuals, and determine the relative magnitude of responses to 
different viral epitopes at this time (chapter 3); then to use tetramer staining to 
assess the magnitude and kinetics of selected epitope-specific responses 
within each patient, the relative dominance of which in early infection was 
known, and also to study the phenotype of the cells involved in these 
responses (chapter 5). Efforts were made to perform this analysis in patients 
who established a range of different persisting viral loads; but unfortunately I 
had only very limited access to samples from patients who controlled virus 
replication well. There were also constraints on the number of epitope-specific 
responses that could be studied in chapter 5. Some of the conclusions made 
here are thus limited by what could be feasibly investigated. One of the 
observations made in this study was that the primary HIV-specific CD8+ T cell 
response in many infected individuals is heavily biased towards a small 
number of immunodominant epitopes, responses to which may expand more 
rapidly in acute/subacute infection than responses to subdominant epitopes. 
Mechanisms that may account for this were explored in chapter 4. The results 
from each part of this study have already been discussed in detail at the end 
of the relevant chapter, so here only the main findings are briefly reviewed and 
discussed; and the implications of these observations for vaccine development 
are considered.
Tetramer analysis of the dynamics of individual epitope-specific responses in 
primary HIV infection (chapter 5) revealed that very high magnitude HIV-
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specific responses can be induced in primary infection, with 22% of CD8+ cells 
being found to be directed against a single epitope in one of the patients 
studied. It was difficult to assess the total magnitude of the entire acute-phase 
HIV-specific CD8+ T cell response from the tetramer analysis of selected 
epitope-specific T cell responses carried out; nonetheless, results from both 
this and other studies (Borrow et al., 1997; Pantaleo et al., 1994) suggest that 
very high magnitude CD8+ T cell responses can be expanded in primary HIV 
infection in patients who control viral replication well and poorly. In addition, 
results from the initial analysis of the magnitude of the ‘entire’ HIV-specific 
CD8+ T cell response during early infection (determined by assessing 
responses to overlapping peptides corresponding to the clade B consensus 
sequence in IFN-y ELISPOT assays (chapter 3)), suggested that the 
magnitude of the total response at this time in different individuals was not 
significantly related to the level of persisting virus subsequently established, 
with a high magnitude response being observed in all patients. Likewise other 
studies have also found no relationship between the magnitude of the HIV- 
specific CD8 response in primary infection and the viral load (Addo et al., 
2003; Cao et al., 2003). This suggests that the magnitude of the response is 
not the most important determinant of the efficiency of control of viral 
replication. A study carried out in the LCMV infection model which addressed 
the magnitude and protective capacity of different epitope-specific CTL 
responses also found that the magnitude of a response does not necessarily 
correlate with its protective capacity (Gallimore et al., 1998). Kinetic and/or 
qualitative aspects of the primary HIV-specific CD8+ T cell response may thus 
be of greater importance in determining the efficiency with which viraemia is 
controlled.
When the kinetics of expansion of different epitope-specific responses were 
compared in different patients (chapter 5), it was found that the first response 
(of those studied) within each patient was typically relatively slow to develop; 
the average time between the peak viral load and ‘first’ epitope-specific 
response reaching its recorded maximum was 39 days. A delay in the 
expansion of the HIV-specific CD8 response was also observed in rW -  
stimulated IFN-y ELISPOT assays (chapter 3), but here it was not known 
whether the very low magnitude responses detected at the earliest timepoints 
tested was due to the death of highly activated cells in the assay or reflected 
the presence of a low magnitude response in vivo at these timepoints.
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However the tetramer studies confirmed that the apparent delay in the 
response for patient MM27 in the rW-stimulated IFN-y ELISPOT assay was a 
real delay.
Interestingly, the response which showed the fastest kinetics of expansion 
was observed in SUMA, the patient who established the lowest viral load. This 
response peaked a week (at the most) after the highest recorded viral load. 
Considering the kinetics of viral amplification, small changes in the speed of 
activation and expansion of virus-specific CD8+ T cell responses could have 
profound effects on viral control (Ehl et al., 1997), so the rapid mobilisation of 
a virus-specific CD8+ T cell response in patient SUMA (which was also of high 
magnitude and potentially of high efficacy since it targeted an epitope within 
the early expressed Tat protein) may be one of the factors that contributed to 
the ability of this patient to control early viral replication very efficiently. 
Conversely a delay in expansion of the virus-specific CD8 response may 
contribute to the ineffective control of early viral replication in the majority of 
HIV-infected individuals. This has also been suggested to be of importance in 
HCV infection (Bertoletti & Ferrari, 2003). From studies of the kinetics of virus- 
specific immune responses in primary HBV and HCV infection, the interval of 
time between infection and activation of the response was hypothesised to 
influence the disease profile. In both infections virus-specific CD8+ (and CD4+) 
T cell responses appeared only after 7-10 weeks after infection (Thimme et 
al., 2001; Webster et al., 2000). However, the two viruses replicate at different 
rates, and the slower replication kinetics of HBV allowed sufficient time for 
adaptive responses to develop, while in HCV infection, viral replication 
outpaced the development of the adaptive immune response. These 
differences may contribute to differences in the rate of chronicity for the two 
infections and explain why HBV is more easily controlled by vaccination.
Another observation made in chapter 5 was that in most (if not all) patients, 
responses to different viral epitopes expanded asynchronously in primary 
infection, with more rapidly-expanding responses tending to dominate the 
initial response. The observation made by Pantaleo et al (Pantaleo et al., 
1994; Pantaleo et al., 1997b) of monoclonal/oligoclonal TCR V£ family 
expansions in patients who controlled viral replication poorly may thus be 
explained (at least in part) by initial expansion of responses to a limited 
number of highly immunodominant epitopes. The finding that in patient SUMA 
(who controlled early viral replication well) the immunodominant earliest
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response peaked only one week or less prior to a more subdominant response 
suggests that responses in this patient may have not only evolved faster but 
also less asynchronously than in other patients (providing a partial explanation 
as to why major V/? family perturbations were not apparent in primary infection 
in this patient, or other individuals studied by Pantaleo et al who controlled 
early viral replication efficiently).
Results obtained in chapter 3 indicated that during early HIV infection, the 
HIV-specific CD8+ T cell response in most patients was heavily biased towards 
a few immunodominant proteins/epitopes. Analysis of the epitope breadth of 
the response revealed that there was no significant difference in the number of 
epitopic regions targeted in patients who established persisting viral loads in 
the three uppermost of the four viral load quartiles (low-intermediate, 
intermediate-high and high) as defined by Mellors et al (Mellors et al., 1996). 
Unfortunately, no patients who established low persisting viral loads were 
available for inclusion in this analysis. Previous analysis of the epitope breath 
of the response in a patient who established a very low persisting viral load 
(SUMA), showed that in this patient a response of considerable breadth 
(targeting > 40 epitopes) was induced in primary infection (Jones et al., 2004); 
however epitope mapping here was carried out using reagents based on the 
patient’s autologous virus sequence, so the results are not directly comparable 
to those obtained in this study. Whether a broader response is induced in 
patients who control viral replication most efficiently thus remains unclear. 
Other studies that have addressed the epitope breadth of the CD8+ T cell 
response in primary HIV infection have found no association between the 
number of CD8+ T cell epitopes recognised and the concurrent viral load 
(Addo et al., 2003; Cao et al., 2003; Dalod et al., 1999b); although these 
analyses have not addressed the relationship between primary response 
breadth and the subsequent efficiency of control of virus replication. Notably, a 
recent study carried out by Addo et al in chronically-infected patients found 
that the breadth and magnitude of responses was no different in LTNPs 
compared to progessors (Addo et al., 2004).
In summary, available data suggest that the primary HIV-specific CD8+ T cell 
response in those patients who control virus replication most efficiently may 
differ from the response made in the majority of infected individuals not in 
terms of magnitude, but in terms of the kinetics with which it is expanded, with 
the most rapidly-expanded epitope-specific responses reaching peak
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magnitude within a few days of the peak in acute viral replication, and 
responses of other specificities beginning to expand concurrently and peaking 
shortly thereafter. By contrast, in many infected individuals there may be a 
delay of as much as several weeks before the first epitope-specific responses 
to be expanded reach their peak, and responses of different epitope 
specificities may expand very asynchronously so that a small number of 
epitope-specific responses are highly immunodominant during primary 
infection (although by early infection, the epitope breadth of the response may 
not be significantly different from that in patients who control virus replication 
well). The limited analyses of the clonal breadth of epitope-specific T cell 
responses during primary infection carried out in chapter 3 did not suggest 
that this differed significantly in patients who controlled virus replication with 
differing efficiency, although more extensive studies would be required to 
enable more definitive conclusions to be drawn about this.
Likewise, studies carried out in chapter 5 revealed no differenced in the 
phenotypic maturation/differentiation state of CD8+ T cells responding to 
dominant viral epitopes in primary infection in patients who controlled virus 
replication with differing efficiency. However it is possible that other features of 
the response that were not analysed here may differ in different infected 
individuals, such as the proliferative capacity or effector function (e.g. cytolytic 
capacity or cytokine production) of HIV-specific CD8 T cells. CD8+ T cell 
proliferative capacity and cytolytic effector functions were found to be 
preserved in LTNPs (Migueles et al., 2002), indicating that these may be 
important correlates of good viral control.
Differences in the nature of the primary HIV-specific CD8+ T cell response in 
patients who establish different persistent viral loads may be a consequence 
and/or a cause of differences in the level of viral replication.
As discussed in chapters 4 and 5, factors that influence the induction and 
maintenance of CD8+ T cell responses include antigenic stimulation, 
interaction with APCs, exposure to innate cytokines/chemokines and CD4+ T 
cell help.
In primary HIV infection APC numbers may be reduced, and their functional 
capacity impaired (Lore et al., 2002; Lore & Larsson, 2003; Pacanowski et al., 
2001). DCs from HIV-infected patients have been found to have impaired 
ability to stimulate T cell proliferation (Donaghy et al., 2003; Knight & 
Patterson, 1997). In vitro experiments using a HIV-infected human DC line
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showed that the inability to stimulate allogeneic T cell proliferative responses 
may be due to multiple factors including IL-10 and gp120-induced apoptosis 
(Beuria et al., 2005).
There are also abnormalities in the number and functional capacity of PDCs 
during primary HIV infection (Kamga et al., 2005; Pacanowski et al., 2001). 
These cells act as an important source of type I IFNs and potentially also other 
innate cytokines involved in CD8+ T cell activation and homeostasis. 
HIV-specific CD4+ T cell responses are impaired from primary infection 
onwards (Gloster et al., 2004; Musey et al., 1999; Oxenius et al., 2000), so 
there is likely to be a paucity of help for CD8+ T cell activation.
In the context of high level primary viral replication, these defects in immune 
functions will likely be most severe and CD8+ T cell activation/expansion most 
markedly compromised. In addition, a high antigen load in itself may lead to 
dysfunction of CD8 cells due to sustained TCR signalling in the absence of 
appropriate co-stimulation. As discussed in chapter 4, there may be 
preferential expansion of selected CD8+ T cell responses (e.g. high affinity 
responses and/or responses involving cells in the memory pool), with 
associated suppression of other responses. Potential reasons to explain why 
certain responses are able to preferentially expand and come to be more 
dominant early on in infection were explored in chapter 4. One such reason 
was that certain responses may be less dependent on help for their expansion 
(Franco et al., 2000), and so under conditions where CD4 help is limiting, they 
preferentially expand. It was suggested that help-independent responses may 
be impaired in their ability to differentiate into memory cells (Kan-Mitchell et 
al., 2004), and so this is another reason as to why the biasing of the response 
to a limited number of epitopes may be detrimental. Another reason is that the 
dominant response may suppress the expansion of other responses 
(Rodriguez et al., 2002; Sette & Fikes, 2003). In line with this, in another study 
of HIV infection, it was suggested that CD4 cells were needed for effective in 
vivo activation of CTL and that lack of help prevents a broad response from 
evolving (Hay etal., 1999).
By contrast, in patients where viral replication is initially lower (perhaps due to 
properties of the infecting virus isolate, host genetics and/or features of the 
innate response), defects in APC functions and the HIV-specific CD4+ T cell 
response will be less severe. For example, strong HIV-specific CD4+ T cell 
responses have been observed in primary infection in patients such as SUMA 
who control early virus replication well (Gloster et al., 2004), and are also
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preserved in LTNPs (Rosenberg et al., 1997). In addition, the number of 
peripheral blood PDCs and MDCs in LTNPs were found to be unaltered 
compared to those in control individuals, whereas in progressors numbers 
were severely decreased (Almeida et al., 2005). Under conditions where APC 
function and help are relatively preserved, synchronous expansion of CD8+ T 
cells of multiple specificities may be supported. Interestingly, HIV-specific cells 
in patient SUMA who had preserved CD4 function, were not more terminally 
differentiated than those in other patients, suggesting even where CD4 help is 
present, incomplete differentiation of HIV-specific CD8+ T cells still occurs. 
Supporting this hypothesis, it is notable that rapid, synchronous expansion of 
virus-specific CD8+ T cells of multiple epitope specificities is observed in acute 
LCMV infection of mice, where APCs are rapidly activated to support CD8 T 
cell priming (Montoya et al., 2005; Murali-Krishna et al., 1998), whereas in 
HCV-infected individuals where DC functions are thought to be impaired 
(Anthony et al., 2004; Bain et al., 2001; Sarobe et al., 2002) and CD4 T cell 
responses are weak (Chang et al., 2001; Gerlach et al., 1999; Thimme et al., 
2001; Wedemeyer et al., 2002), virus-specific CD8+ T cell responses expand 
slowly and asynchronously (Lechner et al., 2000a; Timm et al., 2004), and 
virus-specific CD8 T cells exhibit an ‘immature’ phenotype similar to that of 
HIV-specific CD8 T cells (Appay et al., 2002; Urbani et al., 2002).
The speed with which a high magnitude virus-specific CD8+ T cell response is 
mobilised is likely to play a critical role in determining the efficiency with which 
viral replication is contained, as demonstrated by a study by Ehl et al (Ehl et 
al., 1997). When different spleen cell populations (from naive, acutely-infected 
and memory mice) were adoptively transferred into recipient mice pre-infected 
with LCMV, it was found that the CTL from memory mice provided less 
protection than CTL from acutely infected mice. This difference in the 
protective efficacy of the transferred cells was likely to have been due to the 
reactivation time required by the memory cells and the contrasting ability of 
cells from the acutely-infected donors to provide immediate effector function. 
Thus in this situation, a delay in the response had an important impact on the 
ability of the cells to provide antiviral protection.
Notably however, a subsequent study in which the protective capacity of 
different subsets of memory T cells was compared in a slightly different 
adoptive transfer model, where the recipient mice were infected with LCMV 
following cell transfer, revealed that central memory cells were more effective
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than effector memory cells, because of their potential to expand and generate 
large numbers of effector cells (Wherry et al., 2003b). However whether the 
time needed for such cells to be activated upon encounter with a virus for 
which the response kinetics are now thought to be critical, may limit their 
usefulness remains to be seen.
The breadth (both epitope breadth and clonal breadth) of the CD8+ T cell 
response induced in primary HIV infection may also have an important impact 
on the efficiency of control of early viral replication. Viral evolution to escape 
from epitope-specific CD8 T cell responses is thought to constitute an 
important immune evasion strategy in HIV-1 infection (Goulder & Watkins,
2004). CTL escape viral variants can start to emerge during the acute phase 
of infection, and may be selected for to completion in the in vivo viral 
quasispecies within as little as a few weeks (Allen et al., 2000b; Borrow et a/., 
1997; Jones et al., 2004; O'Connor et al., 2002) -  the kinetics and extent of 
viral escape from the primary CD8+ T cell response may thus potentially have 
an important impact on the efficiency of control of early viral replication.
CTL escape is promoted when a response makes a particularly important 
contribution to control of viral replication, due to its magnitude and/or efficacy 
and immunodominance. It follows that a response which exerts broad and 
even pressure on the virus will be associated with the least amount of escape, 
as the benefit to be gained from escape from any one particular component of 
the response will be less. This was illustrated in a study of the emergence of 
CTL escape variants in patient SUMA, and two other patients who had less 
broad, and more biased responses (Jones et al., 2004). There was much less 
extensive CTL escape in patient SUMA compared to other patients (who 
established higher persisting viral loads).
Having a response of greater clonal breadth can also be advantageous in 
limiting viral escape, as suggested by the broad usage of TCR V£ families by 
virus-specific CD8+ T cells and their associated cross-recognition of variant 
epitopes observed in HIV-2-infected patients (Lopes et al., 2003). Such 
patents typically show a much less severe disease course than HIV-1-infected 
patients. By providing the potential for recognition of multiple variants of an 
epitope peptide, greater heterogeneity of TCR usage in an epitope-specific 
CD8 response may thus help to restrict viral escape.
Therefore, while it could be envisaged that a response which can be rapidly 
activated could be advantageous in early containment of viral replication, there
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is a risk of it becoming significantly immunodominant, to the detriment of the 
ensuing efficiency of control of virus replication. The rapid kinetics of the initial 
response of patient SUMA may have contributed to the efficiency of viral 
control in this patient, but the rapid expansion of HIV-specific CD8+ T cells of 
other specificities may have prevented the initial response coming to dominate 
the entire response, and restricted the extent to which the overall response 
was escaped. Viral escape from CTL recognition may pose a huge threat to 
the success of to CTL-based vaccines. The emergence of viral mutations that 
escaped recognition by dominant epitope-specific CTL in vaccinated 
macaques who initially controlled SIV challenge effectively has been reported 
(Barouch et al., 2002); such escape was associated with rapid progression to 
AIDS.
This suggests that to achieve optimal control, a therapeutic or prophylactic 
vaccine should aim to preserve or elicit CTL responses of evenly high 
magnitude and efficacy to a series of epitopes (since this will minimise the 
emergence of CTL escape variants), and that are able to be activated rapidly. 
This should target invariant, functionally constrained regions in the virus, 
where escape is likely to be restricted by costs to intrinsic fitness (Kelleher et 
al., 2001; Wagner et al., 1999), and/or proteins which are expressed early in 
the viral lifecycle (since these may have a kinetic advantage in recognising 
HIV-infected cells before new viral progeny have been released (Gruters etal., 
2002; van Baalen etal., 2002)).
There is a risk however of skewing the immune response towards 
immunodominant epitopes when trying to induce an immune response to 
multiple epitopes simultaneously in prime-boost protocols due to competition 
of CTL for APC (Palmowski et al., 2002; Rodriguez et al., 2002). In order to 
induce a broad response, it may be necessary to use separate constructs 
encoding individual epitopes or proteins for the boosting phase, such that APC 
separately present the epitopes (Palmowski etal., 2002).
Given the importance of a functional CD4 response any vaccine-elicited CD8 
response should be raised in the context of good CD4 function, for insufficient 
help may impact on the priming and formation of functional memory 
responses. The virus-specific CD4 response may also act together with other 
arms of the immune system, such as the antibody response, to contain 
ongoing viral replication at levels which do not exhaust the CD8 response 
(Planz et al., 1997). It is also important to preserve APC function to provide 
appropriate co-stimulation to enable optimal priming of CD8 cells, since a lack
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of fully functional APCs could result in the aberrant activation of HIV-specific 
CD8+ T cells. The co-stimulatory signals provided by DCs are also thought to 
be important in inducing high avidity CD8 cells (Oh et al., 2003), which are 
more effective in mediating protective immunity (Alexander-Miller et al., 1996; 
Gallimore etal., 1998).
That a vaccine-induced virus CD8+ T cell response alone cannot provide long 
term control of HIV-1 replication, and that the induction of other components of 
the immune response is important was illustrated in macaques who were 
immunised using a prime/boost regimen which induced a multi-specific 
mucosal CTL response but not an Env-specific antibody response, and then 
subsequently challenged with pathogenic SIV (Vogel et al., 2003); SIV-specific 
cellular responses were able to control primary viral replication, but without 
neutralising antibody, the virus-specific response was unable to control 
chronic phase viral replication.
Overall, the most effective control of HIV replication is thus likely to require the 
induction of a fully integrated innate, humoral and cell-mediated immune 
response from the early stages of infection, and this should be the goal of 
vaccination strategies.
In summary, the results from this thesis suggest the importance of not only the 
magnitude, but also kinetic and qualitative features of the virus-specific CD8+ 
T cell response in primary HIV infection in determining the efficiency of control 
of early virus replication. These findings have a number of implications for 
both the prophylaxis and treatment of HIV infection.
First, they suggest that among the aims of a successful prophylactic HIV 
vaccine should be the generation of a pool of central memory cells of multiple 
epitope specificities that would be present at the time of infection to act rapidly 
to limit initial viral replication (particularly in the gut mucosal tissues where 
much of the initial infection and damage of memory CD4 cells takes place (Li 
et al., 2005; Mattapallil et al., 2005)), and subsequent dissemination around 
the body. A reduced initial level of viral replication and damage to the CD4 cell 
compartment may in turn enable increased levels of functional effector CD8 
cells to develop with enhanced ability to control viral replication during chronic 
infection. In addition, prophylactic vaccines should ideally also elicit other 
responses, including neutralising antibody responses that may contribute to 
control of virus replication both in the critical early stages of infection and at
385
later timepoints; and virus-specific CD4+ T cell responses that may be of 
importance for the induction and maintenance of effective virus-specific CD8+ 
T cell responses.
Second, they emphasise the importance of events in primary HIV infection in 
determining the overall disease course, suggesting the value of exploring the 
potential utility of rapid diagnosis of HIV infection and "acute phase” 
therapeutic intervention as a means of inducing better long-term control of 
virus replication.
Third, it is clear that there are shortcomings of the immune response in 
patients chronically-infected with HIV. Deficits in APC function and/or CD4+ T 
cell responses, escape from initially dominant/efficacious CD8+ T cell 
responses and/or defects in CD8+ T cell function may all have occurred by this 
time, necessitating design of therapeutic strategies to reverse/overcome these 
defects. The latter presents many obstacles, but is given impetus by findings 
such as those described here which indicate that at least in a minority of 
patients, immune responses are induced that mediate sustained control of 
viral replication over time.
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